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ABSTRACT: “Optimization of Antimicrobial Therapy for Gram-
positive bacterial infections in children using a translational 
pharmacological approach” 	
Nosocomial bloodstream infection (BSI) is the most common type of 
hospital-acquired infection in paediatric patients and a major cause of morbidity and 
mortality worldwide. Methicillin-resistant staphylococci (CoNS and MRSA) are a 
leading cause of hospital-acquired neonatal sepsis and BSI. Glycopeptides 
(vancomycin and teicoplanin) constitute the current mainstay of therapy. There is 
limited antimicrobial PK-PD data available for neonates and children and optimal 
drug exposures resulting in maximal efficacy and suppression of resistance are not 
known. A translational pharmacological approach can be used to build the evidence 
required to optimize the current use of antimicrobial therapy in children.  
Pre-clinical experimental (in vitro and in vivo) and clinical PK-PD work was 
conducted throughout this thesis to improve our understanding of the PK-PD 
relationships of vancomycin and teicoplanin against CoNS and MRSA. The in vitro 
HFIM defined the relevant PD indexes and free drug exposures associated with 
maximal bacterial killing and suppression of resistance. The in vivo models (a rabbit 
central-line associated BSI and a mouse neutropenic thigh infection model) validated 
the in vitro findings. CRP concentrations were incorporated as an in vivo PD input. A 
clinical PK study of teicoplanin in 57 patients (neonates, infants and older children) 
was conducted and the population PK parameters estimated. PK-PD modelling 
techniques were used to analyse the PK-PD data and bridge the experimental results 
to human patients by means of Monte Carlo (MC) simulations. 
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Vancomycin and teicoplanin displayed a concentration-dependent pattern of 
activity. An AUC:MIC ratio was associated with maximal antibacterial activity and 
suppression of resistance. Based on MC simulations, the probability of the in vivo 
target attainment with currently used teicoplanin dosage regimens results insufficient 
to treat a majority of patients with MRSA infection. High teicoplanin PK variability 
was identified in children. Weight, age and renal function were the best explanatory 
covariates of PK variability. Wider drug exposure distribution is observed in the 
paediatric population with respect to adults. A patient-tailored TDM approach with 
the aid of a Bayesian feedback adaptive control tool is required to ensure individual 
patients achieve optimal drug exposures in a precise and safe manner. 
The defined pre-clinical optimal targets of exposure for vancomycin-CoNS 
and teicoplanin-MRSA now need to be prospectively evaluated in patients. Currently 
used teicoplanin dosage regimens in both, adults and children, may be insufficient to 
treat a high proportion of patients with serious MRSA infection. Current EUCAST 
clinical breakpoint may need to be revised for teicoplanin against MRSA. The 
current strategy of using teicoplanin fixed population-based antibiotic regimens 
results in a wide range of drug exposures in neonates and children. An individualised 
dosing and TDM approach can ensure optimal target attainment at the individual 
level and in real-time.   
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Chapter 1 
General Introduction 
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1.1- OVERVIEW 
Gram-positive bacterial infections are a leading cause of infectious mortality 
and morbidity in hospitalised children (H Wisplinghoff et al. 2003). In addition, the 
increasing prevalence of antimicrobial drug resistance or decreased susceptibility to 
current treatment regimens is a threat to public health worldwide (Sader et al. 2013; 
Ahlstrand et al. 2011). There are few antibiotics in the developmental pipeline and 
there is a renewed interest in investigating and optimising the use of well-established 
antibiotics (European Medicines Agency 2011; Ruggieri et al. 2014). However, 
insufficient PK/PD data is available for children and current dosage 
recommendations are outdated and lacking evidence. 
There is an urgent need to develop evidence-based dosing regimens to treat 
Gram-positive bacterial infections that are efficacious, with reliable 
pharmacodynamics in children, as well as a favourable side-effect profile. Innovative 
PK/PD techniques can be used to identify antimicrobial regimens that result in 
successful bacterial killing, suppression of antimicrobial resistance and minimal drug 
toxicity. PK/PD relationships established in pre-clinical studies are predictive of 
therapeutic responses in humans (Craig 2014). Furthermore, the development of 
software to aid in the individualization of dosing to treat these infections represents a 
potential highly valuable tool to improve the clinical outcomes (Hope et al. 2013). 
The overall “hypothesis” of this work is that innovative PK/PD techniques can 
be used to identify regimens of antimicrobials that are associated with maximal 
antibacterial killing and prevention of resistance in neonates and children with severe 
(hospital-acquired) Gram-positive bacterial infections, particularly bloodstream 
infections (BSI). 
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1.2- EPIDEMIOLOGY AND BURDEN OF GRAM-POSITIVE BACTERIAL 
INFECTIONS IN NEONATES AND CHILDREN: FOCUS ON 
STAPHYLOCOCCAL INFECTIONS 
1.2.1- Epidemiology and burden of Gram-positive bacterial infections in 
neonates and children 
Bacteraemia in children is a potentially life-threatening condition, which 
obliges immediate and effective antimicrobial therapy (Sharland 2007). Three of the 
most important influences on bacteraemia incidence are age, vaccination coverage 
and exposure to invasive procedures. For instance, higher rates are reported in 
younger children, infants and neonates, reflecting the relative immaturity of their 
immune system, as well as the increasingly broader use of medical devices in pre-
term and term neonates (Michael Cohen-Wolkowiez. et al 2009).  
Neonates have deficiencies in both the innate and adaptive immunity, and in 
the interaction between the two systems (Wynn et al. 2009). For instance, they have 
decreased complement components, reduced expression of some antimicrobial 
proteins and diminished production of type I interferon and Th1 polarizing cytokines 
(with a Th2-skewed response). They present with quantitative and/or qualitative 
impairments in neutrophil, monocyte, macrophage and dendritic cell function (Levy 
2007). There exists also differences between pre-term and healthy term neonates 
with respect to absolute cell counts of B cells and the frequency of regulatory T cells, 
more pronounced in the earliest pre-term neonates (GA< 30 weeks)(Huenecke et al. 
2016). All these deficiencies in cellular and non-cellular immune responses lead to 
an impaired phagocytosis and decreased pathogen clearance in neonates as compared 
to older children and adolescents.  
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Nosocomial bloodstream infection (BSI) is the most common type of 
hospital-acquired infection in paediatric patients and a major cause of morbidity and 
mortality worldwide (H Wisplinghoff et al. 2003). A report from a bacteraemia 
surveillance study in England (1992-2005, General Practice Research Database and 
Hospital Episode Statistics), in children aged under five, revealed that in 1992, 
around a 50% of bacteraemia were due to Gram-positive bacteria (Sharland 2007). 
However, this increased to over 75% in 2003 with Coagulase-negative staphylococci 
(CoNS) and Staphylococcus aureus (SA) becoming the leading significant bacterial 
pathogens reported, as shown in figure 1.1 (Sharland 2007). Another report from the 
Health Protection Agency (HPA) database described more recently the trends in the 
incidence of bacteraemia in England and Wales across the whole child age range (1 
month-15 years old)(Henderson et al. 2010). Over a 10-year period (1998-2007), 
total annual reports of bacteraemia increased with a mean 6.5% rise per year and in 
2007, just over half of the cases were accounted for by 4 groups of Gram-positive 
microorganisms: CoNS (28%), SA (10%), non-pyogenic streptococci (9%) and 
Streptococcus pneumoniae (7%) (Henderson et al.2010). 
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Figure 1.1 - Bacteraemia in children < 5 years old in England and Wales, 1992-2005. *2005 data 
published as provisional (Sharland 2007).  
 
On a more global basis, a report from a prospective evaluation involving 49 
US hospitals over a 6-year period (1995-2001), showed that in children up to 16 
years old, a 65% of the isolates recovered from BSI were Gram-positive bacteria, 
24% Gram-negative, 11 % fungi and 0.14% anaerobes. Among those, CoNS 
accounted for almost half of all nosocomial BSI (43%), followed by enterococci, 
Candida spp., and SA (9% each). Interestingly, when age groups were compared, the 
proportion of CoNS isolates diminished from 46% in < 1 year olds to 31 % in > 5- 
year-olds, whereas the proportion of SA and Enterococcus sp. increased from 8 and 
9%, respectively in the younger children to 12% in the older paediatric patients 
(statistical significance of these differences was not reported). According to the 
predisposing factors of BSI, intravascular devices were the most common ones. In 
this multi-centre study, the crude mortality rate of nosocomial BSI during 
hospitalization was 14 % (475 /3452 patients) (H Wisplinghoff et al. 2003). 
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In countries with limited resources, the trends in the aetiology of paediatric 
BSI appear different to those stated in high-income countries (HIC). Although 
limited reports are available, several studies have shown a predominance of Gram-
negative bacterial infections in hospitals. For instance, a retrospective 4-year study 
from a Ghanaian tertiary referral teaching hospital, showed that Gram-negative 
bacteria was most frequently isolated in BSI in children and infants than Gram-
positive bacteria (57.5% and 54.4% versus 40.7 and 45.1% respectively) (Obeng-
Nkrumah et al. 2016). Notably, neonates were excluded from this study. 
Furthermore, a systematic review of community-acquired neonatal and infant sepsis 
in low and middle-income countries (LMIC), including the aetiology and antibiotic 
resistance patterns of neonatal sepsis, was conducted in order to estimate the efficacy 
of WHO antibiotic guidelines. Nineteen studies were identified from 13 countries 
from Asia and Africa. Among neonates, SA, Klebsiella spp. and E. coli accounted 
for 55% of all isolates. In infants outside the neonatal period, the most frequently 
isolated pathogens were SA, E. coli, Klebsiella spp., Salmonella spp. and 
Streptococcus pneumoniae, accounting for 59% (Downie et al. 2013). In summary, 
the available evidence underlines a higher prevalence of Gram-negative than Gram-
positive bacteria in the aetiology of BSI in LMIC than in HIC and many 
epidemiological factors could be involved in this microbiological shift. For instance, 
there is increasing evidence that clinical pathogens vary incidence density with 
temperature (Schwab et al. 2014). Nonetheless, similarly to the reports from HIC, SA 
was the most common isolated causative pathogen overall in these studies.   
In hospital morbidity rates of BSI and sepsis remain high, particularly among 
preterm infants, while contributing to adverse and potentially disabling 
neurodevelopmental outcomes. This risk of morbidity is inversely proportional to 
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gestational age (GA) at birth (Stoll et al. 2010). The persistent inflammatory state of 
infection has been reported as the main noxa on the developing brain, which is not 
directly related to the specific pathogen (Adams-Chapman & Stoll 2006; Mitha et al. 
2013).  
A significant persistent challenge for the clinician is how to effectively treat 
Gram-positive bacterial infection given the increasing diversity of drug-resistant 
pathogens and the limited treatment options. Thus, it is important to find ways to 
optimally treat the most common causes of hospital-acquired infection, namely 
Gram-positive BSI and sepsis, in these vulnerable populations in order to eradicate 
the causative microorganism and minimize inflammation. 
 
1.2.2- Coagulase-negative Staphylococcal Infections 
The pathogenic potential of CoNS became accepted by the end of 1980s, but 
at the time most of the underlying molecular mechanisms were unknown. Modern 
and molecular-phenotypic methods have expanded our knowledge on its clinical 
significance. As opportunistic microorganisms, colonization of different parts of the 
skin and mucosa, including the gastro-intestinal tract of the host, is the key source of 
invasive staphylococcal infections (Soeorg et al. 2013). Demographic and medical 
developments have contributed to its increasing health burden. Like other 
nosocomial pathogens, increasing rates of resistance are even a greater problem for 
CoNS than for SA. Although CoNS possess fewer virulence properties than SA, host 
susceptibility plays a main role in the pathogenesis, and therapeutically, CoNS are 
challenging for three reasons: 1) the uncertainty with respect to the clinical 
distinction between significant infection versus contamination, 2) the great 
proportion of methicillin-resistant strains and 3) the decreasing susceptibility to 
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glycopeptides (von Eiff et al. 2002; Butin et al. 2015), currently the mainstay of 
therapy. 
Taxonomy and classification 	
CoNS represent a heterogeneous group within the genus Staphylococcus that 
is not based on phylogenetic relationships. A simplified but useful and widely 
accepted scheme for the classification based on clinical and diagnostic approaches is 
used in human medicine. That is, staphylococci are divided into coagulase-positive, 
almost exclusively represented by SA, and coagulase-negative- CoNS-, initially 
viewed as non-pathogenic. As of 2014, the genus Staphylococcus consists of 47 
species and 23 subspecies. Of these, 38 are recognized as CoNS and 13 of them, 
known to colonize humans (Venkatesh et al. 2006a). The clinically defined “ S. 
epidermidis group” comprises S. epidermidis and S. haemolyticus as the most 
prevalent species, as well as S. capitis, S. hominis, S. warneri and S. lugdunensis 
(novobiocin susceptible strains) implicated in native and prosthetic valve 
endocarditis, foreign body infections, osteomyelitis and in infections among 
immune-suppressed patients (Becker et al. 2014; Ruhe et al. 2004; Elamin et al. 
2015). The novobiocin resistant strains include S. saprophyticus and S. xylosus with 
the former being a well-known cause of urinary tract infections in immune-
competent women (Widerström et al. 2007). Recently, Lamers et al proposed a 
refined classification of 6 species groups and 15 cluster groups based on molecular 
data of the genus Staphylococcus. For a complete overview of the phylogenetic 
classification of staphylococcal species and sub-species extended by the diagnostic 
characteristics, as proposed by Lamers et al., see figure 1.2 (Lamers et al. 2012). 
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Figure 1.2-Phylogenetic classification of staphylococcal species and sub-species extended by the 
diagnostic characteristics, as proposed by Lamers et al.(Lamers et al. 2012) taken from the 
review by Becker et al (Becker et al. 2014).  	
Pathogenesis and virulence of CoNS 	
Most of the research conducted into CoNS virulence factors has been mainly 
focused on S. epidermidis, particularly in reference to adhesion and biofilm 
formation characteristics in foreign-body/device-associated infection (Veenstra et al. 
1996; Heilmann et al. 1997).  
Four main steps compose this process: 
1) Attachment to unmodified polymer surface.  
Bacterial adherence to polymer surfaces generally depends on bacteria cell 
surface characteristics and on the nature of the biomaterial. Initial attachment to 
unmodified polystyrene is mediated, at least in part, by two antigenically related 
staphylococcal surface proteins (SSP-1 and SSP-2)(Veenstra et al. 1996). The 
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surface-associated autolysin AtLE is also involved, not only in this initial 
attachment, but also binds to the extracellular matrix protein vitronectin in the 
second step of the process (Heilmann et al. 1997). In addition to proteins, a capsular 
polysaccharide/adhesin (PS/A) has been associated with adhesion and biofilm 
formation in a rabbit model of endocarditis caused by S. epidermidis. Furthermore, 
immunisation with this PS/A has resulted in protection against infection (Shiro et al. 
1994). 
2) Attachment to polymer surface coated with extracellular matrix 
proteins.  
This step can be achieved through transcutaneous migration and/or 
haematogenous seeding from a distant site (von Eiff et al. 2002). After insertion of 
the medical device, the polymer material rapidly becomes coated with plasma and 
extracellular matrix proteins such as fibrinogen, fibronectin, vitronectin, 
trombospondin and von Willebrand factor (Herrmann et al. 1988; Herrmann et al. 
1997). 
At later stages of infection, these proteins deposited in polymer-coated 
surfaces facilitate the colonisation from further staphylococci through specific cell-
surface-receptor. For instance, adherence of clinical isolates of coagulase-positive 
and negative staphylococci to biomaterials is enhanced by surface-bound fibronectin, 
particularly in SA while this varies among S. epidermidis strains (Herrmann et al. 
1988). Besides proteins, cell-wall teichoic acid is also involved in the adherence of S. 
epidermidis to proteins, such as fibronectin (Hussain et al. 2001). 
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3) Proliferation and accumulation in multi-layered cell clusters. 
Biofilm formation. 
 This helps the microorganism to evade the host mechanisms of defence and 
the antibiotic effect. After adherence to the biomaterial surface, the Staphylococci 
multiply and accumulate as multi-layered cell clusters. This process involves 
intercellular adhesion. The importance of S. epidermidis polysaccharide intercellular 
adhesin (PIA) has been shown in vivo. A PIA-negative mutant was significantly less 
virulent than the isogenic wild-type strain in a mouse model of subcutaneous foreign 
body infection and in a rat model of central venous catheter-associated infection 
(Rupp, Ulphani, Fey, Bartscht, et al. 1999; Rupp, Ulphani, Fey & Mack 1999). The 
ica ABC genes mediate cell clustering and PIA synthesis in S. epidermidis. An 
additional open reading frame (icaD) has been identified (Heilmann et al. 1996; 
Gerke et al. 1998). The ica ADBC operon mediates biofilm accumulation, PIA 
production and haemagglutination (Fey et al. 1999). It has been shown in strains of 
S. epidermidis obtained from blood cultures of patients with prosthetic device-
associated sepsis that there was a strong association between pathogenesis and both, 
biofilm formation and the presence of the ica gene cluster. As opposed, skin and 
mucosal isolate colonisers were usually biofilm-negative and lacked the ica genes 
(Ziebuhr et al. 1997; Cherifi et al. 2013). Furthermore, PIA inhibits phagocytosis and 
killing by polymorphonuclears (Vuong, Kocianova, Voyich, et al. 2004). 
 
4) Biofilm detachment and metastatic seeding. 
Finally, upon biofilm maturation, individual or clusters of bacteria may 
disaggregate and disperse via the bloodstream. Then, further sites in the body may be 
colonised leading to the metastasis of infection. This disintegration may be mediated 
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by several mechanisms, such as extracellular enzymes and the small peptides called 
phenol-soluble modulins (PSMS)(Mehlin et al. 1999; Dubin et al. 2001; Oleksy et al. 
2004). 
Other potential virulence factors in S. epidermidis are several proteases, 
toxins (e.g d-toxin), production of lantibiotics that interfere with other bacteria on 
skin and mucous membrane colonisation and mechanisms of iron acquisition from 
the host (Chamberlain & Brueggemann 1997; McKevitt et al. 1990; Kupke & Gotz 
1996; Modun et al. 1998). In addition to the ica operon, another virulence-associated 
mobile genetic element is the arginine catabolic mobile element (ACME), which 
comprises 2 gene clusters: a six-gene arc operon that encodes an arginine 
deiminidase and the opp3 that encodes an oligopeptide permease system (Diep et al. 
2008). The role of ACME has not been completely determined, but various studies 
have shown that increases the ability of S. epidermidis strains to colonize skin and 
mucosa, as well as enhances haematogenous dissemination to target organs (Du et al. 
2013; Diep et al. 2008). 
Host response interactions 	
Opsonophagocitosis is the primary host defence mechanism against CoNS 
infection (Krediet et al. 1998). CoNS biofilm exerts immunomodulatory properties 
while stimulating the production of prostaglandins by monocytes, which inhibits T-
cell proliferation and function (Stout et al. 1992).  In the last decade, research has 
shown that increased levels of biofilm production are conversely associated with a 
decreased incidence of tissue invasion, and lower C-reactive values have been 
demonstrated in neonatal CoNS sepsis caused by biofilm-positive versus biofilm-
negative isolates (Vuong, Kocianova, Yao, et al. 2004; Klingenberg et al. 2005). This 
research supports the theory that this could limit the immune system to counteract 
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the infection and points to host-response evasion of CoNS (within the biofilm) as the 
main virulence factor. Conversely, a strong association between biofilm production 
and both phenotypic and genotypic antibiotic resistance has also been shown 
(Klingenberg et al. 2005). 
Nonetheless, there is a paucity of data that links virulence factors, antibiotic 
resistance and clinical outcomes in CoNS infection, as opposed to SA infection. 
Clinical significance of Coagulase-negative Staphylococcal infections in the child 	
CoNS infection is the most common cause of laboratory confirmed blood 
stream infection (LCBSI) in the paediatric and neonatal intensive care setting 
(National Nosocomial Infections Surveillance (NNIS) system report, 2001; Elward et 
al. 2005). It is frequently isolated in patients who are low and very low birth weight 
and/or pre-term infants, immunosuppressed (e.g febrile neutropenia in oncologic 
patients), have significant burns or have indwelling intravascular devices, ventricular 
shunts, peritoneal catheters or other implanted/inserted medical devices (Vergnano et 
al. 2011; Stoll et al. 2002; El-Mahallawy et al. 2009). In the intensive care setting, 
these infections represent an important cause of global morbidity, prolonged hospital 
stay and mortality, as well as considerable increased costs in patients who develop 
nosocomial BSI in comparison with non-infected patients with similar underlying 
conditions and the same number of ventilator days (Elward et al. 2005). 
Paediatric oncologic patients, bone marrow transplant recipients and children 
with burns are at high risk for acquiring CoNS bloodstream infections (Miedema et 
al. 2013; Santucci et al. 2003). In a national surveillance study comprising England 
and Wales over a 10-year period in children aged 1month-15 years old, CoNS 
bacteraemia represented a 28% of the organisms causing bacteraemia in hospitalized 
children (Henderson et al. 2010). 
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CoNS infection in the neonate and infant 	
Neonatal sepsis is associated with significant morbidity and mortality (Levit 
et al. 2014; Stoll et al. 2010). It is generally classified as early-onset or late-onset 
sepsis. Early onset reflects infection with organisms acquired before or during birth. 
Late onset occurs more than 72 h after birth and reflects nosocomial infection 
(Hornik et al. 2012). The incidence of neonatal sepsis is inversely proportional to 
gestational age and birth weight. Very low birth weight (VLBW < 1500 grams) 
represents 5 % of all births. Among VLBW neonates, culture-proven early onset 
sepsis is seen in 2% of neonates and late-onset in 25% (Hornik et al. 2012). 
CoNS are the most common cause of late-onset sepsis, being responsible for 
30-54% of all cases in some studies (Vergnano et al. 2011; Stoll et al. 1996; Stoll et 
al. 2002). Furthermore, central-line associated infections (CLABSI) are the most 
common risk factor for CoNS sepsis, particularly in the neonatal intensive care unit 
(NICU)(Milstone et al. 2013).  
Morbidity is a major issue due to the potential impairment on brain 
development (e.g white matter injury due to inflammation, hypoxia and ischaemia). 
Developmental delay and disability is increased among children that suffer from 
recurrent infection during the neonatal period (Glass et al. 2008). 
1.2.3- Staphylococcus aureus (SA) infections 	
Staphylococcus aureus (SA) colonises the skin and mucosa of about 30% of 
healthy humans, however, as opportunistic microorganism, it continues to be an 
important cause of serious health-care-associated and community-acquired infections 
worldwide (Wertheim et al. 2005). In the UK alone, around 9,100 cases are reported 
voluntarily each year with an associated mortality of about 29% (Public Health of 
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England 2014)(Wyllie et al. 2006). Its oxacillin-resistant form (MRSA) has been the 
most important cause of antimicrobial resistant healthcare-associated infection 
globally.  
Although current surveillance data from US and Europe indicate a decrease in 
the incidence of healthcare-associated MRSA invasive infections compared to 
baseline data, MRSA remains a significant pathogen and a public health priority with 
high associated morbidity and mortality (Centers for Disease Control and Prevention 
2014; European Centre for Disease Prevention and Control 2015). This may be due 
to the intrinsic virulence of SA, to the sub-optimal antimicrobial therapy with 
important delays in the administration and to the increasing multi-drug resistance of 
strains displayed in the last decade. In addition, the evidence supporting an optimum 
management of SA bacteraemia is still poor and clinical practice is driven mainly by 
the results of observational studies as well as by educated guess.  
Taxonomy and classification 	
 SA belongs to the genus Staphylococcus and it represents almost exclusively 
the coagulase-positive diagnostic sub-group. The refined phylogenetic-diagnostic 
classification of staphylococcal species and subspecies proposed by Lamers et al. 
(Lamers et al. 2012) shows its location within the genus. See Figure 1.2. 
Molecular-based epidemiologic studies have revealed that 5 major MRSA 
clones account for near a 70% of hospital MRSA isolates worldwide (Iberian, 
Brazilian, New York-Japan, Hungarian and Paediatric)(Oliveira et al. 2002). The 
epidemiological factors that contributed to the dissemination of only a few MRSA 
clones are not yet well elucidated. In Europe, MRSA isolates that cause invasive 
infections are less diverse than invasive MSSA isolates and MRSA spa types (small 
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region of one gene typed) have a predominant geographic distribution within distinct 
clusters of health networks (Grundmann et al. 2010).  
Pathogenesis and virulence of SA 	
 The ability of SA to cause invasive and/or severe infection depends upon a 
large variety of virulence factors to enable adherence, aggression, invasion, 
persistence and/or evasion of the immune system, often located on mobile genetic 
elements that are transferred horizontally through the SA population. Adherence to 
surfaces and phases of biofilm formation is a common first critical event in 
establishing colonization and/or infection among staphylococci. The additional 
phases of the process are shared with the CoNS microorganisms as detailed above. 
A number of genes both in the SCC-mec region and outside this region, have 
been identified in complicated infections, including bacteriophage-encoded genes, 
such as regulatory factors and autolysins, with likely roles in tissue adhesion and 
biofilm formation (Gill et al. 2011). In addition, molecular connections between 
virulence and antibiotic resistance have been found with the newly identified psm-
mec gene that encodes for a phenol soluble modulin (a-type PSM) with significant 
cytolytic and immune evasion capacity within the SCCmec region, so far believed to 
be encoded in the core genome of the bacterium (Queck et al. 2009).  
 Compared to CoNS, SA is characterized by high aggressiveness that involves 
not only a wide array of cytolytic toxins, but also pyrogenic toxin superantigens 
(PTSAgs) and exfoliative toxins, such as the toxic shock syndrome toxin 1 (TSST-1) 
that contribute to poorer clinical outcomes and mortality in SA bacteraemia (Maeda 
et al. 2016). A further strategy of SA to evade the host response are the small-colony 
variants (SCVs), a well described adapted phenotype of SA that confer intracellular 
persistence and antibiotic-refractory infections (Tuchscherr et al. 2010). Several lines 
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of research are currently centred in further understanding the association between 
virulence factors, pathogenesis and antimicrobial resistance in SA infections with the 
aim of improving the existing control and therapy measures, including vaccination 
and disease prevention. 
Clinical significance of SA infections in the child 	
 The clinical spectrum of SA infection in children ranges from asymptomatic 
nasal carriage to skin and soft tissue infections (SSTIs), osteomyelitis, septic 
arthritis, infective endocarditis, bacteraemia, sepsis and death (Kaplan 2016; McNeil 
et al. 2016). Colonization is an important factor in the pathogenesis of infections 
caused by SA. Children are particularly susceptible to colonization with prevalence 
as high as 56.7% depending on the age group, being higher in the young infant 
population (Regev-Yochay et al. 2009; Williamson et al. 2016). They also present 
with a pattern of persistent colonization and constitute the main vectors in 
disseminating SA throughout the community and in the hospitals (Williamson et al. 
2016). As opposed to CoNS, a single positive blood culture for SA should always be 
defined as clinically significant, given the intrinsic pathogenicity of SA and the high 
number and frequency of complications following SA bacteraemia (Naber et al. 
2009). 
SA infections in the neonate and infant 	
Invasive SA bloodstream infections in the neonate and infant, particularly in 
the pre-term infant, present with a wide range of serious complications: brain or 
visceral abscesses, meningitis, orbital cellulitis, osteomyelitis, septic arthritis, 
endocarditis, pneumatoceles and lung abscesses, septic ileus, septic shock and death 
(Healy et al. 2004). Interestingly, community-associated MRSA strains have also 
emerged in the past decade as an important cause of LOS in the NICU with even 
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greater morbidity and mortality than hospital-associated strains, despite appropriate 
therapy (Healy et al. 2004). 
In addition, prospective neonatal data for VLBW infants (<1500 g) has 
showed that mortality from MRSA versus MSSA bacteraemia and/or meningitis is 
high with both MRSA (26%) and MSSA infections (24%). Thus, the authors 
recommend that in this special population, the efforts in infection prevention and 
control should not only be focused in MRSA but also in MSSA screening and 
isolation as they have equivalent morbidity and mortality (Shane et al. 2012). 
 
1.3- TREATMENT, MANAGEMENT AND DRUG RESISTANCE PATTERNS 
OF STAPHYLOCOCCAL BLOODSTREAM INFECTIONS IN CHILDREN 
(CoNS AND SA) 
1.3.1- Treatment and management of CoNS infections (bacteraemia) 	
Several factors need to be taken into account for the appropriate management 
of CoNS infections and these are: the species (S.epidermidis group vs S.lugdunensis 
vs S.saprophyticus), the site of infection, the patient´s immune status and the 
presence of an inserted medical device. Glycopeptide therapy, with vancomycin or 
teicoplanin, represents the mainstay of antibiotic therapy, given the high rates of 
methicillin resistance, 70-92% in some studies (Krediet et al. 2004). Co-trimoxazole, 
if the isolate is susceptible, or newer antibiotics such as daptomycin, linezolid or 5th 
generation cephalosporins also constitute possible alternatives. For MS-infections, b-
lactamase-resistant penicillins or cephalosporins (1st or 2nd generations) can be 
appropriate.  
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Combination therapy of agents with cell wall activity and rifampicin has been 
shown to be synergistic, although there is no randomized and/or extensive clinical 
evidence to support this. For instance, the persistence of CoNS bacteraemia in 
neonates (³5 days of positive blood cultures despite appropriate antibiotic therapy) 
has been shown to respond successfully to the addition of iv rifampicin to 
glycopeptides in small case series (Tan et al. 1993; Shama et al. 2002). 
For infections caused by S.lugdunensis there is a paucity of controlled clinical 
data to inform its most effective antimicrobial therapy. b-lactamase-resistant 
penicillins and 1st/2nd generation cephalosporins might be appropriate in the 
empirical treatment. In the case of infective endocarditis by this pathogen, supportive 
therapy is also necessary (e.g valve replacement)(Liu et al. 2010). Likewise, the case 
of uncomplicated UTI caused by S.saprophyticus (subspecies saprophyticus) might 
be appropriately treated with co-trimoxazole, however, duration of therapy is 
considered to be more appropriate for 7 days rather than 3 days as per the case of 
other causative pathogens (Guay 2008). 
In the context of foreign body and/or catheter related infections, the decision 
to remove the intravascular catheter or initiate empirical therapy while trying to 
salvage the device, is still a matter of debate and a therapeutic challenge, particularly 
in the paediatric and neonatal population. For example, a cohort study conducted in 
148 infants with central venous catheter (CVC) and positive blood cultures caused by 
CoNS, the early removal of the CVC (within 3 days of diagnosis) and treatment with 
vancomycin alone, achieved eradication of bacteraemia. If early removal was not 
possible, eradication of bacteraemia was possible in 46% of neonates with 
vancomycin alone and late removal. If bacteraemia lasted longer than 4 days, 
eradication was not possible without CVC removal (Karlowicz et al. 2002a). In 
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another study, retrospective in nature, looking at 72 neonates with CoNS CLABSI, 
the successful treatment and salvage of the catheter was possible in 51.3% of 
patients. However, the longer the bacteraemia was (> 4 positive blood cultures), the 
greater the risk of having deleterious clinical outcomes (end organ damage and 
death)(Benjamin et al. 2001). 
 In order to save the CVCs, a systematic literature review reported the 
supportive role of associated antibiotic lock therapy for both preventing and treating 
CLABSIs (Segarra-Newnham & Martin-Cooper 2005). A prospective randomized 
controlled trial in 85 critically ill pre-term neonates, also showed the advantage of 
vancomycin lock therapy (25 µg/mL) as prophylaxis in reducing the incidence of 
CLABSI (Garland et al. 2005). In summary, biofilm formation associated to inserted 
medical devices, reduces the efficacy of antibiotics while increasing considerably 
their MICs due to their impaired penetration. If CVC removal is clinically possible 
and is performed early, a short course of antibiotic therapy (5-7 days) is sufficient, 
however, if the line is retained, longer systemic and lock therapy for 10-14 days 
should be provided (Mermel et al. 2009). Nonetheless, there is no preferred choice 
established due to the lack of controlled clinical data. 
 Finally, prosthetic joint infections caused by staphylococci require longer 
courses of therapy (2-6 weeks) after debridement and retention of the prosthesis, 
followed by longer oral courses. IDSA recommends either 1st/2nd generation 
cephalosporins or b-lactamase-resistant penicillins if MS-isolates, but vancomycin is 
the antibiotic of choice in the case of MR-staphylococci. Alternatives are 
daptomycin, linezolid or combination therapy with rifampicin (Mermel et al. 2009). 
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1.3.2- Treatment and management of SA bacteraemia 	
Currently, UK and US guidelines suggest that uncomplicated SA and MRSA 
bacteraemia (a positive blood culture and exclusion of endocarditis, no implanted 
prostheses, defervescence within 72 hours of therapy, negative follow-up blood 
cultures 2-4 days after initial set and no evidence of metastatic sites of infection) 
should be treated with vancomycin for a minimum of 14 days, and for 4-6 weeks if 
there is a deep infectious focus (Gould et al. 2009; Mermel et al. 2009; Liu, Bayer, 
Cosgrove, Daum, Fridkin, Gorwitz, Kaplan, Karchmer, Levine, Murray, Rybak, D. 
A. Talan, et al. 2011). There is strong evidence to suggest that prompt removal or 
drainage of medical devices/ infected foci improves outcome (Thwaites et al. 2011). 
In children, duration may range from 2-6 weeks depending on source, 
presence of endovascular infection and metastatic foci of infection. Glycopeptide 
therapy, namely vancomycin and teicoplanin are the agents of choice. Data regarding 
the safety and efficacy of alternative agents in children are limited, although 
daptomycin 6-10 mg/kg/dose iv once daily may be an option. Clindamycin and 
linezolid may be considered but should not be used if there is concern of infective 
endocarditis or endovascular source. Finally, the decision to use combination therapy 
with rifampicin or gentamicin should be individualized, although the addition of 
gentamicin to vancomycin in adults is not recommended (Liu, Bayer, Cosgrove, 
Daum, Fridkin, Gorwitz, Kaplan, Karchmer, Levine, Murray, Rybak, D. A. Talan, et 
al. 2011). 
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1.3.3- In vitro susceptibility testing 
Phenotypic approaches 	
Antimicrobial susceptibility testing for staphylococci is based on the 
reference methods of the Clinical and Laboratory Standards Institute (CLSI) and the 
European Union Committee for Antimicrobial Susceptibility Testing (EUCAST). 
Phenotypic-based approaches have reduced sensitivity and specificity for the 
determination of methicillin-resistance in CoNS and SA due to the hetero-resistance 
phenomenon. Applying cefoxitin as a disk diffusion test to grown cultures has 
overcome many of the associated issues. 
Susceptibility testing for glycopeptides is method dependent. The standard 
method should be broth microdilution (Leclercq et al. 2013). In contrast, the disk 
diffusion method is unable to distinguish between the wild-type phenotype and those 
isolates with non vanA-mediated resistance. GISA (glycopeptide-intermediate 
resistance SA) infections are not treatable with high doses of glycopeptides, 
therefore, the EUCAST reduced the resistance breakpoint to 2 mg/L in order to avoid 
GISA isolates being reported as susceptible. Thus, there is no difference in reporting 
GISA/VISA and GRSA/VRSA isolates. A modified population analysis profile-
under the curve (PAP-AUC) has been described for reporting hetero-resistance in 
glycopeptides, but this is not practical in routine use, so several screening assays 
have been developed, particularly for SA, such as the macro-Etest method, also 
applied in CoNS (S.epidermidis and S.haemolyticus)(Ahlstrand et al. 2011). 
 
Nucleic acid detection-based approaches 	
For the detection of MRSA for screening and surveillance purposes, there are 
rapid PCR-based methods, however, these do not exist for MR-CoNS. Nonetheless, 
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in-house PCR approaches exist for CoNS that cover the methicillin-resistance 
determination, species identification and for even biofilm formation gene detection 
(Iorio et al. 2011). 
Recently, a rapid test to detect methicillin-resistance in SA through the 
PBP2a antigen has been introduced in a paediatric hospital for the rapid and accurate 
diagnosis of skin and soft tissue infections (Yu et al. 2016). 
 
1.3.4- Antimicrobial resistance in Staphylococci to current treatment options 
A continuous increasing loss of susceptibility towards most of the available 
antibiotics has been reported for CoNS over the past decades. CoNS are thought to 
represent an important reservoir of genetic elements, mobile by nature, that lead to 
resistance not only to b-lactams, but also to other antibiotic classes and may be 
transferred into medically significant staphylococci, both coagulase-negative and 
positive species.  
In recent years, CLSI and EUCAST have reduced susceptibility breakpoints for 
CoNS (with the exception of S. lugdunensis) and SA, therefore, susceptibility 
categories of older studies may underreport resistance among CoNS populations 
(Clinical and Laboratory Standards Institute 2012; European Committee on 
Antimicrobial Susceptibility Testing 2015). 
 
Resistance to b-lactamase activity 	
This phenotype is caused by penicillinases, which represent mainly plasmid-
mediated (also chromosomally-mediated) staphylococcal b-lactamase encoded by 
the blaZ gene (Olsen et al. 2006). Penicillinases show specificity for penicillins and 
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act via hydrolysis of the b-lactam ring. Shortly after the introduction of the first 
penicillinase-stable penicillin as a therapeutic agent in the early 1960s, about a 10% 
of S. epidermidis isolates tested resistant to methicillin (“calbenin” or “staphcillin”). 
Subsequently, dramatic increases in the percentage of resistant isolates have been 
noted, particularly for the isoxazyl-penicillins and/or penicillinase-stable b-lactams, 
but also for ciprofloxacin, clindamycin, erythromycin, gentamicin, fusidic acid and 
rifampicin (Lyytikäinen et al. 1996; Kresken & Hafner 1999; Andrews et al. 2000). 
A significant correlation between % of methicillin resistance and usage of 
penicillinase-stable b-lactam agents has existed over the years (Lyytikäinen et al. 
1996). 
Nowadays, penicillin-susceptible S. epidermidis and S. haemolyticus occur 
very rarely (< 10%) among isolates recovered from hospitalized patients (Kresken et 
al. 2011). Testing for b-lactamase production in Staphylococci spp. is discouraged by 
the EUCAST due to this high prevalence of resistance to penicillins in most 
countries, as well as additional technical testing problems (Leclercq et al. 2013). 
Furthermore, the vast majority of clinical human CoNS isolates possess SCCmec 
(Staphylococcal Cassette Chromosome) elements as the main driver of resistance to 
b-lactams.  
Resistance to b-lactams by expression of an additional penicillin-binding protein 
(PBP) 	
In staphylococci, the expression of an additional PBP, designated PBP2a or 
PBP2´, leads to complete b-lactam resistance (penicillins, most cephalosporins and 
carbapenems), with the only exception of the recently introduced cephalosporins 
with MRSA activity, such as ceftobiprole and ceftaroline. This PBP2a is encoded by 
the mecA gene, part of a mobile genetic element called Staphylococcal Cassette 
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Chromosome (SCC)mec, and shows reduced binding affinity for b-lactam 
antibiotics, in contrast to the intrinsic set of staphylococcal PBPS 1 to 4 (Katayama 
et al. 2000).  
The molecular organization of this staphylococcal resistance to b-lactams is 
complex with a recognized increasing diversity of polymorphisms at the gene level 
within the SCCmec element and the large SCC family. To date, 11 types and several 
subtypes have been reported for the SCCmec element. In CoNS, SCCmec types III, 
IV and V, either alone or in various combinations, are the most prevalent types 
(Zong et al. 2011). Furthermore, there exists several mecA gene homologs, 32 unique 
alleles that clusters into 4 distinct branches (mecA, mecA1 and 2, mecB and mecC). 
The branch that contains the “classical mecA gene” involves the vast majority of 
methicillin-resistant CoNS (MR-CoNS) and the common MRSA lineages. The 
cassette (SCCmec) is constituted of three main elements: 1) the mec gene complex, 
2) the ccr gene (cassette chromosome recombinase) complex and 3) the joining 
“junkyard” or J regions, each of those comprising additional virulence and resistance 
genes. To describe a MR-CoNS or MRSA strain in terms of its SCCmec 
composition, a complex nomenclature has been established by the International 
Working Group on the Classification of Staphylococcal Cassette Chromosomal 
Elements (International Working Group on the Classification of Staphylococcal 
Cassette Chromosome 2009). 
The percentage of MR-CoNS has continuously increased with prevalence of 80% 
or more (Kresken et al. 2011; Sader & Jones 2012; Gordon et al. 2012). In addition, 
MR-CoNS are, in general, more often multi-resistant than methicillin (oxacillin)-
susceptible isolates (Natoli et al. 2009). 
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Resistance to glycopeptides, lipopeptides and lipoglycopeptides 	
The exact mechanism of glycopeptide resistance among CoNS is still unknown.  
There are three phenomena leading to glycopeptide therapy failure that have been 
postulated in staphylococci (mostly in SA): 
1.-The development of vancomycin-intermediate SA (VISA) isolates and the 
recognized precursor subpopulations named hetero-resistant VISA (h-VISA), 
identified in 1996 (Hiramatsu, Hanaki, et al. 1997). Since, these isolates can also be 
resistant to teicoplanin, the term glycopeptide-intermediate SA (GISA and h-GISA) 
is also used. Their complex resistance mechanisms include cell wall alterations 
(reorganization and thickening) and reduced autolytic activity (Cui et al. 2006; 
Boyle-Vavra et al. 2001; Howden et al. 2010). Cell wall thickening has also been 
reported for CoNS (S. epidermidis and S. haemolyticus)(D Sanyal & Greenwood 
1993; Biavasco et al. 2000). Glycopeptide-resistant CoNS may have an excess of 
glycopeptide binding sites due to the overproduction of peptidoglycan in the bacteria 
cell wall (Biavasco et al. 2000). Thus, the basic mechanisms leading to glycopeptide 
resistance, although highly heterogeneous, appear to be similar between CoNS and 
SA. 
2.-The development of VRSA isolates. The first vancomycin-resistant SA (also 
glycopeptide-resistant strains) VRSA and GRSA, containing the gene vanA was 
isolated in 2002 in US (Centres for Disease Control and Prevention (CDC) 2002). 
Although the acquired vancomycin-resistance determinants (vanA, vanB, vanD, 
vanE, vanF and vanG) had been reported from vancomycin-resistant enterococci 
(VRE), this was the first time that these determinants were isolated in SA(Woodford 
2001). The presence of vanA in this VRSA was suggested to have been acquired 
through exchange of genetic material from the VRE also isolated from the same 
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patient. Conjugative transfer of the vanA gene from enterococci to SA had been 
demonstrated previously in vitro and in vivo (Noble et al. 1992). In Europe, the first 
case of infection with VRSA occurred in Portugal in 2013 in 74-year old woman 
who underwent amputation of two gangrenous toes-isolated from the pus of the toe 
amputation wound. The vancomycin and teicoplanin MICs were >256 and 24 mg/L, 
respectively. The strain was sequence type ST105, SCCmec type II and harboured 
the mecA and vanA genes. The concomitant isolation of VRE (Enterococcus 
faecalis) suggested the possible source of the vanA gene for the acquisition of the 
vancomycin resistance, similarly to the cases reported previously in the US (Melo-
Cristino et al. 2013). 
In CoNS, the implications of a recent report on highly vancomycin resistant 
strains (MIC³ 256 mg/L tested by Etest) recovered from the saliva of migratory birds 
in Kansas and harbouring van genes is unknown (Ishihara et al. 2013). A recent 
observation of 3 S. epidermidis isolates containing the vanA and vanB1 genes within 
a collection of 30 isolates from ICU patients in Kampala (Uganda) warrants also 
further evaluation (Okee et al. 2012). 
3.-The so-called phenomenon “Vancomycin MIC creep”. This event describes 
a population drift in clinical SA isolates towards reduced vancomycin susceptibility, 
but with MICs values that are still below the susceptibility breakpoint (Steinkraus et 
al. 2007; Wang et al. 2006). However, it is still a matter of debate as there are other 
several studies that have not shown any changes or reductions on the vancomycin 
MICs over time (Holmes & Jorgensen 2008; Musta et al. 2009). To date, there have 
not been reports of vancomycin MIC creep in CoNS, although there is a high and 
increasing prevalence of heterogeneous glycopeptide intermediate resistance  
(hGIS)(Ahlstrand et al. 2011). 
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The following table summarizes the reports on glycopeptide (teicoplanin and 
vancomycin) resistance or reduced susceptibility among staphylococci recovered 
from patients with descriptions on their likely underlying mechanism(s). 
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Study Study 
Characteristics 
Isolates MIC90 /Range 
(method)  
% Resistance  
(total number) 
Mechanism Notes 
(Schwalbe 
1986) 
Case report of a 
patient with 
diabetes and end-
stage renal disease 
with repeated 
episodes of 
peritonitis caused 
by CoNS (with 
CAPD) 
S.haemolyticus  
(2 or 3 different 
isolates-out of 
8 recovered- 
according to 
biochemical 
patterns) from 
peritoneal fluid 
Teicoplanin: 8-64 mg/L 
Vancomycin: 2-8 mg/L 
(microdilution procedure 
with modifications) 
(NCCLSI) 
NR -The authors 
suggest that CoNS 
have the ability to 
acquire vancomycin 
resistance.  
-Mechanism is not 
clear. 
-Stepwise increase in 
vancomycin resistance 
from MICs of 2 to 8 
mg/L over 88 days of 
vancomycin therapy. 
-Teicoplanin was 
ineffective in a 
uniform way and no 
stepwise resistance 
was seen.  
(Goldstein 
et al. 1990) 
Investigation of the 
activities of 
teicoplanin and 
vancomycin 
against CoNS 
during 
Nov 1988-April 
1989 
CoNS (n= 362 
clinical 
isolates) 
S.epidermidis 
(74%) 
S.haemolyticus 
(19%) 
Teicoplanin:0.5-32 mg/L 
Vancomycin: 0.5-8 mg/L 
(Agar dilution method, 
CLSI)  
Teicoplanin: R: 1.7% and 23.2% 
intermediate R 
Vancomycin: < 0.3% R 
 
Interpretative criteria NCCLSI for 
vancomycin breakpoints (applied to 
teicoplanin in this study): S £4, I: 8-16 
and R ³32 mg/L) 
NR Most of the teicoplanin 
resistant strains were 
isolated from patients 
with no previous 
exposure to 
teicoplanin or 
vancomycin 
(Sanyal et 
al. 1993a) 
 
Study of the in 
vitro characteristics 
of glycopeptide-
resistant strains 
through passage in 
glycopeptide-
containing and free 
broth 
3 isolates of 
S.epidermidis 
isolated from 
the peritoneal 
fluid of two 
patients on 
CAPD from the 
same renal unit. 
Patients were 
previously 
exposed to 
vancomycin. 
Teicoplanin: 32 mg/L 
Vancomycin: 4-32 mg/L 
(Broth dilution method) 
Teicoplanin: R 100% 
Vancomycin: R 33.3%, I: 33.3%, S: 
33.3% 
 
Interpretative criteria NCCLSI for 
vancomycin breakpoints (applied to 
teicoplanin in this study): S £4, I: 8-16 
and R ³32 mg/L) 
Constitutive 
resistance (not 
inducible) and not 
increased by 
passage in the 
presence of 
vancomycin or 
teicoplanin. 
Resistance 
phenotype stable 
(after 25 sequential 
sub-cultures) 
- There was a loss of 
antibiotic effect when 
cultures were exposed 
to sub-MIC 
concentrations and 
grew to stationary 
phase, more marked 
for teicoplanin. The 
authors suggest this 
could be due to an 
increased capacity of 
the cell wall of 
resistant strains to bind 
to glycopeptides (at 
sites other than D-
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alanyl-D-alanine target 
site). 
(Hiramatsu, 
Aritaka, et 
al. 1997) 
The prevalence of 
VRSA (Mu50) and 
Mu3-like strains 
(MIC 3 mg/L) was 
investigated in 203 
hospitals in Japan 
-1149 MRSA 
isolates from 
Japanese 
hospitals 
-h-VRSA vancomycin 
MIC range (1-4 mg/L) by 
NCCLS method. 
MICs were determined 
with BHI agar plates and 
1mg/L vancomycin 
increments (1-10 mg/L)-
concentration able to 
inhibit 5x105 CFU/mL 
after 16 h incubation- and 
compared with micro-
broth dilution by NCCLS 
method. 
-Only 1 strain/1149 (N20) in addition to 
Mu50 had a vancomycin MIC of 4 
mg/L (NCCLS method). This strain 
produced subclones with a vancomycin 
MIC of 8mg/L at a high frequency of 
10-4  
-A 2.96% (34/1149) was h-VRSA, able 
to grow sub-populations in the presence 
of vancomcyin 8 mg/L  
 
-The authors 
suggest that 
vancomycin 
resistance of VRSA 
appears to be 
achievable without 
the acquisition of 
extrinsic genes, by 
two-step drug 
selection of 
originally 
vancomcyin 
susceptible MRSA 
of clonotype II-A in 
Japan. 
-PFGE pattern similar 
in Mu50 and the h-
VRSA strains with 
clonotype II-A (about 
a 70% of all MRSA 
strains in Japan in the 
90´s), characterized by 
the production of 
coagulase type-2 and 
TSST-toxin-1. 
(Sieradzki 
et al. 1998) 
Single-hospital 
study during a 5-
month period 
(between 1995-
1996) to 
investigate 
decreased 
susceptibilities of 
teicoplanin and 
vancomycin 
against CoNS 
41 MR-CoNS 
-24 different 
patterns in 28 
isolates tested 
for clonality. 
-Most of the 
isolates were 
suspected to be 
involved with 
infection 
 
Teicoplanin: 4-16 mg/L 
after 48 h  
8-32 mg/L after 72h 
Vancomycin:2-4 mg/L 
(Standard broth 
microdilution method-
CLSI) 
 Teicoplanin: 68.3% low-level R 
(28/41) 
Vancomycin:0% R but heterogeneous 
subpopulations could grow on cultures 
containing 6-12 mg/L of vancomycin. 
 
- Sub-MIC 
teicoplanin 
concentrations 
produced: 
inhibition of 
autolysis and 
formation of 
cellular aggregates, 
which disintegrates 
in the stationary 
phase to individual 
bacteria, with 
removal of 
antibiotic, similarly 
-S. epidermidis (n=5) 
and S.haemolyticus 
(n=1) (ATCC strains, 
n=2 from the pre-
glycopeptide era) were 
also used for PAPs 
experiments, showing 
all homogeneous 
susceptibility to 
vancomycin but 
heterogeneous reduced 
susceptibility to 
teicoplanin, suggesting 
species intrinsic 
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to what has been 
previously 
described in 
vancomycin R 
MRSA. 
 
resistance phenotypes 
in the latter. 
(Tacconelli 
et al. 2001) 
One year 
prospective case-
control study (1:3) 
to assess the 
incidence, risk 
factor and 
genotypic patterns 
of glycopeptide-
resistant CoNS 
bacteraemia 
535 CoNS 
isolates from 
BSI: 
S. epidermidis 
(70%), S.hominis 
(12%), 
S.haemolyticus 
(9%), S.capitis 
(9%), S.warneri 
(2%), other CoNS 
(1%) 
No MIC range reported. 
Broth microdilution 
(NCCLSI) and Etest 
Teicoplanin resistance 
defined as an MIC³ 18 
mg/L and for vancomycin 
MIC³ 8 mg/L 
Teicoplanin R: 3.5% (19/535) R  
Both teicoplanin and vancomycin R: 
0.19 %(1/535)  
Glycopeptide R: 3.7% (20/535);  
MR-CoNS: 69.5%  
NR 
 
-Different patterns 
with a high degree of 
polymorphism 
(ribotyping and 
computer analysis of 
fingerprinting) 
-Previous exposure to 
b-lactams and 
glycopeptides, 
multiple 
hospitalization and 
concomitant 
pneumonia were the 
risk factors of 
glycopeptide 
resistance CoNS BSI. 
(Arias et al. 
2003) 
Multi-centre 
prospective 
surveillance of 
antimicrobial 
resistance in 
enterococci and 
staphylococci in 
Colombian 
hospitals (2001-
2002) 
Isolates: 
-CoNS (177) 
-SA (296) 
-MRSA (155) 
-MSSA (141) 
from clinical 
samples 
Teicoplanin/Vancomycin: 
-0.12-4 / 0.12-4 mg/L 
-0.06-4/ 0.25-4 mg/L 
-0.06-4/2-6 mg/L 
-0.25-4/0.25-4 mg/L 
(Agar dilution method: 
NCCLSI) 
 
Both teicoplanin and vancomycin: 
-0% 
-0% 
-0% 
-0% 
-Oxacillin-R: 73% 
NA -All isolates were 
investigated with PCR 
multiplex assay for the 
detection of the mecA 
gene. 
-All MRSA isolates 
were screened for 
VISA 
-In enterococci, 
resistance to 
glycopeptides was 9.7 
% (presence of 
vanA:58.3% and 
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vanB: 41.7% genes) 
(Cui et al. 
2003) 
Investigation of 
cell wall thickness 
in clinical VRSA 
strains through 
daily passage in 
drug-free and 
vancomycin 
containing 
medium. 
-16 strains of 
clinical VRSA 
from 7 
different 
countries 
-48 strains 
underwent cell 
wall thickness 
and MIC 
determination 
-Initial MIC range of 
parental strains: 
-Vancomycin: 1-10 mg/L 
-Teicoplanin: 2-29 mg/L 
-Imipenem: 1-64 mg/L 
-Oxacillin: 0.25-1024 
mg/L 
(MIC test done with BHI 
agar and 1 mg/L of drug 
increments, except for 
oxacillin, where they 
used conventional 2-fold 
dilution) 
-From subcolonies of passage-derived 
strains grown on plates containing 4 
mg/L vancomycin:  
-Vancomicn MIC range 5-9 mg/L with 
a frequency of 4.25x10-6 to 1.64x10-3  
-Teicoplanin MIC: 6-32 mg/L 
-Imipenem: 1-64 mg/L 
-Oxacillin: 1-512 mg/L 
 
*(Association between the conversion 
of VSSA to h-VRSA with hetero-to 
homoconversion of MR-caused by b-
lactam selection) 
-Cell wall thickness 
may be a 
phenotypic 
determinant for 
vancomycin 
resistance in SA. 
-The authors also 
suggest that the use 
of b-lactams in 
MRSA infection 
might be a risk 
factor for the 
emergence of h-
VRSA, but the 
mechanism remains 
unclear*  
-All of the VRSA 
strains had thickened 
cell walls, which 
became thinner with 
the loss of vancomycin 
resistance and 
decreased MICs after 
drug-free passages but 
became thick again (all 
except one of the 
parent strain passage-
derived) after 1 step of 
vancomycin passage. 
(Trueba et 
al. 2006) 
 
 
 
 
 
 
 
 
 
Retrospective 4-
year (2000-2004) 
study of all 
staphylococci 
collected in the 
laboratory from 
clinical samples 
N=2476 
staphylococci 
-CoNS (1039): 
-S.epidermidis 
(60.8%), 
S.haemolyticus 
(9.9%),  
-S.hominis 
(13.2%),  
-other CoNS 
(16.1%) 
-SA(1437) 
AST method (French 
Society of Microbiology): 
10 µl of 6x108 CFU/mL 
on MH agar plates with 5 
mg/L teicoplanin. 
Readings made after 24h 
at 37ºC. 
Teicoplanin resistance 
MIC > 8mg/L. 
2000 
 
 
7.2% 
 
17.9% 
 
9.5% 
 
4% 
 
2.8% 
2001 
 
 
17.2% 
 
25% 
 
7.4% 
 
10.3% 
 
1.3% 
2002 
 
 
35.2% 
 
55.5% 
 
21% 
 
14.6% 
 
0.9% 
2003 
 
 
46.1% 
 
31.2% 
 
20.9% 
 
5.9% 
 
0.9% 
2004 
 
 
30.4% 
 
35.7% 
 
14.8% 
 
8.7% 
 
1.2% 
NR 
-Co-resistance with 
ciprofloxacin 
occurred in 60% of 
the S. epidermidis 
strains 
-The authors do not 
relate the marked rise 
of teicoplanin 
resistance among S. 
epidermidis isolates 
with spread of any 
predominant clones or 
with teicoplanin 
consumption.  
(Kratzer et 
al. 2007) 
In vitro study of 
the activity of 
daptomycin and 
N= 105 CoNS 
strains from 76 
bone marrow 
Vancomycin MIC90= 2 
mg/; Daptomycin: 0.25 
mg/L; Tigecycline: 0.5 
-All strains were susceptible to 
daptomycin, tigecycline and 
fosfomycin. 
NR  
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tigecycline 
compared to 
vancomcyin and 
fosfomycin (strains 
collected from 
2000-2006) 
transplant 
patients with 
BSI (n=102 
S.epidermidis, 
n=3 
S.haemolyticus) 
mg/L; Fosfomycin: >250 
mg/L 
(CLSI method) 
(Kuti et al. 
2008) 
PD study of 
glycopeptide 
exposures against 
clinical isolates of 
staphylococci 
collected from 
hospitals in Brazil 
(2003-2005) 
Isolates: 
-SA (119) 
-MSSA (79) 
-MRSA (40) 
-CoNS (82) 
-MS-CoNS (8) 
-MR-CoNS (74) 
 
Teicoplanin/Vancomycin 
0.25-4/1-4 mg/L 
0.25-4/1-2 mg/L 
0.5-4/ 1-4 mg/L 
0.5-64/1-4 mg/L 
1-8/1-2 mg/L 
0.5-64/1-4 mg/L 
(Etest and interpreted 
according to CLSI: R³32 
mg/L for CoNS 
teicoplanin and 
vancomycin and I: 4-8, 
R³ 16 for SA for 
vancomycin) 
Teicoplanin/Vancomycin R: 
-0%/ I:0.8% 
-0%/ 0% 
-0%/ I: 2.5% 
-3.7%/0% 
-0%/0% 
-4.1%/0% 
*90.2% MR-CoNS 
NR -Linezolid showed to 
have a greater 
probability of attaing 
the PD target 
(AUC/MIC > 82.9) 
than teicoplanin and 
vancomycin did 
(AUC/MIC > 345) 
against staphylococci. 
(Hope et al. 
2008) 
Multi-centre 5-year 
study involving 25 
hospitals in UK 
and Ireland, each 
collecting up to 10 
consecutive 
isolates of both SA 
and CoNS per year 
-SA (1448) 
-MSSA(840) 
-MRSA (608) 
-CoNS (1214) 
-MS-CoNS 
(401) 
-MR-CoNS 
(813) 
Teicoplanin/Vancomycin: 
-0.5-8/0.5-4 mg/L 
-0.5-16/0.5-4 mg/L 
 
-0.12-32/0.5-4 mg/L 
 
-0.12-32/0.5-8 mg/L 
Teicoplanin: 
-0% R 
-0.2% R 
 
-1.5% R (7.6% Intermediate R) 
 
-3.1% R (23.4% Intermediate R), only 
one strain with vancomycin 
intermediate resistance, MIC 8 mg/L 
NR 
-Thirty-four CoNS 
isolates from 2006 
(17%) had the 
mupA (not sought 
before) gene and 
only two isolates 
lacked the mecA 
gene. 
-The prevalence of 
MR-CoNS (about a 
70%) was strongly 
associated with multi-
resistance, particularly 
with ciprofloxacin, 
clindamycin, 
rifampicin, teicoplanin 
and trimethoprim. 
(Natoli 
2009) 
Hospital 
microbiological 
records reviewed 
to identify reduced 
susceptibility to 
glycopeptides 
-CoNS (1609) 
isolates from 
patients with 
BSI in ICU and 
haematological 
transplant 
 Teicoplanin MIC range: 
- 2-16 mg/L (in transplant 
ward isolates) 
- 4-32 mg/L (ICU wards) 
Vancomycin MIC range: 
-2-4 mg/L in both wards 
-5.4% of CoNS (87/1609) showed 
reduced susceptibility to glycopeptides 
and of those,  
-Only 5.7% of the total (92/1609) and 
14.9% of those with reduced 
glycopeptide susceptibility (13/87) 
NR 
-Strains were 
induced to express 
glycopeptide 
resistance by 
culture on 
-Infections caused by 
CoNS with reduced 
glycopeptide 
susceptibility, 
represented 11% and 
20% of all CoNS-
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wards  
 
(EUCAST interpretative 
criteria, automated 
system and Etest) 
considered to be associated with 
infection (11 S.epidermidis and 2 
S.haemolyticus) 
-53.8 % of those associated with 
infection and reduced susceptibility, 
(7/13) showed a teicoplanin MIC ³ 8 
mg/L and all (13/13) vancomycin MIC³ 
2 mg/L 
 
 
vancomycin agar 
screen plates (CLSI 
and CDC 
guidelines) with 6 
mg/L of 
vancomycin. 
related BSI in 
haematology 
transplant ward and 
ICU, respectively in 
this study 
(Ahlstrand 
et al. 2011) 
 
Retrospective 
single-center study 
where all positive 
blood cultures with 
CoNS were re-
evaluated during 3 
decades for the 
presence of 
reduced 
susceptibility to 
glycopeptides 
Bloodstream 
isolates of 
S.epidermidis 
(387) and 
S.haemolitycus 
(19) from 
patients with 
haematological 
malignancies 
NR for teicoplanin/ For 
vancomycin median MIC 
2 mg/L 
(Standard Etest, 
macromethod Etest and 
GRD Etest) 
-31-45% hGIS (macromethod test) 
-53-67% (GRD Etest) 
NR - This study shown 
non-long term 
glycopeptide MIC 
creep as per standard 
Etest. 
 
(Karlowsky 
et al. 2011) 
In vitro activity of 
dalbavancin and 
telavancin against 
staphylococci and 
streptococci from 
patients in 
Canadian hospitals 
(2007-2009) 
Isolates 
-MSSA (1980) 
-MRSA (631) 
-MSSE (202) 
-MRSE (34) 
Vancomycin: 
-MIC90 1 (0.25-2) mg/L 
-MIC90 1 (0.5-4) mg/L 
-MIC90 2 (0.12-4) mg/L 
-MIC90 2 (1-2) mg/L 
CLSI method and 
interpretative criteria 
2016. 
Vancomycin R: 
0% 
0% 
0% 
0% 
NA The rank order of 
potency (based on 
MIC90 of glycopeptides 
against both SA and 
S.epidermidis was 
dalbavancin (0.06 
mg/L) >telavancin (0.5 
mg/L) > vancomycin 
(1-2 mg/L) 
(Guzek et 
al. 2013) 
Collection of 
staphylococci and 
enterococci strains 
from patients 
treated in the ICU, 
Isolates: 
-CoNS (37) 
-MSSA (89) 
-MRSA(24) 
-E.faecium (11) 
Teicoplanin/ Vancomycin 
0.094-8/0.75-2 mg/L 
0.19-2/0.5-2 mg/L 
0.38-1.5/0.38-1.5 mg/L 
0.094-0.5/0.38-1 mg/L 
-Teicoplanin 
-16.2% (6/37) 
-0% 
-0% 
-0% 
NR -In this study, 
teicoplanin exhibited 
greater clinical 
efficacy against 
enterococcal 
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surgical and 
Muskuloskeletal 
infection units of 
the Military 
Institute of 
Medicine 
(Warsow, Polonia) 
-E.faecalis (39)  
0.047-0.75/0.38-3 mg/L 
Etest and EUCAST 
interpretative criteria 
(teicoplanin R in CoNS> 
4mg/L, in SA >2 mg/L) 
 
-0% 
-All isolates were susceptible to 
vancomcyin 
infections, efficacy of 
vancomcyin nd 
teicoplanin against 
MRSA was 
comparable and 
vancomcyin displayed 
mora favourable MICs 
than teicoplanin 
against CoNS. 
(Sader et 
al. 2013) 
Study of the in 
vitro activity of 
ceftaroline against 
staphylococci from 
US hospitals with 
decreased 
susceptibility to 
linezolid, 
daptomycin or 
vancomycin (2008-
2011) 
-Isolates: 
-SA (19350) 
-MRSA (9875) 
*A 51% MR-
SA 
-CoNS (3270) 
-MR-CoNS 
(2268) 
*A 69.4% MR-
CoNS 
Vancomycin MIC90 
-1 mg/L 
-1 mg/L 
 
 
-2 mg/L 
-2 mg/L 
 
Resistance/decreased susceptibility 
among SA: 
-Linezolid: 0.07% (14 strains). MIC³8 
mg/L 
-Daptomycin: 0.09% (18). MIC³2 mg/L 
-Vancomycin: 1.9 % (369) MIC³2 
mg/L 
Resistance/decreased susceptibility 
among CoNS: 
-Linezolid: 1.6% (51 strains), MIC³8 
mg/L 
-Daptomycin:0.12% (4), MIC³2 mg/L 
-Vancomycin: NR 
NR Ceftaroline showed a 
potent in vitro activity 
against SA and MRSA 
(MIC90 1mg/L) and 
against CoNS isolates 
(MIC90 0.5 mg/L), 
including MR-CoNS 
(MIC90 0.5 mg/L), 
linezolid-resistant 
(MIC90 0.5 mg/L) and 
daptomycin non-
susceptible strains 
(MIC 0.03-0.12 mg/L) 
ATCC: American Type Culture Collection; BHI: brain heart infusion; BSI: Bloodstream infection; CAPD: Continuous Ambulatory Peritoneal Dialysis; CFU: Colony Forming 
Units; CDC: Centers for Disease Control; NCCLSI: former CLSI: Clinical and Laboratory Standards Institute; GRD: Glycopeptide resistance detection; ICU: Intensive Care Unit; 
MR: Methicillin-resistance; MS: Methicillin-susceptible; NR: Non-reported; NA: Non-applicable; R: resistance; S: Susceptible; I: Intermediate; PAP: population analysis profile; 
PCR: polymerase chain reaction; PFGE: Pulsed-field gel electrophoresis; TSST: Toxic shock syndrome toxin.  
Table 1.1- Glycopeptide (vancomcyin and teicoplanin) resistance or reduced susceptibility reports among staphylococci. 
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Daptomycin is a bactericidal lipopeptide that also targets the cell membrane of 
Gram-positive bacteria. Several mechanisms leading to resistance have been studied, 
mostly in SA, however, they have not been completely clarified. For instance, 
increased cell wall teichoic acid production and their D-alanylation with progressive 
cell wall thickening, may contribute to daptomycin resistance (Bertsche et al. 2013). 
In addition, several single nucleotide polymorphisms in various gene loci (e.g. the 
multipeptide resistance factor gene, mprF) have been identified (Friedman et al. 
2006). So far, daptomycin has exhibited potent activity against CoNS as it was 
shown in a multi-centre surveillance study with 42 countries involved, with more 
than 22.000 clinical isolates investigated over 9 years (2002-2010). In this study, 
daptomycin inhibited 99.8% of CoNS at £ 1mg/L (susceptibility breakpoint) and was 
up to 16-fold more active than vancomycin (Sader & Jones 2012). 
The lipoglycopeptides, dalbavancin, oritavancin and telavancin possess potent in 
vitro activity against staphylococci with lower MIC values than those of vancomycin 
and teicoplanin (Zhanel et al. 2010). To date, there has not been single-step, high 
level (frequencies < 10-10) dalbavancin, oritavancin or telavancin resistance. After 24 
passages of SA and S. haemolitycus at sub-MIC concentrations, dalbavancin MICs 
increased 2-fold for SA and 4-fold for S. haemolyticus, however the causes have not 
been fully elucidated (Kim et al. 2007). For oritavancin, despite the in vitro 
demonstration of moderate-level resistance (MIC £16 mg/L) among enterococci 
harbouring vanA and vanB genes (Arthur et al. 1999); there have not been cases of 
resistance among clinically isolated pathogens. In vitro, telavancin has shown a low 
incidence of spontaneous resistance among staphylococci and enterococci 
(Kosowska-Shick et al. 2009). 
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Resistance to oxazolidinones 	
For linezolid, three mechanisms have been elucidated that produce resistance in 
staphylococci: 1) accumulation of single point mutations in the 23S rRNA (domain 
V)-binding site in at least two copies of the rRNA gene operons; 2) more 
infrequently, mutations in the rplC and rplD genes in the peptide translocation centre 
of the ribosome, encoding the 50S ribosomal proteins L3 and L4, respectively and 3) 
acquisition of the plasmid-borne ribosomal methyl-transferase gene, cfr (Kloss et al. 
1999)(Pillai et al. 2002; Locke et al. 2009; Toh et al. 2007). The latter, cfr-mediated 
resistance is of serious concern due to its possible high horizontal transfer capability. 
For instance, a multi-centre outbreak of a cfr-containing linezolid resistance 
S.epidermidis has already been reported (Bonilla et al. 2010). Furthermore, an isolate 
of S.epidermidis was reported in Spain, after an outbreak of cfr-mediated linezolid 
resistant SA in the ICU, containing a concurrence of all three described mechanisms 
leading to linezolid resistance (Baos et al. 2013). Nonetheless, to date, linezolid 
resistance is rare but concerns are growing. 
Resistance to tetracyclines and glycylcyclines 	
The resistance to tetracyclines among staphylococci and other range of 
bacteria remains on the acquisition of mobile genes (tet and otr), which leads to 
ribosomal protection via the dissociation of the drugs from their ribosomal binding 
sites, and also to drug efflux via the active transportation of tetracyclines outside the 
bacterial cell (Connell et al. 2003; Butaye et al. 2003). There have been reports of 
tetracycline-resistant CoNS isolates, being higher the prevalence in MR-CoNS 
(18.6%) than in methicillin-susceptible ones (7.6%) (Flamm et al. 2015). 
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Tigecycline (minocycline derivative compound) represents a new class of 
glycylcyclines with bacteriostatic broad-spectrum activity that overcomes the 
development of resistance of classical cyclines, as it is not a substrate for tetracycline 
efflux pumps (Chopra et al. 2002). For staphylococci, the mechanism(s) of 
tigecycline resistance remains unknown, however, in vitro decreased susceptibility 
among MRSA has been reported through a novel family of efflux pumps (mepA) 
(McAleese et al. 2005). A year after the introduction of tigecycline, a surveillance 
multi-centre study carried out in Germany in 2007, reported on S. epidermidis (142 
isolates) and SA (308 isolates) susceptibility to tigecycline with MIC90 in the range £ 
0.125-0.5 mg/L. Only three isolates of S.haemolitycus (4.5% of S.haemolitycus) 
exhibited an MIC over the breakpoint (> 0.5 mg/L) (Kresken et al. 2009).  
Resistance to fusidic acid, fosfomycin and rifampin 	
These agents, although considered “old antibiotics” are increasingly being 
considered because of its still potent activity against Gram-positive (fusidic acid) or 
against both Gram-positive and Gram-negative bacteria (fosfomycin and rifampicin). 
However, they develop rapid resistance if used in monotherapy, therefore they are 
mainly used in combination, despite the lack of PK/PD evidence to support these 
strategies and basically being based on clinical experience. 
For fusidic acid, there exist spontaneous mutations in the fusA gene that 
dispose to an altered ribosomal translocase, the elongation factor G, which is the 
drug target for protein synthesis inhibition. A fusB mechanism has also been 
described for staphylococci that can be chromosomal or plasmid-mediated, and that 
encodes an inducible elongation factor G-protecting protein. Particularly, in SA and 
S.saphrophyticus, fusC and fusD homologs, respectively, have also been reported 
(O’Neill et al. 2007). In a multi-centre study in 13 European countries with a 
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collection of 3.134 staphylococci isolates, fusidic acid resistance (MIC³ 2 mg/L-
EUCAST) ranged between a 10.7% in SA strains (288/2700) to a 37.5% in CoNS 
isolates (155/434) (Castanheira, Watters, Mendes, et al. 2010). On a more global 
basis, a study including the US, Canada and Australia, among clinical staphylococci 
(n=4167 SA and n=790 CoNS), only a 1.7% overall displayed fusidic acid resistance. 
This was higher among CoNS ranging from 7.2% in US to 20% in Canada 
(Castanheira, Watters, Bell, et al. 2010). 
 Resistance to fosfomycin can be mediated by either chromosomal or plasmid-
borne mechanisms. Relatively little is known about chromosomally mediated 
resistance in Gram-positive bacteria (defects in the transport system that takes up 
fosfomycin-glpT or uhpT-)(Młynarczyk et al. 1985). In plasmid-mediated, fosA gene 
encodes a glutathione S-transferase that inactivates fosfomycin (Llaneza et al. 1985). 
In staphylococci, a homolog fosB has also been reported (Etienne et al. 1989). A 
Greek study from 2008 including 1846 Gram-positive bacterial isolates (disk 
diffusion method for susceptibility test), reported a 22.5% of CoNS (216/961) 
displaying in vitro resistance to fosfomycin. However, in this study only a 0.7 % of 
SA (3/419) including MRSA exhibited fosfomycin resistance (Falagas et al. 2009). 
 Rifampicin resistance in staphylococci is most frequently due, but not only, to 
point mutations in the regions of the rpoB gene, which encodes the b-subunit of the 
bacterial RNA polymerase and leading to aminoacid substitutions at or near the drug-
binding site (Tupin et al. 2010). In a Swedish study investigating the susceptibility 
among S.epidermidis isolated form prosthetic joint infections, approximately a 39% 
of isolates were resistant to rifampicin (MIC> 32 mg/L) and about a 15% of CoNS 
tested resistant in a multi-centre study in Colombia (Hellmark et al. 2009; Arias et al. 
2003). 
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Resistance to mupirocin 	
Reports on the increasing prevalence of high-level mupirocin resistance in CoNS 
reaching a 61% are of serious concern as this topical antibiotic is widely used in 
nasally colonized with MRSA patients. In addition, this resistance is mediated by 
plasmids carrying the gene mupA, which can be transferred to SA. These plasmids 
are also associated with genes encoding resistance to multiple antibiotics (Bathoorn 
et al. 2012; Lepainteur et al. 2013). Resistance to mupirocin in SA is also reported to 
be widespread in children. Routine mupirocin testing might be essential before 
MRSA decolonization strategies or the topical treatment of skin infections (Antonov 
et al. 2015). 
 Resistance to biocides and antiseptics 	
Biocides and antiseptics conform an important part of the infection control 
armamentarium, especially in the ICUs. In a recent study from a French neonatal 
ICU, a 41.2% of CoNS isolates recovered from CLABSIs in preterm neonates, 
presented reduced susceptibility to at least one used antiseptic (12% to chlorexidine; 
24% to benzoalkanium and 33% to acriflavine), which is of concern as several 
resistance determinants are located on plasmids and transposons with resistance 
genes encoding antibiotic resistance (Lepainteur et al. 2013). 
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1.4- PHARMACOLOGICAL APPROACHES TO OPTIMISE 
ANTIMICROBIAL THERAPY IN CHILDREN 
 
In the paediatric population, there is often suboptimal drug dosage 
information that does not take into account the developmental changes that influence 
drug disposition across childhood. Simplified dosing approaches and extrapolation 
from adult studies have been proved to be inadequate since they are based on 
assumptions around the idea that human growth is a linear process (Kearns et al. 
2003). There is surprisingly very little pharmacological data that supports regimens 
that are widely used in children and neonates. In addition, many doses in existing 
formularies, including the British National Formulary for Children, are dated from 
more than two decades ago and lacking evidence (BMJ Group, the Royal 
Pharmaceutical Society of Great Britain 2015b). As a consequence, inadequate or 
sub-therapeutic dosing could lead to increased preventable drug-related toxicity or 
ineffective treatment with the subsequent potential for developing antimicrobial 
resistance.  
Neonates and children have important differences when compared to adults in 
terms of drug absorption, disposition, metabolism and elimination (Kearns et al. 
2003). There are also significant differences in the pathophysiology of underlying 
diseases and in the epidemiology and resistance patterns of organisms infecting 
children and neonates (Biedenbach et al. 2004). The optimal definition of dosage 
regimens in children requires and in-depth understanding and targeted study of these 
differences. This major research gap has been addressed with the introduction of the 
European Union Paediatric Regulation in 2006 to ensure that any medicinal product 
for use in children undergoes extensive studies before use in the target population, 
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but also with global research initiatives in Paediatrics (GRIP), a European Union-
funded research network that promote the developing of our understanding of 
paediatric clinical pharmacology (The European Parliament and The Council of the 
European Union 2006).  
Therefore, there is an urgent need to update current dosage regimens with 
new high-quality evidence, based on pre-clinical and clinical data derived from target 
populations, that accounts for its specific population developmental and disease-
specific variability as well as for the changing patterns of infection and resistance.  
 
1.4.1- Understanding the differences in the clinical pharmacology of 
antimicrobials in children: developmental pharmacology 
Dosing equations largely used in the past (e.g Young´s formula) has been 
replaced by normalization of the drug dose to either body weight or body-surface 
area. This is in recognition that human growth is not a linear process across 
childhood, and that many age-related changes occur in body composition and organ 
functionality, which affect the drug´s pharmacokinetic behaviour and thus, its 
pharmacodynamics. Nonetheless, this approach might be adequate for initiating 
therapy, but it is certainly insufficient during maintenance dosing or long-term 
treatment, where regimens should be individualized according to the different PK, 
PD or both of patients. 
For instance, the relatively larger extracellular and total-body water spaces in 
neonates and young infants as compared with adults, combined with a higher ratio of 
water to lipid in the adipose tissue, results in lower plasma drug concentrations in 
these compartments for hydrophilic drugs. In contrast, the influence of age on the 
apparent volume of distribution is not as marked for lipophilic drugs, which are 
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primarily distributed in the tissues (Singh et al. 2001). Furthermore, age-related 
changes in the composition and amount of plasma proteins (e.g. albumin) can also 
affect the distribution of highly protein bound drugs (Grandison & Boudinot 2000). 
A decrease in the amount of total plasma proteins in the neonate, for example, 
increases the free fraction of the drug and thus, determines the exposure of the active 
moiety. In addition, during the neonatal period, an increase in endogenous 
substances, such as bilirubin, and the presence of foetal albumin, are able to displace 
a drug from albumin binding sites, contributing also to the higher availability of the 
free actions of highly protein bound drugs (e.g ceftriaxone, teicoplanin, etc)(Sethi et 
al. 2016). 
In terms of drug metabolism, a consistent observation in clinical studies is an 
age-dependent increase in plasma clearance of drugs metabolized by the liver in 
children < 10 years old as compared with adults. Therefore, in these cases, younger 
children necessitate relatively higher weight-based dosing of these drugs (Singh et al. 
2001). The activity of many cytochrome P-450 (CYP) isoforms and a single 
glucuronosyl-transferase (UGT) isoform is markedly reduced during the first two 
months of life. Distinctive patterns of isoform-specific developmental changes in the 
biotransformation of drugs are apparent for phase I (oxidation) and Phase II 
(conjugation) drug-metabolizing enzymes. The acquisition of adult activity over time 
is enzyme and isoform-specific (Kearns et al. 2003). Literature review on CYP 
ontogeny has been deliberately reduced as the drugs involved in this thesis 
(vancomycin and teicoplanin) are mostly (90 and 98% respectively) renally cleared 
(De Hoog et al. 2004)(A. P. R. Wilson 2000). 
In relation to the renal elimination of drugs, is now well described that 
nephrogenesis begins at 5 weeks gestation and is complete by 36 weeks gestation, 
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followed by postnatal changes in organ blood flow. The GFR increases rapidly 
during the first two weeks of postnatal life and then rises progressively until adult 
values, reached at 8 to 12 months of age (Rhodin 2009). Similarly, tubular secretion 
is immature at birth and reaches adult capacity during the first year of life. 
 Collectively, developmental changes in renal function can alter considerably 
the plasma clearance of drugs that are extensively renally eliminated. Therefore, 
knowledge of these changes is fundamental in the adequate age-selection of optimal 
dosing (e.g ceftazidime)(van den Anker et al. 1995) as well as in dose intervals (e.g 
gentamicin)(Brion et al. 1991). Concomitant medication may also alter the normal 
pattern of renal maturation in neonates (van den Anker et al. 1994).  
Failure to account for all these differences can expose neonates and young 
infants, particularly, to potentially toxic levels of drugs. 
Allometric scaling of clearance in paediatric pharmacology and PK 
modelling 
Body size is an important determinant of drug exposure in children. Children 
have higher dose requirements on a mg*kg-1 basis compared to adults due to the fact 
the clearance scales to body surface area by raising weight to a power that ranges 
around 0.63 (glomerular filtration) to 0.78 (hepatic clearance)(Rhodin 2009; Johnson 
et al. 2005). Allometry is the study of the relationship between body size and 
physiology. Allometric scaling for size with a fixed exponent of 0.75 is widely 
accepted to predict or describe clearance of drugs in children adequately, whilst 
adding biological information on the effect of body size without adding an extra 
parameter to be estimated. Conclusively, smaller people will have shorter half-lives 
due to their proportionately higher clearance and thus, elimination constant (Standing 
2016). 
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However, this approach does not perform as well in neonates and young 
infants due to the rapid physiological and maturation changes in drug elimination 
that occur early in life. Therefore, a method for scaling for both size and maturation 
is needed. The use of both allometric scaling of clearance to size and the use of a 
sigmoid maturation function driven by PMA has been proposed, as follows: 
!" = !"$ ∗ &$70 ).+, ∗ -./0122(-./500122 + -./0122) 
 
Where Cl=clearance (L/h), Clt= clearance of a typical 70 kg adult (L/h), wt= 
body weight (kg), PMA= post-menstrual age (weeks) and Hill= the Hill coefficient 
or shape parameter. 
Recently, a systematic comparison of models for scaling clearance in children 
showed that several published modelling approaches gave similar fits to the data and 
no model out-performed the standard model proposed above. This highlighted the 
added benefit of standardising scaling using a single method to facilitate paediatric 
population PK modelling knowledge between studies (Germovsek et al. 2016). 
Finally, the apparent volume of distribution should scale linearly with body 
weight since blood volume is proportional to weight, especially for highly protein-
bound drugs, such as teicoplanin (Standing 2016). 
1.4.2- The role of PK/PD determination and analysis in optimising antimicrobial 
therapy  
Modern antimicrobial pharmacology postulates that the shape of the 
antimicrobial concentration-time curve relative to the microbial susceptibility- the 
latter represented by the pathogen´s minimum inhibitory concentration (MIC)-, is an 
important determinant of drug effectiveness. Three summary PK parameters are used 
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to capture this information: 1) the time of the dosing interval that the non-protein 
bound, or free fraction (f) of the drug, is able to maintain a concentration above a 
threshold, the MIC, (% fT>MIC). This time-dependence index is suggested to be the 
best descriptor of the activity for some antimicrobials (e.g. b-lactam antibiotics); 2) 
the peak concentration achieved (fCmax/MIC), which better describes the 
concentration-dependent activity for other antimicrobials (e.g aminoglycosides); and 
3) the area under the concentration-time curve (fAUC/MIC), which may be more 
important in predicting therapeutic success in drugs with both concentration and 
time-dependence activity, such as in quinolones and glycopeptides, for instance 
(Mouton et al. 2005; Roberts et al. 2014).  
The rationale behind which PK/PD index best correlates with efficacy 
depends on several factors such as the mechanism of action, the microbial kill 
kinetics, the degree of protein binding and the degree of tissue distribution. In 
general, antimicrobials with a mechanism of action of inhibition of either protein or 
bacterial synthesis, display concentration-dependent killing and correlate well with 
either fAUC/MIC or fCmax/MIC (e.g aminoglycosides). On the other hand, 
antimicrobial agents that act on the cell wall synthesis display mainly time-
dependent activity and correlate with % fT>MIC (e.g b-lactams). However, a major 
exception is with antimicrobials that display a prolonged post-antibiotic effect (PAE) 
and correlate better with fAUC/MIC despite the mechanism of action (Barbour et al. 
2010). 
Knowledge of these PK/PD indices are used in the design of dosing strategies 
that aim to achieve PD targets that are associated with optimal antimicrobial effects 
for any specific drug/organism combination. Clinicians may also use this information 
to inform their choice in the way a drug is administered as well as in dose 
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modifications or adjustments, which may be required in different clinical scenarios, 
populations and individual patients.  
The introduction and development of in vitro and in vivo infection models 
over the past three decades, have allowed accurate study of PK/PD relationships and 
definition of optimal PK/PD targets for “old” and new drugs that are associated with 
maximal effect and suppression of resistance in patients. Importantly, recent clinical 
analysis have described, in the majority of cases, similar PK/PD optimal targets in 
patients to those that have been observed in pre-clinical studies, thus confirming the 
utmost relevance of the latter studies as the first step in getting the dosing regimens 
right the first time that are studied in humans (Roberts et al. 2014). In summary, the 
role of PK/PD studies is becoming increasingly recognized in drug development, in 
revisiting and building the evidence behind dosing recommendations used in well-
established antibiotics in adults and especially in paediatrics, as well as in the 
understanding and tackling of the antimicrobial resistance emergence problem. 
In vitro PK/PD studies 	
 The information relative to the effect of different antimicrobial concentrations 
on the time-course of microbial killing and suppression of the emergence of 
resistance can be achieved in vitro through static time-kill experiments and dynamic 
models of infection (Singh & Tam 2011). 
 Static time-kill experiments investigate the effect on the pathogen exposed to 
fixed antimicrobial concentrations at differing MICs and enable the preliminary 
study of the bacterial growth and killing dynamics, the effects on the starting 
bacterial inoculum and the probability of resistance emergence along drug exposure. 
However, these studies do not represent the clinical scenarios (Bergen et al. 2011). 
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 On the other hand, dynamic models, address this main limitation of static 
studies while exposing the bacteria to drug changing concentrations along the course 
of therapy to better mimic for the in vivo PK/PD profile. The microorganisms are 
exposed to antimicrobials in reaction vessels and perfused continuously with fresh 
media to promote growth and remove metabolic waste. The vessels can be repeatedly 
sampled to monitor growth-kill kinetics and drug resistance in relation to the drug 
exposure over time. Dynamic models can be tailored to investigate specific clinical 
scenarios, such as medical-device associated infections, biofilms, co-culture with 
human epithelial cells, the effects of human plasma, etc (Gloede et al. 2010). Hollow 
fibre systems are one of the most widely employed techniques, whereby 
microorganisms are contained in a cartridge of capillaries over which drugs, nutrients 
and waste products can freely diffuse. They also allow to mimicking specific 
population PK profiles with differing organ function and maturation (e.g renal 
function) and its linked PD effects (Bergen et al. 2016). 
In vivo PK/PD studies 	
 Animal infection models have been used in the therapeutic evaluation of 
antimicrobials for decades. In contrast to in vitro studies, they provide the 
opportunity to study drug efficacy while accounting for the host immune response 
and the pathogen virulence in vivo (D. Andes 2002). They also enable the 
investigation of the PD effects at the site of infection (e.g the lung). Most of the in 
vivo PK/PD studies have been performed in small rodents (mainly mice) and rabbits. 
Studies can also be designed to mimic a specific infection syndrome, such as 
pneumonia, a BSI or meningitis (Docobo-Pérez et al. 2012). Furthermore, multiple 
endpoints can be used in assessing the PD: survival/mortality, bacterial counts, 
biomarkers, pro-inflammatory cytokines, etc. Nonetheless, the establishment of an 
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infection may require the animals to be rendered neutropenic by prior administration 
of an immunosuppressant (e.g cyclophosphamide)(Zuluaga, Salazar, C. a Rodriguez, 
et al. 2006). 
 The main challenge or limitation of small animal models is that the PK 
profile can be very different to that observed in humans due to much faster drug 
clearances. Therefore, careful experimental design with respect to doses, frequency 
and method of administration is required (D. Andes 2002). Many logistical and 
ethical considerations are additional requirements and the principles of the “three 
Rs” (replace, reduce and refine) need to be implemented to ensure good science and 
the support of the public for the use of animals in research (Kilkenny et al. 2010). 
PK/PD population mathematical modelling 	
  The use of PK/PD mathematical modelling has allowed for the accurate and 
robust analysis of the PK/PD relationships, together with the maximisation of clinical 
data. It is carried out to identify and quantify PK/PD variability in the population 
(e.g. in vitro experimental hollow-fibre cartridges, animal participants and/or 
patients) and to record the experience from that collection of patients/subjects in the 
form of a population model that can be subsequently used as prior information 
(Bayesian prior) to predict the drug´s behaviour or the PK/PD relationships in a 
similar and larger population of patients/subjects, as well as in the individuals 
receiving the same drug (Jelliffe et al. 2000). 
 Population analysis allows for sparse sampling from each individual because 
information is shared within the population. In a PK model the simplest structural 
model includes one compartment and two PK parameters, typically the volume of 
distribution and clearance. However, more complex structural models, e.g. including 
two compartments and four PK parameters plus additional PD parameters to describe 
	 73	
the time course of the microorganism growth-kill dynamics, are often required to 
accurately describe changes in PK/PD relationships observed over time in subjects.  
There are parametric and non-parametric methods for mathematical 
population modelling (Bustad et al. 2006). The parametric methods allow separating 
inter-individual variability in the population from the intra-individual variability in 
the individual subjects, and from the variability caused by the assay error. Examples 
of parametric methods are: the standard two-stage approach, the iterative two-stage 
Bayesian method and the non-linear mixed effects modelling method (NONMEM) 
developed by Sheiner and Beal (Boeckmann et al. 2011). The non-parametric 
modelling methods do not make assumptions about the shape of the parameter 
distributions (e.g Gaussian, multi-modal). They can detect unsuspected 
subpopulations of subjects and obtain multiple parameter estimates, basically one for 
each subject (Jelliffe et al. 2000). The main weakness is that they cannot separate the 
various sources of variability into their respective components. Examples of non-
parametric methods are: non-parametric expectation-maximisation (NPEM) and non-
parametric adaptive grid (NPAG), both of which use exact computation of the 
likelihood (Bustad et al. 2006). 
Once a population PK and/or PK/PD model has been developed, Monte-Carlo 
simulations are the most widely used statistical strategy to compute concentration-
time profiles for a larger population to explore further the PK/PD variability and/or 
the proportion of patients/subjects reaching a certain PD target (Tam et al. 2006). 
However, the use of a fixed target has limitations since the whole distribution of the 
time-course of bacterial killing and resistance emergence is not considered. 
In conclusion, PK/PD mathematical models can combine available 
knowledge of the exposure-effect relationships of antimicrobials, which may be 
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based on in-vitro, animal or clinical data, with clinical population specific PK data. 
This enables, for instance, bridging the information from the bench to the bedside, by 
allowing the study of more safe and effective candidate dosing regimens in the most 
targeted clinical setting (e.g preterm neonates with haematogenous Candida 
meningo-encephalitis) (Hope & Drusano 2009).  
 
1.4.3-Clinical PK studies in children: features and regulations 
Children present unique challenges and demands for the conduct of high 
quality clinical trials. Rich PK sampling in critically ill and/or low birth weight 
infants may be unfeasible and difficult to justify. Rapid changing physiological, 
pathological and developmental variables may also be captured through repeated 
sampling, the use of well-validated biomarkers and target specific studies. Statistical 
methods such as D-optimal design theory can be used to define the most informative 
sampling times throughout the dosing interval while minimising the number of 
samples needed (Tam et al. 2003). The use of dried blood spots and ultra-low sample 
volumes can also minimise this issue. In addition, PK/PD analyses and bridging the 
experimental findings to humans, both adults and children, allow to study the right 
dose at the first time in clinical studies, which also facilitates and decreases the 
number of patients recruited to trials (Hope & Drusano 2009). 
In the last decade, both the FDA and the EMA have developed strategies to 
facilitate the prompt and safe investigation of medicinal compounds in children and 
neonates. For instance, they both support the extrapolation of information from 
adults to children provided there are adequate safety data in the latter and the 
pharmacodynamics can be assumed to be the same in both populations (Steinbrook 
2002; European Medicines Agency 2011). This approach requires the development 
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of robust population PK models in both adults and children, which enables the design 
of regimens, that allows drug exposures in both populations to be matched. However, 
the safety of a drug cannot often be extrapolated from adult data, and the course of 
the disease and the PD are not always the same between adults and children, not even 
between neonates and young infants and older children and adolescents. A paediatric 
investigational plan (PIP) is now a pre-requisite by the EMA at the end of Phase I 
studies of new compounds for the approval of new agents, thus the careful design of 
paediatric PK/PD studies that incorporate risk proportionate approaches have 
become mandatory in the development of new antimicrobial compounds (European 
Medicines Agency 2011). 
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1.5- PHARMACOKINETICS-PHARMACODYNAMICS (PK/PD) OF 
STAPHYLOCOCCAL BLOODSTREAM INFECTION MAINSTAY OF 
THERAPY AGENTS: VANCOMYCIN AND TEICOPLANIN CURRENT 
PAEDIATRIC DOSING RATIONALE 
1.5.1- PK/PD of Vancomycin 
Introduction: indications and use 	
 Vancomycin is a glycopeptide agent, introduced into clinical medicine in 
1956 for the management of severe Gram-positive bacterial infections, particularly 
the advent of penicillin-resistant and later on, methicillin-resistant staphylococcal 
infections (Levine 2006). It is a high molecular weight molecule that inhibits the cell 
wall synthesis of Gram-positive bacteria by the formation of stable complex murein 
pentapeptides, thus causing inhibition of further peptidoglycan formation.  
 Vancomycin came into disuse in the 1960s because of adverse effects, such 
as, generalised skin eruptions, phlebitis and more importantly, renal failure and 
deafness. After the purification of the compound and thus, the improvement on its 
safety profile, it became again increasingly used in the 1980s over the next three 
decades due to the widespread appearance of resistant pathogens, namely MRSA, 
methicillin-resistant CoNS and penicillin-resistant Streptococcus pneumoniae. It also 
became the drug of choice, as an oral agent, for pseudomembranous enterocolitis 
(Fekety & Shah 1993; Levine 2006). 
 The practice of vancomycin routine TDM has been a matter of intense debate 
for many years due to conflicting evidence in relation to the current use of serum 
drug concentrations to predict and prevent drug-induced toxicity, and as a proxy 
measure of efficacy in treating infections. Currently, the IDSA recommends to 
monitoring only troughs, and not peaks, just before the fourth dose in patients with 
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normal renal function. Concentrations are recommended to be maintained > 10 mg/L 
to avoid development of SA resistance and to achieve a 15-20 mg/L range for 
effectiveness, as such range would achieve an AUC/MIC ratio ³ 400 in most patients 
if the microorganism MIC is £ 1 mg/L (Rybak et al. 2009). However, this 
recommendation is based on limited clinical evidence data from adult patients with 
invasive MRSA infection (Moise-Broder et al. 2004).  
The concept of introducing PK/PD knowledge into clinical practice marked 
an important milestone into vancomycin therapy. However, there are remaining 
questions around the efficacy and safety of this approach, the optimal dosing and the 
monitoring of vancomycin in special populations-including children and neonates- 
and also, against a variety of Gram-positive microorganisms with differing 
susceptibility patterns. 
Pharmacokinetics 	
The PK profile of vancomycin has been characterized by either one, two or 
three- compartment PK structural models. It is administered intravenously for 
systemic therapy with a standard infusion time of at least 1 hour to reduce adverse 
events (Rybak 2006). Its pharmacokinetic profile is summarized as follows: 
In patients with normal renal function, it has a a-distribution phase of 
approximately 30 minutes to 1 hour and a b-elimination half-life of 6 to 12 hours. 
The volume of distribution is 0.4-1 L/kg (Rybak 2006). Its protein binding has been 
assumed and predicted to be approximately 50% and 41.5%, respectively, but 
considerable variability has been reported (Butterfield et al. 2011). 
It is eliminated primarily unchanged by glomerular filtration (80-90%) and 
the remaining amount by non-renal mechanisms that remain unknown. Mean total 
body clearance is around ranges of 0.71-1.31 ml/min/kg (Matzke et al. 1986). 
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In neonates, due to the developmental characteristics, a larger volume of 
distribution and decreased total clearance has been described, compared to older 
children and adults. Average volume of distribution at steady state in term neonates 
ranges from 0.57 to 0.69 L/kg, and 0.38-0.97 L/kg in pre-term infants, although very 
few studies are available. Mean elimination half-life times in neonates of varying 
gestational and post-natal ages are around 3.5-10 hours, reflecting lower values for 
clearance. Clearance values vary between 0.63 ml/kg/min (0.038 L/kg/h) and 1.4 
ml/kg/min (0.084 L/kg/h)(De Hoog et al. 2004).  
Vancomycin penetrates into the majority of body spaces, although the 
concentrations achieved are variable and dependent, to some extent, to the degree of 
tissue inflammation. For instance, vancomycin CSF penetration was significantly 
higher in the meningitis group (serum to CSF ratio=48%) than in the group without 
meningitis (serum to CSF ratio=18%)(Albanèse et al. 2000). Similarly, penetration 
into the lung is highly variable and reports differ between patients without 
inflammation (14%) and critically ill patients with ventilator-associated pneumonia 
(24%) (Lamer et al. 1993). 
Pharmacodynamics  	
 A number of in vitro and animal studies have been performed to determine 
the relationship between vancomycin concentration and killing activity. Initially, 
most in vitro killing curve experiments evaluating fixed vancomycin exposure 
concentrations as small increments of the MIC against S. aureus and S. epidermidis 
demonstrated that killing activity does not change as a function of increasing 
concentration (2 to 64 x MIC) and that the best predictor of vancomycin efficacy was 
the fraction of time that the concentrations are above the MIC (%T/MIC)(Löwdin et 
al. 1998). In a dynamic in vitro model mimicking the adult elimination half-life of 
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vancomycin (6 hours), the stepwise increasing concentrations of vancomycin (5-40 
mg/L) did not affect the rate or extent of bacterial killing against SA (Larsson et al. 
1996). In vitro time-kill curves using concentrations between 2-50 mg/L in the 
logarithmic phase of growth of 12 isolates of CoNS, did not show either any 
correlation between killing rates and vancomycin concentration (Ackerman et al. 
1992).  
On the contrary, in vitro and neutropenic mouse thigh infection models have 
determined that the area under the concentration curve divided by the MIC 
(AUC/MIC) is the best predictor of the activity of vancomycin against methicillin-
susceptible S. aureus (figure 1.3). Furthermore, in a Streptococcus pneumoniae and 
SA non-neutropenic mouse peritonitis model, it was demonstrated that the peak 
serum concentration divided by the MIC (peak/MIC) and the AUC/MIC were the 
pharmacodynamic indexes with the most predictive value (Jenny Dahl Knudsen et al. 
2000). More recently, the concentration and time-dependent killing of vancomycin 
(AUC/MIC driven activity) was confirmed against MRSA infection in an in vitro 
dynamic HFIM with once daily dosing of vancomycin (Nicasio et al. 2012).  
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Figure 1.3- Relationship between PK/PD indices for vancomycin and bacteriological efficacy 
against MS-SA. 
The plot illustrates the change in colony-forming units (CFU) in an experimental mouse thigh 
infection model along the drug exposure in three different ways. It shows that AUC/MIC is the 
most relevant PK-PD index for predicting efficacy against MS-SA. Data are taken from (Rybak 
2006).[Original unpublished work from Ebert S et al. Abstract-439.	 Program and abstracts of 
the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy (New York). 
Washington, DC: American Society for Microbiology, 1987:173. 24]. 
 
Paediatric Clinical Vancomycin PK studies and rationale for current dosing 
regimens  
The current European Society for Paediatric Infectious Diseases (ESPID) 
Manual of Childhood Infections-“The Blue Book”- recommends the following 
dosage regimens in neonates and children: 1) neonates < 29 weeks postmenstrual age 
(PMA): 15 mg/kg every 24 hours; 2) neonates 29-35 weeks PMA: 15 mg/kg every 
12 hours and 3) neonates > 35 weeks PMA and older children: 15 mg/kg every 8 
hours, all doses adjusted according to the recommended trough concentrations 
(Sharland et al. 2016). A dose of 15 mg/kg every 6 hours (60 mg/kg/day) is 
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recommended by the IDSA in children (Liu, Bayer, Cosgrove, Daum, Fridkin, 
Gorwitz, Kaplan, Karchmer, Levine, Murray, Rybak, D. a. Talan, et al. 2011). In 
addition, the BNFC recommends trough concentrations of 10-15 mg/L for most 
indications and 15-20 mg/L for less sensitive strains of MRSA (BMJ Group, the 
Royal Pharmaceutical Society of Great Britain 2015b). This vancomycin dosing for 
neonates, however, is based on expert opinion and not on clinical trial data. For 
instance, de Hoog M et al. reported 17 different dosing regimens being used in pre-
term neonates (De Hoog et al. 2004). 
 Vancomycin administered as an intermittent infusion is one of the most 
studied antibiotics via population PK modelling. Many studies have reported 
vancomycin PK parameters in children and neonates, using concentrations that have 
been mainly obtained from routine therapeutic drug monitoring. They have also 
investigated factors influencing inter-individual variability (e.g body-weight/size, 
age and renal function) and have proposed optimized dosing regimens that have not 
been investigated prospectively and uniquely internally validated (Seay et al. 1994; 
Grimsley & Thomson 1999; De Hoog et al. 2000; Lamarre et al. 2000; Capparelli et 
al. 2001; Kimura et al. 2004; Mulla & Pooboni 2005; Anderson et al. 2007; Allegaert 
& Anker 2007; Lo et al. 2010; Marqués-Miñana et al. 2010). Nonetheless, results of 
these studies have not been compared in a randomized clinical trial for effectiveness 
and consensus on optimal dosing has not been reached in clinical practice. 
Similarly to teicoplanin, in neonates and children, there is no evidence data 
relating serum vancomycin concentrations to effect. Few studies have evaluated 
whether current dosing can actually achieve the recommended IDSA vancomycin 
PK/PD optimal target AUC/MIC > 400. For instance, using Monte Carlo Simulation 
with clinical PK published data from children, AUC/MIC predictions were 
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calculated across a range of doses (40-60 mg/kg/day), suggesting that, even when the 
microorganism MIC is 1 mg/L, a dose of 40 mg/kg/day did not achieve the target. 
Even at the highest recommended dose of 60 mg/kg/day, the PK/PD target was 
neither achieved when the microorganism MIC was 2 mg/L (Frymoyer et al. 2013). 
On the other hand, a retrospective study examining neonatal vancomycin PK data, 
showed that for the majority of patients studied, a trough > 10 mg/L was adequate to 
achieve the PK/PD target AUC/MIC > 400. However, the authors highlight the 
difficulty of achieving consistently target exposures in this population age-group 
given the high clinical and PK variability (Frymoyer et al. 2014).  
In summary, the definition of optimal vancomycin PK/PD targets against 
staphylococcal infections and the optimal dosing to achieve those remains to be 
elucidated from pre-clinical and clinical studies in the paediatric population. In 
addition, uncertainty about vancomycin-induced nephrotoxicity and otoxicity still 
remains and although rare, a clear relation between serum concentrations and toxicity 
has not been demonstrated (De Hoog et al. 2004). Furthermore, given the high 
population heterogeneity, in order to make a significant clinical and microbiological 
outcome impact, a combination of strong PK/PD evidence together with robust 
dosing support tools to help clinicians with dose and monitoring individualization, 
will be likely needed. 
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1.5.2- PK/PD of Teicoplanin 
Introduction: Indications and use 	
 Teicoplanin is a lipoglycopeptide agent that has been marketed in Europe by 
Sanofi-Aventis Ltd. under the trade name of TargocidÒ since 1989 (The Electronic 
Medicines Compendium 2014). It acts by binding to the outer layers of bacterial 
peptidoglycan before binding to the terminal amino acyl-D-alanyl-D-alanine 
precursor preventing peptidoglycan elongation, therefore, disrupting the bacterial cell 
wall synthesis. Teicoplanin is bactericidal against the majority of aerobic and 
anaerobic Gram-positive bacteria (A. P. R. Wilson 2000).  
Its use, together with vancomycin, has increased rapidly in the last decade 
due to the rise of methicillin resistant staphylococcal infections. With a similar mode 
of action to that of vancomycin, teicoplanin displays a better safety profile. It has 
been shown in two extensive systematic reviews and meta-analysis that teicoplanin is 
less nephrotoxic than vancomycin (Svetitsky et al. 2009; Cavalcanti et al. 2010). 
This favourable safety profile together with a distinct pharmacokinetic profile, with a 
longer half-life that allows once daily dosing, makes it very suitable for the treatment 
of serious Gram-positive bacterial infections in neonates and children (BMJ Group, 
the Royal Pharmaceutical Society of Great Britain 2015a).  
Nonetheless, a number of issues have prevented a more extensive use of 
teicoplanin, in comparison to vancomycin, worldwide. The first one relates to the 
composition and synthesis of the compound. Teicoplanin is derived from the 
actinomycete Actinoplanes teichomyceticus and it is a mixture of 5 major 
components (A2-1, A2-2, A2-3, A2-4, A2-5), a hydrolysis component (A3-1) and 4 
minor components (RS-1 to RS-4). The A3-1 component is the core glycopeptide 
that is common to all teicoplanin-like compounds (Bernareggi et al. 1992). This 
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complexity on its structure reflects the main concerns with respect to the composition 
and disapproval by regulatory authorities of teicoplanin generic products, as well as 
their potential impact on the pharmacodynamics (The European Medicines Agency 
2010). Another issue relates to measuring teicoplanin concentrations in clinical 
samples. A number of analytical methods have been used (e.g. Bacillus subtilis 
bioassay, solid-phase enzymatic receptor assay [SPERA], fluorescence polarisation 
immunoassay [FPIA] and high-performance liquid chromatography [HPLC]. FPIA 
has the highest specificity and reliability and is the method of reference (McMullin et 
al. 1994). The readouts from these different assays differ, thus the conclusions form 
PK/PD studies are dependent on the analytical method that was used. Finally, there is 
an important lack of knowledge of the pharmacodynamics of teicoplanin that is 
clearly represented in the following table summarizing the EUCAST rationale for the 
selection of teicoplanin clinical breakpoints and its evidence relative to the 
pharmacodynamics, which is blank. Briefly, until recently, a Cmin of >10 mg/L (15-
20 mg/L for deep-seated infections) has been associated with higher clinical cure 
rates for most indications than levels of 5 mg/L (Harding et al. 2000). The state of 
the art with respect to teicoplanin pharmacodynamics will be described in this 
section. 
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Table 1.2- Rationale for the teicoplanin EUCAST clinical breakpoints, version 2.1 (2010). 
http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Rationale_documents/Teicoplanin_r
ationale_2.1.pdf 
 
The uncertainties concerning the optimal dosage of teicoplanin have 
discouraged its use in some centres over vancomycin, as well as its license in 
countries such as the US. This is due to the poor results of early comparative clinical 
trials and different methodological approaches to those followed in Europe. Initially, 
low doses of teicoplanin (3mg/kg) in monotherapy for the treatment of 
staphylococcal sepsis were used with little success (Calain & Waldvogel 1990). 
Later on, when even higher doses (6mg/kg daily) were used in monotherapy, resulted 
in inferiority when compared to vancomycin (15mg/kg q12 h) for the treatment of 
SA endocarditis. The trial was stopped early before significance was reached (Gilbert 
et al. 1991). Higher dosages of teicoplanin were used in other US small trials (10-30 
mg/kg/daily) and resulted in similar efficacy than vancomycin (trough levels > 20 
mg/L), but still were considered to be of lower cost-effectiveness and safety to that 
of vancomycin [unpublished] (Wilson et al. 1994). In European trials, on the other 
hand, cure rates at 6 mg/kg/day were satisfactory in monotherapy, and were allowed 
to be given with concomitant agents (amynoglycosides) in more difficult to treat 
patients (Lewis et al. 1988). 
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Local use and practice of teicoplanin in Alder Hey Children’s NHS Foundation 
Trust Hospital (AHFT) and The Liverpool Women’s NHS Foundation Trust 
Hospital (LWH) (neonatal unit) 
Traditionally, vancomycin was the drug of choice for the treatment of CoNS 
infections at the Neonatal Intensive Care Unit (NICU) at the Liverpool Women´s 
Hospital (LWH) until 2003. Since then, teicoplanin has been used as the first line 
treatment agent for CoNS infections and as second line treatment for empirical late –
onset infections due to its safety and ease of administration properties. Regarding the 
treatment of serious Gram-positive bacterial infections in older children, clinicians at 
AHFT tend to use more frequently vancomycin over teicoplanin, particularly due to 
the uncertainty about the evidence behind teicoplanin dosage regimens. However, 
teicoplanin is used as first line empirical agent in the treatment of central line-
associated infections and other potential hospital acquired infections in the pediatric 
intensive care unit (PICU). 
Prescription rates are considerable between both hospitals. In the last 9 years in 
the Neonatal Unit at The Liverpool Women’s Hospital, pre-term and term neonates 
have been prescribed teicoplanin as second line anti-Gram positive microbial for late 
onset bacterial infection with percentages over total year admissions ranging from 
3.8 (1302 admissions) to 10.1% (1217 admissions) in 2009 and 2007, respectively. 
That is about 50 to 123 neonates on teicoplanin each year, as compared with 20.7 
and 49.5% of patients that received benzylpenicillin (first line therapy) the same 
years in the same unit (269 to 603 babies per year). In Alder Hey Children’s 
Hospital, teicoplanin is a stock item; assumptions around vial usage per month 
indicate that a maximum of 150 and 200 doses of 400 mg and 200 mg respectively, 
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are used per month- assumption made 1 vial equals 1 paediatric dose- (D. Sharpe, 
personal communication). 
Pharmacokinetics 	
The pharmacokinetic profile of teicoplanin is summarized as follows: 
It is not absorbed orally and is not substantially metabolized (only a 2-3% of 
the drug is metabolized). Intramuscular administration is well tolerated and its 
absorption is rapid. Systemic availability is nearly 100%. A 6 mg/ kg dose 
intramuscularly is associated with a peak serum concentration of 12 mg/L after 4 
hours compared with 43 mg/L at 30 minutes of intravenous administration in adults 
(Antony et al. 1991). 
The pharmacokinetics of teicoplanin follow a tri-exponential decay, being the 
α, β and ϒ half-lives, 0.4 to 1 hour, 4.7 to 15.4 hours and 83 to 168 hours, 
respectively. The volume of distribution (Vd) is 0.9 to 1.6 L/kg at steady state. 
Notably, longer sampling periods (up to three weeks) provide the greater values in 
the terminal elimination phase (A. P. Wilson 2000). 
Teicoplanin is predominantly bound to plasma proteins (around a 90%) and 
binding appears to be linear with rising concentrations to 300 mg/L (Bernareggi et al. 
1991). The protein-binding ability to neonatal serum has also been investigated. At 
concentrations ranging from 10 to 100 mg/L, the rate of binding was 71.9-80.5%, 
considerably lower than in adults (Sando et al. 2004).  
The kinetics of distribution is not dependent on dose. Being highly bound to 
serum proteins (albumin), the free fraction is not related to overall serum 
concentrations. In a study by Del Favero and colleagues in 5 adult volunteers, the 
values of half-life, volume of distribution at steady state and initial volume of 
distribution, did not differ significantly after individual doses of 15, 20 and 25 
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mg/kg, and the AUC (area under the concentration-time curve) increased linearly 
(Del Favero et al. 1991). 
On the other hand, tissue distributions have been shown to be very variable 
and standard teicoplanin dosages may not achieve desirable concentrations for the 
MIC of the targeted microorganisms. Teicoplanin concentration in bone diminishes 
importantly after 48 hours following a single dose, being even less satisfactory in 
cartilage. It does not reach the cerebrospinal fluid well but intraventricular 
administration can be used. Similarly, it has a poor intraocular and fat penetration. 
However, therapeutic concentrations have been found in wound exudates after 
intravenous administration (A. P. R. Wilson 2000). 
In adult patients with ventilator-associated pneumonia (VAP), a high dose 
regimen of 12 mg/kg of teicoplanin, proved to reach target unbound trough serum 
concentrations above 2 mg/L (corresponding to a target trough total serum 
concentration of approximately 20 mg/L), which were similar to lung epithelial 
lining fluid concentrations (ELF). Therefore, the authors showed an adequate lung 
penetration of teicoplanin at high doses, in a small sample size of 13 critically ill 
participants (Mimoz et al. 2006).  
Teicoplanin is eliminated via the kidneys, being most of the drug eliminated 
in the terminal phase. Clearance of the unbound drug is by glomerular filtration and 
both tubular reabsorption and renal secretion are minimal. Renal clearance has been 
between 8.1 and 10 ml/h/kg in various studies and total body clearance has been 
reported to be 11 ml/h/kg. The terminal phase half-life has been reported to be 
around 168 hours with conventional doses in healthy volunteers (Antony et al. 1991). 
However, at high multiple doses (30 mg/kg), the volume of distribution has been 
noted to decrease significantly, with no change in clearance and therefore, a decrease 
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in the terminal half-life around 96 hours, probably due to a saturated process of 
tissue protein binding (Smithers et al. 1992). 
In children, teicoplanin PK have been characterized following a tri-
exponential model with a distribution (α) and two elimination phases (β and γ half-
lives (Terragna et al. 1988; Reed et al. 1997), but also have been described following 
the kinetics of a two compartment model (Tarral et al. 1988; Dufort et al. 1996; 
Sánchez et al. 1999). For more detailed information, please see summary tables 1.3 
and 1.4. 
Pharmacodynamics  	
Despite its extensive use, there is relatively very few PK/PD data for 
teicoplanin, compared to vancomycin. Classically, dosage regimens have been 
determined by the need to achieve concentrations in serum and targeted tissue over 
the MIC of the majority of likely microorganisms throughout the dosing interval. 
Nonetheless, clinical trials have demonstrated that higher doses may be required in 
some deep-seated infections. Currently, a trough (pre-dose concentration) of 15 mg/L 
(measured by FPIA) is proposed in the summary of product characteristics (SPC) by 
days 3-5 of therapy for most indications in both adults and children. This has been 
recently increased to 20 mg/L and 30-40 mg/L for the treatment of deep-seated 
infections and infective endocarditis, respectively, without changing the 
recommended dosage regimens (The Electronic Medicines Compendium 2014). 
These recommendations are based on scant clinical evidence in adult patients and 
with a poor understanding of the pharmacodynamics of teicoplanin (Matthews et al. 
2007; Sato et al. 2006; Ueda et al. 2012).  
Pre-clinical teicoplanin PK/PD studies are scarce. A pre-clinical PD study 
carried out in a mouse peritonitis model caused by Streptococcus pneumoniae or SA 
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suggested, a decade ago, that both fCmax/MIC and %f T/MIC were the relevant PK-
PD indexes describing teicoplanin activity in this model. A maximum peak free drug 
concentration (fCmax) over MIC ratio of at least 2-3 was required for efficacy (J D 
Knudsen et al. 2000). 
Small clinical trials in adults have acknowledged the importance of 
considering teicoplanin exposure in terms of area under the concentration-time curve 
(AUC0-24), combined with the patients characteristics (e.g clearance, body weight) to 
achieve an appropriate microbiological response (Kanazawa et al. 2011). For 
instance, an AUC0-24 of at least 800 mg*h/L was necessary to eradicate or cure 
MRSA infections (MIC of 1 mg/L) in ICU patients (Hagihara et al. 2012). More 
recently, an AUC/MIC ratio of ³ 900 mg/h/L has been suggested for bacteriological 
response in a study with 46 patients with MRSA infection (Takeda et al. 2016a). 
Paediatric Clinical PK studies and rationale for current regimens 	
In 1993, the UK Association of the British Pharmaceutical Industry (ABPI) 
data sheet recommended, for children, 3 loading doses of 10 mg/Kg at 12 hourly 
intervals followed by 6 mg/kg daily with increased maintenance dose to 10 mg/kg in 
severe infections (based on serum pre-dose concentrations that should not fall below 
10 mg/L). For neonates, a loading dose of 16 mg/kg once followed by 8 mg/kg 
thereafter every 24 hours is recommended. Current British National Formulary for 
Children (BNFC) (2015) dosage recommendations remain the same after twenty 
years, and they are based on scarce evidence data (BMJ Group, the Royal 
Pharmaceutical Society of Great Britain 2015b). In addition, due to this lack of 
safety and efficacy data, teicoplanin is not licensed in the EU for the use in neonates 
and infants < 2 months of life. 
.
	 91	
Table 1.3- Classical Teicoplanin Pharmacokinetic Studies 
 
Reference Population Sample size 
Dosage regimen 
Methodology Results 
(Lemerle et al. 1988) 
“Teicoplanin in combination 
therapy for febrile episodes in 
neutropenic and non-
neutropenic paediatric 
patients” 
Children with 
neutropaenia with 
severe suspected or 
proven Gram-positive 
infection in 
combination with 
other agents for 
Gram-negative 
bacteria (mean age 7 
yo 2 m) 
 
 
 
 
 
 
 
 
 
 
20 -Serum concentrations were measured on days 
1,2,5,9 and 14 and then once a week with a 
trough assay, and a peak assay one hour after the 
end of the half-hour infusion. 
-Each isolate was investigated for sensitivity to 
antibiotics and MIC of teicoplanin 
-Serum bacteriostatic and bactericidal activity 
was measured on day 5 before and 1 hour after 
the end of infusion. 
-SPERA assay 
-Mean of 7 samples per patient 
-Each patient had at least two samples 
taken at expected minimum level and 
two at expected peak level. 
-The low dose group (6 mg/Kg) 
showed a mean trough level of 4.1 
mg/L and a mean peak level of 20.5 
mg/L. 
-The high dose group (10 mg/Kg) 
showed a mean trough level of 11.2 
mg/L and a mean peak level of 36.3 
mg/L. 
-Assessment of clinical efficacy was 
done in 7 patients: 5 cures and 2 
failures, being the failures in the low 
dose group. 
-All failures are not explained by PKs 
as in all cases serum concentrations 
were above the MIC. 
-The authors recommend the dose of 
10 mg/Kg daily with a second loading 
dose the first day for children with 
neutropaenic fever. 
The first 7 patients: 
6mg/Kg per infusion 
(twice the first day, 
then daily); the 8th 
patient had twice 6 
mg/Kg the 1st day, 
then 8mg/kg daily; 
two patients had 8 
mg/kg/12h the 1st day, 
then 10mg/kg daily. 
The last 13 patients 
had 10 mg/kg each 
infusion. 
(Terragna et al. 1988) 
“Pharmacokinetics of 
teicoplanin in paediatric 
patients”. 
 
 
 
Children (2-12 yo), 
male, requiring 
prophylaxis against 
Gram-positive 
bacteria before minor 
surgery or for 
medical indications. 
(weight: 13-32 kg) 
13 - Blood samples (3ml) taken just before dosing 
and at 1,3,6,12,24,48,72,96,120,144,168 and 
192h after dosing in the prophylaxis group. 
-Blood samples taken at 5min, 1,3,6 and 12 h 
after first administration and just before each 
subsequent dose up to 15 days in the treatment 
group. 
-Sampling time 13 days in the prophylaxis 
group. 
-Urine was collected for 8 days post-
administration. 
-Open Tri-compartment model to the individual 
data and a non-compartmental analysis. 
-Microbiological assay for plasma and urine. 
-No adverse events were reported. 
Local and systemic tolerability were 
good. 
-Cmax (1h) (non-compartmental 
analysis): 14.79±0.82 mg/L 
-AUC (mean): 207.98 mg.h/L 
-CL=0.0148 L/h/kg; 
-V(terminal)1.25L/kg; Vss: 0.80 L/Kg 
; terminal half-life 58h 
-These main PK parameters are similar 
to those obtained from adult volunteers 
with same dose and assay methodology 
except for C and volume of the central 
compartment. Authors relate these 
 Single dose of 
3mg/kg iv (3-5 min 
infusion) for 
prophylaxis and 
6mg/kg every 12h 
first day and then, 
daily for 4 patients for 
treatment. 
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-Age and weight were analysed as covariates by 
linear regression. 
 
differences to fewer experimental 
points in first part of the study. 
-No indication of linear correlation 
between terminal half- life and age or 
weight was found. 
(Tarral et al. 1988) 
“Pharmacokinetics of 
teicoplanin in children” 
6 children (4-12yo) 
hospitalised for 
severe urinary 
infection and treated 
with cefotaxime iv 
and 4 neonates (3d-
25d) in intensive care 
and treatment with 
mezlocillin and 
netilmicin. 
10 (6 children and 4 
neonates) 
-Blood samples taken at 10 min and 1,4,12 and 
24h after the end of infusion, up to ten days. 
-Total 24h collection in children. 
-Serum and urine teicoplanin concentrations 
determined by HPLC. 
-Open two-compartmental model for serum 
concentrations. 
- In children: 
-AUC: 221.64 μg/h/ml 
-Vc: 0.1286 L/Kg 
-Vss: 0.5432 L/kg 
-CLT: 28.19 ml/h/kg 
-In neonates: 
-AUC: 392.93 μg/h/ml 
-Vc: 0.3073 L/kg 
-Vss: 0.6139 L/kg 
-CLT: 15.78 ml/h/kg 
-In summary:  
-Trough serum concentrations at 24h 
were too low for MIC (2.04 mg/L). 
They recommend 10 mg/kg/day for 
children and 6mg/kg/day for neonates, 
who had lower elimination rates and 
clearance parameters. 
Single dose of 6mg/kg 
iv over a 10-min 
infusion in children 
and 20 min infusion in 
neonates. 
Peller et al (1993) 
 “Safety and efficacy of 
teicoplanin in the treatment of 
Gram-positive infections in 
paediatric patients in 
Germany”  
Children hospitalised  
(2m-15 yo) with 
suspected or proven 
Gram positive 
bacterial infections 
12 children got serum 
concentrations of 
teicoplanin assayed  
(out of 51) 
-Open multicentre study of efficacy and safety 
of teicoplanin in hospitalized children. 
-Microbiological confirmation in 31 patients. 
-No PK/PD modelling was applied. 
-Method of teicoplanin assay not reported. 
-After the second dose, mean peak 
levels ranged between 40-70 mg/L and 
mean trough levels were 10-20 mg/L. 
-Teicoplanin was considered to be very 
effective (83% cures and 17% 
improvements with no failures of 
therapy) and well-tolerated for the 
treatment of Gram positive bacterial 
infections. 
LD: 10 mg/kg every 
12 h x 3; MD: 10 
mg/Kg in severe 
infections/ 6mg/kg in 
mild-moderate 
infections every 24h 
(iv infusion 10-30 
min) 
(Kacet et al. 1993) 
“Teicoplanin and amikacin in 
neonates with Staphylococcal 
infection” 
 
Neonates with proven 
staphylococcal 
infections 
 
52 (mean GA: 30.8 
wks)  
Post-natal age (0-3 
months) (mean birth 
weight 1400g) 
-Efficacy study of the combination of 
teicoplanin+ amikacin in the treatment of severe 
staphylococcal infections. 
-Teicoplanin serum levels were measured from 
samples taken after the first, fifth and last dose 
-Peak and trough levels were higher in 
Group 2. 
-Trough after the 1st and 5th dose in 
Group 1 were often low compared with 
the MICs of the infecting organism, 
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Group 1: LD: 10 
mg/kgx1, then 
6mg/kg daily; 
Group 2: 
LD: 15mg/kg x1, then 
8 mg/kg daily. 
Combined with 
amikacin 
(30 min infusion) 
(at the end of infusion for peak levels and 
immediately before for trough levels). 
-Dose was changed into a higher dose in Group 
2 after reviewing first 30 patients. 
-Sampling time (mean): 14 days 
-No PK/PD modelling was performed. 
 
whereas concentrations in Group 2 
were satisfactory. 
-Tolerance was good in both groups. 
-Clinical and bacteriological outcomes 
were similar in both groups. 
(Dufort et al. 1996) 
“Teicoplanin 
pharmacokinetics in paediatric 
patients”  
 
 
 
Children 3m to 15 yo 
with febrile 
neutropaenia that 
underwent BMT 
21 divided into 2 
groups A(n=9), 
B(n=12) 
-Patients monitored from the 2nd day after start 
of treatment and periodically thereafter. 
-Doses were individualized according to plasma 
levels attained by a bi-compartmental simulation 
computer program 
-FPI 
-Sampling times:  peak at 1.5h post-dose, a 
value at 3h in the beta-phase of elimination and 
trough 1 h before next dose. 
 
 
-No significant differences in the PK 
profiles according to three age groups 
(<2y;2-12y;>12y) 
A: trough levels <10 mg/L were not 
reached in 5 out of 9 patients 
B: all attained trough levels >10 mg/L 
-Tolerance was excellent 
-Mean parameters (SD): 
-VC: 0.19±0.044 L/kg 
-CLT: 28.8±9.45 ml/h/kg 
-AUC: 223±19μg/h/ml 
-t⅟2: 21.4±4.9 h 
A: LD 10 mg/kg x 3 
at 12 h interval+ 
MD 10 mg/kg every 
24 h 
B: same LD+ MD 20 
mg/kg every 24 h+ 
ceftazidime or 
aztreonam 
(1h infusion) 
(Reed et al. 1997) 
 “The pharmacokinetics of 
teicoplanin in infants and 
children” 
Infants and children 
2.4-11 yo following 
and elective surgical 
procedure 
12 
 
 
 
 
-Blood sampling over 6 days 
-Multiple timed blood (1.5-2ml) at 20-30 min, at 
45 min and at 1,2,6,12 and 24 h after the 
beginning of first dose; 1,4,8 h after start of 
second dose; 1,8 and 24 h after start of 3rd dose; 
1 and 12h after 4th dose and 0,30,45 min and 
1,2,6,12 and 24 h after the start of 5th dose + 
additional blood samples. 
-Urine over first 24h was collected. 
-HPLC and microbiological assay. 
-Three-compartment PK analysis. 
-A trend identified between teicoplanin 
body CL (decreasing) with increasing 
age. 
-No statistically significant 
associations with age. 
- Mean parameters: 
-VdSS: 0.56; t ½ 16.1; CLt: 36.5. 
-A dose of 8mg/kg every 12 h should 
achieve target serum trough 
concentrations of 11 mg/L in children. 
Higher doses may be needed for deep-
seated infections and/or endocarditis. 
6mg/kg iv once daily 
for 5 consecutive days 
over 20-30 min 
infusion 
(Degraeuwe et al. 1998) 
“Use of teicoplanin in preterm 
neonates with Staphylococcal 
late onset neonatal sepsis” 
Preterm neonates 26-
32 wks, postnatal age 
5-47 days, 
Birth-weight 570-
23 -Open, non-randomized descriptive study 
-Individual Pk during multiple-dose iv infusion 
with peak and trough levels 
-FPI 
-Not PK analysis possible due to 
inaccurate dosing 
-32% had trough levels <10 mg/L 
-90% microbiological and clinical cure 
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1740 g LD 15 mg/Kg x1, 
followed by MD 
8mg/kg every 24 h+ 
iv gentamicin 
in Gram positive septicaemia 
(Sánchez et al. 1999) 
“Teicoplanin 
pharmacokinetics in critically 
ill paediatric patients” 
Children (7d-12yo) 
*the two neonates (7 
and 10 d old) 
admitted to PICU 
with nosocomial 
infection. 
Weights: 2.7-40 kg 
21  
LD 10 mg/kg x3, at 
12h interval, followed 
by MD 10 mg/kg once 
daily x 7days 
-Blood extracted at 30 min, 2.6h and 12 h after 
first dose and before the next dose after 24h, 48h 
and 72h and on the 7th day of treatment. 
-HPLC 
-Compartmental PK analysis 
-No significant differences in the mean 
serum concentrations and PK 
parameters between <3m,3-12m and 
>12m age groups+ from the two 
neonates. 
-AUC: 224.5 mg/l/h 
-11% of trough levels were >10mg/L 
AUC: Area under the concentration-time curve; C, CL: Clearance; Cl creat: creatinine clearance; Cmax: Concentration maximum; CLT: Total clearance; FPI: Fluorescence polarization Immunoassay; 
HPLC: High-performance liquid chromatography; LD: Loading dose; MD: Maintenance dose; MIC: Minimum inhibitory concentration; PICU: Paediatric Intensive Care Unit; SD: Standard deviation; 
SE: Standard error; SPERA: Solid Phase enzyme receptor assay; t½: half-life time; V: Volume of distribution; Vc: Volume of distribution (central compartment); Vss: Volume of distribution at steady 
state. QMS: Quantitative microsphere system. 
Table 1.3- Classical Teicoplanin Pharmacokinetic Studies. 	
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Table 1.4- Population Teicoplanin Pharmacokinetic Studies 
 
Reference 
 
Population Sample size 
Dosage regimen 
Methodology Results 
 (Aarons et al. 1998) 
 “Plasma and tonsillar tissue 
pharmacokinetics following 
intramuscular administration to children”  
 
 
 
 
Children (3-12 yo) 
with medical 
indications for the 
surgical removal of 
tonsils. 
Weights: 12.8-39.8 
kg 
37 in7 groups 
 
1 y 2: 5mg/kg x1  
3: 5mg/kg x2, 12h apart 
4 y 5: 5mg/kg x3, 12 h apart 
6 y 7:10 mg/kg x1 
All doses were provided im 
and two formulations were 
used. Drug was used 
prophylactically. 
-Up to 2 blood samples and 1tissue 
sample were taken after the 1st 
administration of teicoplanin 
-Receptor-antibody sandwich assay  
-A one-compartment open disposition 
model with first order absorption 
from the im site used to describe the 
plasma-concentration-time profile 
-Population mean parameters and 
variances were determined by fitting 
the model to the plasma data by a 
maximum likelihood method 
employing a modified EM algorithm. 
-Model then fitted to tonsillar data by 
nonlinear least squares. 
-Population mean estimates of 
CL/F and V/F were 0.024/h/kg 
and 0.61/kg with very little inter-
individual variability, 23% for 
each parameter. 
-68% of population predictive 
value for Cmax/dose was 4.6-7.6 
mg/L following administration of 
a 5mg/kg dose to a 20kg child. 
-Dose, body weight or 
formulation had no further 
influence on the PK parameters. 
-Following 5mg/kg dose to a 
20kg child, the Cmax/dose was 
3.9 mg/L 
-Terminal half-life 17.6h 
-Tonsillar tissue half-life=0.95h 
(Lukas et al. 2004) 
“Pharmacokinetics of teicoplanin in an 
ICU population of children and infants”  
 
Children (4m-12 yo) 
admitted to the PICU 
with developed 
Gram+ infections 
Weight:4-28 Kg 
 
20 
A: LD 10 mg/kg x3, 12 h 
apart 
+ 10mg/Kg every 24h 
B: LD same + 15 mg/Kg 
every 24h 
(1 h iv infusion) 
 
-Open, randomized and prospective 
design. 
-Sampling period: 1h before 1St, 3rd 
and 5th maintenance dose+ 1 and 3 h 
after each of those doses. 
(6 samples per subject) 
 
-Appreciable but non-statistical 
differences in PK mean and 
median parameters between the 
two age groups (<12m and >12m) 
-Teicoplanin basic bi-
compartmental population 
parameters were (SE):  
CL: 0.23 l/h (0.12) 
V1: 3.16 l (0.46); 
CV% 52% (26%) 
V2: 4.7 L (0.41); T⅟2 α, β 2.0 
and 79.3 h 
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-The frequency of Cmin < MIC 
for SA was higher in older 
children 
-Age dependence in PK covariate 
analysis. 
(Zhao et al. 2015a) 
“Population pharmacokinetics and dosing 
optimization of teicoplanin in children 
with malignant haematological disease” 
Children with 
malignant 
haematological 
disease 
Age (0.5-16.9 yo) 
Wt: 7.7-90.6 kg 
N=85  
Received current 
recommended teicoplanin 
dosing regimen: 10 mg/kg 
q12 x3, then 10 mg/kg q24 
h 
-TDM and opportunistic blood 
samples (n=143 available for 
analysis) 
-QMS (immunoassay) using CDX 
automate for teicoplanin 
determination 
-A 2-compartment PK model with 
first order elimination was developed 
with NONMEM 
 
-n=41 children had sub-
therapeutic teicoplanin levels 
(Cmin< 10 mg/L) 
-CL=0.491 L; Vc=12.9 L 
-Bodyweight and CLcreat were 
the significant covariates 
-For a target AUC of 750 mg·h/L, 
doses need to be increased to 18 
mg/kg in infants, 14 mg/kg in 
children and 12 mg/kg in 
adolescents 
AUC: Area under the concentration-time curve; C, CL: Clearance; Clcreat: creatinine clearance; Cmax: Concentration maximum; FPI: Fluorescence polarization Immunossay; 
HPLC: High-performance liquid chromatography; LD: Loading dose; MD: Maintenance dose; MIC: Minimum inhibitory concentration; SD: Standard deviation; SE: Standard 
error; SPERA: Solid Phase enzyme receptor assay; t½: half-life time; V: Volume of distribution; Vc: Volume of distribution (central compartment); Vss: Volume of distribution at 
steady state. QMS: Quantitative microsphere system. 
 
 
Table 1.4- Population Teicoplanin Pharmacokinetic Studies. 
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As summarised in the tables above, there is a wide heterogeneity of PK 
results for children and neonates. Some classical PK studies, have failed to show a 
correlation between the PK parameters determined and age or weight. Other authors, 
conversely, have identified some trends of a relationship with age. For instance, 
Reed and colleagues suggested that drug clearance decreased with increasing age 
(Reed et al. 1997). However, they all state the need for further studies to better define 
the influence of patient clinical characteristics in teicoplanin disposition, especially 
in neonates and infants. In more recent population PK studies, different dosage 
regimens have been used providing different levels of outcome. For instance, Lukas 
and colleagues showed that a15 mg/kg regimen rather than the recommended 10 
mg/kg dose regimen achieved better target Cmin in infants and children being nursed 
in the ICU. Nonetheless, there was a wide disparity in different age-populations 
groups. This was further supported in the Monte Carlo Simulations, particularly for 
older children (Lukas et al. 2004).  
On the whole, population teicoplanin PK studies in children and neonates are 
very scarce yet and heterogeneity among published reports does not allow drawing 
definitive conclusions. The variation in the methodology and design (sampling 
strategy, duration of blood and urine sampling, sample sizes, age-groups, different 
teicoplanin assays, different PK models) between studies, probably accounts for the 
differences reported in teicoplanin pharmacokinetic data. However, despite the 
apparent disposition differences among paediatric studies, in general, they tend to 
reflect a more rapid clearance and a smaller volume of distribution (except for 
neonates) than observed in adults. In addition, the selected populations present with 
intrinsic various physiological alterations that could alter antibiotics disposition. A 
well-designed PK study in a representative population that account for the extensive 
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inter-individual variability, with neonates, infants and older children, is still needed 
in order to develop an evidence-based teicoplanin optimal dosage regimen. 
No pharmacodynamic studies of teicoplanin have been conducted in children 
or neonates. 
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1.6- PROJECT AIMS 
 
Aim 1:  Characterize the preclinical PK/PD of staphylococcal infections 
(methicillin-resistant CoNS and SA) using current mainstay therapy (teicoplanin and 
vancomycin) in neonates and children. Define the magnitude of drug exposure 
targets that are associated with maximum antibacterial effect and suppression of drug 
resistance. 
Aim 2:  Characterize the clinical population PK of teicoplanin in neonates, 
infants and children. 
Aim 3:  Construct the software (and population PK model) with clinical data 
for teicoplanin, that can be used as a tool for the individualisation of regimens in 
neonates and children to achieve optimal drug exposures for desired efficacy and 
safety. 
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Chapter 2 
General Materials/Patients 
and Methods 
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2.1- ORGANISM: IN VITRO IDENTIFICATION AND SUSCEPTIBILITY 
TESTING 
2.1.1-Coagulase-negative Staphylococci 
 
Five clinical strains were recovered from two different neonatal intensive care 
units (NICUs) in the United Kingdom (Liverpool Women´s Hospital and St. 
George´s Hospital in London): three strains of S. epidermidis (122648, 122761, 
121164) and two strains of S. capitis (122828, 062012) were used in the hollow fibre 
infection model and one strain of each species (122648,122828) in the rabbit animal 
model (courtesy of Dr Timothy Neal-Liverpool Women´s Hospital). These species 
were chosen on the basis of its prevalence and clinical significance in neonatal 
infections as well as on the basis of recent outbreaks of S. capitis in European NICUs 
(Becker et al. 2014; Klingenberg et al. 2005; Rasigade et al. 2012). The bacteria were 
stored at -80º C in Microbank TM vials (Pro-lab diagnostics, South Wirral, UK). 
The isolates were identified using Matrix-assisted laser desorption ionization 
time-of-flight mass spectrometry (MALDI-TOF-MS) by Dr Neal. The minimum 
inhibitory concentration (MIC) for the 5 strains was conducted on 10 occasions, in 
Müller-Hinton (MH) broth (Sigma-Aldrich, UK) using broth microdilution 
methodology as described by the Clinical Laboratory Sciences Institute (CLSI) and 
the European Committee of Antimicrobial Susceptibility Testing 
(EUCAST)(Clinical and Laboratory Standards Institute 2015; European Committee 
on Antimicrobial Susceptibility Testing 2003). All the strains used were oxacillin 
resistant also by E-test (Oxoid Limited, Hants, UK). 
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2.1.2- Staphylococcus aureus 
 
 Staphylococcus aureus subsp.aureus, MRSA ATCCÒ 
43300Ô(ATCCÒ, Middlesex, UK) was used for all in vitro and in vivo experiments. 
Isolates were stored at -80º C in Microbank TM vials (Pro-lab diagnostics, South 
Wirral, UK). 
The MIC for the strain was determined using EUCAST broth microdilution 
methodologies on 3 separate occasions by EUCAST Reference Laboratory 
(European Committee on Antimicrobial Susceptibility Testing 2003). The strain used 
was oxacillin resistant also by E-test (Oxoid Limited, Hants, UK). 
2.2- DRUGS 
2.2.1- Vancomycin 
 
Vancomycin hydrochloride for intravenous infusion clinical formulation 
(Vancocin 500 mg, Flynn Pharma Limited, Dublin, Ireland) was used for both the in 
vitro and in vivo infection models. For the preparation of drug containing plates, 
vancomycin hydrochloride powder (Sigma-Aldrich, UK) was used. 
Vancomycin concentration determination 
 
 Analyses of vancomycin concentrations in rabbit plasma and MH broth were 
performed on a Ultra High performance Liquid-Chromatography tandem Mass 
Spectrometry system (UHPLC/MS-MS) consisting of a Agilent 6420 Triple Quad 
(Agilent Technologies, Berkshire, UK) in electro-spray positive ion mode (ESI), and 
an Agilent 1290 series (Agilent Technologies, Berkshire, UK) equipped with a 
quaternary pump, online degasser, column heater, auto sampler and chiller. The 
method used a zorbax eclipse plus C18 column 2.1 x 50mm 1.8µ (Agilent 
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Technologies, Berkshire, UK) and a 20µL injection volume. A standard curve 
encompassing 0.05–50 mg/L for plasma and 0.1-50mg/L for broth were constructed 
from a stock solution of vancomycin at 1000 mg/L in methanol further diluted in 
methanol to obtain the desired concentration (Fisher Scientific, Loughborough, UK).  
The internal standard (IS) was phenacetin (Sigma Aldrich, Dorset, UK) 0.1mg/L in 
acetonitrile (Fisher Scientific, Loughborough, UK).  The mobile phase was 100% 
0.1% trifluoroacetic acid (TFA) in water 0% acetonitrile with 0.1% TFA (v/v) with a 
gradient profile changing to 20% and 80% respectively over 2 minutes with an 
overall run time of 3 minutes and flow rate of 0.5 mL/min. The mass transitions were 
monitored on m/z 724.91 to 1305.4 for vancomycin and 180.1 to 110.0 for IS. The 
data was acquired and processed using the Mass Hunter B.6.0.0 software package. 
The CV% for vancomycin was ≤12.9% over the concentration range 0.05-50 mg/L. 
The limit of detection was 0.05 mg/L for plasma and 0.1mg/L for broth, the intra and 
inter-day variation was ≤8.3%. This method and analysis was performed by Joanne 
Goodwin and Sarah Whalley. 
 
2.2.2- Teicoplanin 
 
 Teicoplanin for intravenous infusion (Targocid 400/200 mg, Sanofi Aventis, 
Surrey, UK) was used for the in vitro and in vivo pre-clinical studies. This is also the 
product used as per standard of care in the National Health System (NHS) and 
therefore, the same formulation was prescribed to patients recruited to the PK 
clinical trial. 
For the preparation of drug containing plates, teicoplanin hydrochloride 
powder (Sigma-Aldrich, Dorset, UK) was used. 
 
	 104	
Teicoplanin concentration determination 
 
 A fluorescence polarization immunoassay (FPIA; Thermo Fisher 
Scientific, Germany) was used for the quantification of teicoplanin concentrations in 
serum. This is a homogeneous particle-enhanced turbidimetric immunoassay that 
utilizes the Quantitative Microsphere System (QMS) technology and was 
implemented on an automated analyzer Abbott Architect ci4100. The assay is based 
on competition between drug in the sample and drug coated onto a microparticle for 
antibody biding sites of the teicoplanin antibody reagent. A concentration-dependent 
agglutination inhibition curve was obtained with minimum and maximum rate of 
agglutination at the highest and lowest teicoplanin concentrations, respectively.  The 
limit of quantification (LOQ) was < 3.0 mg/L. The dynamic range was 3-100 mg/L 
and total precision (inter and intra-day) was < 6%. This method and analysis was 
performed by Kevin Padmore. 
 
2.3- IN VITRO HOLLOW FIBRE INFECTION MODEL 
 
 A hollow fibre infection model (HFIM) was used to simulate a typical 
neonatal and paediatric pharmacokinetic (PK) profile in order to study the dynamic 
response of CoNS and SA to different concentrations of vancomycin and teicoplanin, 
respectively. In both cases, the basic model consisted of a central compartment 
circuit (containing 300 mL of MH broth) and a hollow fibre (HF) cartridge (Fiber 
Cell Systems, USA) for each dosage regimen investigated plus a control arm. The 
drug was injected into the central compartment using a programmable syringe driver 
(Aladdin pump, World Precision Instruments, UK) together with a continuous flow 
of fresh MH broth infused through a pump from a reservoir (205U, Watson-Marlow, 
UK). The pump was run at a rate that represented the simulated drug clearance (in 
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mL/h). A second peristaltic pump connected the MH broth from the central 
compartment to the hollow fibre cartridge (C2011, Fiber Cell Systems, USA) with a 
rate about ten times higher than the previous rate, which then returned to the central 
compartment. Finally, the circuit was completed by the removal of waste from the 
central compartment via the second peristaltic pump in order to maintain and iso-
volumetric system. A schematic representation of the HFIM is shown in figure 2.1. 
The bacteria were grown in the HF cartridge and left untreated for 24 hours to 
allow the biofilm formation. Each microbial strain was studied in a different 
experimental run to avoid cross-contamination. Each experimental run consisted of 
simultaneous circuits (different dosage regimens and a drug-free control system). 
The final inoculum was confirmed by quantitative culture on MH agar. This 
inoculum was expected to reach a density of approximately 9-10 log 10 CFU/mL 24 
hours post-inoculation and before treatment in the HF. A bacterial density of > 102 
CFU/mL from a sonicated catheter by quantitative broth culture reflects catheter 
colonization in patients. For quantitative blood cultures, a colony count of 
microorganisms grown from blood obtained through a catheter hub should be at least 
3-fold greater than the colony count from blood obtained from a peripheral vein to 
best define a catheter-related bloodstream infection (CRBSI)(Mermel et al. 2009). 
Despite using the IDSA guidelines for the diagnosis of CRBSI for the choice of 
inoculum sizes, to our knowledge, there is no reported mean bacterial density data 
from blood cultures in neonates/children to be diagnostic of LOS or CLABSI.  
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Figure 2.1- Schematic representation of the in vivo HFIM. 
Illustration made by Patrick Lane (ScEYEnce Studios). 
2.4- IN VIVO CLABSI RABBIT MODEL 
 
All in vivo experiments were conducted under a Home Office project license 
(40/3630) and approved by the University of Liverpool Animal Welfare Committee. 
All animals were cared for in line with national guidance in the Biomedical Services 
Unit (University of Liverpool). A non-neutropenic rabbit model of neonatal CLABSI 
was developed and used to study the response of CoNS to different regimens of 
vancomycin (Vancocin 500 mg, Flynn Pharma Limited). Male New Zealand white 
rabbits (2.68-3.67 kg) were used for all experiments. Two clinical strains of CoNS 
(S. epidermidis 122648 and S. capitis 122828) that were obtained from neonates 
were used for these experiments. Forty-two rabbits were studied (22 rabbits were 
infected with S. epidermidis and 20 rabbits with S. capitis). Each experiment 
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consisted of 6 rabbits (2 controls and 2 different dosage groups of two rabbits each).  
A veterinarian established a central venous access with a rabbit jugular vein 
catheter with Smith´s P.A.S PortÒ Elite (SAI Infusion Technologies, Illinois, US) 
under general anesthesia. This enabled the reproduction of a CoNS infection through 
the central line and subsequent biofilm formation. A schematic representation of the 
CLABSI model is shown in figure 2.2. 
A 1 mL volume of 8 log10 CFU/mL was administered via the central catheter 
of each rabbit and locked with 0.5 mL of lock solution (500 IU/mL of heparin in 
10% dextrose). After two hours, up to 0.5 mL of lock solution was removed and the 
line flushed with 0.5 mL of sterile 0.9% saline. This inoculum was designed to 
establish a non-lethal model of CLABSI in the rabbits. Each experiment lasted 96 
hours. All rabbits were sacrificed 0.5h after the final samples on day 4. At autopsy, 
the catheters were removed and the tip taken for quantitative culture. 
 
	
Figure 2.2 - Schematic representation of the in vivo rabbit CLABSI model. 
Illustration made by Patrick Lane (ScEYEnce Studios). 
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2.5- IN VIVO MICE THIGH INFECTION MODEL 
 
 A neutropenic mice thigh infection model was conducted to evaluate the 
pharmacodynamic effect of teicoplanin different drug concentrations against an 
MRSA infection after 26 hours. 
Each experiment consisted of 9 male CD1 mice (16-20 grams) that were 
rendered neutropenic on day -4 and -1 with the intra-peritoneal administration of 
cyclophosphamide (Baxter, Liverpool, UK) (150 and 100 mg/kg, 
respectively)(Zuluaga, Salazar, C. A. Rodriguez, et al. 2006). On day 1, mice were 
inoculated with 2x106 CFU/ml of an MRSA strain (ATCC 43300) in each posterior 
thigh at a volume of 50 µL. Then mice were evaluated at 2, 12 and 26 post infection, 
when the appropriate mice were culled and the thighs removed and placed in 
separate culture tubes with phosphate buffered saline (PBS) for quantitative culture 
in MH agar.  
Teicoplanin therapy was commenced 2 h post-infection and was administered 
i.v. every 12 hours. Dosages of 2.5, 15 and 100 mg/kg/day were chosen to 
investigate the total bactericidal effect and the suppression of resistance based on 
preliminary dose-finding studies. PK sampling was performed at: 0, 0.5, 1, 2, 4 and 
12 hours post-dose. Three mice were used per dose-time-point. Samples were 
immediately spun and plasma stored at -80ºC until analysis.  
The health of mice was assessed at hourly intervals and any signs of ill health 
were recorded. Mice were weighed daily to ensure they did not fall below 20 % of 
their original weight. In this case, mice were culled. 
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2.6- C-REACTIVE PROTEIN (CRP) AS A BIOMARKER OF INFECTION  
Concentrations of C-reactive protein (CRP) were used (mg/L) as the primary 
PD endpoint in the rabbit CLABSI model. CRP serial levels are useful in the 
assessment of neonates with acute infection as clinical signs are often unspecific 
and/or subtle, and blood cultures are only intermittently positive (Benitz et al. 1998). 
A fall in the value usually assists in the evaluation of infection management (Ehl et 
al. 1997). CRP quantitative determination constituted a clinically relevant marker of 
infection to reflect the individual balance between the bacterial burden and the 
immune system. 	
2.6.1- CRP determination in the Pre-clinical studies 
 
 A two-site enzyme linked immunoassay (ELISA) kit was used to 
determine CRP measurements in the plasma of rabbits (Caltag Medsystems, UK). 
Blood samples (0.5 mL) for CRP were taken at 0, 2, 24, 48, 72 and 96 hours post-
infection. Serum was stored at -80ºC until analysis. 
 
2.6.2- CRP determination in the Clinical trial 	
A Multigen CRP VarioÒ (Abbott, Wiesbaden, Germany) latex immunoassay 
was used for the immunoturbidimetric determination of CRP in the plasma of 
patients, implemented in the Abbott Architect ci4100 system. The limit of 
quantification (LOQ) was < 0.2 mg/L (reported clinically as < 4 mg/L) for the 
standard and wide range methods (analyte concentration at which the CV=20%). The 
dynamic range was 0.2-480 mg/L (wide range method) and total precision was £ 6%. 
A CRP cut-off value > 10 mg/L was considered positive. This method was 
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determined in the Pathology Clinical laboratory of Alder Hey NHS Children´s 
Hospital as standard of care. 
 
2.7- CLINICAL TEICOPLANIN PK STUDY  
2.7.1- Study design, study site, patient population and sample collection 
 
Study design 
 
This was a therapeutic clinical Phase IV open-label pharmacokinetic study 
that collected data acquired from sparse blood sampling strategies to develop a 
paediatric population pharmacokinetic model of teicoplanin. The aim of the study 
was to characterize the pharmacokinetic profiles of teicoplanin in paediatric (and 
neonatal) patients when used in hospital in the routine clinical context. 
Study site and patient population 	
The study was conducted in the Neonatal Unit of the Liverpool Women´s 
Hospital NHS Foundation Trust (LWFT) and in the selected wards of the Alder Hey 
Children´s NHS Foundation Trust (AHFT). Paediatric patients (0-<16 years of age) 
were recruited from Alder Hey Children´s Hospital, which has a catchment of 
approximately 7.6 million people. In addition, both pre-term and term neonates from 
26 to 44 weeks postmenstrual age (PMA) were recruited from Alder Hey Children´s 
NHS Foundation Trust and Liverpool Women´s NHS Foundation Trust (Liverpool, 
United Kingdom). 
Information on patient-specific covariates which may affect the teicoplanin 
PK profile and that are routinely gathered during clinical care were captured for the 
study including: gestational age, post-natal age, concomitant medications, medical 
history, weight, height and renal function (serum creatinine). In addition, CRP 
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concentrations were determined as per standard of care and information collected for 
the study. 
Eligibility criteria  
	
All patients that received teicoplanin for proven or suspected methicillin-
resistant Gram-positive bacterial sepsis and/or central-line associated infection and 
likely to survive more than 72 hours were eligible for the study. 
	
Inclusion criteria: 
In-patients at Alder Hey Children's NHS Foundation Trust or Liverpool Women's 
NHS Foundation Trust who are either: 
a. Neonates (both term and pre-term (24-39 weeks gestational age), or 
b. Infants and Toddlers (aged 1 month to 24 months) or 
c. Children aged 2 to <16 years old, and 
Who must be receiving teicoplanin for suspected or confirmed Gram-positive 
bacterial infection while in hospital, as part of their routine clinical care. 
Exclusion criteria: 
Neonate, Infant/Toddler/Child considered unlikely to survive 72 hours after 
recruitment (as judged by the clinical team caring for the patient).  
The approximate working target number of participants was as follows in 
each age category: 
                   Age category Target number for 
recruitment 
1. Preterm newborn neonates 
                 - 24-27 wks 
                  -28-31 wks 
12 
3 
3 
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                  -32-35 wks 
                  -36-39 wks 
3 
3 
2. Term neonates (0-27 days) 12 
3. Infants and toddlers (1 month to 23 months) 10 
4. Children (2-11 yrs) 10 
5. Children (12-<16 yrs) 10 
Table 2.1- Working target number of patients to be recruited by age category. 
Drug dosage and sample collection 	
The teicoplanin dosage administration was in accordance with local or 
national guidelines. Teicoplanin was used at the discretion of the treating 
neonatologist/paediatrician. The regimen for neonates £ 44 weeks PMA was a 
loading dose of 16 mg/kg, followed 24 hours later by 8 mg/kg administered once 
daily via a 30- minute i.v. infusion. The regimen for older children (> 1 month old) 
was the following: three loading doses of 10 mg/kg every 12 hours, followed by 10 
mg/kg once daily thereafter via an i.v. bolus administration.  
Participants had the usual blood tests as per routine clinical practice. In 
addition, at the same time as other blood sampling, when possible, an extra aliquot of 
blood (0.2 ml) was obtained for teicoplanin blood levels. The time of the blood 
sample was precisely recorded, as with the time, dose and frequency of the 
teicoplanin, and any other medication that the participant was receiving out. 
Sampling strategy 	
Based, on the available literature on teicoplain pharmacokinetics, our 
sampling regimen was designed to be: 1, 3, 6 and 24 hours after the dose was infused 
(over 5 minutes in older children) at first and at steady state dose intervals. An 
additional wash-out sample was also collected 24 hours after the last dose of 
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treatment, when possible. The 1 h post dose was determined to estimate the 
concentration peak or Cmax, 3 and 6h were determined to estimate the distribution 
and elimination phases, as well as the 24h trough and wash-out samples to complete 
the estimation of the terminal elimination (average terminal half-lives described 
above and others, between 6.5 and 20.5 h in children)(Reed et al. 1997; Tarral et al. 
1988; Sánchez et al. 1999; Lemerle et al. 1988; Aarons et al. 1998) The blood was 
sampled by experienced paediatric/neonatal nurses according to unit policies, which 
includes measures to minimize pain and distress. 
The volume of blood sampled (0.2 mL) complied with the recommendations 
made by the European Agency Medicines (EMA) and the Medicines for Children 
Research Network (MCRN) guidelines. Sampling, therefore, did not exceed 3% of 
the total blood volume during any four-week period or 1% at any single time. If a 
participant was involved in simultaneous trials, the overall limit of 3% would remain 
the maximum (Hawcutt et al. 2010). A record of the number of samples taken was 
kept to assessing the amount of blood taken. 
Blood samples were taken either by sampling from an indwelling arterial or 
venous line (if they were available for blood sampling) or venipuncture or heel prick 
method. They were taken as per unit policy during the dosing interval as part of a 
sampling episode required for routine clinical care. Study samples were collected 
into appropriate bottles and transferred to the laboratory where they were analyzed. 
The sampling times were calculated from the start of the first infusion of teicoplanin, 
except for the first sample that was taken 1 hour from the end of the infusion on day 
1. 
In conclusion, the sampling strategy was therefore as follows: 1 hour from the 
end of the infusion and 3, 6 and 24 hours from the start of the infusion at each dose 
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interval. Four samples were taken in the first day of treatment and then at the 5th-7th 
day of treatment.  
Neonates less than 1000 g had only 2 samples taken on alternate times to 
minimize blood loss but allocated to one of 3 subgroups with 2 specific time points 
each, to ensure representation of each period. They were assigned to each subgroup 
by simple random method as they were recruited. 
Group Weight Sampling times per dosing interval on day 
1 and day 5-7 of teicoplanin treatment 
Maximum 
blood volume 
for all study 
samples*(ml 
per Kg body 
weight) 
A >1000g T1 T3 T24 1.2 ml 
< 
1000g 
A1 T1  T24 0.8 ml 
A2 T1 T3  
A3  T3 T24 
B >1000g T1 T6 T24 1.2 ml 
<1000g B1 T1  T24 0.8 ml 
B2 T1 T3  
B3  T3 T24 
Table 2.2- Sampling strategy subgroups in neonates below and over 1000 grams to minimize 
blood loss. 
Sample time window 
To ensure the samples provided accurate data, the samples were required 
within a 20-minute interval of the allocated sampling time (10 minutes before or 
after the allocated time). The research team discussed the timing of samples required 
with the clinical team and parents to ensure care was coordinated at this time and 
with minimal disruption of patient’s routine. However, some additional blood 
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sampling episodes were required for the purposes of the PK study and this was made 
clear during the consent process. 
Microbiology 	
Microbiological specimens, including blood culture isolates, were collected 
as part of routine clinical care and processed in the NHS laboratory. Positive 
microbiological samples were then stored for MIC investigations, determined by the 
Epsilon Test (ETest) (bioMérieux, Hampshire, UK) where a manufactured strip 
containing a predefined concentration gradient of antibiotic is applied to an 
inoculated plate and following incubation, a clear zone of no growth is produced. 
Then the MIC was read off the scale printed on the strip following EUCAST/BSAC 
methodology (Andrews 2006). 
 
2.7.2- Clinical trial methodology and preparation 
Feasibility study and planned recruitment time 	
A prospective feasibility study was conducted during a 4 month-period to 
evaluate the target recruitment wards in Alder Hey Children´s Hospital. These wards 
were: PICU, neonatal ward, HDU and Oncology. 
In the last 6 years, 50 to 123 neonates had been on teicoplanin each year in 
the Neonatal Unit at the Liverpool Women’s NHS Foundation Trust (minimum and 
maximum numbers in 2009 and 2007, respectively). That is, a median of 86.5 
neonates a year in the 6-year period and about 7 neonates/ month. 
Approximately 35-50% of parents will consent to participation in a simple 
PK study (unpublished data: M. Turner, based on recruitment rate in a previous 
neonatal ciprofloxacin PK study, which included 4 extra blood tests). That implied 
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that a number of 2 to 5 neonates could be recruited each month at the same neonatal 
unit. In order to achieve a target number of 22 neonates (including both pre-term and 
term), between 5 and 11 months of recruitment was planned to be necessary. 
Staff training 	
Once the recruitment wards were selected, clinical staff was trained on the 
study characteristics by the clinical investigator (myself) and the lead research nurses 
(Sarah Siner and Patrick MacGowan). The research team was more specifically 
trained on the study and standard operating procedures. 
Study Procedures 	
Study Introduction 
Both the study and the study team (chief investigator, clinical investigator and 
research nurses) were introduced verbally to the parents of the child (and to the older 
child) by a member of the clinical and/or research team. 
Informed Consent 
Informed consent was obtained by the Chief Investigator, Clinical 
Investigator and/or nominated deputy as recorded on the Sponsor’s Delegation of 
Responsibilities Log. All individuals taking informed consent had received training 
in Good Clinical Practice (GCP) and study-specific training. 
Consent to enter the study was obtained after a full account had been 
provided of its nature, purpose, risks, burdens and potential benefits, and the 
parent(s) has had the opportunity to deliberate. In the case of unmarried parents, the 
father was only able to provide consent if he was named on the child’s birth 
certificate. 
Periods shorter than 24 hours were permitted if the parent(s) felt that further 
deliberation would not lead to a change in their decision, and provided the person 
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seeking consent was satisfied that the parent(s) had fully understood and deliberated 
on the information given. Likewise, periods longer than 24 hours were permitted 
should the parent(s) request this. The investigator or designee explained that the 
parent(s) were under no obligation to enter the trial and that they could withdraw 
their child at any time during the trial without having to give a reason. 
A copy of the signed Informed Consent Form (ICF) along with a copy of the 
most recent approved Parent/Patient Information Sheet (PIS) were given to the study 
participant. The original signed consent form was kept at the study site, one filed in 
the medical notes and one file in the trial master file (TMF). A copy of the consent 
form was also given to the parents. 
The study team adopted a process of “ongoing consent” during which the 
progress of participants and the study were discussed, parents were given repeated 
opportunities to ask questions, clarify any issues about the study and confirm or 
withdraw their agreement to their child participating in the study. The aim of this 
process was to optimize the comfort of parents with the study when the time came 
for blood sampling or to give parents the opportunity to withdraw consent if they felt 
that was appropriate. 
Discontinuation/withdrawal of participants and stopping rules 
Participants had to be withdrawn if the inclusion criteria were no longer met, 
or if the exclusion criteria were met. Reason for withdrawal was recorded. In 
accordance with Good Clinical Practice (GCP), parents or legal guardians could 
withdraw their child or infant from the trial at any time without explanation. If 
participants exited the study prior to the first study teicoplanin level being obtained, 
they were not evaluable and therefore were replaced. 
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Subject/Patient recruitment process 
Patient recruitment at a site was only started once the trial team had ensured that 
the following essential documents were in place: 
1. The main REC approval 
2. Final sponsorship and host site approval 
3. Sponsor agrees that the investigator and the study team have read and 
understand study-associated responsibilities and the Delegation of Duties 
Agreement is signed. 
4. Study team and clinical team at the site are trained in the study procedures. 
5. Signed Clinical Trial Site Agreement (CTSA) 
6. MHRA approval for a Clinical Trial of Investigational Medicinal Product 
(CTIMP) 
7. R&D approval 
All subjects who wished entering the study were fully screened and their 
parent(s) consented by the Principal Investigator and/or a nominated deputy as 
recorded on the Sponsor´s Delegation of Responsibilities Log. Parents were 
informed about the study using parent information sheets. 
  Children under 8 yrs, 8-12 yrs and 12-16 yrs were provided with specific age-
group patient information leaflets for their assent to participate in the study. 
However, parent/legal representative informed consent was always sought in 
children under 16 years old (see annexes). 
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Study assessments 	
Screening assessment 
Participants were screened to ensure that all of the inclusion criteria and none 
of the exclusion criteria were met. 
Baseline assessment 
A clinical assessment consisted of a standard physical examination conducted 
by a health care professional with appropriate clinical training and experience, and 
study-specific training, which was in the delegation log.  
Demographic information, birth weight, current weight, current height, 
medical history (including level of care), concomitant medication, details of 
teicoplanin dosing, microbiology samples and results from current episode (including 
MIC of the microorganism cultured if available). Blood results from haematology 
(Hb, haematocrit, full blood count), biochemistry (renal function, albumin, CRP) and 
blood gas analysis that were required for clinical care were also collected. 
Subsequent assessment 
Medical history (since baseline), concomitant medication, details of 
teicoplanin dosing, microbiological samples sent and results (since baseline), 
teicoplanin serum levels, haematology and biochemistry results. 
End of study assessment 
A scavenged sample, if possible, was collected 24 hours after completion of 
teicoplanin study. Clinical data were collected at the end of the study and if required 
by the clinical team, further haematology and biochemistry results were also 
collected.  
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Summary Chart of Study assessments 
Study 
procedure 
Following 
admission 
to the 
ward/ 
unit 
At time 
judged 
suitable 
by 
clinical 
staff 
Clinical 
suspicion of 
infection/ 
sepsis 
Clinical 
decision to 
start 
teicopla-
nin 
Sam-
pling 
Day 1 
and day 
5-7 
Final dose 
of teicopla-
nin 
24 hours 
after 
comple-
tion of 
treatment 
(only if 
possible) 
Introduction of 
the study to 
parents or legal 
representatives 
x       
Consent  x x x    
Blood culture 
as per clinical 
practice 
  x     
Gram positive 
suspected or 
proven 
   x    
Enrolment (if 
eligible) 
   x    
Teicoplanin 
administered 
    x   
Baseline 
assessment 
   x    
PK blood 
sampling ± 
DNA sampling 
    x x x 
Subsequent 
assessment 
    x x  
End of study 
assessment 
     x x 
Table 2.3- Summary chart of PK study assessments. 
 
Data management 	
Confidentiality 
All data were handled in accordance with the Data Protection Act 1998. The 
Case Report Forms (CRFs) did not bear the subject’s name or other personal 
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identifiable data. The subject’s initials, Date of Birth (DOB) and trial Identification 
Number (ID) were used for identification. 
Data Collection Tool 
Case Report Forms were designed by myself (clinical investigator) and the 
final version was approved by the Sponsor. All data were entered legibly in black ink 
with a ball-point pen. It was the Investigator’s responsibility to ensure the accuracy 
of all data entered and recorded in the CRFs. The Delegation of Responsibilities Log 
identified all trial personnel responsible for data collection, entry, handling and 
managing the database. 
For the purpose of this trial data was recorded in the CRF from the source 
documents, which included medical notes, drug prescription charts and computerised 
laboratory reporting systems. Then, data were transferred into an electronic CRF 
(eCRF) and subsequently, to a spread-sheet (e.g Excel®) for further analysis with the 
appropriate software. 
Data handling for analysis 
For the pharmacokinetic elements of the study, participant teicoplanin levels 
were entered into a secure Excel database by Kevin Padmore and transferred to the 
eCRF by the clinical investigator.  
 
Mathematical PKPD modelling and statistical analysis 	
Primary endpoints 
The primary endpoints were the population PK parameters of teicoplanin 
drug clearance and volume of distribution for the paediatric, neonatal and joint 
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population models generated in Pmetrics (version 1.2.6. University of Southern 
California, California, United States). In addition, when PD information was 
available and linked to the PK data, population PD parameters (i.e EC50: teicoplanin 
concentration needed to provide a half-maximal effect in CRP reduction) were also 
estimated. 
 
Secondary endpoints 
The secondary endpoint was the proportion of patients reaching currently 
recommended drug exposure targets (i.e Cmin > 10-15 mg/L by day 3-5 of 
therapy)(The Electronic Medicines Compendium 2014). Additional calculation of 
drug exposures achieved in terms of area under the concentration-time curve (AUC0-
24 ) was conducted.  
 
Sample size calculation 
The exploratory nature means that distributions in the final model are not 
known in advance. In general, sample size should be based on the number of 
potential covariate relationships to be studied. Typically, a standard population PK 
study would include at least 50 patients. Tam and colleagues investigated the sample 
size necessary to provide robust PK predictions when using population modelling 
with Monte Carlo simulations to predict PK variability of antimicrobials. In order to 
obtain reasonably robust predictions, they have recommended that a non-parametric 
model derived from a sample population size of at least 50 is necessary (Tam et al. 
2006). 
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Mathematical PK/PD modelling 
All teicoplanin data were analysed using a non-parametric population 
modelling methodology (Non-Parametric Adaptative Grid, NPAG) with the 
population pharmacokinetic software program Pmetrics (version 1.2.6. University of 
Southern California, California, United States, [http://www.lapk.org/pmetrics.php]) 
(Neely et al. 2012) for R (version 3.1.0, Institute for Statistics and Mathematics, 
Vienna, Austria, [http://www.r-project.org/](R Team 2013).  
Different structural PK models were evaluated. The inverse of the assay 
variance was used as the weighting function for all models. The effect of different 
clinical covariates was assessed during the model-building process, to determine 
which covariates should be retained in the final model. The final PK model was used 
to generate empirical Bayesian estimates of population and individual PK parameters 
for teicoplanin. Given the anticipated PK variability in the population, the Bayesian 
posterior estimates for each patient’s PK parameters from the final PK model were 
fixed and the PD parameters were then estimated by fitting the PD component of the 
model to each patient’s CRP data. The Bayesian posterior estimates for each subject 
were used to estimate the concentration–time profiles for teicoplanin and CRP for 
each patient. Average AUC and trough (Cmin) for each 24 h of therapy were 
calculated from the Bayesian posterior estimates. 
Summary statistics from the demographic data were analysed with SPSS 
Statistics version 21 (IBM Corporation, New York, United States). 
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 More detailed information with respect to the clinical and pre-clinical PK/PD 
modelling methods can be found in Methods section 2.8 and in the specific methods 
sections of each Results Chapters. 
2.7.3- Ethical approval and trial registration 
Risk/benefit analysis 	
The study participants received teicoplanin as part of their routine clinical 
care at the current local or nationally recommended treatment dose, dose interval, 
infusion rate and route of administration. Their routine clinical care was not be 
affected by participation in the study. The majority of additional study samples were 
obtained at the same time as blood sampling for routine clinical care. This required a 
small amount of extra blood. If insufficient blood was obtained, analysis for clinical 
care always took priority. Participants were also asked to contribute extra blood 
sampling episodes. The additional aliquots or samples were clearly labelled as 
research samples, batched and analyzed retrospectively. The teicoplanin levels 
measured in the study were not used in the clinical management of the participants. 
All sampling episodes were conducted by experienced paediatric or neonatal staff 
that took account of the needs and preferences of the child and their family. 
Pharmacological and non-pharmacological analgesia was used in accord with local 
guidelines and the wishes of participants and their families. In general, participants 
were not at increased risk of adverse events as there were no additional interventions 
compared to their routine NHS care. The participants who contributed study specific 
sampling episodes were exposed only to the minimal risks of sampling in a dedicated 
paediatric facility. 
The benefits were that precise PK models and PK information would improve 
the care of children treated with teicoplanin in the future. 
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Management of potential study risks 
In order to prevent participants becoming anaemic from excessive additional 
sampling, the volume of additional blood taken per participant complied with the 
EMA and MCRN recommendations on paediatric and neonatal research (Hawcutt et 
al. 2010).  
Ethical approval and trial registration 	
The study was approved by the Medicines and Healthcare Products 
Regulatory Agency (clinical trial authorisation reference number: 21362/0003/001-
0002) and the National Research Ethics Service and Regional Committee (REC: 
13/NW/0023). Written informed consent was obtained from parents and/or legal 
guardians. The study was registered in the European Clinical Trials Database 
Registry (EudraCT): 2012-005738-12. 
2.7.4- Monitoring plan 	
Study safety monitoring 	
During teicoplanin therapy, the study team conducted a systematic daily 
review of patient records until 3 days after the last dose using electronic patient data 
system and consulted carers and parents in order to identify adverse events. 
Clinical blood samples 
All Biochemistry/ Haematology analyses carried out during the course of 
teicoplanin for routine care were assessed for safety parameters. No study-specific 
blood sampling episodes were undertaken for safety purposes. 
Study data precision monitoring 
Reliability and data accuracy was monitored according to specific trial tools 
for the precision of sampling and also to avoid data recording imprecisions. 
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An internal trial data-monitoring group, led by myself, supervised and 
ensured the completeness of these procedures. 
Quality Control and Quality Assurance 
The study was also monitored by the LWFT and the AHFT Research and 
Development departments. 
2.7.5- Regulatory Compliance 	
Safety reporting 	
Although the study design reflected the need for information gathered at 
Phase II of drug development, this was in fact a post-marketing study (Phase IV). 
The medication is used widely in this age group. The expected adverse events are 
described in the summary of product characteristics (SmPC). The aim of the study 
was not to report on safety. The Sponsor did not wish to receive reports about well-
recognised adverse events during teicoplanin administration. All health care 
professionals were encouraged by the MHRA to report all suspected adverse drug 
reactions to the MHRA using the Yellow Card system. This study did not seek to 
duplicate that reporting. Accordingly, the Sponsor defined a list of expected adverse 
events it did not wish to be reported. The trial included mechanisms for the expedited 
reporting of suspected, unexpected serious adverse reactions. 
2.8- PK/PD MATHEMATICAL MODELLING 
2.8.1- Population PK/PD modelling 
 
Data from the PK and PK/PD studies were analysed using a population non-
parametric methodology with Pmetrics. This software is an R library for 
	 127	
pharmacokinetic/dynamic modeling which includes the population program Non- 
Parametric Adaptive Grid Algorithm (NPAG) (Neely et al. 2012). In NPAG, the 
ordinary differential equations defining the structural pharmacokinetic (and/or 
pharmacodynamic models) are solved on a multidimensional “box” of pre-specified 
size, which is first sampled using a low-discrepancy Faure generator to create an 
initial grid of discrete support points.  Each support point is a vector consisting of 
one value for each dimension of the box.  Each value corresponds to a PK or PD 
parameter. The corresponding likelihood for each combination of data and grid-point 
is computed to produce a likelihood matrix. The number of support points contained 
within the grid is reduced via the exclusion of low probability grid points. Each 
parameter (dimension) of the remaining points is perturbed a fixed percentage of the 
pre-specified parameter range, while simultaneously fixing the other parameter 
values. These new grid points are added (in effect new daughter grid points are 
“sprinkled” around the initial grid point) and the likelihood value for the expanded 
grid is calculated. There is an iterative reduce-expand-reduce cycle using decreasing 
perturbations until convergence is reached (i.e. the log-likelihood value of the latest 
grid does not increase over that which immediately precedes it). At every step, the 
grid likelihood is calculated using a highly efficient convex program. The final 
distribution (reduced grid and associated likelihoods) is saved. In order to ensure that 
a local minimum has not been found, the entire optimization is repeated until the 
likelihood of the final grid does not change over two successive optimizations. The 
NPAG algorithm makes no assumption regarding the shape of the population 
distribution except that the optimal distribution is discrete and of size no greater than 
the number of observed patients. One reason that NPAG is fast is that size of the 
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likelihood matrix is reduced to approximately the number of patient observations 
very early during the optimization. 
One distinct advantage of using a population methodology is the ability to 
obtain: (1) estimates of measures of both central tendency and dispersions for the 
population as a whole; and (2) estimate the pharmacokinetic parameters for each 
individual within the population. This is achieved using Bayesian estimation, by 
defining the maximum a posteriori probability in the following manner: 
 
where: P is the parameter value in question. The objective function provides a 
measure of the difference between the model prediction and the observed data and is 
minimized in the optimization process. The population mean, median or modal 
values can be used as the Bayesian prior in order to obtain the Bayesian estimates for 
the individual subjects—the choice depends on the fit of the observed-versus-
predicted values and associated measures of precision and bias. 
These measures to assess whether a model is well fitted to the data include, 
but are not limited to: 
a. Observed-versus-predicted values before and after the Bayesian step  
b. Model parameter values 
c. AIC (Akaike information criterion), BIC (Bayesian Information 
Criterion) 
d. Measures of precision and bias 
e. Simulated model behaviour: e.g Visual Predictive Checks (VPCs) 
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Pmetrics enables weighting by 1/y, where y is usually the standard deviation of 
the observation.  For pharmacokinetic data the most orthodox approach is to use 
information from the assay variance. Pmetrics enables a polynomial to be used as the 
weighting function in the following way:  
Standard Deviation=C0+C1*concentration+C2*concentration+ C3*concentration. 
This relationship is estimated by fitting a polynomial of the appropriate order (e.g. in 
excel) to the relationship between concentration (the independent variable) and the 
observed standard deviation across various parts of the assay (e.g. low, medium and 
high concentrations).  
Error polynomials for bacterial density counts (log10 CFU/mL) and CRP 
measurements were obtained by fitting the same structural mathematical model to 
the pharmacokinetic and pharmacodynamic data from each of the infection models, 
using the maximum likelihood estimator in the parametric program ADAPT 5 (W. X. 
D’Argenio DZ, Schumitzky A 2009).  
 
2.8.2- Monte Carlo Simulations and PTA analysis 
 
 Monte Carlo simulations were used to explore the extent of PK variability in 
a larger simulated population and its influence on the achievement of target drug 
exposures and PD endpoints. In this thesis project two different programs and 
methodologies were employed.  
Firstly, ADAPT 5, which uses a parametric expectation maximization method 
(W. X. D’Argenio DZ, Schumitzky A 2009). Using this method, the structural 
mathematical model (a series of ordinary differential equations), a mean estimate of 
each of the PK model parameters and the variance of these parameters must be 
known. A diagonal covariance matrix may be entered which involves the variance of 
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each parameter vector. Alternatively, the full covariance matrix may be entered, 
which also describes any relationship between the parameters. Either normal or log-
normal distributions for each of the parameters are assumed. The ability to 
recapitulate the original parameter values and their dispersions was used to select 
which parameter distribution was utilised. 
 Secondly, Pmetrics was used, which uses a semi-parametric sampling 
methodology, rather than assuming a normal or a log-normal distribution (Neely et 
al. 2012). The final structural PK model was used, which consisted of a number of 
support points. Each support point comprised a set of model parameter values and 
the associated probability of those values that describe groups of patients in the 
population. Each support point served as the mean for a multivariate normal 
distribution, weighted by the probability of the point, with covariance equal to the 
covariance matrix of the full model divided by the number of points. This semi-
parametric sampling from this weighted, multivariate, multi-modal normal 
distribution, generated a novel population of 1000-5000 parameter sets for 1000 to 
5000 patient profiles receiving a teicoplanin regimen.  
 Finally, Monte Carlo simulations were also used to study the 
probability of target attainment (PTA) in the simulated populations of standard and 
candidate teicoplanin dosage regimens. This analysis allowed: 1) the bridging of 
experimental findings with respect to relevant PD targets to human patients and 2) to 
reflect on the adequacy of current EUCAST in vitro susceptibility breakpoints 
(Turnidge & Paterson 2007). The distribution of the MRSA MICs determined using 
EUCAST methodology from 0.032 to 16 mg/L were plotted against the probability 
of success to achieve a predefined target exposure (i.e. AUC:MIC ratio). Fractional 
target attainment was calculated for the various regimens and the AUC/MIC targets 
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against the MIC distribution for MRSA and teicoplanin (European Committee on 
Antimicrobial Susceptibility Testing 2010). 
 
2.8.3- Exposure-effect relationships 
 
To determine the PK/PD index that best described bacterial killing, the 
suppression of drug resistance (in pre-clinical models) or CRP reduction in vivo and 
in patients, scatter plots were constructed that related the AUC:MIC, Cmax:MIC and 
Cmin:MIC with both the observed antibacterial effect (or CRP reduction) and the 
emergence of a drug resistant subpopulation from the pre-clinical models. A non-
linear regression Emax inhibitory model was fitted to the data using Prism software 
for Mac OSX (GraphPad Software Inc., La Jolla, CA). The coefficient of 
determination and visual examination of the fit was used to discriminate the various 
pharmacodynamic indices. 
2.8.4 Dose optimisation software  
 
The dose optimisation software (BestDose) is based on the concepts 
developed by the University of Southern California Laboratory for Applied 
Pharmacokinetics and Bioinformatics (LAPKB)	 (http://www.lapk.org) which uses a 
multiple-model Bayesian adaptive control algorithm. A multiple-model approach 
allows the use of multiple discrete individual models (at most, one for each patient) 
as a discrete collection of points to find the most likely population parameter 
distribution (Macdonald et al. 2008). This software was used in the last RESULTS 
chapter of the thesis (chapter 7) to: 1) update the general paediatric population 
teicoplanin´s PK parameter probability distribution for an individual patient, and 2) 
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to use the updated, individual model to match measured concentrations, predict 
future concentrations, and calculate dosages to achieve target concentrations.  
The teicoplanin BestDose software included the structural final model 
equations relating input (dosing information) to output (plasma concentrations) and 
the discrete joint probability distribution of the values of the equation variables (PK 
parameters) in the population, consisting of a discrete number of support points and 
their associated probability (the Bayesian prior). It also included a patient “past” file 
that contained the observed drug concentrations and details of the administered 
teicoplanin regimen, and a patient “future” file, which contained the target drug 
concentrations deemed to be optimal for the patient, as well as the initial estimates of 
the required drug dosages and frequency of administration. The software then 
calculated the drug regimen having the least weighted squared error in target goal 
achievement over the Bayesian posterior distribution. 
Detailed methodology information with respect to the PK/PD modelling can be 
found in specific methods section of the Results Chapters. 
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Chapter 3 
 
Pharmacokinetics and Pharmacodynamics of 
Vancomycin for Coagulase-Negative 
Staphylococcal infection: Experimental Basis for 
Optimal Use of Vancomycin in Neonates 
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3.1- ABSTRACT 	
Objectives: Coagulase-negative staphylococci (CoNS) are the most common cause of 
neonatal late onset sepsis. Information on the vancomycin PK/PD against CoNS is 
limited. The study aim was to characterize the vancomycin PK/PD relationships for 
CoNS and investigate neonatal optimal dosage regimens. 
Methods: A hollow fibre and a novel rabbit model of neonatal central-line associated 
bloodstream CoNS infections were developed. The results were then bridged to 
neonates by use of population pharmacokinetic techniques and Monte Carlo 
simulations. 
Results: There was a dose-dependent reduction in the total bacterial population and the 
C-reactive protein levels. The AUC:MIC and Cmax:MIC ratios were strongly linked with 
total and mutant resistant cell kill. Maximal amplification of resistance was observed in 
vitro at fAUC:MIC of 200 mg*h/L. Simulations predicted that neonates < 29 weeks 
postmenstrual age are under-dosed with standard regimens. 
Conclusions: The AUC:MIC and Cmax:MIC ratios are the pharmacodynamic indices 
that best explain total and resistance cell kill in CoNS infection. This suggests that less 
fractionated regimens are appropriate for clinical use and continuous infusions may be 
associated with increased risk of emergence of antimicrobial resistance. This study has 
provided the pharmacodynamic evidence to inform an optimized neonatal dosage 
regimen to take into a randomized controlled-trial. 
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3.2- INTRODUCTION 	
Neonatal sepsis is associated with poor neurodevelopmental outcomes (Adams-
Chapman & Stoll 2006; Mitha et al. 2013). This occurs independently of the causative 
pathogen, probably as a result of the systemic inflammatory response. Late onset sepsis 
(LOS) in neonates is an important cause of global morbidity, prolonged hospital stay 
and mortality (Levit et al. 2014; Stoll et al. 2010; Hornik et al. 2012). CoNS account for 
30-54% of all cases of LOS (Vergnano et al. 2011; Stoll et al. 1996; Stoll et al. 2002) 
and over 80% of CoNS are methicillin-resistant (Hilmar Wisplinghoff et al. 2003). 
Central line-associated bloodstream infections (CLABSIs) are the most common risk 
factor of CoNS sepsis in neonates (Milstone et al. 2013). However, the treatment of 
these infections in neonates is problematic. Line removal is often not possible because 
of clinical instability and/or difficulty re-establishing venous access (Karlowicz et al. 
2002b). In contrast, in adults, line infections caused by CoNS are usually readily 
treatable with glycopeptides and line removal. There are few, if any, clinical sequelae in 
the absence of other indwelling foreign devices or material.  
Vancomycin is a first-line agent for the treatment of serious infections caused by 
resistant Gram positive pathogens (Mermel et al. 2009) and is increasingly used in the 
neonatal intensive care unit (NICU)(Clark et al. 2006). Reduced susceptibility of CoNS 
to vancomycin has been reported (Schwalbe et al. 1987; Schwalbe et al. 1990; Sanyal et 
al. 1993b; D. Sanyal & Greenwood 1993; Sanyal et al. 1991; Raad et al. 1998; 
Srinivasan et al. 2002; Rasigade et al. 2012; Hira et al. 2013). There is surprisingly little 
information to guide the optimal use of vancomycin in neonates. Hence, it is important 
to find ways to optimally treat CoNS in neonates to eradicate the organisms and 
minimise inflammation. 
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In this chapter, we defined the PK/PD of vancomycin for CoNS infections using 
both a hollow fibre infection model (HFIM) and a novel rabbit model of neonatal 
CLABSI. S. epidermidis and S. capitis were used as the challenge strains. We 
considered the antibacterial effect of vancomycin, the emergence of drug resistance and 
reductions in circulating concentrations of C-reactive protein (CRP) as 
pharmacodynamic endpoints. We bridged these experimental results to neonates to 
identify regimens for further study in clinical trials. 
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3.3- MATERIALS AND METHODS 	
3.3.1- Organisms, Susceptibility Studies and Mutational Frequency 	
Coagulase-negative staphylococci (CoNS) were used for all experiments. Five 
clinical strains were recovered from two different NICUs in the United Kingdom: three 
strains of S. epidermidis (122648, 122761, 121164) and two strains of S. capitis 
(122828, 062012) (courtesy of Dr Neal; Liverpool Women´s Hospital). The MIC for the 
5 strains was determined using CLSI and EUCAST microbroth dilution methodologies 
on 10 separate occasions (Clinical and Laboratory Standards Institute 2012; European 
Committee on Antimicrobial Susceptibility Testing 2015). 
The mutational frequency of a less-susceptible population was calculated as the 
ratio of the number of colonies that grew on vancomycin-containing Mueller-Hinton 
(MH) agar plates at a concentration of 4 mg/L divided by the number of colonies that 
grew on drug-free agar (Nicasio et al. 2012). 
3.3.2- Vancomycin concentration determination 	
Analyses of vancomycin concentrations in rabbit plasma and MH broth were 
performed on an Ultra High performance Liquid-Chromatography tandem Mass 
Spectrometry system (UHPLC/MS-MS) as described previously in general methods 
(chapter 2). This method and analysis was performed by Joanne Goodwin and Sarah 
Whalley. 
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3.3.3- In vitro Model of Neonatal Bloodstream Infection in a Hollow Fibre System 	
Vancomycin hydrochloride for intravenous infusion (Vancocin 500 mg, Flynn 
Pharma Limited, Dublin, Ireland) was used. A HFIM was used to simulate a typical 
neonatal pharmacokinetic profile and study the pharmacodynamic responses of CoNS to 
different regimens of vancomycin (Felton et al. 2013). An elimination half-life of 13 
hours for vancomycin was used (Seay et al. 1994). 
For each experiment, fresh bacterial isolates were grown on blood agar plates 
(Oxoid Limited, Hampshire, UK) and incubated at 37º C for 24 hours. Bacteria were 
then inoculated into the extra-capillary space of each hollow-fibre (HF) cartridge. The 
initial inoculum used was approximately 4.5 log10 CFU/mL. This inoculum was 
expected to reach a density of approximately 9-10 log 10 CFU/mL 24 hours post-
inoculation and before treatment in the HF. The desired inoculum was confirmed by 
quantitative culture on MH agar plates (Sigma-Aldrich, Hants, UK). The HFIM was 
incubated at 37ºC in ambient air. A bacterial density of > 102 CFU/mL from a sonicated 
catheter by quantitative broth culture reflects catheter colonization in patients. For 
quantitative blood cultures, a colony count of microorganisms grown from blood 
obtained through a catheter hub should be at least 3-fold greater than the colony count 
from blood obtained from a peripheral vein to best define a catheter-related bloodstream 
infection (CRBSI)(Mermel et al. 2009). Despite using the IDSA guidelines for the 
diagnosis of CRBSI for the choice of inoculum sizes, to our knowledge, there is no 
reported mean bacterial density data from blood cultures in neonates/children to be 
diagnostic of LOS or CLABSI. 
A total of five experiments each consisting of seven hollow fibre arms (control 
and six drug-treated arms) were conducted. Each experiment was performed with a 
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different CoNS strain (three for S. epidermidis and two for S. capitis). 
3.3.4- In Vitro Pharmacokinetic and Pharmacodynamic Studies 	
Initial dose-finding studies were conducted with neonatal-like concentration-
time profiles of vancomycin that corresponded to equivalent human dosages of 7.5, 15 
and 30 mg/kg/day. The total daily dose of vancomycin was administered as: (a) 1 hour 
infusion every 24 hours (q24h); (b) fractionated as half the total daily dose administered 
twice daily as 1 hour infusion (q12h) or (c) via a 24 h continuous infusion (CI). 
Treatment was initiated 24 hours post-inoculation. PK samples were collected at 0, 1, 2, 
6, ±12- if q12-hourly administration- and 24 h post-end of infusion (1 h infusion) at first 
dosing interval and at steady-state (day 6 of therapy). Experiments were conducted for 
up to 10 days to simulate the typical duration of clinical therapy and enable the 
generation of antimicrobial resistance. The AUC, Cmax or Peak and Cmin vancomycin 
concentrations at steady state and the burden of bacteria at the end of therapy were 
determined. 
Total and vancomycin resistant bacterial density were quantified at each time-
point by plating on drug-free and vancomycin (4 mg/L-2xMIC and clinical breakpoint-) 
containing MH agar plates (Sigma-Aldrich)(European Committee on Antimicrobial 
Susceptibility Testing 2015). 
Bacterial samples (1 mL) were withdrawn from each of the HF cartridges and 
aliquots of 0.1 mL were plated on agar plates at 0, 2, 6 and 24 hours post-infection and 
every 24 hours thereafter immediately prior to dosing. “Resistant” bacteria were defined 
as the number of colonies counted on the drug-containing plates. 
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3.3.5- In vivo Model of Neonatal CLABSI in Rabbits 	
All experiments were conducted under Home Office project license (40/3630) 
and approved by the University of Liverpool Animal Welfare Committee. A non-
neutropenic rabbit model of neonatal CLABSI was developed and used to study the 
response of CoNS to different regimens of vancomycin (Vancocin 500 mg, Flynn 
Pharma Limited). Male New Zealand white rabbits (2.68-3.67 kg) were used for all 
experiments. Two clinical strains of CoNS (S. epidermidis 122648 and S. capitis 
122828) obtained from neonates were used. Forty-two rabbits were studied (22 rabbits 
were infected with S. epidermidis and 20 rabbits with S. capitis). Each experiment 
consisted of 6 rabbits (2 controls and 2 different dosage groups of two rabbits each).  
A 1 mL volume of 8 log10 CFU/ml was administered via the central catheter of 
each rabbit and locked with 0.5 mL of lock solution (500 IU/mL of heparin in 10% 
dextrose). After two hours up to 0.5 mL of lock solution was removed and the line 
flushed with 0.5 mL of sterile 0.9% saline. This inoculum was designed to establish a 
non-lethal model of CLABSI in the rabbits. Experiments lasted for 96 hours. All rabbits 
were sacrificed 0.5h after the final samples on day 4. At autopsy, the catheters were 
removed and the tip taken for quantitative culture. 
3.3.6- Pharmacokinetic and Pharmacodynamics Studies In a Rabbit Model of 
CLABSI 
Vancomycin therapy was initiated 24 hours post-inoculation and was 
administered i.v. via the marginal ear vein. Dosages of 10, 20, 50, 100 and 150 
mg/kg/day were administered once and/or twice daily, as two divided doses, via an i.v. 
bolus based on previous dose-finding studies (Nicolau et al. 1993; Ahmed et al. 1999). 
Blood (0.5 mL) samples for pharmacokinetic analysis were collected from each rabbit 
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during the first dosing interval and then at steady state. Samples were collected pre-dose 
and at 2, 4, 12 and 24 hours post-dose from the opposite marginal vein to the vein used 
for the administration of the drug. Plasma samples were stored at -80ºC until analysis.  
Concentrations of CRP were used (mg/L) as the primary pharmacodynamic 
endpoint in rabbits and determined using a commercially available ELISA kit (Caltag 
Medsystems, Buckingham, UK). Blood samples (0.5 mL) for CRP were taken at 0, 2, 
24, 48, 72 and 96 hours post-infection. Serum was stored at -80ºC until analysis. 
Blood samples (0.5 mL) were cultured in paediatric culture media bottles 
(BacT/AlertÒ FA plus, Biomérieux SA, Lyon, France) before the first dose and every 
24 hours thereafter, and incubated at 37ºC for 48 h before plating 0.1 mL of blood 
culture medium on drug-free and drug-containing MH agar plates (i.e. vancomycin at 4 
and 8 mg/L) (Sigma-Aldrich). 
Quantitative counts from the tip of the catheter that was removed at autopsy 
were estimated. The catheter tips were inserted in 5 mL of PBS and sonicated for 15 
minutes (60°C) before plating 0.1 mL of serial 10-fold dilutions on drug-free and drug-
containing MH agar plates (4 and 8 mg/L) (Sigma-Aldrich). 
3.3.7- PK/PD Mathematical Modelling 	
All PK and PD data were co-modelled using a non-parametric population 
methodology using Pmetrics v.1.2.9 (Neely et al. 2012). The structure of the PK/PD 
mathematical model fitted to HFIM PK/PD data was based on a previously published 
model of bacterial resistance, (Gumbo et al. 2004) and took the following form: 
 
(1) !"#!$ = 	' 1 − *+,- ∗ /1 
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(2) !01!$ = 234567 ∗ /2 ∗ 1 − "19":;<;=>0 − ?@=>0A∗01∗ BCDE FG(*IJAFG9 BCDE FG  
(3) !0:!$ = 23456' ∗ /3 ∗ 1 − "19":;<;=>0 − ?@=>0L∗0:∗ BCDE FM(*IJLFM9 BCDE FM  
 
Equation 1 describes the rate of change of the amount of vancomycin (mg) in 
the central compartment (X1). Equation 2 and 3 describe the rate of change of burden 
of a susceptible bacterial population (S) and a resistant/mutant (R) bacterial population 
in the HFIM. (POPmax (CFU/mL): the theoretical maximum bacterial density; 
KgmaxS/R (log10 CFU/mL/h): maximum rate of growth in both populations; KkmaxS/R 
(log10 CFU/mL/h), the rate of bacterial killing induced by vancomycin; C50S/R (mg/L): 
vancomcyin drug concentrations that produce half-maximal killing; HS/HR: slope 
functions for killing). 
The model fitted to the rabbit CLABSI PK/PD data was similar, but 
incorporated an additional term to describe immunological killing because a decline in 
CRP levels was also seen in control rabbits that only received vehicle. 
(4) !"#!$ = 	' 1 − *+,- ∗ /1 − NOP ∗ 61 + NPO ∗ /2 
(5) !"1!$ = 	NOP ∗ /1 − NPO ∗ /2 
(6) !":!$ = (23456 ∗ /3 ∗ (1 − ":;<;=>0 − 2NR4 ∗ /3 ∗ /4 − ?@=>0∗":∗	 TCDE F*IJF 9 TCDE F  
(7)		!"U!$ = 2R456 ∗ /4 ∗ 1 − "UVWX"  
 
Equation 4 and 5 describe the rate of change of vancomycin (mg) into and from 
a central (X1) and a peripheral compartment (X2). Equation 6 and 7 describe the rate 
of change of CRP concentrations (mg/L) (X3) in the rabbits and change of immune 
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system function (X4) over time. (IMAX, Kimax and KKim: theoretical maximum rise, 
rate of rise of the immune function and rate of CRP suppression exerted by the immune 
system, respectively). 
The fit of each of the PK/PD models to the respective datasets was assessed in 
the following ways: (1) the log-likelihood value; and (2) both the coefficient of 
determination (r2) of the linear regression and visual inspection of the observed-
predicted plots before and after the Bayesian step. 
To determine the PK/PD index that best explained bacterial killing and the 
emergence of drug resistance in the HFIM, scatter plots were constructed that related 
the AUC:MIC, Cmax:MIC and Cmin:MIC with both the observed antibacterial effect and 
the emergence of a drug resistant subpopulation. A non-linear regression model was 
then fitted to the data using Prism software (GraphPad Software Inc., La Jolla, CA). The 
coefficient of determination was used to discriminate the various pharmacodynamic 
indices. 
 
3.3.8- Neonatal Pharmacokinetic Data and Monte Carlo Simulations 	
The experimental data were bridged to the clinic using a recently developed 
population pharmacokinetic model of vancomycin for neonates ‘(Dr. W. Zhao et al, 
INSERM, personal communication)’. The model was developed from plasma 
concentrations obtained from 1463 neonates with post-menstrual age (PMA) range 
23.3-52.4 weeks and weight range 415-11400 g, from multiple investigators in the 
following age groups: (1) < 29 weeks PMA, n= 335; (2) 29-35 weeks PMA, n=618; and 
(3) >35 weeks PMA, n=510. 
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Monte Carlo simulations were performed using NONMEM (performed by Dr 
W. Zhao). The currently recommended vancomycin regimens for each neonatal age 
group were studied, which are as follows: <29 weeks 15 mg/kg q24h; 29-35 weeks 15 
mg/kg q12h and >35 weeks 15 mg/kg q8h (Sharland et al. 2016). The AUC at steady 
state was determined for the simulated neonates using this regimen. A number of 
optimized regimens were then studied, with the goal of achieving parity in drug 
exposure (AUC) across the different age groups. 
CRP data from a cohort of 10 neonates (aged 26 weeks-39 weeks PMA, weight 
range 690-5080 g) recruited as part of a teicoplanin pharmacokinetic study (EudraCT 
number 2012-005738-12) was used to place the rabbit CRP values profile in a clinical 
context. 
A range of drug exposures (AUCs) linked to the predicted CRPs at 96 h (last 
experimental time-point) was established by means of individual population simulations 
conducted in ADAPT 5 (X. W. D’Argenio DZ, Schumitzky A 2009) using the 
population PK/PD parameter medians from the rabbit PK/PD mathematical model. The 
number of simulated neonates achieving the range of drug exposures was then matched 
to the predicted linked population CRPs for both standard and optimized therapies. 
Measures of central tendency and dispersion for the CRP levels were calculated. 
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3.4- RESULTS 
3.4.1- Strains, MICs and mutational frequency 	
The broth microdilution modal MIC for all the strains by both methodologies 
used was 2 mg/L. All the strains were oxacillin resistant by Etest (Oxoid). Following 
48-h incubation, the frequency of mutants able to grow on plates that contained 2xMIC 
was between 1.7x10-3 (S. capitis 122828) and 8.19x10-6 (S. epidermidis 121164). 
3.4.2- HFIM of CoNS 	
A human neonate-like vancomycin half-life and plasma concentration-time 
profiles were readily generated in the HFIM (Figure 3.1). The different species and 
strains of CoNS grew well in the HFIM. The initial density of organisms was 
approximately 4.5 log10 CFU/mL, which grew over 24 hours to a final density of 
approximately 10 log10 CFU/mL.		
Figure 3.1- Pharmacokinetics and pharmacodynamics of vancomycin against S. epidermidis 
122648 (raw data) to show: A) The PK profiles of 30, 15 and 7.5 mg/kg/day, B) Total population 
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bacterial density decline (log10 CFU/mL) and C) Resistant sub-population bacterial density decline 
(log10 CFU/mL).	
3.4.3- Pharmacodynamics of Vancomycin against CoNS in the HFIM: Dose 
Finding Studies 	
There was a dose-dependent decline in the total bacterial density with increasing 
drug exposure with all the strains investigated. In contrast, lower dosages of 
vancomycin (7.5 mg/kg/day) resulted in the emergence of a vancomycin resistant 
population, which was not observed with the use of higher dosages (30 mg/kg/day) 
(figure 3.2.A and B).  
 
	
Figure 3.2.A-Pharmacodynamics of vancomycin against the 5 CoNS strains investigated in the 
HFIM (raw data). The figure shows the bacterial density decline (log10 CFU/mL) of the total 
population (on top, filled symbols) and the resistant sub-population (bottom, empty symbols) for 
the lower (7.5 mg/kg/day) and higher (30 mg/kg/day) dosages studied plus the drug-free control 
experiments. 
 
	 147	
	
Figure 3.2.B- Pharmacodynamics of vancomycin against five CoNS strains in the HFIM after 
PK/PD population modelling. 
Panel (a) shows the total bacterial density (log10 CFU/mL) decline along the different fAUC/MIC 
reached at steady state (96-120 h) in all the experiments. An Emax sigmoid inhibitory model was 
fitted to the data (r2 =0.62). Panel (b) shows the resistant bacterial population decline along the 
same PD index. Panel (c) shows the probability of emergence of resistance compared to controls 
with each 100 range of fAUC/MIC ratios at steady state.  
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3.4.4- In vitro Dose Fractionation Studies 	
A daily dosage of 15 mg/kg/day resulted in logarithmic killing (> 4 log10 
CFU/ml cell kill) regardless of the schedule of administration, but daily administration 
of drug achieved the greatest logarithmic kill. The emergence of vancomycin resistance 
was more pronounced in the continuous infusion arms compared with intermittent 
therapy for strains S. epidermidis 121164, S. capitis 062012 and S. capitis 122828 
regardless of the mutational frequency (Figure 3.3). Regression analyses, using an 
inhibitory sigmoid Emax model showed a strong correlation between both fCmax:MIC 
and fAUC:MIC and bacterial killing (r2 = 0.95 for both indices). Nonlinear regression 
analysis also showed a strong association between fCmax:MIC and fAUC:MIC and 
suppression of vancomycin resistance for all the strains, including S. capitis 122828, 
which had the highest mutational frequency of resistance (Figure 3.4). %fT> MIC was 
not investigated because all the dosage regimens fractionated had T> MIC of 100 %. 
A vancomycin fAUC/MIC ratio at steady state > 400 mg*h/L was associated 
with near maximal bacterial killing and suppression of emergence of resistance (Figure 
3.2.B a and b). Progressively higher drug exposure of vancomycin (AUC:MIC) 
resulted in progressively higher degrees of bacterial killing. An “inverted U” was 
observed with maximal amplification of resistance with a fAUC:MIC of approximately 
200 (Figure 3.2.B c). The PK/PD parameter values from the population PK/PD model 
are shown in table 3.1. 
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Figure 3.3- Dose-fractionation vancomycin studies (15 mg/kg/day) in the HFIM. 
a) S. epidermidis 121164, the strain with the lowest mutational frequency to resistance, b) S. capitis 
062012 and c) S. capitis 122828. Regimens consisted of 15mg/kg once daily-q24(1), twice daily-q12 
(2) and 24h continuous infusion-CI (3) in the HFIM. Full symbols show the data points (bacterial 
density count in drug-free plates) for the total bacterial population. Clear symbols represent data 
points (bacterial density count in 4mg/L vancomycin drug-containing plates) for the resistant sub-
population. Dotted lines represent the lower limit of quantification (LOQ) of 1 log10 CFU/mL. 
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Figure 3.4- Pharmacodynamics of vancomycin against CoNS (S. capitis 122828). 
The strain with the highest mutational frequency to vancomycin resistance, in the HFIM. The 
endpoint is the bacterial density count (Log10 CFU/mL) at the end of 9 days in the HFIM. An 
inhibitory sigmoid Emax model was fitted to the total bacterial population versus the PD index and 
a non-linear regression model was fitted to the resistant subpopulation versus PD index (a): 
fAUC/MIC; (b): fCmax/MIC; (c): fCmin/MIC). 
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3.4.5- Vancomycin Pharmacodynamics in the CLABSI Rabbit Model 	
 Vancomycin was well tolerated with regimens £ 100 mg/kg/dose. Higher 
dosages caused acute infusional toxicity that was lethal. Vancomycin induced a dose-
dependent decline in CRP (Figure 3.5 a, b, c). A neonatal CRP profile during 
teicoplanin therapy in a cohort of 10 neonates with suspected or confirmed CoNS 
sepsis was comparable to the CRP profiles observed in rabbits (Figure 3.5 d). 
 
	
Figure 3.5- Concentration-time profile of CRP in rabbits and neonates. 
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 (a) Control rabbits and for the rabbits receiving the lowest and highest dose of vancomycin 
along the 4 days of experiment (b) and (c), respectively in the CLABSI rabbit model. Panel (d) 
shows the CRP profile in neonates at 0, 24 (first day of treatment) and 96 h of therapy with 
teicoplanin for comparison. 
 
The median estimated clearance in the PK/PD model was 0.576 L/h and the 
Vc (volume of distribution in the central compartment) was 0.56 L. The distributional 
and elimination t1/2 were 0.18 and 0.9 hours, respectively. The r2 for the observed-
versus-predicted plots obtained after the Bayesian step from the PK-PD population 
model for vancomycin and CRP concentrations was 0.957 and 0.756, respectively. 
The PK/PD parameter values from the population PK/PD model are shown in Table 
3.1. Predicted (Bayesian posteriors) median AUCs at steady state ranged between 
41.09 (10 mg/kg/day q24) and 487.5 mg*h/L (100 mg/kg/day q12).  
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Population PK/PD parameter in vitro model 
(free drug concentrations) 
Population PK/PD parameter in vivo 
model (total drug concentrations) 
 Mean (SD) Median Mean (SD) Median 
Cl (L/h) 0.03 (0.02) 0.025 0.65 (0.2) 0.58 
Vc (L) 0.5 (0.2) 0.44 0.86 (0.4) 0.56 
Population PD parameter in vitro model Population PD parameter in vivo model 
KgmaxS (log10 CFU/mL*h-1 
or mg/L*h-1)  
1.2 (0.3) 1.12 3.9 (3.6) 2.89 
KgmaxR (log10 CFU/mL*h-1) 0.61 (0.5) 0.52 NA NA 
Popmax (CFU/mL or mg/L) 2.5x109(2.9x109) 1.5x109 207.1 (18.7) 219.7 
H 5.25 (2.9) 4.1 8.7 (7.2) 3.99 
HR 7.03 (5.5) 3.8 NA NA 
KkmaxS (log10 CFU/mL*h-1 
or mg/L*h-1) 
1.3 (0.3) 1.25 0.21 (0.2) 0.14 
Kimax NA NA 0.19 (0.006) 0.18 
EC50S (mg/L) 7.99 (7.8) 5.96 6.93 (4.4) 6.07 
EC50R (mg/L) 20.2 (15.6) 18.9 NA NA 
Kkim NA NA 0.02 (0.005) 0.02 
IMAX NA NA 5.3 (0.6) 5.3 
IC1 (CFU/mL)/(mg/L) 4.8x104 (2.4x104) 4.1x104 3.72 (3.9) 3.13 
IC2 (CFU/mL) 163 (37) 98 NA NA 
Cl= Clearance; Vc=Volume of distribution in the central compartment; Kgmax= maximum rate of bacterial growth (in vitro 
model) ; Popmax= theoretical maximum bacterial density; H=Hill slope; C50= Vancomycin concentration producing half-
maximal bacterial kill/CRP reduction; Kkim= maximum rate of CRP reduction induced by the immune system; 
IMAX=theoretical maximum rise of the immune system; Kimax=maximum rate of rise of immune system function; IC= 
initial condition in bacterial density/CRP (1 for the susceptible population and 2 for the resistant population). S and R 
correspond to the total susceptible population and the resistant bacterial population, respectively.  
Table 3.1- Population PK/PD parameter values for both the vancomycin HFIM and the 
CLABSI rabbit model against CoNS infection. 
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Quantitative cultures from blood cultures were only intermittently positive for 
blood.  The total bacterial density from the catheter tips at autopsy is shown in 
Figure 3.6. 
	
Figure 3.6- Central catheter tip cultures at autopsy from the CLABSI rabbit model. 
 (Pooled data means and standard error of means) for each of the dosage regimens and the 
strains investigated (S. epidermidis 122648 and S. capitis 122828) (Log10 CFU/mL). 
 
The relationship between AUC:MIC and the CRP at the end of the 
experiment is shown in Figure 3.7. A total drug AUC:MIC at steady state of 76 
mg*h/L was required to achieve a 50% decrease of CRP by 96 h (end of 
experiment). However, to achieve near maximal effect (80% decrease of CRP at 96 
h), a total drug AUC:MIC of 520 mg*h/L was required for both isolates of CoNS 
(Figure 3.7). 
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Figure 3.7- Pharmacodynamic target AUC/MIC ratio of vancomycin against CoNS in the rabbit 
CLABSI model. 	
3.4.6- Bridging Study 	
The distribution of expected CRP values in a population of 1000 simulated 
neonates for each PMA linked to their respective drug exposures (AUCs) receiving 
current dosage regimens showed that with standard therapy, neonates < 29 weeks 
PMA resulted to be under-dosed in comparison to the older age groups. The median 
predicted CRP from the simulations for neonates <29 weeks, 29-35 weeks, and > 35 
weeks all receiving the currently recommended vancomycin regimen was 58.4, 
49.53, and 49.23 mg/L, respectively. An optimized dosage regimen for the <29 
weeks age group of 30 mg/kg/day (15 mg/kg q12h) reduced the CRP to values 
comparable to the ones of older age- groups (median 49.12 mg/L) (Figure 3.8). 
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Figure 3.8- Bridging study in neonates. Predicted CRP-AUC linked histograms showing the 
distribution of simulated neonates per PMA age group. 
 (a) < 29 wk, (c) 29-35 wk and (d) > 35 wk, receiving currently recommended dosage regimens 
and a proposed optimized vancomycin regimen (b) 15mg/kg q12 for <29 week PMA-group. CRP 
means, standard deviations and medians are shown. 
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3.5- DISCUSSION 	
The inflammatory state that accompanies CoNS infection may contribute to 
poor neurodevelopmental outcomes in neonates (Adams-Chapman & Stoll 2006; 
Mitha et al. 2013). The aim of neonatal therapy is thus, to manage both infection and 
inflammation in the presence of an infected central line that ordinarily cannot be 
removed.	 The optimal vancomycin regimen to achieve this goal is not known, and is 
the focus of this study. We developed two new experimental models to investigate 
the PK/PD of vancomycin against CoNS, which yielded different, but 
complementary information.  
 The HFIM enables human neonatal concentration-time profiles to be 
simulated and is the ideal model to quantify bacterial killing and the emergence of 
antimicrobial resistance under drug pressure. However, its main weaknesses are the 
lack of an immune system and proteins for drug protein binding, which might have 
an impact on drug efficacy. In contrast, the rabbit CLABSI model is a closer mimic 
of neonatal infection and disease that employs CRP as the primary model readout to 
assess the response to antimicrobial therapy. While we acknowledge that several 
factors extraneous to drug exposure, such as immunological effectors and the 
inoculum may also have an impact on CRP concentrations we observed similar CRP 
concentration time profiles in rabbits and neonates receiving glycopeptide therapy 
(Figure 3.5). Furthermore, as is the case in human neonates in the NICU, blood 
cultures are only intermittently positive for CoNS in the rabbit CLABSI model, and 
infection causes inflammation without causing fulminant sepsis and death. All these 
attributes suggest the rabbit model is a faithful mimic of neonatal disease, and can be 
used for future assessment of antibiotics for neonates. This is despite the fact of the 
different vancomycin pharmacokinetics (mainly different drug clearance, see table 
	 158	
3.1) in the rabbits as opposed to the simulated neonatal clearance in the HFIM, which 
was corrected by dosing rabbits to aim clinically relevant drug exposures in terms of 
AUCs. 
Studies conducted in the HFIM suggest that vancomycin exhibits 
concentration-dependent killing. Both the AUC:MIC and the Cmax:MIC readily 
account for the experimental data when the total and resistant subpopulations were 
considered (Figure 3.4, Panels a and b). There is a progressive decline in bacterial 
density with increasing AUC:MIC. In contrast, a characteristic “inverted U” was 
observed when drug exposure was linked with the emergence of drug resistance 
(Tam et al. 2007; Zinner et al. 2003).The concentration-dependent effect of 
vancomycin on bacterial killing is consistent with other studies in MRSA and S. 
pneumoniae infections (Jenny Dahl Knudsen et al. 2000; Nicasio et al. 2012). The 
PK/PD data strongly suggest that the use of less fractionated regimens is appropriate 
in the clinic, with no pharmacodynamic evidence that vancomycin continuous 
infusions may be beneficial for treatment of CoNS. Furthermore, intermittent drug 
administration may facilitate the clinical use of vancomycin (by freeing up an i.v. 
line), minimize toxicity (because Cmin is linked to toxicity)(Lodise et al. 2009) and 
minimize the emergence of drug resistance.  
In the HFIM, the drug exposure that predicts near maximal killing and is 
required to suppress the emergence of drug resistance is a fAUC:MIC >400, which is 
equivalent to a fAUC > 800 mg*h/L (because the MIC of the study strains is 2 
mg/L), and a total drug AUC of approximately 1330 mg*h/L ( total AUC/MIC of 
665) if 40% protein binding is assumed (Butterfield et al. 2011; De Cock et al. 2016). 
Such a value is higher than the total drug AUC:MIC value of 400 that is widely cited 
for treatment of invasive MRSA (Moise-Broder et al. 2004; Le et al. 2013; Frymoyer 
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et al. 2013; Liu, Bayer, Cosgrove, Daum, Fridkin, Gorwitz, Kaplan, Karchmer, 
Levine, Murray, Rybak, D. a. Talan, et al. 2011), and therefore raises the question of 
the clinical relevance of the experimental findings from the HFIM. The rabbit 
CLABSI model provides some additional context for this finding. Here, a total drug 
AUC:MIC of 520 (corresponding to a total drug AUC of 1040 (MIC = 2 mg/L) and a 
fAUC:MIC of 312) is required for near complete CRP suppression (Figure 3.7). The 
HFIM studies suggest this magnitude of drug exposure also prevents the emergence 
of CoNS mutants (Figure 3.2.B b and c).  
Collectively therefore, both experimental models suggest: (1) higher 
AUC:MIC targets (total 665 and 520 for the HFIM and the rabbit model 
respectively) than are currently proposed for MRSA infection in adults are required 
for maximal bacterial kill, prevention of amplification of a resistant subpopulation 
and suppression of circulating CRP in the setting of a retained central line; and (2) 
the dose fractionation studies suggest that less fractionated regimens may be better in 
terms of bacterial kill and preventing the emergence of drug resistant subpopulations.  
The recommended vancomycin regimens for neonates vary widely, but 
commonly used regimens in Europe are as follows: (1) 15 mg/kg/day q24h in < 29 
weeks PMA (2) 15 mg/kg q12h in 29-35 weeks PMA and (3) 15 mg/kg q8h in >35 
weeks PMA (BMJ Group, the Royal Pharmaceutical Society of Great Britain 2015b; 
Sharland et al. 2016). The bridging study provides an opportunity to examine the 
potential adequacy of these regimens. After examining the experimental data, we 
decided not to define a cut-off value to classify therapeutic success and failure 
because of the arbitrary nature of such a value. The absence of clinical data makes 
any split somewhat difficult to justify. Rather, we used the whole exposure-effect 
relationship obtained from the rabbit model, ultimately using a clinically relevant 
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readout of circulating CRP concentrations. Simulations suggest that neonates < 29 
weeks PMA are under-dosed with respect to the older age- groups and have higher 
predicted CRP values. A regimen of 15 mg/kg q12h is needed to achieve a similar 
reduction in CRP concentrations compared with older neonates and infants.  
This study provides the pharmacodynamic rationale to explore the use of 
higher dosages in neonates <29 weeks PMA. These ideas can now be tested in a 
multi-centre Phase IIb clinical trial. Somewhat surprisingly, the vancomycin 
exposure that is required for maximal anti-bacterial effect appears higher than is 
widely accepted for the treatment of more virulent Gram-positive organisms. The 
PK/PD data and models provide an insight into the difficulties of managing infection 
in critically ill neonates with a trade between bacterial killing, preventing emergence 
of drug resistance and minimizing drug related toxicity.  
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Chapter 4 
 
Pharmacokinetics and Pharmacodynamics of 
Teicoplanin Against Methicillin Resistant 
Staphylococcus aureus 
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4.1- ABSTRACT 	
Objectives: There is limited information on teicoplanin pharmacodynamics to ensure 
the most optimal dose-exposure-effect relationships. The overall study aim was to 
identify the relevant pre-clinical PK/PD indices for teicoplanin to predict efficacy and 
suppression of resistance in MRSA infection.  
Methods: A hollow-fibre infection model simulating a paediatric PK profile and a 
standardised neutropenic murine thigh infection model were developed. The PK/PD 
data generated was then co-modelled for each infection model using a non-parametric 
population modelling approach with Pmetrics. The posterior Bayesian estimates derived 
for each model were then used to study the exposure-effect relationships using a 
sigmoid Emax inhibitory model. Monte Carlo Simulations from previous developed 
population PK models in adults and children were used to explore the PTA for a variety 
of teicoplanin dosage regimens against current EUCAST wild-type susceptibility range.  
Results: There was a concentration-dependent activity of teicoplanin in both the in vitro 
and in vivo models. A total in vivo AUC/MIC of 610.4 (total exposure of 305.2 mg*h/L) 
for an MRSA strain with an MIC of 0.5 mg/L was needed for efficacy (2 log10 cell kill) 
against a total bacterial population. A total AUC/MIC ratio of ~ 1500 (total exposure of 
~ 750 mg*h/L) was needed to suppress the emergence of resistance.  
Conclusions: This study improves our understanding on teicoplanin pharmacodynamics 
against MRSA and defines an in vivo AUC/MIC target for efficacy and suppression of 
resistance. Additional studies are needed to further corroborate the PK/PD index in a 
variety of infection models and in patients. 
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4.2- INTRODUCTION 	
Teicoplanin is a glycopeptide with a similar spectrum of antibacterial activity to 
vancomycin (The Electronic Medicines Compendium 2014; Cavalcanti et al. 2010). 
Teicoplanin is licensed in the EU and other countries for the treatment of moderate-to-
severe methicillin-resistant Gram-positive bacterial infections in children and adults 
(The Electronic Medicines Compendium 2014). Teicoplanin was developed before 
contemporary PK/PD techniques and there is little pharmacodynamic information that 
provides a rationale for the optimal use of this agent.  
Drug exposure targets that are associated with a high probability of a successful 
clinical outcome are relatively poorly defined. Initial regimens were designed to achieve 
a Cmin of 5-10 mg/L (A. P. R. Wilson 2000). More recently, this drug exposure target 
has been increased to > 15 mg/L for the majority of clinical indications (e.g. bacteremia, 
pneumonia, complicated skin and soft-tissue infections). Higher targets of 20 and 30-40 
mg/L are now advocated for the treatment of bone/joint infections, and infective 
endocarditis, respectively (The Electronic Medicines Compendium 2014). These 
updated targets are based on small retrospective studies in adults (Harding et al. 2000; 
Ueda et al. 2012). Herein, we describe the pharmacodynamics of teicoplanin against 
MRSA. We used a well-characterised hollow fibre infection model (HFIM) and a 
murine thigh infection model of MRSA to establish these relationships. We considered 
both the antibacterial effect of teicoplanin and the emergence of resistance to 
teicoplanin as primary study endpoints. We evaluated the relevant PK/PD indices that 
best described the killing of susceptible sub-populations and prevented the emergence 
of resistance. We finally bridged the experimental results to human patients to reflect on 
the adequacy of current EUCAST in vitro susceptibility breakpoints. 
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4.3- MATERIAL AND METHODS 	
4.3.1- Organism, Susceptibility Studies and Mutational Frequency 	
MRSA ATCCÒ 43300Ô(ATCCÒ, Middlesex, UK) was used for all 
experiments. The isolate was stored on beads at -80ºC. The MIC for the strain was 
determined using the EUCAST broth microdilution methodology on three separate 
occasions (European Committee on Antimicrobial Susceptibility Testing 2003). The 
mutational frequency of a subpopulation with MIC >=8 mg/L was determined using 
teicoplanin drug containing MH agar (Sigma-Aldrich, Dorset, UK), as previously 
reported (Nicasio et al. 2012). 
4.3.2- Teicoplanin concentration determination 	
Concentrations of teicoplanin were measured using a commercially available 
fluorescence polarization immunoassay (FPIA; Thermo Fisher Scientific, Germany). 
This is a homogeneous particle-enhanced turbidimetric immunoassay that utilizes the 
Quantitative Microsphere System (QMS) technology and was implemented on an 
automated analyzer Abbott Architect ci4100. The assay is based on competition 
between drug in the sample and drug coated onto a microparticle for antibody biding 
sites of the teicoplanin antibody reagent. A concentration-dependent agglutination 
inhibition curve was obtained with minimum and maximum rate of agglutination at the 
highest and lowest teicoplanin concentrations, respectively. The limit of quantification 
(LOQ) was < 3.0 mg/L. The dynamic range was 3-100 mg/L and overall (intra and 
inter-day) precision was < 6%. This method was performed by Kevin Padmore. 
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4.3.3- In vitro Model of MRSA Infection in a Hollow Fibre System 	
Teicoplanin for intravenous infusion (Targocid 400 mg, Sanofi Aventis, Surrey, 
UK) was used for all experiments. A paediatric pharmacokinetic profile was simulated 
in the HFIM. An elimination half-life of 6.4 hours for teicoplanin was targeted in all the 
experiments, which was based on a median clearance estimate from a previous 
population pharmacokinetic model in children (Ramos-Martin et al. 2014). 
For each experiment, fresh bacterial isolates were grown on blood agar (Oxoid 
Ltd., Hants, UK) and incubated at 37º C for 24 hours. Bacteria were then inoculated into 
the extra-capillary space of each hollow-fibre (HF) cartridge. The desired starting 
inoculum (~6 log10 CFU/mL) was confirmed by quantitative culture on MH agar plates 
(Thermo Fisher Scientific, Runcorn, UK). The HFIM was incubated at 37ºC in ambient 
air. 
4.3.4- In Vitro Pharmacokinetic and Pharmacodynamic Studies 	
Initial dose-finding studies were conducted using concentration-time profiles of 
teicoplanin corresponding to human dosages of 10-100 mg/kg/day. Dosages that 
encompassed the exposure-response relationships for bacterial killing and the 
emergence of resistance were defined in preliminary experiments.  
 A total daily dose of 10 and 30 mg/kg/ day of teicoplanin was administered in 
the following ways: (a) a bolus administered every 24 hours (q24h); (b) two half 
dosages administered q12h; and (c) the total daily dose infused over a 24 h period (CI). 
Treatment was initiated 24 hours post-inoculation. Experiments were conducted for up 
to 7 days to simulate the typical duration of clinical therapy and provide the opportunity 
to observe the emergence of antimicrobial resistance.  
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4.3.5- In vitro Pharmacokinetic Studies 	
PK samples (1 mL) were withdrawn from the central compartment of the HFIM 
before each dose and at 1, 3, 6, 12 and 24 hours. Sampling occurred during the first dose 
interval and at day 6 of therapy. The area under the teicoplanin concentration time curve 
(AUC0-24), maximum concentration (Cmax or peak) and minimum (Cmin) teicoplanin 
concentrations at steady state (144-168 h), were calculated from the Bayesian posterior 
estimates for the PK parameter values from each fibre (see below). 
 
4.3.6- In vitro Pharmacodynamic studies 	
Bacterial samples (1 mL) were withdrawn from the extra-capillary space of each 
HF cartridges and ten-fold serial dilutions (100µL) were plated to both free and drug-
containing agar plates. Sampling occurred at 0, 2, 6 and 24 hours post-infection and 
every 24 hours thereafter (immediately prior to dosing). Total and resistant 
subpopulations were quantified. To investigate whether the mutants that grew on drug-
containing plates had an elevated MIC, approximately 10 colonies were selected from 
each plate and the MIC was re-estimated as previously described.  
 
4.3.7- Pharmacokinetic and Pharmacodynamic Studies in a Murine Thigh 
Infection model 	
A well-characterised neutropenic murine thigh infection model was used to 
provide a complementary perspective on the pharmacodynamics of teicoplanin to that 
provided by the HFIM. All experiments were conducted under UK Home office project 
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license PPL 40/3630 and approved by the University of Liverpool’s Animal Welfare 
and Ethics Review Board.  
Male CD1 mice (16-20 g) were rendered neutropenic on day -4 and -1 with 
intra-peritoneal administration of cyclophosphamide (Baxter, Liverpool, UK) (150 and 
100 mg/kg, respectively)(Zuluaga, Salazar, C. A. Rodriguez, et al. 2006). On day 1, 
mice were inoculated with 2 x 106 CFU/mL MRSA (43300) in each posterior thigh 
muscle in a 50 µL volume. Teicoplanin was commenced 2 h post-infection and was 
administered i.v. every 12 hours. 
 
4.3.8- In vivo Pharmacokinetic studies 	
Dosages of 2.5, 15 and 100 mg/kg/day were chosen to investigate the total 
bactericidal effect and the suppression of resistance based on preliminary dose-finding 
studies. PK sampling was performed at: 0, 0.5, 1, 2, 4 and 12 hours post-dose. Three 
mice were used per dose-time-point. Samples were immediately spun and plasma stored 
at -80ºC until analysis.  
 
4.3.9- In vivo Pharmacodynamic studies 	
At the time of sacrifice (at 2, 12 and 26 h post-infection) both thighs were 
aseptically removed and placed in separate culture tubes with 2 mL PBS. Samples were 
individually homogenised using a polytron disperser VDI 12 (VWR, Lutterworth, UK). 
One hundred µL aliquots from 10-fold serial dilutions were plated to drug free and MH 
agar containing teicoplanin 8 mg/L. The mean value of the bacterial burden from the 
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left and right thigh from each mouse was determined.  The mean and SD of a group of 
three mice was then calculated. 
 
4.3.10- PK/PD Mathematical Modelling 	
A mathematical model was fitted to the experimental data from the HFIM and 
mice. The population PK program Pmetrics was used for all fitting (v.1.2.9, University 
of Southern California, Los Angeles, CA)(Neely et al. 2012) for R (version 3.1.0, 
Institute for Statistics and Mathematics, Vienna, Austria)(R Team 2013). The structural 
model took the form: 
 (1) !"#!$ = 	' 1 − *+,- ∗ /1 
(2) !01!$ = 234567 ∗ /2 ∗ 1 − "19":;<;=>0 − ?@=>0A∗01∗ BCDE FY(*IJAFY9 BCDE FY  
(3) !0:!$ = 23456' ∗ /3 ∗ 1 − "19":;<;=>0 − ?@=>0L∗0:∗ BCDE FM(*IJLFM9 BCDE FM  
 
Equation 1 describes the rate of change of the amount of teicoplanin (mg) in the 
central compartment (X1). Equation 2 and 3 describe the rate of change of burden of a 
susceptible bacteria population (S) and a resistant/mutant (R) bacteria population in the 
HFIM/murine model. The rate of growth is a balance between bacterial growth and 
death. POPmax (CFU/mL) is the theoretical maximum bacterial density; KgmaxS/R 
(Log10CFU/mL/h) is the maximum rate of bacterial growth in both subpopulations; 
KkmaxS/R (Log10 CFU/mL/h) is the rate of bacterial killing induced by teicoplanin; 
C50S/R (mg/L) represent the teicoplanin drug concentrations that produce half-maximal 
killing in both sub-populations; HS/HR are the respective slope functions. 
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There were three output equations for the model: (1) Y(1)=X(1)/V, which 
described the time course of teicoplanin concentrations; (2) 
Y(2)=DLOG10(X(2)+X(3)), which described the time course of the total population; 
and Y(3)=DLOG10(X(3)), which described the time course of the resistant 
subpopulation. 
The goodness of fit of each model to the data was assessed using a combination 
of the following: (1) the log-likelihood value, (2) the Akaike information criterion 
(AIC), (3) the coefficient of determination (r2) from the linear regression of the 
observed-predicted plots before and after the Bayesian step, and (4) a minimization of 
bias and imprecision values of the observed-predicted plots.  
 
4.3.11- Exposure-effect relationships and optimal targets 	
To determine the PK/PD index that best described bacterial killing and the 
suppression of drug resistance, scatter plots from the in vitro dose-fractionation studies, 
were constructed that related the AUC:MIC, Cmax:MIC and Cmin:MIC with both the 
observed antibacterial effect and the emergence of a drug resistant subpopulation from 
the HFIM. The relevant PK/PD index was then further explored with the in vivo mice 
data. A non-linear regression model was fitted to the data using Prism software 
(GraphPad Software Inc., La Jolla, CA). The coefficient of determination and visual 
examination of the fit was used to discriminate the various pharmacodynamic indices. 
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4.3.12- Monte Carlo Simulations and Probability of Target Attainment (PTA) 
analysis 	
 Monte Carlo simulations were performed with Pmetrics. A population of 1,000 
simulated patients was generated for each teicoplanin regimen. These simulated patients 
were used to examine the outcomes of candidate regimens of teicoplanin. For the adult 
simulations we used the population PK estimates and covariance matrix from a 
previously developed population PK model (Ramos-Martin et al. 2014). For the 
paediatric simulations, we used the population PK estimates and covariance matrix from 
a previously developed PK model in children (submitted for publication). For children, 
the weight-based dose of teicoplanin (mg per kg) was administered to each simulated 
patient as a 3-minute i.v. infusion. The weight-based dosage was converted to an 
absolute dosage for i.v. administration (as would happen at the bedside) by multiplying 
by the simulated weight (for example, a 20 kg child receiving 10 mg/kg would receive 
200 mg of teicoplanin). The following covariate limits were used for the simulations: 
weight: 9-62.2 kg; age: 1-16 years old and estimated GFR (Schwartz): 49-178.1 
mL/min/1.73 m2). A variety of candidate regimens were investigated: the standard 
teicoplanin dosing and regimens 2 and 3 with the same daily maintenance dose but 
different frequency of dosing (q24h vs q12h). We considered this relevant to evaluate 
the impact of the frequency in AUC and Cmin attained drug exposures. Estimation of the 
drug exposures in terms of AUC0-24 and Cmin at steady state (between days 3 and 4 of 
treatment) were performed for each dosage regimen for both adults and children. 
For the PTA analysis, a target AUC/MIC (stasis and 2 log10 cell kill in the 
murine model) was used. The distribution of the MRSA MICs determined using 
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EUCAST methodology from 0.032 to 16 mg/L were plotted (European Committee on 
Antimicrobial Susceptibility Testing 2010). Fractional target attainment was calculated 
for the various regimens to identify the achievement of the AUC/MIC targets by 
comparing the PTA against the teicoplanin MIC distribution for MRSA. 
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4.4- RESULTS  	
4.4.1- In vitro susceptibility and mutational frequency 	
The modal teicoplanin MIC for the MRSA ATCC 43300 was 0.5 mg/L. The 
strain was oxacillin resistant by E-test (Oxoid). The mutational frequency (at 16 x MIC) 
was 1.02 x 10-7. MICs from resistant mutants at the end of in vitro experiments (168 h) 
were up to five two-fold dilutions higher (2 to ³ 16 mg/L).  
4.4.2 -Pharmacodynamics of Teicoplanin against MRSA: Dose Finding Studies and 
Dose Fractionation Studies in the HFIM 
There was a dose-dependent decline in the total bacterial density following 
exposure to teicoplanin. Total bactericidal effect was achieved with dosages of ³ 10 
mg/kg/day q24h and suppression of resistance with dosages ³ 30 mg/kg/day q24h 
(Figure 4.1.A). The estimated t1/2 of teicoplanin in the HFIM was 8.7 hours. 
In figure 4.1.B the population PK/PD final model observed versus predicted 
plots are shown. The r2 of the linear regression were 0.9 and 0.7 for the PK and PD, 
respectively, after the Bayesian step. 
 The results from the dose fractionation studies are shown in Figure 4.2. Non-
linear regression analysis showed a strong correlation between fCmax: MIC, fAUC:MIC 
and fCmin:MIC and bacterial killing (r2 = 0.92, 0.9 and 0.86 respectively). There was also 
a strong association between fCmax:MIC and fAUC:MIC and suppression of teicoplanin 
resistance (r2  =0.79, 0.95 respectively).  In contrast, a weaker relationship was apparent 
between fCmin:MIC and suppression of teicoplanin resistance (r2 =0.45). 
In the HFIM, a teicoplanin fAUC/MIC ratio at steady state ³ 576 mg*h/L was 
associated with a 2 log10 CFU/mL decline in bacterial density and ³ 1325 was required 
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to suppress the emergence of resistant clones (Figure 4.2.a). For the resistance studies, 
a characteristic “inverted U” was observed with maximal amplification of resistance 
with a fAUC:MIC of approximately 400-600 mg*h/L (Figure 4.2.a).  
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Figure 4.1.A- Dose finding studies results in the HFIM showing the total bactericidal effect of 
teicoplanin against MRSA with dosages ³30 mg/kg/day and the emergence of drug resistance with 
10 mg/kg/day. 
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Figure 4.1.B- Population teicoplanin PK/PD model from the HFIM showing the observed versus 
predicted PK concentrations (mg/L) (top) and PD total bacterial densities (log10 CFU/mL) (bottom) 
plots, respectively, for the population and the individual posterior predictions. 
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Figure 4.2- Teicoplanin pharmacodynamics against MRSA in the HFIM. 
An Emax sigmoid model was fitted to the data (Bayesian individual posterior estimates from the 
population PK-PD model). a) fAUC (144-168 h) vs total and resistant bacterial density at the end of 
therapy (168 h); b) fCmax (145 h) vs total and resistant bacterial density at the end of therapy and c) 
fCmin (144 h) vs total and resistant bacterial density at the end of therapy. On the right column, the 
effect against the resistant bacterial populations is shown. A dashed line shows the limit of 
quantification (LOQ) for bacterial load. 
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4.4.3- Murine MRSA Neutropaenic Thigh Infection Model 	
 There was a dose-dependent decline in total bacterial density in the thighs of 
mice treated with teicoplanin. Teicoplanin was bactericidal (³ 2 log10 cell kill) for all 
regimens. There was emergence of a resistant sub-population with all regimens 
investigated with the appearance of an inverted U (Figure 4.3b).  
Based on the HFIM studies (above), the AUC:MIC was used as the dynamically 
linked index for both effect and the emergence of resistance in the mouse (Figure 4.3). 
A teicoplanin total drug AUC0-24/MIC ratio of » 88.8 and 610.4 mg*h/L was associated 
with stasis and near maximal bacterial killing (2 log10 cell kill), respectively. A total 
drug AUC0-24:MIC ratio ³ 1400-1500 mg*h/L was required for near complete 
suppression of emergence of resistance.  Maximal amplification of resistance was seen 
with total drug AUC0-24/MIC ratios of 500-700 mg*h/L (Figure 4.3b). 
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Figure 4.3- Teicoplanin total AUC/MIC ratio against MRSA total and resistant bacterial density 
from the 26 h mouse thigh infection model. 
Each symbol (filled circle) represents the mean of data for three mice. Effect=8.23-((5.24x 
(AUC:MIC)0.94 )/((AUC:MIC)0.94 +98.5 0.94). Figure 4.2(a) shows the concentration-dependent decline 
in the total bacterial density reaching ³ 2 log10 cell kill CFU/g after AUC/MIC ratios of 600 mg*h/L. 
Thin dashed lines represent the mean bacterial load at the start of therapy (stasis) and 1 and 2 log10 
drop cell kill. Thick dash line represents the LOQ. Figure 4.2(b) shows the characteristic “Inverted 
U” phenomenon in the resistant subpopulation with amplification of resistance at AUC/MIC ratios 
between ~500-700 mg*h/L and near maximal effect at ³1500 mg*h/L.  
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The population PK/PD observed versus predicted plots from the mouse 
neutropaenic model are shown in figure 4.4. The r2 of the linear regression after the 
Bayesian step were 0.99 and 0.95 for the PK and PD, respectively. The population 
PK/PD model parameter estimates from both pre-clinical models are summarised in 
table 4.1.  
 
 
	
Figure 4.4- Population PK/PD model observed versus predicted plots for the in vivo mouse 
neutropaenic thigh infection model showing the predicted population and individual teicoplanin PK 
concentrations (mg/L)(top) and PD total bacterial densities (log 10 CFU/mL)(bottom). 
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4.4.4 Monte Carlo Simulations and PTA analysis 	
The PTA analyses showed that adult and paediatric patients receiving a standard 
dosage regimen for a target of a total AUC/MIC ratio of 610.4 were only successfully 
treated (³ 90% probability of success) if the MIC of the strain was £ 0.125 mg/L in 
adults and £ 0.064 in children. The achievement of AUC/MIC targets required for in 
vivo stasis  (AUC/MIC 88.8) allowed a successful treatment of strains with MICs £ 1 in 
adults and £ 0.5 in children.  If an increased teicoplanin dosage was used along with a 
pharmacodynamic target of 88.8, then a satisfactorily high probability of target 
attainment was achieved for MIC values £ 2mg/L in both adults and children. The PTA 
plots and fractional target attainment are shown in figure 4.3.  
Calculations of drug exposures simulated at steady state (days 3-4) in terms of 
AUC0-24 and Cmin are shown in table 4.2 for each population (adults and children) and 
dosage regimen simulated. 
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Population PK/PD parameter in vitro model 
(free drug concentrations) 
Population PK/PD parameter in vivo 
model (total drug concentrations) 
 Mean (SD) Median Mean (SD) Median 
Cl (L/h) 0.04 (0.02) 0.04 0.08 (0.05) 0.06 
Vc (L) 0.5 (0.2) 0.5 0.6 (0.4) 0.34 
Population PD parameter in vitro model Population PD parameter in vivo model 
KgmaxS (log10 CFU/mL *h-1) 0.62 (0.19) 0.68 0.42 (0.03) 0.4 
KgmaxR (log10 CFU/mL*h-1) 0.15 (0.09) 0.2 0.09 (0.06) 0.06 
Popmax (CFU/mL) 1.6^109 
(1.2^109) 
1.3^109 1.3^108(8^107) 2^108 
H 8.6 (2.6) 9.9 13.7 (3.7) 15.1 
HR 13.9 (2.6) 16 14.1 (5.2) 17.1 
KkmaxS (log10 CFU/mL*h-1) 0.7 (0.2) 0.7 0.52 (0.06) 0.51 
KkmaxR (log10 CFU/mL*h-1) 0.7 (0.4) 0.4 0.75 (0.15) 0.79 
EC50S (mg/L) 11.6 (3.6) 11.8 1.2 (0.3) 1.2 
EC50R (mg/L) 40.2 (9.9) 38.03 64.1 (9.8) 70 
IC1 (CFU/mL) 9.8^104 
(9.4^104) 
10^103 4^104 (8^103) 3.6^104 
IC2 (CFU/mL) 20.2 (15.2) 13.04 159 (162) 206 
Cl= Clearance; Vc=Volume of distribution in the central compartment; Kgmax= maximum rate of bacterial growth; 
Popmax= theoretical maximum bacterial density; H=Hill slope; C50= Teicoplanin concentration producing half-maximal 
bacterial kill; IC= initial condition in bacterial density (1 for the susceptible population and 2 for the resistant population). S 
and R correspond to the total susceptible population and the resistant bacterial population, respectively. In the murine 
model: CFU/mL corresponds to CFU/g. 
Table 4.1- Population PK and PD parameter estimates from the HFIM and the neutropaenic mice 
thigh model. 
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Dosage regimen simulated AUC72-96 median (IQR) 
(mg*h/L) 
Cmin 96 h median (IQR) (mg/L) 
Adults 
1) Standard: 400 mg x 3LD q12h 
+400 mg q24h  
205 (170.9-254.4) 8.72 (7.23-10.8) 
2) 800 mg x 3LD q12h + 800 mg 
q24h 
410.7 (342.1-509.6) 17.4 (14.5-21.6) 
3) 800 mg x 3LD q12h + 400 mg 
q12h  
499.03 (413.4-600.4) 20.96 (17.2-25.5) 
Children 
1) Standard: 10 mg/kg x 3LD 
q12 + 10 mg/kg q24h  
237.4 (114-475.5) 5.4 (1.7-13.4) 
2) 30 mg/kg x 3LD q12h+30 
mg/kg q24h  
711.4 (342.1-1426.2) 16.2 (5.1-40.1) 
3) 30 mg/kg x 3LD q12h+15 
mg/kg q12h 
560.05 (258.7-1298.6) 19.7 (7.9-47.7) 
Table 4.2- Simulated drug exposures (AUC72-96 and Cmin 96) in adults and children between days 3 
and 4 of therapy for standard and dosage increased regimens. 
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Figure 4.5- Monte Carlo Simulations and PTA analysis. 
a) PTA in adult patients receiving standard and increased dosage regimens for a target AUC/MIC 
of 610.4 and 88.8 mg*h/L by day 3-4 of therapy; b) PTA in paediatric patients (1-16 years old) with 
standard and increased dosage regimens for a target AUC/MIC of 610.4 and 88.8 mg*h/L. The 
underlying grey bars on each plot represents the wild-type EUCAST reported distribution for 
teicoplanin against MRSA. The tables show the fractional target attainment for each of the 
simulated dosage regimens against the MRSA teicoplanin MIC distribution. 
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a) Adults
b) Children
Dosage regimen AUC:MIC 88.8 AUC:MIC 610.4 
Standard 94% 10% 
Regimen 2 98% 44% 
Regimen 3 99% 53% 	
Dosage regimen AUC:MIC 88.8 AUC:MIC 610.4 
Standard 84% 29% 
Regimen 2 96% 64% 
Regimen 3 94% 56% 	
	 184	
4.5- DISCUSSION  	
In this study the AUC:MIC ratio was the pharmacodynamic index that best 
links the administration of teicoplanin with the antibacterial effect and the emergence 
of resistance. A total drug AUC/MIC ratio of 88.8 and 610.4 mg*h/L results in stasis 
and a 2-log cell kill, respectively. A previous study in mice also suggests teicoplanin 
displays concentration-dependent antibacterial activity with both Cmax/MIC and 
%T>MIC identified as the relevant pharmacodynamic indices (J D Knudsen et al. 
2000). We demonstrate that all pharmacodynamic targets result in the amplification 
of resistant mutants (Figure 4.2). Thus, the antibacterial effect resulting from 
clinically relevant drug exposures is always tempered by the emergence of drug 
resistance, and the two are inextricably related. Higher teicoplanin exposure 
thresholds (e.g. AUC:MIC » 1500) that are predicted to prevent the emergence of 
resistance are not obtainable using current regimens. 
The magnitude of drug exposure that produces stasis in immunocompromised 
mice is relevant for patients with S. aureus bacteraemia (oritavancin and linezolid), 
and complicated skin and skin structure infections (linezolid and 
tigecycline)(Bhavnani et al. 2006; Boylan et al. 2003; Rayner et al. 2003; Andes et 
al. 2002; Ambrose et al. 2007; van Ogtrop et al. 2000). A teicoplanin AUC:MIC of 
88.8 is likely relevant for patients with skin and skin structure infections. As it can be 
seen from Figure 4.3, such a target is readily achievable for simulated patients 
receiving currently licensed regimens with fractional target attainment rates of 84% 
and 94% in children and adults, respectively.  For more serious staphylococcal 
infections, such as pneumonia, a higher pharmacodynamic target is generally 
required (Ambrose et al. 2003; Ambrose et al. 2007). An AUC:MIC of 610.4 
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produces logarithmic bacterial killing in mice. This estimate is consistent with 
several retrospective clinical studies in which teicoplanin AUCs ³ 750-800 mg*h/L 
and AUC:MIC³ 900 are associated with favourable clinical outcomes in adults with 
serious MRSA infections (Hagihara et al. 2012; Takeda et al. 2016b; Kanazawa et al. 
2011). A higher AUC:MIC ratio is also consistent with the recent upward revision in 
target Cmin concentrations recommended in the SPC for the treatment of patients with 
deep-seated staphylococcal infections (The Electronic Medicines Compendium 
2014). The difficulty of achieving these higher exposure targets with currently 
recommended regimens is highlighted by the fact that fractional attainment rates are 
only 10% and 29% of simulated adults and children, respectively. 
The administration of a fixed teicoplanin regimen is reasonable for skin and 
skin structure infections. Standard teicoplanin therapy results in target attainment in a 
majority of patients and the wild-type population can be largely covered. In contrast, 
more serious infections that require higher drug exposures require routine TDM. Too 
few patients receiving a fixed regimen achieve an adequate AUC:MIC of 610.4 and 
are at risk of concentration-dependent therapeutic failure. For these patients, drug 
measurement and dosage adjustment is required. An alternative strategy is the use of 
combination chemotherapy. There is a large amount of preclinical data that has 
explored the potential benefits of combining glycopeptides with rifampicin, 
fosfomycin and b-lactams (de Matos et al. 2014; Tang et al. 2012; Leonard 2012; 
Werth et al. 2013; Dilworth et al. 2014). These ideas are being studied in several 
prospective clinical trials. ARREST (ISRCTN 37666216) is evaluating the potential 
benefit of adjunctive rifampicin in S. aureus bacteraemia (Thwaites et al. 2012) and 
CAMERA-2 (NCT02365493) is investigating the combination of glycopeptides with 
b-lactams to treat hospitalised patients with MRSA bacteraemia (Tong et al. 2016).  
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Monte Carlo simulations and the PTA analysis suggest that patients infected 
with strains at the upper end of the wild type distribution may be difficult to treat. 
This appears to be the case even if a stasis endpoint is used. The ECOFF using 
EUCAST methodology is 2 mg/L (European Committee on Antimicrobial 
Susceptibility Testing 2010). At this MIC, only 60% and 70% of children and adults, 
respectively, receiving a standard regimen is predicted to achieve a stasis target. This 
is strong evidence to consider a reduction in the breakpoint by at least a dilution to 1 
mg/L (Turnidge & Paterson 2007). For more serious infections that require higher 
pharmacodynamic targets the situation is worse and the breakpoint divides the wild-
type population. 
We must acknowledge that only a single strain was studied in the murine 
model and HFIM. Nevertheless, two experimental models were used that yielded 
complementary information and allowed us to exploit the respective strengths of 
each. The murine thigh model is well characterised, has the advantage of simulating 
protein binding and is a mimic of complicated skin and skin structure infections that 
are common clinical problems. In contrast, the hollow fibre infection model enabled 
us to explore the pharmacodynamic relationships important for the emergence of 
resistance. Together, the findings from these two model systems and 
pharmacodynamic analyses suggest that teicoplanin should be used with some 
caution for the treatment of strains with MICs at the upper edge of the wild type 
population. Therapeutic drug monitoring is a requirement for the treatment of serious 
infections to minimise the probability of concentration dependent therapeutic failure.  
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Chapter 5 
 
Population Pharmacokinetics of Teicoplanin in 
Children 
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5.1- ABSTRACT 
 
Objectives: Teicoplanin is frequently administered in children to treat Gram-positive 
bacterial infections. However, little is known about the pharmacokinetics (PK) of 
teicoplanin in children to justify the optimal dosing regimen. The aim of this study was 
to determine the population PK of teicoplanin in children and evaluate current dosage 
regimens.  
Methods: A PK hospital-based study was conducted. Current dosage recommendations 
were used for children up to 16 years of age. Thirty-nine children were recruited. Serum 
samples were collected at first dose interval (1, 3, 6 and 24 h) and at steady state. A 
standard 2-compartment PK model was developed, followed by structural models that 
incorporated weight. Weight was allowed to affect clearance (CL) using linear and 
allometric scaling terms.  
Results: The linear model best accounted for the observed data and was subsequently 
chosen for Monte Carlo simulations. The PK parameters medians/means (SD) were: 
CL= [0.019/0.023 (0.01)]*weight (L/h/kg), Volume 2.282/4.138 (4.14) (L), Kcp 
0.474/3.876 (8.16) (h-1), Kpc 0.292/3.994 (8.93) (h-1). The percentage of patients with 
Cmin< 10 mg/L was 53.85%. The median/mean (SD) total population area under the 
concentration-time curve (AUC) was 619/527.05 (166.03) mg*h/L. Based on Monte 
Carlo simulations, only 30.04 % (median AUC = 507.04), 44.88 % (494.1) and 60.54% 
(452.03) of patients weighting 50, 25 and 10 kg respectively, attained trough 
concentrations >10 mg/L by day 4 of treatment. 
Conclusions: Teicoplanin population PK is highly variable in children with a wider 
spread of AUC distribution as compared with adults. Therapeutic drug monitoring 
should be a routine requirement to minimize sub-optimal concentrations. 
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5.2- INTRODUCTION 	
Gram-positive bacterial infections are an important cause of morbidity and 
mortality in neonatal and paediatric intensive care units (Venkatesh et al. 2006b; 
Verstraete et al. 2014). A significant rise in infections caused by methicillin-resistant 
Staphylococcus aureus (MRSA) and methicillin-resistant coagulase-negative 
staphylococci (CoNS) has led to an increased use of glycopeptides in the last decade 
(Tiemersma et al. 2004; Van Den Hoogen et al. 2009). Both vancomycin and 
teicoplanin are used for treatment of invasive infections caused by Gram-positive 
organisms and especially those that are resistant to β-lactam antibiotics (Mermel et al. 
2009; Gould et al. 2012). The currently recommended regimen for teicoplanin in adults 
is 3 loading doses of 400 mg 12 hourly, followed by a maintenance dose of 400 mg/day. 
In contrast, children receive 3 loading doses of 10 mg/kg 12 hourly, followed by a 
maintenance dose of 10 mg/kg q24h (BMJ Group, the Royal Pharmaceutical Society of 
Great Britain 2015b). Importantly, however, there is relative paucity of information to 
justify these regimens in children and even less information to identify optimal dosing 
strategies. 
Teicoplanin is a glycopeptide antibiotic agent that has bactericidal activity 
against Gram positive aerobic and anaerobic bacteria (A. P. R. Wilson 2000). It is 
widely used for the treatment of invasive infections such as septicaemia, intravascular 
device-associated infections, endocarditis and septic arthritis caused by methicillin-
resistant Gram-positive pathogens. Despite its extensive use, there are comparatively 
few pharmacokinetic-pharmacodynamic (PK/PD) data for teicoplanin compared with 
vancomycin. There is even less information on the PK of teicoplanin in neonates and 
children and evidence for currently recommended regimens is scant. 
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Regulatory authorities, such as the European Medicines Agency (EMA) have 
developed strategies to facilitate the safe and effective use of medicines in neonates and 
children (The European Parliament and The Council of the European Union 2006). The 
EMA supports the extrapolation of information from adults to children provided there 
are adequate safety data in the latter and the pharmacodynamics can reasonably 
assumed to be the same in both populations. This approach requires the development of 
robust population pharmacokinetic (PK) models in both adults and children, which in 
turn facilitates the design of regimens that enables drug exposures in both populations 
to be matched.  
Teicoplanin is largely used without routinely measuring levels in the majority of 
paediatric patients. In our paediatric hospital setting, we have anecdotal evidence of 
clinical failures with teicoplanin therapy and have also observed “MIC creep” for CoNS 
often found at the breakpoint (4mg/L) (shown in figure 5.0). 
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Figure 5.0- MIC cumulative data from Alder Hey Children´s NHS Foundation Trust 
(Microbiology) corresponding to November 2010-February 2012. Data on 40 CoNS isolates 
recovered from paediatric blood cultures. 
 
 To further investigate the clinical pharmacology of teicoplanin and to provide 
an insight into effective regimens for children, we performed a population PK study. 
The specific objectives of this study were as follows: (1) to describe the population PK 
of teicoplanin in children in a hospital setting; (2) to explore the percentage of patients 
attaining a pre-dose concentration (Cmin) > 10 mg/L; (3) define the area under the 
concentration-time curve (AUC) distributions following the administration of currently 
recommended paediatric regimens; and (4) compare the extent of variability in drug 
exposure to that observed in adults. 
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5.3- MATERIALS/PATIENTS AND METHODS 
5.3.1- Study design, paediatric patient population and sample collection 	
An open label, hospital-based PK study using a sparse blood sampling strategy 
was conducted. Patients ³1 month-<16 years of age were recruited from Alder Hey 
Children´s Hospital. The study was approved by the Medicines and Healthcare products 
Regulatory Agency (Clinical Trial Authorization number 21362/00003/001-0001) and 
the National Research Ethics Service and Regional Committee. The trial was registered 
with the European Clinical Trials Database Registry (EudraCT: 2012-005738-12). 
Participants were screened and recruited according to three age-categories to 
ensure a representative sample was obtained. Such an approach is consistent with the 
European Medicines Agency E11 Guidance for Clinical Trials of Investigational 
Products (CTIMP) in paediatrics (European Medicines Agency 2011). The following 
categories were used 1-23 months, 2-11 years and 11-<16 years. A prospective 
feasibility assessment over 4 months conducted before the trial indicated that the 
pediatric intensive care unit, the oncology Unit, and the intermediate care units were the 
locations with a higher prescription rate of teicoplanin and therefore, these units were 
chosen for targeted screening and recruitment of participants. All patients that were 
prescribed teicoplanin and likely to survive more than 72 hours, were eligible for the 
study. Written informed consent was obtained from parents and/or legal guardians.  
Teicoplanin was used at the discretion of the treating physician. The dosage 
regimen for children > 1 month of age was as follows: 10 mg/kg every 12 hours for 3 
loading doses followed by 10 mg/kg once daily. Teicoplanin was infused over 5 
minutes in children. The duration of treatment was also at the discretion of the treating 
physician. 
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Blood samples (0.2 mL) were obtained throughout the first and last dose interval 
(1, 3, 6 and 24h post-dose). If the first dose administration occurred before informed 
consent had been obtained, a pre-dose sample was also obtained. When possible, a 
washout sample was collected 24 hours after the last dose was administered. Samples 
were centrifuged at 1500 g for 10 minutes and serum was stored at -80º C prior to 
analysis. The following demographic variables with a potential impact on the PK of 
teicoplanin and/or influence the determination of teicoplanin (concomitant medications) 
were also collected for each patient: weight, height and serum creatinine. 
5.3.2- Adult patient population 	
Adult patients with normal renal function who were previously treated with 
chemotherapy because of acute lymphocytic or acute non-lymphocytic leukaemia, and 
subsequently developing febrile neutropenia were recruited to a prospective 
observational PK study, as previously reported (Pea et al. 2004). All patients received 
teicoplanin for the first 72 hours. Subsequently, if a Gram-positive organism susceptible 
to teicoplanin was isolated and /or resolution of fever was documented within 72 hours, 
teicoplanin therapy was continued for at least 8 days. There were two dosing groups: 
firstly, the standard dosing group received standard loading and maintenance dosages of 
teicoplanin (400 mg every 12 hours for three doses followed by 400 mg once daily); 
secondly, the high dosage group received a higher loading regimen (800 followed by 
400 mg, 12 hours apart on day 1; 600+400 mg 12 hours apart on day 2 followed by a 
high maintenance regimen (400 mg every 12 hours on day 3 and thereafter). 
Teicoplanin was infused over 15 minutes. Blood samples were collected at defined 
times: 1 h after the first dose to assess the peak level and at 12, 24, 48, 72, 96, 120 and 
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144 hours to estimate terminal elimination. These adult PK data were kindly shared by 
Professor Federico Pea. 
Demographic data was analysed with SPSS Statistics version 21 (IBM 
Corporation, New York, United States, [http://www-01.ibm.com/software/analytics/ 
spss/downloads.html]). 
5.3.3- Teicoplanin Concentration Determination 	
A fluorescence polarization immunoassay (FPIA; Thermo Fisher Scientific, 
Germany) was used for the quantification of teicoplanin concentrations in serum. This is 
a homogeneous particle-enhanced turbidimetric immunoassay that utilizes the 
Quantitative Microsphere System (QMS) technology and was implemented on an 
automated analyser Abbott Architect ci4100. The assay is based on competition 
between drug in the sample and drug coated onto a microparticle for antibody biding 
sites of the teicoplanin antibody reagent. A concentration-dependent agglutination 
inhibition curve was obtained with minimum and maximum rate of agglutination at the 
highest and lowest teicoplanin concentrations, respectively.  The limit of quantification 
(LOQ) was < 3.0 mg/L. The dynamic range was 3-100 mg/L and total precision was < 
6%. The method was performed by Kevin Padmore in the AHFT´s Clinical Pathology 
Laboratory. 
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5.3.4- Population Pharmacokinetic Models  	
All data were analysed using a non-parametric population modelling 
methodology (Non-Parametric Adaptative Grid, NPAG) with the population 
pharmacokinetic software program Pmetrics (version 1.2.6. University of Southern 
California, California, United States, [http://www.lapk.org/pmetrics.php]) (Neely et al. 
2012) for R (version 3.1.0, Institute for Statistics and Mathematics, Vienna, Austria, 
[http://www.r-project.org/](R Team 2013). The inverse of the estimated assay variance 
was used as the weighting function for all models. 
Three structural models were explored and used in this study. The first 
represented a standard two-compartment PK model with time-delimited zero-order 
intravenous infusion and first-order elimination from central compartment. The model is 
described by the differential equations 1a and 1b below. 
 Z/ 1Z[ = ' 1 − 2OP + 7\]^O ∙ / 1 + 2PO ∙ / 2 		(15) Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																				(1a) 
 
Where X(1) and X(2) represent the amount of teicoplanin in milligrams (mg) in 
the central (c) and peripheral (p) compartments, respectively. R (1) is the rate of 
infusion of drug into the central compartment in mg per hour (mg/h). The central 
compartment has volume (Vc) in litres (L), from which there is clearance (SCL) in litres 
per hour (L/h). The central and peripheral compartments are connected by the first-order 
rate constants Kcp and Kpc (h-1). 
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The effect of weight and serum creatinine on the population PK of teicoplanin 
was explored. The Bayesian estimates for clearance and volume of distribution from 
each patient were obtained from the standard model (above) and plotted against weight 
and serum creatinine, using both linear and logarithmic scales. Since both linear and 
logarithmic relationships between clearance and weight appeared tenable, linear and 
allometric models that incorporated weight as a covariate were developed. The linear 
model took the following form: Z/ 1Z[ = ' 1 − 2OP + 7\]bcdPe ∙ feR3ℎ[^O ∙ / 1 + 2PO ∙ / 2 		 25  Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																																																	(2a) 
 
Where SCLslope represented the slope of the linear relationship between 
clearance and weight. The other terms and relationships are the same as were described 
for the standard model. The intercept of the linear relationship between clearance and 
weight was initially included in the structural model, but estimates from preliminary 
runs were approximately zero. Consequently, in the linear model SCL= 
SCLslope*weight. 
Since a relationship between the log10-transformed estimates for weight and 
clearance from the standard model was also apparent, the performance of an allometric 
power model was also investigated. Such model has been used to determine the effect of 
size on the pharmacokinetics of various compounds in children and neonates 
(Wurthwein et al. 2005; Hope et al. 2007). The allometric scaling exponent in equation 
3a was fixed at 0.75. In addition, only clearance and not volume appeared to have a 
relationship with weight, and therefore clearance was normalized to a 70 kg adult, as 
described elsewhere (Hope et al. 2007). 
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 The differential equations describing the allometric model are as follows: 
Z/ 1Z[ = ' 1 − 2OP + 7\]b[Z ∙ feR3ℎ[70
J.kI
^O ∙ / 1 + 2PO ∙ / 2 						(35)							 
Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																																																			(3a) 
Where SCLstd represents the normalized estimate for clearance in a 70 kg 
individual, the other parameters are described above.   
For the adult data, a standard two-compartment structural model was used. 
5.3.5- Model evaluation, comparison and performance 	
For each model, scatter plots of the observed-predicted relationships for each 
individual patient and the population as a whole were examined. Goodness-of-fit was 
evaluated on the basis of a visual inspection of the data, coefficient of determination of 
a linear regression of the observed-versus-predicted values in the scatter plot after the 
Bayesian step, as well as the slopes and intercepts of the regression. The log-likelihood 
values of each model were used to compare models. Statistical comparisons were made 
using the likelihood ratio test, where twice the likelihood difference was evaluated 
against a ᵪ² distribution with the appropriate number of degrees of freedom. Predictive 
performance was based upon the weighted mean error and the bias-adjusted weighted 
mean squared error. 
5.3.6- Monte Carlo Simulations 	
Monte Carlo simulations were performed using the linear model for children and 
the standard model for adults. The structural model was implemented within the 
simulation module of the pharmacokinetic program ADAPT 5 (W. X. D’Argenio DZ, 
Schumitzky A 2009). The covariance matrix was inserted into subroutine PRIOR. 
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Another subroutine within ADAPT 5 (courtesy of David D’Argenio, University of 
Southern California) enabled teicoplanin to be administered to each of 5,000 simulated 
patients on a weight basis (in mg per kg). For each simulated patient, the weight-based 
dose of teicoplanin (administered in mg per kg) was converted internally to an absolute 
dose of teicoplanin (in mg) by multiplying by the simulated weight. Thus, the 
simulation process mimicked drug administration as it occurred at the bedside in which 
the dose of teicoplanin was planned on an mg per kg basis, but the absolute amount of 
drug administered to each patient was determined with reference to weight. To ensure 
consistency with the clinical trial, teicoplanin was infused over 5 minutes to simulated 
children older than 1 month of age with fixed weights of 10, 25 and 50 kg. For adults, 
the same methodology was used applied to their dosage regimen and infusion time. 
Both normal and log-normal parameter distributions were explored and 
discriminated on the basis of their ability to recapitulate the original parameter means 
and their dispersions. All calculations were performed at steady state between day 4 and 
day 5 post-initiation of treatment. The area under the concentration-time curve from 
time 96-120 h (AUC₀₋₂₄) was determined by integration and the proportion of patients 
achieving the desired drug exposure. A Cmin >10 mg/L was used as the PK target 
throughout the study, as this has been suggested to be the current surrogate for efficacy 
for both, adults and children for most indications (Harding et al. 2000). 	
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5.4- RESULTS 
5.4.1- Demographics 	
A description of demographic data by the age categories is presented in table 
5.1. A total of 39 patients recruited over 8 months (between April 2013 and December 
2013), contributed 49 treatment episodes. Eight patients contributed to > 1 episode (six 
patients contributed two episodes, and two patients contributed three episodes, 
respectively). The mean age (standard deviation) was 4 (4.3) years. The mean weight at 
inclusion to the study (SD) was 17.27 kg (13.3), and 53.8% (n=21) were male. The 
mean height (SD) was 97.68 (34.76) cm, but was only recorded in 30 patients. Patients 
had a mean serum creatinine at start of treatment (SD) of 5.52 (50.08) µmol/L, only 
recorded in 32 patients. 
The majority of patients had undergone cardiac surgery and was being nursed in 
the oncology unit (43.6%). The next largest population group was the patients being 
treated on the intensive care unit (33.3%). The remaining participants were being 
treated for general medical (20.5%) and cardiac medical (2.6%), in which teicoplanin is 
often used to treat catheter-associated bloodstream infections. 
Thirty-three adult patients, 11 in the standard dosage group and 22 in the high 
dosing group were analyzed, 54.5% of them were male. Mean age (SD) was 47.2 (13.9) 
years. The mean weight (SD) was 67.7 (13.6) kg and the mean creatinine at the start of 
treatment (SD) was 69.41 (23.78) µmol/L. They all had been previously treated with 
chemotherapy because of acute lymphocytic or acute non-lymphocytic leukaemia, and 
subsequently developing febrile neutropenia. 
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Age Category 
N 
(% total) 
Age (years) Weight (kg) Height (cm) 
Creatinine 
(µmol/L) 
1-23 months 
16  
(41.02) 
0.25  
(0.45) 
6.26  
(2.04) 
65.84* 
(11.93) 
71.54 (75.68) 
2-11 years 
20  
(51.3) 
5.4  
(2.23) 
21.18  
(7.14) 
112.41** 
(14.36) 
43.3 # 
(13.9) 
11-16 years 
3  
(7.7) 
14.7  
(0.58) 
49.97  
(10.6) 
166.9  
(3.59) 
55  
(8.48) 
Total 
39 
(100) 
4  
(4.3) 
17.27 
(13.3) 
97.7*** 
 (34.8) 
54.5## 
(50) 
Table 5.1- Demographics of patients according to age categories. 
Data are expressed as means (SD)*n=11; ** n=16; ***n=30; #n=13, ##n=32 
 
5.4.2- Pharmacokinetic data 	
A total of 306 pharmacokinetic (PK) serum samples were collected and 298 PK 
samples were included in the analysis (mean of 7.6 samples per patient) for the children. 
Eight observations were excluded from the analysis for the following reasons: in one 
patient, a single concentration obtained immediately at the end of 1 hour infusion was 
substantially higher than the usual peak observed with other patients, and was 
inconsistent with other observations from the same patient. On further investigation, 
this patient was found to have a single lumen line that was used for drug administration 
and sampling. The remaining seven observations were excluded because of incorrect or 
absent time records. Sampling time period was up to a maximum of 264 for some 
patients, and up to 144-168h for the majority of patients (Figure 5.1) 
As seen in figure 5.1, the teicoplanin concentration-time profile for the 39 
paediatric patients was highly variable. Overall, twenty-one patients (53.85%) had 
serum concentrations below 10 mg/L, the serum concentration frequently used to guide 
dosage adjustment.  
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Figure 5.1- Teicoplanin serum concentrations in the 39 patients. 
Patients were dosed according to recommended regimens. Children > 1month: 3 loading doses 
every 12 hours, then once daily.  
 
5.4.3- Population Pharmacokinetic Models 	
The population parameter estimates from each of the models developed are 
summarized in Table 5.2.  The relationship between the Bayesian estimates of 
clearance, obtained using the median population parameter values from the standard 
model and weight is shown in Figure 5.2. For the three models, the fit of the data was 
acceptable (r² 0.742-0.814) with comparable measures of bias and precision. However, 
the better (more positive) log-likelihood value for both the linear and the allometric 
model, suggested that the inclusion of weight as a covariate enabled a significant 
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portion of the observed variance to be explained. The linear model was finally chosen to 
account for the observed data (r² 0.79), shown in Figure 5.3 (A, B). For adults, the data 
from both dosing groups (n=33) was examined using a standard two-compartment 
model, shown in Figure 5.3 (B, C). The model diagnostics are shown in Table 5.3. 
The Bayesian estimates for the AUCs from each of the 39 paediatric patients are 
shown in Figure 5.4. The mean (SD) total population (n=39) AUC was 527.049 
(166.035) mg*h/L. 
 Mean Median SD 
Clearance (L/h) 0.396 0.279 0.347 
Vc (L) 4.259 2.592 3.597 
Kcp(h-¹) 3.344 0.434 7.742 
Kpc(h-¹) 4.424 0.252 9.742 
Clearance slope (L/h/kg) 0.023 0.019 0.010 
Vc (L) 4.138 2.282 4.143 
Kcp(h-¹) 3.876 0.474 8.156 
Kpc(h-¹) 3.994 0.292 8.930 
Allometric    
Clearance Ɵ (L/h/ kg0.75) 0.045 0.040 0.020 
Vc (L) 3.447 1.975 3.579 
Kcp(h-¹) 4.897 0.564 9.054 
Kpc(h-¹) 4.227 0.228 9.638 
Standard for adults    
Clearance (L/h) 1.166 1.097 0.376 
Vc (L) 7.925 7.669 1.849 
Kcp(h-¹) 1.179 1.158 0.449 
Kpc(h-¹) 0.154 0.155 0.087 
Table 5.2- Population Teicoplanin PK parameters estimated values in children and adults. 
Clearance slope=Clearance /weight because Cl=Cl slope*wt; Clearance Ɵ = Clearance /[(weight/70) 0.75] 
because Cl=Cl Ɵ*(wt/70) 0.75; Vc= Volume of distribution in central compartment; Kcp= first-order constant 
rate from the central to peripheral compartment; Kpc= first-order constant rate from peripheral to central 
compartment. 
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Figure 5.2- Evaluation of relationships between the Bayesian PK parameter individual estimates 
from the standard model for clearance and the weight of patients. 
(A) Linear relationship between Bayesian Clearance estimates versus weight. (B) Linear 
relationship of the log-transformed values of Bayesian Clearance estimates versus weight. Dotted 
lines represent the 95% CI of the regression line. 
 
	
Figure 5.3- Observed versus predicted plots for the population and Bayesian posterior values in the 
linear model for children (A) and (B), respectively, and for the population and Bayesian posterior 
values in the standard model for adults (C) and (D). 
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 Log-likelihood r² * Slope (95%CI)* Intercept (95%CI)* 
Standard -987.60 0.814 0.839 (0.793-0.884) 3.67- (2.49-4.85) 
Linear -979.212 0.79 0.848 (0.799-0.898) 3.1 (1.81-4.4-) 
Allometric -983.428 0.742 0.917 (0.857--0.978) 3.15 (1.68-4.61) 
Standard - adults -501.381 0.906 0.967 (0.927-1.01) 1.62 (0.841-2.4) 
Table 5.3- Population PK model diagnostics for teicoplanin in children and adults. 
*Relative to the regression line fitted for the observed versus predicted values after the Bayesian step.  
 
 
 
 
	
Figure 5.4- AUC distributions from the Bayesian posterior estimates from the linear PK model in 
children. 
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5.4.4- Monte Carlo Simulations 	
Monte Carlo Simulations were performed with the linear model in children 
(n=5,000). The extent of the predicted variability in serum teicoplanin concentrations 
and the resultant AUCs within a simulated human population receiving the current 
dosage regimen for children older than 1 month of age, at steady state (between days 4 
and 5 of treatment) and for fixed weights 10 kg (1-23 months), 25 kg (2-11 years) and 
50 kg (11-16 years) were obtained. Based on these simulations, only 30.04 % (median 
AUC₀₋₂₄ = 507.04), 44.88 % (494.1) and 60.54% (452.03) of patients weighting 50, 25 
and 10 kg respectively, attained trough concentrations >10 mg/L by day 4 of treatment. 
For adults, simulations (n=5,000) were performed with the standard model and current 
recommended regimen of three loading doses of 400 mg every 12 h and 400 mg once 
daily thereafter. Median AUC₀₋₂₄ was 291.81mg*h/L, with 25 and 75 percentiles of 
236.04 and 364.63, respectively. The simulated AUC distributions for children and 
adults are shown in Figure 5.5. A total of 24.8% of simulated adult patients attained 
trough concentrations >10 mg/L by 96 hours of treatment. 
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Figure 5.5- AUC distributions based on Monte Carlo simulations for children at fixed weights and 
for adults (not fixed weight). 
Measures of medians, 25 and 75 percentiles (P25 and P75, respectively) 
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5.5- DISCUSSION 	
We conducted a PK study in children and developed a population PK model to 
quantify inter-patient variability. We encountered a series of findings that can be used to 
improve the use of teicoplanin in children. Of greatest concern was the low proportion 
of patients attaining minimum serum concentrations (Cmin >10 mg/L) at steady state 
with current recommended dosages. This is consistent with previous PK studies of 
teicoplanin in children (Dufort et al. 1996; Sánchez et al. 1999; Strenger et al. 2013). 
For example, Dufort et al. reported that 55.6% of febrile neutropenic patients did not 
achieve Cmin >10 mg/L (Dufort et al. 1996). Similarly, Sánchez et al. revealed 89% of 
patients had low concentrations (Cmin< 10 mg/L) in a study of critically ill children and 
infants (Sánchez et al. 1999). The mean estimate of clearance in our study (0.023 
L/h/kg) was similar to those published by Dufort et al. (0.029 L/h/kg), and slightly 
lower than reported by Sánchez et al (0.045 L/kg/h). Our findings are also in agreement 
with those of a retrospective study showing that among 340 treatments with teicoplanin 
in paediatric patients of different ages (92 neonate/infant episodes, 69 toddler episodes, 
62 school-age children episodes and 117 adolescent episodes) initial Cmin at day 2 to 4 
after 10–15 mg/kg every 12 h for three loading doses and every 24 h thereafter were < 
10 mg/L in 14.1% of cases (Strenger et al. 2013).  
Previous studies have investigated the impact of age on the pharmacokinetics of 
teicoplanin in children. In a population of 13 children (2-12 years), Terragna et al found 
no significant linear correlation between teicoplanin elimination half-life and age 
(Terragna et al. 1988). In contrast, Tarral and colleagues investigated two populations 
separately of children (6 children with a mean age of 7 years, and 4 neonates with a 
mean age of 8.5 days). They showed that, volume of distribution was higher in neonates 
than in children (0.6 L/kg vs. 0.54 L/kg) and clearance was higher in older children than 
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in neonates (0.028 vs. 0.016 L/h/ kg)(Tarral et al. 1988). Finally, Lukas et al conducted 
a population PK analysis in 20 infants and children (4 months-10 years) in the ICU, 
showing also differences amongst two identified sub-populations separated around 12 
months of age. In younger infants (<12 months) a 92% of concentrations were at target 
minimum levels (10 mg/L) versus a 65% of concentrations in older children (≥12 
months)(Lukas et al. 2004). Interestingly, in this study, linear and nonlinear models of 
CL and V with weight failed, despite weight showing a linear relationship with CL and 
V, but only in children under 12 months of age. Instead, weight scaling of CL and V 
was successful describing the PK behaviour in the studied population. The population 
split in the two age categories gave a successful model in the study by Lukas et al. 
Notably, only 4 patients under 12 months contributed to the model. We did not conduct 
a split analysis by age to avoid losing robustness of the predicted pharmacokinetic 
variability in the Monte Carlo simulations by decreasing sample sizes (Tam et al. 2006). 
In our study, by contrast, only the influence of weight related to clearance in a linear 
model, improved the description of our data across childhood. Volume of distribution, 
however, did not show a tenable relationship with weight nor with age.  
In the present study, children had more variability in drug exposures (quantified 
as AUC distributions at steady state) compared with adults (figure 5.5). In this study 
adults had a mean AUC of approximately 300 mg*h/L, although a previous study 
reported a higher mean AUC of 550 mg*h/L (Van Bambeke et al. 2004). In our study, 
children across different weights achieved a median AUC of 619 mg*h/L, which 
compares with drug exposures reported in adults. The relatively higher paediatric PK 
variability supports the use of routine therapeutic drug monitoring (TDM) to enable 
active adjustment of teicoplanin dosages. Collectively, our results suggest that the 
current dosage regimen in children is probably adequate in terms of median drug 
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exposures attained (AUC at steady state), but TDM should be considered to minimize 
the number of patients with sub-optimal drug exposure. Such an approach could 
improve safety, efficacy and prevent the emergence of antimicrobial resistance although 
further studies are required to examine this issue. 
There are a number of issues and challenges that have prevented the more 
extensive use of teicoplanin. The first relates to the composition and synthesis of the 
compound, which is a mixture of six related subcomponents (A2-1, A2-2, A2-3, A2-4, 
A2-5 and A3-1). The A3-1 component is the core glycopeptide that is common to all 
teicoplanin-like compounds (Bernareggi et al. 1992). A degree of concern has been 
expressed related to the composition of generic teicoplanin products, and its potential 
impact on pharmacodynamics. A second issue relates to problems measuring 
concentrations in clinical samples. A number of analytical methods have been used (e.g. 
Bacillus subtilis bioassay, solid phase enzyme receptor assay (SPERA), fluorescence 
polarization immunoassay (FPIA) and high performance liquid chromatography 
(HPLC). Importantly, the readout from these different modalities differs. Thus, the 
conclusions of PK/PD studies are dependent on the analytical method that has been used 
(McMullin et al. 1994). A third issue is a relative lack of knowledge of the 
pharmacodynamics of teicoplanin. A Cmin > 10 mg/L has been associated with higher 
clinical rate cures compared with values of 5 mg/L (Harding et al. 2000). Higher 
troughs serum concentrations (e.g. 15-20 mg/L) have been recommended for the 
treatment of endocarditis caused by S. aureus (Wilson et al. 1994). A pre-clinical 
pharmacodynamic study suggests that a teicoplanin fCmax/MIC ratio of at least 2-3 is 
required for efficacy (J D Knudsen et al. 2000). Other small clinical studies have 
suggested target AUCs as high as 750 mg*h/L are required to eradicate or cure MRSA 
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infections (Kanazawa et al. 2011; Hagihara et al. 2012). There is an urgent need to 
further evaluate the pharmacodynamics of teicoplanin against staphylococcal infections. 
This study has several limitations. Firstly, the study participants largely did not 
have renal impairment. Teicoplanin is eliminated via the kidneys with clearance of the 
unbound drug by glomerular filtration with minimal tubular reabsorption and renal 
secretion (A. P. R. Wilson 2000). The impact of reduced renal function on clearance 
and therefore dosing could not be assessed. Finally, we could not correlate drug 
exposure with clinical outcomes in this study. 
In conclusion, the population PK of teicoplanin is highly variable in children. 
TDM should be considered a component of routine care, although further work is 
required to identify drug exposure targets. The population PK model can now be used to 
construct algorithms for individualized dosing as previously described (Hope et al. 
2013; Felton et al. 2014). 
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Chapter 6 
 
Pharmacokinetics and Pharmacodynamics of 
Teicoplanin in Neonates: Making better use of   
C-Reactive Protein to Deliver Individualized 
Therapy 
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6.1 ABSTRACT  	
Background: There is uncertainty about the optimal teicoplanin regimens for neonates. 
The study aim was to determine the population PK of teicoplanin in neonates, evaluate 
currently recommended regimens and explore the exposure-effect relationships. 
Methods: An open label pharmacokinetic (PK) study was conducted. Neonates from 
26-44 weeks post-menstrual age (PMA) were recruited (n=18). The teicoplanin regimen 
was 16 mg/ kg loading dose, followed by 8 mg/kg once daily. Therapeutic drug 
monitoring (TDM) and dose adjustment were not conducted. A standard 2-compartment 
PK model was developed, followed by models that incorporated weight. A 
pharmacokinetic-pharmacodynamic (PK-PD) model with C-reactive (CRP) serial 
measurements as the PD input was fitted to the data. Monte Carlo simulations (n=5000) 
were performed using Pmetrics. The AUCs at steady state and the proportion of patients 
achieving the recommended drug exposures (i.e Cmin >15 mg/L) were determined. 
Results: The PK allometric model best accounted for the observed data. The PK 
parameters medians were: Clearance=0.435*(weight /70) 0.75 (L/h), Volume 0.765 (L), 
Kcp 1.3 (h-1), Kpc 0.629 (h-1). The individual time-course of CRP was well described 
using the Bayesian posterior estimates for each patient. The simulated median AUC 96-
120 was 302.3 mg*h/L, median Cmin at 120 h was 12.9 mg/L. A 38.8% of patients 
attained a Cmin >15 mg/L by 120h. 
Conclusion: Teicoplanin population PK is highly variable in neonates, weight being the 
best descriptor of PK variability. A low percentage of neonates were able to achieve 
Cmin >15 mg/L. The routine use of TDM and improved knowledge on the PD of 
teicoplanin is required.
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6.2- INTRODUCTION 	
Gram-positive bacterial pathogens are an important cause of nosocomial 
infection in neonates (Stoll et al. 2002). The risk factors include prematurity and the 
extensive use of central venous catheters. There is high attributable mortality and the 
potential for serious longer-term morbidity (Stoll et al. 2002; Marchant et al. 2013; 
Adams-Chapman & Stoll 2006). Teicoplanin is a glycopeptide antibiotic with activity 
against methicillin-resistant staphylococci (MRSA and CoNS) and has several potential 
advantages over vancomycin including better tolerability, lower risk of nephrotoxicity 
and improved ease of administration (Svetitsky et al. 2009; Cavalcanti et al. 2010). In 
older children, there is considerable pharmacokinetic (PK) variability in comparison 
with adults, with a much wider drug exposure (AUC) distribution among children 
(Ramos-Martin et al. 2014). Little is known about the PK of teicoplanin in neonates.  
 Serial concentrations of C-reactive protein (CRP) are a useful adjunct to the 
clinical assessment of neonates with acute infection (Philip & Mills 2000). The 
diagnosis of neonatal bloodstream infection and its subsequent management remains 
challenging. Clinical signs are nonspecific (Marchant et al. 2013). Blood cultures are 
notoriously insensitive and often only intermittently positive in this population because 
of the low yield of small blood volumes collected (Connell et al. 2007; Lutsar et al. 
2014). A fall in CRP is reassuring evidence of response to antimicrobial therapy and 
CRP is frequently used to guide antimicrobial therapy in neonates with proven or 
suspected infection (Benitz et al. 1998; Ehl et al. 1997). Much of this decision-making 
has not been formalised using pharmacokinetic-pharmacodynamic (PK/PD) models or 
dosing algorithms.  
 In this study, we developed a population PK/PD mathematical model to describe 
the serum pharmacokinetics of teicoplanin in neonates with the pharmacodynamics 
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quantified in terms of circulating CRP concentrations. Our objectives were as follows: 
(1) describe and quantify measures of central tendency and inter-patient neonatal PK 
variability; (2) evaluate teicoplanin exposure in the neonatal population with currently 
recommended regimens; and (3) investigate the relationship between drug exposure and 
the time-course of CRP. The latter is a first critical step for the development of 
algorithms to control both serum drug concentrations and clinically relevant biomarkers 
such as CRP. 
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6.3- MATERIALS/PATIENTS AND METHODS 
6.3.1- Study design, patient population and sample collection 	
An open label, hospital-based PK study using a sparse blood sampling strategy 
was conducted. Both pre-term and term neonates from 26 to 44 weeks postmenstrual 
age (PMA) were recruited from Alder Hey Children´s NHS Foundation Trust and 
Liverpool Women´s NHS Foundation Trust (Liverpool, United Kingdom).  
Participants were screened and recruited according to five age categories to 
ensure a range of gestations was studied. The following categories were used for 
recruitment: 24-27, 28-31, 32-35, 36-39 and 40-44 weeks PMA.  All patients that 
received teicoplanin for proven or suspected CoNS sepsis and/or central-line associated 
infection and likely to survive more than 72 hours were eligible for the study. All 
patients also received ciprofloxacin or gentamicin as part of the combined empirical 
therapy for central-line associated bloodstream infection. Additional therapeutic 
interventions were: the use of inotropes, diuretics, paracetamol, anticonvulsants, muscle 
relaxants and assisted mechanical ventilation depending on the individual case. 
Teicoplanin was used at the discretion of the treating neonatologist. The regimen 
for neonates £ 44 weeks PMA was a loading dose of 16 mg/kg, followed 24 hours later 
by 8 mg/kg administered once daily (BMJ Group, the Royal Pharmaceutical Society of 
Great Britain 2015a). Teicoplanin was infused over 30 minutes. Therapeutic drug 
monitoring (TDM) is not routinely performed and dose adjustment was not conducted 
in this study. The duration of treatment was also at the discretion of the treating 
neonatologist.  
Blood samples (0.2 mL) were obtained throughout the first and last dose 
intervals (1, 3, 6 and 24h post-dose). Patients weighing <1000 grams at inclusion could 
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have a maximum of two study-specific sampling episodes per dose interval to minimise 
blood loss. The total sampling period was to a maximum of 168 h for the majority of 
patients. If the first dose administration occurred before informed consent had been 
obtained, a pre-dose sample was obtained. Whenever possible, a washout sample was 
collected 24 hours after the last dose. Samples were centrifuged at 1500 g for 10 
minutes and serum was stored at -80ºC prior to analysis.  
The demographic variables with a potential impact on the PK of teicoplanin 
and/or influence on the determination of teicoplanin (concomitant medications) were 
collected for each patient (i.e. weight and serum creatinine). Concentrations of CRP 
before, during and after teicoplanin treatment were measured as part of standard care. 
Demographic data were analysed with SPSS Statistics version 22 (IBM Corporation, 
New York, United States, [http://www-01.ibm.com/software/analytics/ 
spss/downloads.html]).  
6.3.2- Ethics 	
The study was approved by the Medicines and Healthcare Products Regulatory 
Agency (clinical trial authorisation reference number: 21362/0003/001-0002) and the 
National Research Ethics Service and Regional Committee (REC: 13/NW/0023). 
Written informed consent was obtained from parents and/or legal guardians. The study 
was registered in the European Clinical Trials Database Registry (EudraCT): 2012-
005738-12. 
6.3.3- Teicoplanin Concentration Determination 	
Teicoplanin concentrations were measured using a commercially available 
fluorescence polarization immunoassay (FPIA; Thermo Fisher Scientific, Germany) 
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The limit of quantification (LOQ) was < 3.0 mg/L. The dynamic range was 3-100 mg/L 
and overall precision was < 6%. This method was performed by Kevin Padmore. 
6.3.4- Measurement of CRP Concentrations 
A Multigen CRP VarioÒ (Abbott, Wiesbaden, Germany) latex immunoassay 
was used for the immunoturbidimetric determination of CRP in the plasma of patients, 
and also implemented in the Abbott Architect ci4100 system. The limit of quantification 
(LOQ) was < 0.2 mg/L (reported clinically as < 4 mg/L) for the standard and wide 
range methods (analyte concentration at which the CV=20%). The dynamic range was 
0.2-480 mg/L (wide range method) and total precision was £ 6%. A CRP cut-off value 
> 10 mg/L was considered positive. This method was performed by the Clinical 
Pathology Laboratory in AHFT as per standard of care. 
6.3.5- Microbiological Investigations 	
Microbiological specimens, including blood cultures, were collected as part of 
routine clinical care. Positive microbiological samples were stored for identification 
with a Bruker Biotyper MALDI-TOF MS System (Bruker Daltonics, Billerica, MA) 
and susceptibility testing was performed using E-testÒ (bioMérieux, Hampshire, UK), 
following BSAC methodology (British Society of Antimicrobial Chemotherapy 2006). 
 
6.3.6- Population Pharmacokinetic Models 
 
All data were analysed using Pmetrics (Neely et al. 2012). The inverse of the 
estimated assay variance was used as the weighting function for all models. Three 
structural PK models were explored in this study. The first represented a standard two-
compartment PK model with time-delimited zero-order intravenous input and first-order 
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elimination from central compartment. The model is described by the differential 
equations 1a and 1b below. 
 Z/ 1Z[ = ' 1 − 2OP + 7\]^O ∙ / 1 + 2PO ∙ / 2 		(15) Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																				(1a) 
Where X(1) and X(2) represent the amount of teicoplanin (mg) in the central (c) 
and peripheral (p) compartments, respectively. R(1) is the rate of infusion of drug into 
the central compartment (mg/h). The central compartment has volume (Vc) in liters (L), 
from which there is clearance (SCL) in liters per hour (L/h). The central and peripheral 
compartments are connected by the first-order rate constants Kcp and Kpc (h-1).  
The effect of weight, PMA, post-natal age (PNA), serum creatinine and 
estimated glomerular filtration rate (eGFR) using the Haycock-Schwartz formula 
(K*Height/ serum creatinine)(Martini et al. 2003)( the UK population median height 
values for age and sex were used for each patient; and K=0.33 for pre-term neonates 
and K=0.45 for term neonates) on the population PK of teicoplanin was explored (Brion 
et al. 1986; Schwartz et al. 1984). The Bayesian estimates for clearance and volume of 
distribution from each patient were obtained from the standard model (above) and 
plotted against weight, PMA, PNA, serum creatinine and eGFR, using both linear and 
logarithmic scales. Since both linear and logarithmic relationships between clearance 
and weight appeared tenable, linear and allometric models that incorporated weight as a 
covariate were developed. Ultimately, an allometric power model was used. Such a 
model has been widely used to determine the effect of size on the pharmacokinetics of 
various compounds in children and neonates (Wurthwein et al. 2005; Hope et al. 2007). 
The allometric scaling exponent in equation 3a was fixed at 0.75. Only clearance and 
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not volume had a relationship with weight, and therefore clearance was normalized to a 
70 kg adult, as described elsewhere (Hope et al. 2007). The differential equations 
describing the allometric model are as follows: 
Z/ 1Z[ = ' 1 − 2OP + 7\]b[Z ∙ feR3ℎ[70
J.kI
^O ∙ / 1 + 2PO ∙ / 2 						(35)							 
Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																																																			(3a) 
Where SCLstd represents the normalized estimate for clearance in a 70 kg 
individual; the other parameters are described above.  
After establishing the model that best described the pharmacokinetics of 
teicoplanin, the following pharmacodynamic equation was used to describe the time-
course of CRP concentrations: 
 
 
!" :!$ = (2\'pPqdZ ∗ / 3 ∗ 1 − " :;<;=>0 )) − (2\'pRrℎ ∗/ 3 ∗ ( " #,- s))/( u\50s + ( " #,- s))	    (3c) 
 
Where KCRPprod is the maximum rate of CRP production (mg/L*h-1), POPmax is the 
theoretical maximum CRP concentration (mg/L), KCRPinh is the maximum rate of 
CRP inhibition (mg/L*h-1) induced by the drug, EC50 is the concentration of 
teicoplanin (mg/L) that produces half-maximal effect (CRP inhibition) and H is the 
slope function for the CRP inhibition term. 
 Given the high PK variability in the population and in order to avoid biased 
parameter estimates in the PK/PD model, the Bayesian posterior estimates for each 
patient´s PK parameters (from the final PK model described above) were fixed and the 
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PD parameters were then estimated by fitting the PD component of the model to each 
patient´s CRP data. The Bayesian posterior estimates for each subject were used to 
estimate the concentration-time profiles for teicoplanin and CRP for each patient. 
Average AUC and trough (Cmin) for each 24 h of therapy were calculated from the 
Bayesian posterior estimates.  
6.3.7- Monte Carlo Simulations 	
Monte Carlo simulations were performed using a semi-parametric sampling 
methodology that generated a simulated population of 5,000 neonates receiving a given 
teicoplanin regimen (Neely et al. 2012; Goutelle et al. 2009). For each simulated 
patient, the weight-based dose of teicoplanin (administered in mg per kg) was 
administered to each neonate (30-minute infusion) as an absolute dose of teicoplanin (in 
mg) by multiplying the rate of infusion (in mg/h) by the simulated weight.  
 All calculations were performed at steady state between day 4 and 5 of 
treatment. The proportion of patients achieving Cmin >10, >15, 20, 30, 40 and 60 mg/L 
(the latter as the recommended safety cut-off) was determined. A comparison of the 
variability of distribution of drug exposures (AUCs) achieved in the neonatal simulated 
population was performed with the distribution of drug exposures in older children (1 
month-16 years old) and adults receiving also currently recommended dosage regimens 
of teicoplanin. This comparison was based on Monte Carlo simulations conducted on a 
previous teicoplanin PK study with older children and adults (Ramos-Martin et al. 
2014). 
6.3.8- Exposure-response relationships 	
A newly described PD index (AUC: EC50) was used to link drug exposure with 
therapeutic response (terminal CRP concentration)(Huurneman et al. 2016). The 
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average AUC0-24 was calculated from the Bayesian posterior estimates, divided by the 
median EC50 and the PD index plotted against the CRP Bayesian estimated values at 
the end of therapy. A sigmoid Emax inhibitory model was fitted to the data using the 
following equation:  
w = x5becRre − (u456 ∗ /s/s + u\50s) 
Where X is AUC:EC50, H is the Hill coefficient and EC50 is the median 
Bayesian estimate for the teicoplanin concentration that induces half maximal CRP 
reduction. 
The use of a more conventional index (e.g. AUC:MIC ratio) was infeasible 
because the MIC of the invading microorganism was not available for the majority of 
patients. The EC50 is the estimated drug concentration required to induce half-maximal 
reduction in the CRP concentrations and it is therefore an in vivo estimate of drug 
activity.  	
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6.4- RESULTS 
6.4.1- Demographics 
A total of 18 neonates were recruited from two different hospitals in Liverpool 
(Alder Hey NHS Children´s Foundation Trust and Liverpool Women´s Hospital) over a 
20 month-period (April 2013 and January 2015). Ten patients were recruited from the 
neonatal intensive care unit at the Liverpool Women´s Hospital. The number of 
recruited patients by sub-category PMA (weeks) was: 24-27 (n=1), 28-31 (n=5), 32-35 
(n=2), 36-39 (n=5) and 40-44 (n=5). A description of the demographic data is presented 
in table 6.1. 
 n Range Median (IQR) 
PMA (weeks) 18 26-44 37 (29.7-40) 
Age (days) 18 4-69 17 (10.5-26) 
Weight at birth (kg) 18 0.69-4.2 1.42 (0.9-3) 
Weight at enrolment (kg) 18 0.69-5.08 2.04 (1.16-3.23) 
eGFR (ml/min/1.73 m2) 18 5.4-95.2 42.8(27.8-53.3) 
Creat. (1st day of TEC) (µmol/L) 18 21-265 44.5 (36-57.7) 
Creat. (last day of TEC) (µmol/L) 13 28-114 38 (34-63.5) 
CRP (1st day of TEC) (mg/L) 18 4-172.6 41.9 (12.1-122.25) 
CRP (last day of TEC) (mg/L) 16 4-163.7 6.9 (4-13.1) 
PMA: Post-menstrual age. eGFR= estimated glomerular filtration rate (Schwartz-Haycock). Creat.= creatinine . TEC= 
teicoplanin. CRP = C-reactive protein. IQR= interquartile range. 
Table 6.1- Demographics of neonates included in the PK/PD teicoplanin study. 							
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6.4.2- Teicoplanin and CRP Concentrations 	
The concentration time-profile of teicoplanin and corresponding CRP 
concentrations for each patient is shown in figure 6.1a and 6.1b, respectively. A total 
of 96 PK samples were available for analysis (mean of 5.3 samples per patient). 
Fourteen PK concentrations, from 4 patients were excluded from the analysis because of 
incorrect or absent sampling times. The mean (SD) from the observed teicoplanin 
concentrations was 18 (9.11) mg/L and a median of 17.32 mg/L (range 3.1-38.7 mg/L). 
A total of 104 CRP samples were available for analysis as part of the standard care of 
the patients.  
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Figure 6.1- Teicoplanin and CRP concomitant concentration-time profiles from the neonates. 
a) Teicoplanin (empty circles) and b) CRP (empty triangles) concomitant concentration time-
profiles  
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6.4.3- Microbiological Results 	
A total of 44.4% of recruited patients (n=8) had a positive blood culture obtained 
from either a central or peripheral i.v. line. A total of 33.3% of those recruited (n=6) 
were Gram-positive infections (100% CoNS including S. haemolyticus (n=2), S. 
epidermidis (n=1) and n=3 unidentified species). All were susceptible to teicoplanin 
(MIC£ 4 mg/L using the EUCAST clinical breakpoint)(European Committee on 
Antimicrobial Susceptibility Testing 2015). The remaining 11.1 % (n=2) were Gram-
negative bacterial infections (n=1 had P. aeruginosa and n=1 had Klebsiella oxytoca) 
(These two patients only received two doses of teicoplanin each and were excluded 
from the subsequent exposure-relationship analysis).	
6.4.4- Population Pharmacokinetic models 	
 Both the population PK linear and allometric models performed similarly with 
an acceptable fit to the observed data and comparable measures of bias and precision. 
However, on the basis of the individual Bayesian estimates of the observed-versus-
predicted fit of the data, the allometric PK model better accounted for the observed data 
and was chosen for further analyses. The model diagnostics are shown in table 6.2. For 
the allometric model the linear regression of observed versus predicted values had a 
coefficient of determination of r2 = 0.815 with measures of bias and precision of 0.03 
and 0.8, respectively (shown in figure 6.2a). The population PK parameter estimates of 
the allometric model are shown in table 6.3. 
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Model Log-likelihood Pop r2 * Post r2* Slope (95% CI) Intercept (95% CI) 
Standard PK  -253.8 0.159 0.814 0.925 (-1.3-2.8) 0.768 (-1.3-2.8) 
Linear (weight) PK -254.1 0.271 0.807 0.941 (0.8-1.04) 0.922 (-1.14-2.98) 
Allometric 
(weight) PK 
-254.4 0.249 0.815 0.981 (0.9-1.1) 0.26 (-1.8-2.3) 
Table 6.2- Model diagnostics for the Population Teicoplanin PK models in neonates. 
* relative to the regression line fitted for the observed versus predicted values after the Bayesian step. CI: 
confidence interval.  
 
Population PK 
parameter 
Mean SD Median 
Clstd (L/h) 0.45 0.2 0.43 
Vc (L) 0.81 0.48 0.76 
Kcp (h-1) 1.45 0.99 1.3 
Kpc (h-1) 0.84 1.05 0.63 
Population PD 
parameter 
   
Kgmax (mg/L*h-1) 0.05 0.03 0.05 
Popmax (mg/L) 159.76 62.6 139.15 
H 18.48 3.46 19.99 
Kkmax (mg/L*h-1) 0.05 0.02 0.06 
EC50 (mg/L) 7.1 6.11 5.79 
IC3 (mg/L) 55.32 54.24 24.99 
Table 6.3- Population PK/PD parameter estimates for the allometric model in neonates. 
Clstd= Clearance standardized from [Clearance=Clstd*(wt/70)0.75]; Vc=Volume of distribution in the central compartment; 
Kcp and Kpc= firs-order rate constants from central to peripheral compartments and from peripheral to central 
compartments, respectively; Kgmax= maximum rate of CRP production; Popmax= theoretical maximum CRP 
concentration; H=Hill slope; C50= Teicoplanin concentration producing half-maximal CRP reduction; IC3= initial 
condition in CRP concentrations. 
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Figure 6.2- Individual posterior observed versus predicted plots (after the Bayesian step) from the 
PK/PD model. 
Panel a) PK (teicoplanin concentrations), Predicted teicoplanin concentrations=0.917x-0.06; Panel 
b) PD (CRP concentrations), Predicted CRP concentrations= 1.01x+0.254 
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6.4.5- Population PK/PD Model 
 
The fit of the PK/PD data was acceptable. The linear regression of observed 
versus predicted values had a coefficient of determination of r2 = 0.95 with measures of 
bias and precision of 0.09 and 0.9, respectively (shown in figure 6.2b). The time-course 
of CRP in each individual patient was described with a high degree of precision and 
minimal bias using the Bayesian posterior median estimates for each patient. The 
population PK/PD parameter estimates are summarised in table 6.3. The Bayesian 
individual posterior estimates for the linked PK and the PD are shown in Figure 6.3. 
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Figure 6.3- Individual concentration-time plots after the Bayesian step showing teicoplanin (black) 
and CRP (grey) concentrations. Predicted (continuous line) and observed (crosses) concentrations over 
time for each of the patients. The y axis “observations” refer to both: teicoplanin and CRP concentrations. 
Individuals 1 and 7 were infected with Gram-negative bacteria and only received 2 doses of teicoplanin. 
The individual average Cmin and AUC drug exposures are reported for each patient.
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6.4.6- Monte Carlo Simulations 	
Based on the simulations, the mean (SD) 24-hour steady-state AUC from 96-120 
h was 365.4 (267.1) with a median of 302.3 mg*h/L. The mean (SD) trough at 96 h was 
15.7 (11.7) mg/L with a median of 12.9 mg/L. Only 38.8 % of neonates achieved a Cmin 
at 120h > 15 mg/L.  In addition, 69.1%, 22.4%, 8.56%, 3.92% and 1.1% achieved Cmin 
> 10, 20, 30, 40 and 60 mg/L, respectively. Comparative distribution histograms of the 
achieved AUCs at steady state for the simulated neonates, as well as for simulated older 
children and adult populations are shown in figure 6.4. The neonatal population 
achieved median AUCs at steady state (302.3 mg*h/L) comparable to the median AUC 
attained by a population of adults receiving 400 mg/day (291.81 mg*h/L), but with 
more variability (neonatal AUC IQR= 227.5 versus adult AUC IQR= 101.59 mg*h/L). 
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Figure 6.4- Comparison of simulated (n=5000 per population group) teicoplanin AUC (mg*h/L) 
distribution histograms in different populations. 
a) neonates (0.7-5 kg) b), c) and d) children >1 month-16 years old with fix weights of 10, 25 and 50 
kg, respectively and e) adults receiving current teicoplanin dosage regimen. 
 
	 232	
6.4.7- Exposure-response relationships 	
The Bayesian posterior estimates for the exposure-response relationships (AUC, 
Cmin and AUC:EC50) are shown in figure 6.5. If patients 1 and 7 (infected with 
Pseudomonas aeruginosa and Klebsiella oxytoca, respectively) are excluded, 56 % of 
the patients (9/16) were able to suppress CRP under the cut-off value of 10 mg/L by 96-
120 h. Subject 16 (gastroschisis) was not included in the inhibitory sigmoid Emax 
model (the patient’s data are shown in figure 6.5c). An AUC:EC50 of »68.3 is 
predictive of a terminal CRP £ 10 mg/L. The relationship between AUC:EC50 and 
predicted CRP at the end of therapy is shown in figure 6.5c. Patients with an 
AUC:EC50 >68.3 tended to have a more consistently lower terminal CRP level than 
patients with an AUC:C50<68.3 (p=0.002) (figure 6.6). 
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Figure 6.5- Exposure-response relationships from the Bayesian posteriors from the PK/PD linked 
model. 
a) AUC average, b) Cmin average and c) AUC:EC50 ratio (log10 scale) as the pharmacodynamic relevant 
index versus predicted CRP concentrations at the end of therapy. A sigmoid Emax inhibitory model was 
fitted to the data. Patients with ID 1, 7 (Gram-negative bacterial infection) and 16 (multiple inflammatory 
co-morbidities with persistently high CRP levels> 100 mg/L and negative blood culture) were excluded 
from this analysis but shown in panel c. 
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Figure 6.6- Teicoplanin AUC:EC50 box-plot. 
The plot suggests that patients attaining >68.3 drug exposures (~>AUC 389.3 mg*h/L) had a more 
consistently lower CRP at the end of therapy (Mean 18.18 vs 5.7 mg/L), p value=0.002 (two sample 
t-test). 
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6.5- DISCUSSION 	
Teicoplanin is used for the treatment of serious staphylococcal infections (Kacet 
et al. 1993; Yalaz et al. 2004; Fanos et al. 1997). Currently, teicoplanin is not licensed 
in the EU for treatment of neonates or infants < 2 months of age because of insufficient 
evidence data. This PK/PD study provides a rationale to address the appropriate 
teicoplanin regimen and extent of variability in both drug exposure and response. 
Furthermore, the study provides the necessary tools to take the next critical steps to 
provide truly individualised antimicrobial therapy for neonates receiving teicoplanin. 
The extent of inter-patient PK variability in this neonatal population was high 
(figure 6.1a). Of the multiple covariates that were studied, only weight accounted for 
any portion of the observed PK variability. Incorporation of weight into structural PK 
models resulted in better fits and statistically more likely solutions. Of note, we could 
have equally reasonably related weight to clearance using linear or power scaling terms, 
despite the convention for using a scaling exponent of 0.75 (Hope et al. 2007; Wade et 
al. 2008). We could not demonstrate any relationship between teicoplanin clearance and 
PMA, estimated glomerular filtration rate (eGFR) or serum creatinine. This is somewhat 
surprising because teicoplanin is almost completely renally (98%) cleared by 
glomerular filtration (A. P. Wilson 2000). The absence of any relationship probably 
reflects the small sample size as well as the relatively poor estimates of eGFR in 
neonates using current nomograms. This finding does call into question whether 
teicoplanin dosing should be adjusted on the basis of eGFR and further studies are 
required to specifically address this question. Other factors associated with disease, such 
as variability in regional blood flow, organ perfusion, changes in acid-base balance or 
cardiac output, might have potentially influenced the drug´s disposition characteristics 
in our patient population, however, this also requires further and targeted study. To our 
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knowledge, the pathophysiological mechanisms that describe the pharmacokinetic 
impact of these covariates and how they relate mathematically with the PK parameters 
in order to be included in the structural models and differential equations remain poorly 
defined. Using a non-parametric modelling methodology, we took a pragmatic approach 
by investigating the clinical parameters known to have a significant impact on our 
patient population PK variability (weight as an estimate of size, age and serum 
creatinine/eGFR). 
Monte Carlo simulations suggest that the median AUCs at steady state in 
neonates receiving 16 mg/kg as a loading dose, followed by 8 mg/kg q24 h are 
comparable to adults receiving 400 mg/day. However, there is much larger PK 
variability in the AUCs of neonates (Figure 6.4). While the matching of measures of 
central tendency is straightforward, the best way to match two completely different 
AUC distributions is less clear. The high variability makes identification of a fixed 
weight-based regimen challenging because of the unacceptably high proportion of 
neonates with both low and high drug exposure. Any attempt to address this problem 
results in an unsatisfactory trade between effect and toxicity and eventual 
acknowledgment that TDM is required to optimise dosing and drug exposure.  
 While TDM is the only current way teicoplanin dosing can be optimised, there 
are a number of significant challenges to this process: first and most obviously 
obtaining repeated blood draws in premature neonates is never trivial; second, there is 
persistent uncertainty about drug exposure targets for TDM. A trough concentration of 
15 mg/L (measured by FPIA) is proposed in the summary of product characteristics 
(SPC) by day 3 to 5 of therapy for both adults and children, but recently increased to 20 
mg/L and 30-40 mg/L for the treatment of deep-seated infections and infective 
endocarditis, respectively (The Electronic Medicines Compendium 2014). Moreover, 
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concentrations are not recommended to exceed 60 mg/L, despite little evidence for any 
relationship between serum concentrations and toxicity in neonates (Yamada et al. 
2014). Such recommendations are based on scant clinical evidence in adult patients and 
with only a rudimentary understanding of the pharmacodynamics of teicoplanin 
(Matthews et al. 2007; Sato et al. 2006; Ueda et al. 2012). The use of Bayesian feedback 
tools for dosage individualisation, which requires the availability of robust population 
PK models and optimally sampled concentrations, may enable the attainment of desired 
AUC targets (and surrogate trough concentrations) for any individual patient (Neely et 
al. 2014).  
This study is too small to resolve clinical exposure-response relationships.  
Inadequate power was further compounded by a Gram-positive pathogen being isolated 
in only 6/18 (33.3%) of patients. Hence, there was no opportunity to examine the 
relationship between the magnitude of any traditional pharmacodynamic indices (e.g. 
AUC:MIC) and outcome. Even in larger datasets, the problem of culture negativity is 
frequently present. In this situation, most investigators use a population value (e.g. 
MIC90) to calculate drug exposure for an individual patient. Assuming such patients are 
infected with the most resistant pathogen is conservative, but necessarily biased. The 
use of CRP and a novel pharmacodynamic index (the AUC:EC50) circumvents some of 
these issues. The rationale behind this quotient is that EC50 is an in vivo measure of 
drug potency and the AUC:EC50 is a measure of the exposure of drug relative to the 
potency of its effect. A major advantage of this approach is that it allows for drug 
exposure targets that are more individualised for a specific patient. The EC50 (and 
therefore AUC:EC50) is influenced by both the patient and characteristics of the 
infecting organism. The EC50 captures the impact of multiple variables on exposure- 
response relationships (e.g. in vitro resistance, high bacterial load, a persistent infective 
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focus, biofilms and immune response). In contrast, when the measure of potency is the 
MIC alone, as for AUC:MIC, it is only the organism's characteristics that are 
considered, and all the other factors implicit in EC50 are ignored. The Bayesian 
posterior EC50 estimates ranged widely (0.6-18.7 mg/L), which again reflects highly 
variable pharmacodynamics and in vivo potency. In this study, the AUC:EC50 predicted 
the terminal CRP levels after 5 days of therapy (figure 6.5c) for a majority of patients.  
It is important to highlight that rate of change of CRP in the model equation 
assumes that all the CRP reduction occurs as an effect of the drug, which is not a 
biological absolute truth as the immune system and other effectors extraneous to the 
drug influence on this reduction. Despite the model fitted the data well, a clear 
understanding of its limitation to describe the real clinical setting and interpret the 
results is required. An association of the AUC:EC50 index with additional clinical 
outcomes (e.g. improvement of clinical signs, microbiological cure, no need of 
associated/change of therapy, etc) is deemed necessary for the appropriate evaluation of 
its clinical validity. 
The use of CRP as a biomarker deserves some comment. CRP is widely used in 
clinical practice to guide anti-infective therapy, but much of that process is informal and 
intuitive (Ehl et al. 1997; Bomela et al. 2000; Pourcyrous et al. 1993). In this study, we 
explicitly link teicoplanin serum concentrations and changes in circulating CRP (only 
referred to drug effect). The measurement of CRP in an individual patient provides a 
real-time estimate of the response to drug. There are clearly some advantages to such an 
approach: CRP is quantitative, widely available, well validated, and readily accepted by 
clinicians. It is the most extensively studied biomarker in neonatal sepsis. In addition, a 
recent systematic review has showed higher specificity and predictive values at 
symptom onset and after 24-48 hours than procalcitonin (PCT) in neonatal bacterial 
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sepsis (Hedegaard et al. 2015). PCT has been investigated mainly in early onset sepsis 
and with different cut-off values depending on time after birth. Its value in neonates is 
limited by a marked physiological increase after birth (Turner et al. 2006). The ability to 
link drug concentrations with a biomarker provides the prospect for truly individualised 
therapy where the dosing of drug is designed to manage a biomarker rather than a serum 
drug concentration. However, there are some obvious limitations. CRP is a nonspecific 
marker of infection and inflammation, and adjusting a dose solely on the basis of 
climbing CRP may be dangerous if the CRP elevation is a result of Gram-negative 
bacteraemia as was the case in patients 1 and 7, or the result of a severe non-infectious 
inflammation as appears likely for patient 16 (Figure 6.3). Thus, to guide teicoplanin 
dosing, there needs to be confidence that the CRP elevation is a result of a teicoplanin-
susceptible pathogen. In our study, we had microbiological evidence of a teicoplanin-
susceptible organism in a third of patients. However, there was a high clinical suspicion 
on this being the case for the remaining patients (clinical, laboratory markers of 
infection and specific risk factors such as a central line inserted). In our setting, 
teicoplanin and ciprofloxacin constitute the empirical treatment in the context of 
central-line associated bloodstream infection. All patients received ciprofloxacin or 
gentamicin until a blood culture result became available. The other antimicrobial could 
potentially had an impact on CRP decline in the case of a Gram negative causing 
microorganism. Nevertheless, CoNS was the most commonly isolated microorganism 
and teicoplanin was only discontinued in two patients with Gram-negative infection. 
Interestingly, a recent study has also demonstrated that serial CRP measurements can 
predict whether an organism is sensitive to the empirical antimicrobial therapy in the 
first 48 hours of treatment of neonatal sepsis (Patil et al. 2016). These findings now 
need prospective evaluation. 
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Despite the potential limitations, this study extends the standard pharmacometric 
approach whereby the population PK is described, Monte Carlo simulations are 
performed and post hoc analyses such as the probability of target attainment analyses 
are performed, often using PD targets of questionable clinical significance. While the 
current approach has limitations because of the non-specificity of the biomarker and the 
limited biological validity of the model equation describing the rate of change of CRP, 
the analyses begin to refocus therapeutic arguments on the individual patient, using real 
data to deliver a regimen that is both safe and effective for the clinical problem in hand.	
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Chapter 7 
 
Tools for the Individualised Therapy of 
Teicoplanin for Neonates and Children  
					
	 242	
3.1 ABSTRACT 
 
Objectives: The aim of the study was to develop a population PK model for teicoplanin 
across childhood age ranges to be used as Bayesian prior information in the constructed 
software for individualised therapy.  
Methods: We developed a non-parametric population model fitted to PK data from 
prospectively recruited neonates, infants and older children. We then implemented it in 
the BestDose multiple-model Bayesian adaptive control algorithm to show its clinical 
utility. It was used to predict the required dosages to achieve teicoplanin optimal pre-
dose targets (15 mg/L) from day 3 of therapy. We performed individual simulations in 
an infant and a child from the original population, who provided early first dosing 
interval concentration time-data.  
Results: An allometric model that linked weight to clearance and volume of distribution 
(Ke and V) and incorporating renal function as a power function of eGFR 
(PNA/creatinine for infants < 3 months), best described the data. The median population 
PK parameters were as follows: Ke= 0.03*(wt/70)-0.25 * Renal (h-1); V=19.5*(wt/70) 
(L), being Renal= eGFR0.07 (ml/min/1.73m2) or PNA/creatinine (µmol/L). Increased 
teicoplanin dosages (i.e range 1.2-2.2 times higher) and alternative administration 
techniques (extended infusions and/or fractionated multiple dosing) were required in 
order to achieve the targets safely by day 3 in simulated cases.  
Conclusions: The software was able to predict individual measured concentrations and 
the required dosages and administration techniques to achieve the desired target 
concentrations early in therapy. Prospective evaluation is now needed in order to ensure 
that this teicoplanin individualised therapy approach is applicable in the clinical setting. 
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7.2- INTRODUCTION 
 
The pharmacokinetics (PK) of teicoplanin are highly variable in children and 
neonates (Ramos-Martin et al. 2014; Ramos-Martín et al. 2016). Weight-based dosing is 
advocated (BMJ Group, the Royal Pharmaceutical Society of Great Britain 2015a). 
Weight affects estimates of clearance and has been incorporated into structural PK 
models using linear and allometric scaling functions (Pea et al. 2004; Ramos-Martín et 
al. 2016; Dufort et al. 1996; Sánchez et al. 1999; Zhao et al. 2015a). Different levels of 
renal function (quantified in terms of serum creatinine, eGFR) also explain a portion of 
PK variability in adults and children (Zhao et al. 2015a; Yamada et al. 2012a). 
However, most of the inter-patient variability in PK remains unexplained (Zhao et al. 
2015a; Byrne et al. 2015). Consequently, nomograms based on simple covariates cannot 
be used to adjust dosages to achieve therapeutic targets that are deemed safe and 
maximally effective. 
The area under the concentration-time curve (AUC) to minimum inhibitory 
concentration (MIC) is the pharmacodynamic index that best links teicoplanin drug 
exposure with the observed effect against methicillin-resistant Staphylococcus aureus 
(MRSA) (V. Ramos-Martín, A. Johnson, L. McEntee, N. Farrington, K. Padmore, P. 
Cojutti, F. Pea, M. Neely, W. Hope, submitted for publication). Nevertheless, the pre-
dose concentration (Cmin (mg/L)) is the most widely used measure of drug exposure to 
guide TDM (Tobin et al. 2010). Cmin ³ 15 mg/L by days 3-5 of therapy are 
recommended for most indications (The Electronic Medicines Compendium 2014). 
These targets have recently increased to 20 and 30-40 mg/L in the Summary of Product 
Characteristics (SPC) for the treatment of deep-seated infections (bone and joint 
infections) and infective endocarditis, respectively (The Electronic Medicines 
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Compendium 2014). Currently recommended targets are based on small retrospective 
studies in adults that have explored the relationship between teicoplanin trough 
exposure and clinical outcomes (Ueda et al. 2012; Harding et al. 2000). More recently, 
daily AUCs >750-800 mg*h/L by day three of therapy have been linked to 
microbiological cure of adults with MRSA infection (Kanazawa et al. 2011; Hagihara et 
al. 2012). 
In this chapter, we report the development of a non-parametric population PK 
model of teicoplanin in hospitalised neonates, infants and older children (up to 16 years 
old). We then describe the application of this model for the construction of software that 
provides decision support for dose individualisation of teicoplanin. Such an approach 
enables the achievement of desired drug exposure targets in an optimally precise 
manner and at anytime during the therapeutic course. This approach constitutes a further 
extension of our broad goal of developing the tools and knowledge to deliver optimised 
antimicrobial therapy in neonates and children.  
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7.3- PATIENTS AND METHODS 	
7.3.1- Pharmacokinetic study of teicoplanin in children and neonates 
 
Pharmacokinetic data from 57 children (39 children aged 1 month-16 years old 
and 18 neonates between 26-44 postmenstrual age-PMA- weeks) was available for 
model building. Patients were prospectively enrolled from two different hospitals in 
Liverpool (Alder Hey NHS Children´s Foundation Trust and Liverpool Women´s 
Hospital) over a 20 month-period (April 2013 and January 2015).  These PK data have 
been previously reported in two separate population models (Ramos-Martin et al. 2014; 
Ramos-Martín et al. 2016). In this study, we combined these datasets to develop a joint 
population PK model fitted to data from neonates to older children. Such an approach 
avoids the problem of having multiple pharmacokinetic models for the same drug each 
with an arbitrarily chosen cut-off value for age or size. 
 
Neonates ≤ 44 weeks PMA (post-menstrual age) received a loading dose of 16 
mg/kg followed by 8 mg/kg once daily via a 30 minute- infusion. Children > 1 month of 
age received three loading dosages of 10 mg/kg every 12 hours, followed by 10 mg/kg 
once daily via a bolus iv infusion (2-5 min), according to dosages currently 
recommended by the SPC (The Electronic Medicines Compendium 2014). Plasma 
samples were collected during the first dosage interval and then at steady state (1, 3, 6, 
24 hours post-dose) on days 3-7 of therapy. Neonates < 1000 grams contributed to two 
samples (alternate time-points) per dosing interval because of constraints on sample 
volume. The duration of the treatment course was at the discretion of the treating 
physician. All patients received teicoplanin for proven or suspected methicillin-resistant 
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staphylococcal (either coagulase negative staphylococci-CoNS- or MRSA) sepsis 
and/or central-line associated bloodstream infection. Demographic variables included 
weight, height, age in years, post-menstrual age (PMA) in weeks, postnatal age (PNA) 
in days, serum creatinine and estimated glomerular filtration rate (eGFR) (Schwartz-
Haycock) (Schwartz et al. 1984) were also collected and available for each patient. 
Teicoplanin concentrations were measured using a commercially available 
fluorescence polarization immunoassay (FPIA; Thermo Fisher Scientific, Germany). 
The limit of quantification (LOQ) was < 3.0 mg/L. The dynamic range was 3-100 mg/L 
and overall precision (intra and inter-assay) was < 6%. This method was performed by 
Kevin Padmore. 
 
7.3.2- Development of a population PK model 
A PK model was fitted to the data using Pmetrics 1.4.2 for R statistical package 
3.2.2 that utilises the non-parametric adaptive grid (NPAG) algorithm (Neely et al. 
2012). The inverse of the estimated assay variance was used to weight the data. Initially, 
a standard two-compartment model with time-delimited zero-order intravenous (i.v.) 
input and first-order elimination from central compartment was developed. The standard 
model is described by the differential equations 1a and 1b below. 
 Z/ 1Z[ = ' 1 − 2OP + 2e ∙ / 1 + 2PO ∙ / 2 		(15) Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																				(1a) 
 
Where X(1) and X(2) represent the amount of teicoplanin (mg) in the central (c) 
and peripheral (p) compartments, respectively. R(1) is the rate of infusion of drug into 
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the central compartment (mg/h). The central compartment has volume (Vc) in litres (L), 
from which there is clearance (CL) in litres per hour (L/h), both represented in equation 
(1a) as the elimination rate constant Ke (=CL/V) (h-1). The central and peripheral 
compartments are connected by the first-order rate constants Kcp and Kpc (h-1).  
Once the standard model was developed, the potential effect of growth (size) 
and development/maturity on the PK of teicoplanin was investigated across patients. 
This was conducted using readily clinically accessible measures, such as weight and 
age. The Bayesian individual posterior median estimates for clearance and volume of 
distribution were obtained from the standard model for each patient, and then they were 
plotted against the covariates of interest to interrogate any possible relationships.  
In neonates and children, clearance generally scales with size in a nonlinear 
manner that is best described using a power function. A scaling exponent of 0.75 is 
most frequently used (i.e. Clearance is proportional to weight0.75) for a number of drugs. 
In addition, physiological maturation may also affect clearance and this is especially 
apparent in neonates and young infants (Anderson & Holford 2008; Germovsek et al. 
2016). In our model building process, Ke and V were both scaled with weight using 
linear and allometric scaling terms. Because of the relatively limited sampling strategy 
(particularly in neonates) we did not explicitly estimate the value of the allometric 
scaling exponent. As previously reported, weight was referenced to a 70 kg person and 
related to clearance with a fixed exponent of 0.75 and to volume with an exponent of 
1(Anderson & Holford 2008).  
The development or maturation effect was studied by using age (years), PMA 
(weeks) and/or PNA (days). Since a linear relationship was observed between the 
Bayesian estimates for Ke and V with age (years), a model structure containing this 
relationship was developed and age (years) was scaled linearly to both clearance and 
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volume (before and after allometric scaling of Ke with weight). In addition, the effect of 
age (years) was also studied whilst incorporated into a sigmoidal maturation factor as 
previously shown (Holford et al. 2013). Age (years) or PNA (days) instead of PMA 
(weeks) was further studied to account for the entire paediatric age range in the 
population.  
Finally, we explored the relationship between renal function (quantified terms of 
eGFR and serum creatinine) and estimates of teicoplanin Ke and V in the population. 
We inspected the relationship of renal function and age (also PMA and PNA) to account 
for maturational changes in the neonatal period and early in infancy (Rhodin, Anderson, 
Peters, Coulthard, Wilkins, Cole, Chatelut, Grubb, Veal, Keir & Nick H G Holford 
2009). A cut-off age in the maturation of renal function was explored given the plotted 
eGFR vs age relationship seen in the study population. Daily serum creatinine values 
were collected during teicoplanin therapy to reflect any changes in the renal function 
during the study. GFR was estimated (eGFR) using the Haycock-Schwartz formula 
(K*Height/ serum creatinine)(Martini et al. 2003). For this estimation, measures of 
height or length that were not available from the recruited patients, were obtained from 
the UK paediatric growth charts as population median height values for the age and 
gender. In addition, K=0.33 was used for pre-term neonates and K=0.45 for term 
neonates, as previously reported, to reflect the smaller percentage of muscle mass in 
pre-term vs term infants (Brion et al. 1986; Schwartz et al. 1984). 
An inter-occasion variability (IOV) factor was added to the dataset to account 
for changes in the PK parameters (Ke and V) between the study visits (4 days of 
therapy)(Karlsson & Sheiner 1993). This might be due to the potential rapid 
physiological changes over and beyond renal function, which could have an impact on 
the PK of teicoplanin in this population. 
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The fit of each exploratory model to the data was assessed using a combination 
of the following: 1) the log-likelihood value, 2) the Akaike information criterion (AIC) 
3) the coefficients of determination (r2) from the linear regression of the observed-
predicted plots before and after the Bayesian step, 4) minimization of bias and 
imprecisions of the observed-predicted plots; and 5) a visual predictive check (VPC). A 
model comparison was made using the above-named diagnostics in order to choose the 
final model. 
The final model was fitted to the data using an allometric scaling of weight with 
Ke (containing both Cl and V) as follows: 
 Z/ 1Z[ = ' 1 − 2OP + 2e0 ∙ f[70 yJ.1I ∙ 'er5c ∙ / 1 + 2PO ∙ / 2 		 25  Z/ 2Z[ = 2OP ∙ / 1 − 2PO ∙ / 2 																																				(2a) 
 
Ke=(Ke0*(wt/70)(-0.25))*Renal (The exponent 0.75 corresponds to (- 0.25) because instead of 
(CL/70)0.75, we have used Ke, which is CL/V); V=(V0*(wt/70));  
Renal=eGFRpw or PNA (days)/creatinine if Age< 0.25 years old 
Ke0=Ke01 and V0=V01, unless IOV=2, then Ke0=Ke02 and V0=V02, where IOV=1 for the first PK 
sampling visit and IOV=2 for the second visit. 
 
Where, Ke (Cl/V) is the rate constant of elimination (h-1) including Cl, clearance 
(L/h) and V, the volume of distribution in the central compartment (L); wt is the 
patient´s weight (kg); IOV= inter-occasion variability, IOV= 1 was for concentrations 
<96 hours and IOV=2, for information collected at ≥ 96 hours. The renal function was 
best described as the estimated glomerular filtration rate (eGFR) (ml/min/1.73 m2) to a 
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constant power function (pw), or as the PNA, post-natal age (days) divided by the 
serum creatinine (µmol/L) if the age was < 0.25 years old (3 months old). 
 
 
7.3.3- Building the teicoplanin dose optimisation software 
We incorporated the final population PK model into a teicoplanin multiple-
model Bayesian adaptive dosing controller (the software “cartridge”). The controller is 
based on the concepts and software (BestDose) developed by the University of Southern 
California Laboratory for Applied Pharmacokinetics and Bioinformatics (LAPKB)	
(http://www.lapk.org) (Hope et al. 2013; Neely et al. 2015). The teicoplanin cartridge 
included the structural final model equations relating input (dosing information) to 
output (plasma concentrations) and the discrete joint probability distribution of the 
values of the equation variables (PK parameters) in the population, consisting of a 
discrete number of support points and their associated probability (the Bayesian prior). 
The cartridge was implemented in BestDose version 0.2.4 for R, which used the 
cartridge and each patient´s weight, age, PNA, serum creatinine, eGFR and teicoplanin 
dosing- concentration data to find the least biased and most precise dosage regimen 
relative to a target concentration, as previously described (Hope et al. 2013). 
 
7.3.4- Simulations to demonstrate the utility of the dose optimisation software 	
 To show the potential value of the dose optimisation software as a clinical tool, 
the software was used to predict the required dosage by day 2 of therapy to achieve a 
pre-determined teicoplanin concentration (15 mg/L) from day 3 in two representative 
subjects selected from the study population chosen based on age: 1) a critically ill infant 
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(5 months old-0.46 years old-, 6.3 kg, eGFR 63.84 ml/min/1.73m2) and 2) a critically ill 
older child (5.78 years old, 16.3 kg, eGFR 108.41 ml/min/1.73 m2). We used the past 
real concentration-time and dosing data from these two patients during the first dosing 
interval plus a 48h trough (n=4 observations) to predict the optimised dose and infusion 
time to achieve the desired target concentration safely (i.e avoiding peaks > 60 mg/L, 
regarded as potentially toxic levels (BMJ Group, the Royal Pharmaceutical Society of 
Great Britain 2015a)). A “past” data-file contained the observed concentrations for each 
patient. A “future” data-file contained the required timings of future dosages and target, 
an initial guess of the likely future dose(s) that would be required, as well as the 
infusion time was prepared. The same patients were also investigated with different 
simulated age-related average eGFR: 77 and 127 ml/min/1.73m2, respectively) to 
evaluate the impact of renal function in the patient´s PK profile (Heilbron, M. A. 
Holliday, et al. 1991). 
The dose optimisation software was tested by comparing the estimated predicted 
PK profile plot against the observations, as well as by the linear regression of the 
observed versus predicted concentrations for each individual patient. From the predicted 
concentrations based on the median individual Bayesian posterior parameter 
distribution, we calculated the bias, which is equal to the mean weighted predicted error 
(∑ wpe/N), with wpe = /predicted concentration – the actual concentration)/SD for each 
prediction/observation, and the % bias. We also computed the imprecision, which is the 
mean bias adjusted weighted squared error (∑ wspe/N-mwpe2), and its respective 
percentage for each patient and each experimental run. The weighted mean individual 
PK parameter values and an average 24h AUC estimated by the trapezoidal 
approximation to hourly predictions for each subject were also computed by the 
software. 
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7.4- RESULTS 
7.4.1- Demographics 
 
The demographics and clinical characteristics of the 57 patients used in the 
population PK model are summarised in table 7.1. The majority of patients (n=23, 
40.35%) were recruited from the ICU, in most cases after cardiac surgery. Other 
subjects included oncologic patients with febrile neutropenia (n=17, 29.8%), general 
medical (n=8, 28.1%) and cardiac medical conditions (n=1, 1.75%).  
A total of 394 PK samples were available for analysis with each patient 
contributing a mean of 5.3 and 7.6 observations in the neonates and older children, 
respectively. 
Demographic or clinic 
characteristic 
Median (min-max) 
[IQR range]  
 Children >1 month Neonates Total 
n. of patients 39/39 18/18 57 
Mean observations per 
patient  
7.6 5.3 6.9 
Gender (male:female) 21:18 12:6 33:24 
Wt (kg) 14.8 (3-62.2) 
[16.7] 
2.04 (0.69-5.08) 
[2.07] 
7.5 (0.69-62.2) 
[16.4] 
Height (cm) 97.9 (45-170)* 
[49.25] 
48 (36-52)** 
[11.5] 
72 (36-170) *** 
[65] 
Age (years) 3.3 (0.12-15.8) 
[6.13] 
0.05 (0.01-0.19) 
[0.04] 
0.88 (0.01-15.82) 
[4.9] 
PMA (weeks) NA 37(26-44) 
[10.25] 
NA 
PNA (days) 1204.5 (43.8-5774.3) 
[2237.5] 
17(4-69) 
[15.5] 
321.2 (4-5774.3) 
[2078] 
eGFR (ml/min/1.73m2) 78.94 (6.43-160.3) 
[50] 
42.8 (5.4-95.2) 
[25.5] 
62.06 (5.4-160.3) 
[49.03] 
Serum Creatinine (µmol/L) 41 (27-308) 
[14] 
44.5 (21-265) 
[21.75] 
41 (21-308) 
[15.5] 
Table 7.1- Demographics and clinical characteristics of patients included in the population PK 
model. *n=30; **=UK Pc50 length for gender and age; ***n=30 from the patients, the remaining unavailable data 
for height or length was obtained from the UK paediatric growth charts as the Pc50 height (median value) 
corresponding to the gender and age. NA=not-applicable. 
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7.4.2- Population PK of Teicoplanin in Neonates and Children 
 
 The population PK allometric model (Ke and V with weight) better accounted 
for the observed data than the linearly scaled model and was chosen to build the dose 
controller. This model included a descriptor of renal function that was incorporated as a 
power function term for eGFR (eGFRpw) or as PNA/creatinine. Figure 7.1 shows the 
relationships obtained in the exploratory process of building the structural model. The 
final population PK model explained 28 % of the PK variability in the population (16% 
more with the incorporation of the covariates). PNA/creatinine was used for neonates 
and infants < 3months of age (0.25 years old) as a better descriptor of renal function 
given the two different patterns observed around this age in the eGFR vs age plot 
(Figure 7.1 d.2 and e.1). A model comparison and diagnostics between the standard 
model without covariates, an exploratory model (adding a linear relationship between 
age and Ke), and the final model is shown in table 7.2. For the final model, the linear 
regression of observed versus Bayesian-predicted values had a coefficient of 
determination of r2 = 0.92 with measures of bias and precision of -0.15 mg/L and 0.9 
mg2/L2, respectively. The population and posterior individual observed versus predicted 
plots of the final model are shown in Figure 7.2. A visual predicted check (VPC) based 
on 1000 model-predicted simulated profiles of a subject with homogeneous dosing 
history and sampling schedule (with limit ranges to clinical covariates as per the 
original population) is shown in Figure 7.3. The mean, median and standard deviation 
of the final model population PK parameter estimates are shown in table 7.3. 
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Figure 7.1- Model building exploration of relationships between individual Bayesian posterior 
estimates for clearance (Cl) and volume (V) from the standard model and the clinical covariates. 
 
a) linear and logarithmic relationships between Cl and weight (wt); b) linear relationship between 
V and wt; c) Linear relationship between Cl, V and age; d) Cl and eGFR, eGFR and age (years); e) 
eGFR and age (up to 1 year old) establishing the age cut-off value for the different pattern of the 
power function relationship. The scatterplot between eGFR and PMA (weeks) is also shown (e.2). 
The continuous line shows the linear regression line and the dashed line shows the LOWESS 
(locally weighted scatterplot smoothing) or local regression line, which highlights a Cl-eGFR 
relationship compatible with a power function, where GFR is the independent variable raised to a 
constant (pw) in d.1. 
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Model Standard 
(without covariates) 
Final model 
(allometric without age) 
N. of variables 4 7 
Log-likelihood value 2523 2360 
AIC 2533 2376 
Pop/post Bias 3.8/-0.02 1.1/-0.15 
Pop/post Imprecision 72.2/1.5 12.3/0.9 
Pop r2 0.12 0.9 
Post r2 0.8 0.92 
Table 7.2- Model comparison and model diagnostics with and without covariates. 
AIC: Akaike information criterion; Pop/post Bias: population and posterior mean weighted error 
respectively; Pop/post Imprecision: population and posterior mean bias-adjusted weighted squared error; 
Pop/Post r2 = coefficient of determination for the linear regression of the observed vs predicted plots for 
the population and the posterior fits, respectively. 
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Figure 7.2- Observed-predicted concentrations scatter plots for the final Population PK model. 
Before (population) (top) and after (individual posteriors) the Bayesian step (bottom). 
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Figure 7.3- Visual Predictive Check for the population PK model. 
Continuous lines represent the model predicted-simulated PK profiles as (0.05,0.25,0.5,0.75,0.95) 
quantiles, grey areas are the 95% CI and empty circles the overlaid observations. 
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Parameter Ke01 (h-1) Ke02 (h-1) V01 (L) V02 (L) Kcp (h-1) Kpc (h-1) pw 
Mean 0.038 0.036 22.636 22.472 0.490 0.214 0.125 
Median 0.03 0.025 19.52 22.7 0.23 0.12 0.07 
SD 0.04 0.03 14.23 7.95 0.48 0.27 0.15 
 
Ke= Rate constant of elimination= Ke0*(wt/70)-0.25 *Renal; Renal=eGFRpw or PNA/creatinine if < 0.25 
years old; V=Volume of the central compartment=V0*(wt/70); Kcp and Kpc are the first-order 
intercompartmental rate constants; pw=power function. The epithet 01 and 02 denote the occasion. 
Ke0=Ke01 and V0=V01 for time < 96 hours; otherwise, Ke0=Ke02 and V0=V02.  
Table 7.3- Population PK parameter estimates from the final model. 
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7.4.3- Performance and simulations to demonstrate the clinical utility of the 
teicoplanin dose optimisation software 
The dose optimisation software predicted the PK profile of the individual 
patients and achieved a target with minimal bias and imprecision. The table 7.4 shows 
the bias, % bias, imprecision, % imprecision and the coefficient of determination (r2) of 
the linear regression of the observed vs predicted measured concentrations. Individual 
weighted mean PK parameter values were obtained. The median (range) average daily 
AUC0-24 for each patient is shown. 
Figures 7.4 and 7.5 show representative plots from the dose controller for the 
infant and the older child, respectively. They represent the software predicted PK 
profiles with their respective measured concentrations (red circles) and the target 
concentration (green squares). In the case of the infant, all required optimised doses by 
day 2 of therapy and a day 3 pre-dose target of 15 mg/L were 1.8 to 2.2 times higher 
than currently recommended maintenance dose (10 mg/kg) for 12-h extended infusions 
and a 24-hourly bolus administration, respectively (Fig. 7.4a and 7.4b). The regimen 
with daily 24-hour infusions required similar and subsequent slightly decreased dosages 
(Fig. 7.4c). Increased dosages and differing infusion times did not reach peak 
concentrations >60 mg/L, except for the first case (bolus administration by day 2 of 
therapy). In the case of the 5-year old child, a higher bolus administration of 18.4 mg/kg 
(as opposed to 10 mg/kg maintenance dose) was required for the day 3 pre-dose 15 
mg/L target, although producing peaks > 60 mg/L (Fig. 7.5a). In this patient, extended 
12 and 24-h infusions and even a multiple fractionated 12-hourly dose would have been 
safer alternatives (Fig. 7.5b, c, d). Increased predicted and optimal dosages were from 
13.9 mg/kg (1.4 times higher) to 3.7, 2.6 and 2.2 mg/kg for the multiple fractionated 
doses and pre-dose targets of 15 mg/L. There was not a significant impact, when the 
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simulated patients had an average age-related eGFR, higher than actual estimates. In 
these particular cases, they both required slightly increased dosages (≤2%).  
 
Subject 1_Infant 2_Child 
r2 1 0.97 
Bias -0.42 0.4 
% Bias -2.54 8.46 
Imprecision 0.3 1.64 
% Imprecision 0.05 1.54 
Median (range) of average 
24h AUC (mg*h/L) along the 
treatment course 
493.8 (355.8-574) 368.1 (318.9-388.4) 
 
r2= coefficient of determination of the linear regression of the predicted vs observed 
concentrations; Bias=mean weighted predicted-observed error; % Bias= 100* [mean weighted 
predicted-observed error/observed]; Imprecision= bias-adjusted mean squared error; 
%Imprecision= 100*[bias-adjusted mean squared error/observed]. 
Table 7.4- Summary of the individual prediction diagnostics from the dosing optimisation software 
for the two patients (using past-real data to obtain a target of 15 mg/L from day 3 of therapy).  
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Figure 7.4- Representative plots from an infant patient receiving teicoplanin. 
Pre-dose target of 15 mg/L from day 3 of therapy following a) bolus administration; b) 12h 
infusion; c) 24h infusion and d) multiple 12-hourly dosing. 
[a) Bolus administration: Dose required by day 2: 143.4 mg (22.3 mg/kg); day 3: 97.22 mg (15.4 mg/kg); 
day 4: 87.74 (13.9 mg/kg); b) 12h infusion: Dose required by day 2: 112.02 mg (17.8 mg/kg); day 3: 
81.72 mg (12.97 mg/kg); day 4: 74.64 mg (11.8 mg/kg); c) 24 h infusion: Dose required by day 2: 65.17 
mg (10.3 mg/kg); day 3: 56.98 mg (9.04 mg/kg); day 4: 53.68 mg (8.5 mg/kg); d) Multiple dosing every 
12 h: Doses required by day 2: 85.08 mg (13.5 mg/kg), and every 12 h thereafter 60.69 mg (9.6 mg/kg) 
and 60.48 mg (9.6 mg/kg) and 46.54 mg (7.4 mg/kg)]. 
 
a) b)
c) d)
Infant: 0.46 years old (167.9 days/5 months and a half old); wt: 6.3 kg; eGFR: 63.84 ml/min/1.73 m2 
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Figure 7.5- Representative plots from an older child patient receiving teicoplanin. 
Pre-dose target of 15 mg/L from day 3 of therapy following a) bolus administration; b) 12h 
infusion; c) 24h infusion and d) multiple 12-hourly dosing.  
[a) Bolus administration: Dose required by day 2: 300.62 mg (18.4 mg/kg); day 3: 78.64 mg (4.8 mg/kg); 
day 4: 61.75 mg (3.8 mg/kg); b) 12h infusion: Dose required by day 2: 276.5 mg (17 mg/kg); day 3: 
83.71 mg (5.1 mg/kg) and day 4: 62.38 mg (3.8 mg/kg); c) 24h infusion: Dose required by day 2: 190.81 
(11.7 mg/kg); day 3: 100.92 mg (6.2 mg/kg) and day 4: 70.7 mg (4.3 mg/kg); d) Multiple 12-h dose 
administration: Doses required by day 2: 227.22 mg (13.9 mg/kg); and 12-hourly, thereafter, 36 h: 60.51 
mg (3.7 mg/kg); 48 h: 42.72 mg (2.6 mg/kg); 60 h: 35.55 mg (2.2 mg/kg); 72 h: 31.77 mg (1.9 mg/kg)]. 
 
a)
d)c)
b)
Older child: 5.78 years old (2109.7 days); wt: 16.3 kg; eGFR: 108.41 ml/min/1.73 m2 
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7.5- DISCUSSION  
An improved understanding of the PK/PD of teicoplanin is fundamental to the 
optimal use of this agent (G.L. Drusano 2004). In this study, we developed a population 
PK model in neonates, infants and children to identify PK variability and its explanatory 
clinical covariates within a heterogeneous cohort. Importantly, with the available patient 
covariates, the model can only account for 28% of the observed variability in 
teicoplanin concentrations in this population (Figure 7.2, top), which is consistent with 
other population PK studies in children and adults (Zhao et al. 2015a; Byrne et al. 
2015). In contrast, combining the model with individual patient measurements permits 
accurate prediction of concentrations (Figure 7.2, bottom), a strong argument for the use 
of TDM to control dosing and avoid sub-optimal antimicrobial exposure that will result 
from the wide distribution of drug exposures (Ramos-Martin et al. 2014; Ramos-Martín 
et al. 2016). Pharmacometric approaches to TDM (i.e Bayesian calculations) are best 
suited to aid in the optimised and truly individualised use of antimicrobials in general, 
and of teicoplanin in particular (Macdonald et al. 2008).  
For other antimicrobial agents, such as vancomycin, aminoglycosides and 
voriconazole, the rationale for TDM is compelling because there are generally accepted 
exposure-efficacy and exposure-toxicity relationships. For teicoplanin, a relationship 
between plasma concentration and toxicity has not been established (Tobin et al. 2010; 
Matthews et al. 2014; Yamada et al. 2017; Yamada et al. 2014), which may reduce the 
incentive for physicians to routinely monitor the drug. However, exposure control to 
maximize efficacy should not be neglected. The British National Formulary for 
Children (BNFC) suggests a therapeutic window of >15 to 60 mg/L for children and 
adults (BMJ Group, the Royal Pharmaceutical Society of Great Britain 2015a). This 
window is based on retrospective associations, particularly against MRSA infection 
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(Harding et al. 2000; Strenger et al. 2013; Ueda et al. 2012; Matthews et al. 2014). 
Moreover, low drug exposures increase the probability of clinical failure and 
development of drug resistance (George L. Drusano 2004; Chang et al. 2012). 
Teicoplanin dosage regimens that are stratified by weight and/or renal function 
improve the achievement of target concentrations in adults (Yamada et al. 2012b; Niwa 
et al. 2010). However, high and unexplained PK variability in children and neonates, 
make steady-state empirical dose adjustment 3-5 days after starting teicoplanin or 
changing the dose, a sub-optimal strategy that can result in a high proportion of sub-
therapeutic concentrations < 10 mg/L (i.e 55-89%)(Dufort et al. 1996; Sánchez et al. 
1999; Strenger et al. 2013). This can result in prolonged and unnecessary patient 
exposure outside the optimal range. Hence, an optimal way of performing patient-
tailored TDM would rapidly achieve therapeutic concentrations with minimal sampling 
and avoidance of steady-state requirements.   
Bayesian tools offer just such a way to achieve target concentrations as rapidly, 
accurately and precisely as possible (Macdonald et al. 2008). The Bayesian adaptive 
multiple-model control algorithm was used in this study to: 1) update the general 
paediatric population teicoplanin´s PK parameter probability distributions for an 
individual patient, and 2) to use the updated, individual model to match measured 
concentrations, predict future concentrations, and calculate dosages to achieve target 
concentrations, all without the need for steady state or even precisely timed trough 
samples.  
In the clinical setting, there are several difficulties that can hamper the optimal 
application of the feedback dosing control. Intra-individual, inter-occasion variability 
(IOV) (Karlsson & Sheiner 1993) can cause unexplained PK variability and poor model 
predictions, particularly in neonates and/or critically ill patients who are unstable 
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(Holford et al. 2013; Blot et al. 2014). Quantification of rapid pathophysiological 
changes, such as renal function, and subsequent incorporation as covariates into the PK 
model may allow better prediction of intra-individual variability in this population. We 
found little IOV for teicoplanin in this population. A bedside feedback control tool 
allows updated teicoplanin concentration-time data and patient´s covariate information 
to be re-entered into the software on an iterative way. The algorithm we used in the 
BestDose software permits one to escape the assumption that PK parameter values are 
constant in a patient, making it ideal to capture IOV(Macdonald et al. 2008). This can 
account for real intra-patient variability during therapy.  
Another interesting aspect of our work was the use of post-natal age (PNA) 
divided by serum creatinine (SCr) as a novel marker of renal function. When modelling 
and controlling drug behaviour, it is not necessary to describe renal function using 
traditional equations that estimate GFR, although we did use the Schwartz equation for 
the infants >3 months of age. The goal in pharmacometrics is to find the best descriptors 
of drug behaviour, in this case related to renal function and maturation. We feel that 
PNA/SCr has advantages over any other estimation of renal function, including 
Schwartz, in that it does not use length (height), which can be notoriously inaccurate in 
infants. We have previously found PNA/SCr to be a useful predictor for both 
vancomycin (Yamada et al. 2015) and gentamicin PK (Neely & Floyd 2015) in infants. 
In conclusion, we present a tool to rapidly and accurately predict teicoplanin 
concentrations and calculate doses that optimally achieve desired concentrations in 
paediatrics. We further validate PNA/SCr as a novel predictor of renal drug elimination 
in neonates and young infants. A prospective study evaluating the cost-effectiveness of 
such individualised dosing is now warranted. 
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Chapter 8 
General Discussion and  
Final Conclusions 
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8.1- PROJECT OVERVIEW: A translational pharmacological approach to 
optimise antimicrobial therapy in children 		 This thesis provides novel insights into our understanding of the exposure (PK)-
response (PD) relationships of two well-established glycopeptide agents (vancomycin 
and teicoplanin) against the most prevalent causative pathogens of BSI in neonates and 
children (namely CoNS and MRSA). This constitutes the first critical step for 
optimising the clinical use of these currently available antimicrobial drugs in children.  
This step could be achieved with the use of a translational pharmacological 
approach that combined: 1) the use of pre-clinical infection models, both in vitro and in 
vivo experimental models, 2) the collection of clinical pharmacokinetic and 
pharmacodynamic information (e.g CRP concentrations) from the target population 
(neonates and children) and 3) mathematical modelling techniques that allowed a robust 
analysis of pre-clinical and clinical exposure-response information, the identification 
and quantification of variability and the bridging of experimental findings to patients 
(by means of Monte Carlo Simulations). Finally, we applied the developed population 
clinical PK model across childhood (a summary of prior past information) within a 
Bayesian adaptive control algorithm (BestDose) to allow the individualised therapy of 
teicoplanin.  
The pre-clinical models of infection permitted defining the most relevant PD 
index as well as the magnitude of that index that best linked vancomycin and 
teicoplanin drug exposures with antimicrobial efficacy. This is crucial for setting up the 
experimental basis of an optimal use of the antimicrobial of study (both in terms of 
bacterial killing and preventing/suppressing the emergence of resistant subpopulations). 
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In line with our initial project aims, several key findings were made during this 
PhD project: 
1) Vancomycin displays a concentration-dependent (AUC:MIC) activity 
against CoNS infection (Chapter 3). This observation was achieved in both in vitro and 
in vivo pre-clinical infection models used in the project to mimic a neonatal BSI and a 
CLABSI (in vivo) caused by CoNS. An AUC:MIC ratio was the best 
pharmacodynamically linked index predictive of efficacy against a total bacterial 
population and a resistant (mutant) sub-population. The study suggested that less 
fractionated vancomycin regimens are appropriate for clinical use, and that continuous 
infusion may be associated with increased risk of emergence of resistance. The in silico 
bridging study to human neonates concluded that pre-term neonates < 29 weeks PMA 
were under-dosed in comparison with the older age-groups. These findings provided the 
PK/PD evidence to inform an optimised neonatal dosage regimen to take into a 
randomized controlled trial. 
2) Teicoplanin also displayed a concentration-dependent (AUC:MIC) 
activity against MRSA infection (Chapter 4). This observation was concordant using 
two pre-clinical (in vitro and in vivo) infection systems. A simulation-based PTA 
analysis in adults and children showed that the PK-PD cut off was much lower than the 
currently defined EUCAST MRSA clinical breakpoint for teicoplanin (S£ 2 
mg/L)(European Committee on Antimicrobial Susceptibility Testing, 2010). This 
suggested that current licensed dosage regimens might be unlikely to treat patients 
successfully (both adults and children) in monotherapy; particularly, those infected with 
strains with MICs at the higher end of the current susceptibility range. Conclusively, 
established breakpoints might need to be revised with more supportive, updated and 
comprehensive pre-clinical and clinical datasets. 
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3) Clinical population PK studies of teicoplanin allowed the collection and 
analysis of clinical PK profiles to develop a population PK model in neonates and 
children (Chapter 5 and 6). In the case of the neonates, CRP information was also 
incorporated to the model as the linked PD input (Chapter 6). The population PK (and 
PD when linked to CRP) model revealed a high PK (and PD) variability in the 
population. An AUC:EC50 ratio was explored to account for a more informative PD 
target in the neonates, where results from blood cultures and thus, MICs, are rarely 
available. Weight, as a surrogate of size, age and renal function (eGFR or 
PNA/creatinine) were the most explanatory covariates of such PK variability (Chapters 
5, 6, 7). Nonetheless, a high proportion of the PK variability in neonates, infants and 
children was unexplained and not accounted for by clinical covariates. This supports the 
mandatory use of teicoplanin TDM to ensure adequate drug exposures in individual 
patients. 
4) Teicoplanin individualised therapy (Chapter 7). Given the high and 
unexplained PK (and PD) variability in children, the individualised dosing and TDM of 
teicoplanin is required to maximise its efficacy, minimise toxicity and improve the 
clinical outcomes in this population. We showed the clinical utility of a Bayesian 
adaptive feedback control algorithm (BestDose) to individualise dosing in paediatric 
patients providing early concentration-time observations. Further and prospective cost-
effectiveness evaluation of this tool for dose individualisation is now required. 
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8.2- THE ROLE OF PK/PD DETERMINATION AND ANALYSIS IN 
OPTIMISING ANTIMICROBIAL THERAPY 
          Laboratory-based in vitro and animal data are used to define antimicrobial PD, 
which supports the knowledge and understanding of relevant PK/PD indices descriptive 
of maximal activity. PK/PD relationships established in pre-clinical studies are 
predictive of therapeutic responses in humans (Craig 1998). Although these indices may 
be helpful to inform dose optimisations in different clinical scenarios, more research is 
warranted to validate the clinical relevance of PK/PD relationships observed in vitro 
and in vivo.  
In Vitro PK/PD Studies 	
A HFIM in vitro model was used throughout the pre-clinical chapters of this 
thesis (Chapters 3 and 4). This model enabled the investigation and quantification of the 
bacterial killing-drug effect, as well as the effect against the emergence of drug 
resistance under drug pressure. The beauty of this model relies in the possibility of 
exposing the infective bacteria to daily changing drug concentrations that are 
continually adjusted to mimic either a neonatal or a child PK human profile in vivo. The 
main limitation of this in vitro model, is a lack of immune system, which provides a 
caveat in the interpretation and translation of results to patients. Nonetheless, it also 
means that a drug regimen which is active in vitro (or in a neutropenic animal) is more 
likely to be effective in immunosuppressed patients, such as pre-term neonates, 
critically ill neonates, young infants and children, as well as febrile neutropenic 
oncologic children. 
A high inoculum size above the strain mutational rate together with a delay of 24 
hours to initiate therapy was necessary (i.e reaching inocula sizes ~ 8-9 Log10 CFU/mL) 
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to provide information with respect to the emergence of resistance. These experimental 
conditions in vitro might reflect the worst clinical scenario in a patient, where 
information about clinically relevant bacterial densities for a BSI in a neonate/child is 
not known. An in vivo model can place a more clinically relevant (i.e sub-lethal) 
bacterial load in context, however, the correlation with the patient and the need for a 
probable more conservative drug exposure target needs to be investigated. 
The lack of appropriate comparable protein binding in microbiological growth 
media (MH broth and agar) to human serum constitutes another main limitation of in 
vitro models. Since the physiological conditions (pH, electrolytes, temperature, source 
of proteins, fatty acids, etc) differ, the quantitative determination of the impact of 
protein binding in vitro and in vivo remains challenging. The current diversity of 
models, methods and results looking at the impact of protein binding on antimicrobial 
therapy, particularly for highly protein-bound molecules, contribute to the ongoing 
debate about its relevance and understanding (Zeitlinger et al. 2011). Further and more 
standardised targeted research in this particular area is warranted. In the meantime, 
measurement of protein binding in the experimental medium (and in the animal species 
of study) is desirable in an attempt to mimic physiological conditions as thoroughly as 
possible. 
In vivo PK/PD Studies 	
Animal infection models provide the opportunity to study drug efficacy while 
accounting for the host immune response, virulence of the pathogen and antimicrobial 
susceptibility linked to bacterial load. In this thesis project, the CLABSI rabbit model 
and the mouse neutropenic thigh infection model were closer mimics of human 
disease/response whilst also accounting for total (protein-bound) drug exposures. They 
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both provided complementary information to the HFIM system and validated the in 
vitro findings. Additionally, the CLABSI rabbit model permitted the evaluation of the 
complexities of a central-line associated infection in a critically ill neonate context, 
where the line needs to be retained in the patient and staphylococcal biofilm develops. 
The assessment of a biomarker of antimicrobial response (circulating CRP) was 
also assessed in the rabbit infection model. This was interesting from two points of 
view. The first one, it was a necessary PD readout information for the evaluation of 
exposure-response relationships. The blood cultures were not informative as they 
displayed highly variable results. This is in line with what happens in the clinical setting 
for neonates, where constraints in the blood volume of samples for blood cultures can 
yield insensitive results (Connell et al. 2007). Second, it enabled the incorporation of a 
quantitative PD measure, widely used and validated in the clinical setting, into the 
structural linked PK/PD mathematical models. The use of biomarkers (i.e CRP, 
procalcitonin) have proved to be essential to guide initiation and discontinuation of 
antimicrobial therapy (Bomela et al. 2000; Nouér et al. 2011). However, further 
evaluation is still needed to determine the potential benefits of biomarker modelling in 
the management of patients, as well as in the individualised dosing and TDM approach 
(Huurneman et al. 2016). Importantly, biomarker changes might not be highly specific 
for the treated infection and there needs to be confidence that its dynamics reflect the 
interaction between drug, pathogen and host response. Existing additional factors (e.g. 
surgery and tissue damage) affecting the biomarker response need to be considered in a 
more advanced modelling framework. 
Finally, there still exists some uncertainty as if the pre-clinical infection models 
can reproduce adequately the potentially altered and variable PK and PD, particularly 
observed in pre-term neonates, low birth weight neonates and critically ill patients. In 
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vivo models allow for assessing multiple endpoints including mortality, quantitative 
bacterial counts in blood/ tissues and description of inflammatory responses (e.g. CRP, 
cytokine measurements). However, there still exist important differences between 
species and different patient-populations and sub-populations (e.g. the host immune 
response, the protein-binding affinity, the relevant endpoint) that can affect the clinical 
relevance of animal data.  
In many instances, the magnitude of exposure identified for stasis in 
immunocompromised animals have been similar to the exposure threshold associated 
with good clinical outcomes in patients (Ambrose et al. 2007). A more in-depth 
understanding of the appropriate extrapolation of magnitudes of exposures from pre-
clinical models into the patients is necessary. PK/PD data derived from patients will 
provide the opportunity to confirm knowledge gained from pre-clinical PK/PD infection 
models. 	
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PK/PD Population Mathematical Modelling of Experimental Data and Bridging to 
Patients  
Population PK/PD modelling was conducted to describe, identify and quantify 
the exposure-effect relationships from both pre-clinical and clinical systems. In the case 
of modelling the experimental data, the aim was defining the PK/PD relationships and 
investigating the PD targets predictive of maximal efficacy and suppression of a 
resistant subpopulation. This was achieved by means of fitting the final model-Bayesian 
predictions (i.e for the time-course of drug exposures and bacterial density/CRP at the 
end of therapy) to an Emax inhibitory sigmoid model (Hope & Drusano 2009). 
Population PK/PD modelling methods can be statistically classified as either 
parametric or non-parametric. Each classification can be divided into maximum 
likelihood (ML) or Bayesian approaches (Tatarinova et al. 2013). Throughout the 
project, the non-parametric population modelling software Pmetrics was used. This 
software uses a combination of NPEM (non-parametric expectation maximization) for 
the first cycle of the model fitting process, with the NPAG (non-parametric adaptive 
grid) algorithm of Leary and Burke (Neely et al. 2012). This NP approach does not 
make any assumptions about the underlying distribution of the PK/PD parameter values 
and use an exact computation of the likelihood (ML). For clinical data, the assumption 
that parameter estimates are non-parametrically distributed may be appropriate and 
enables the detection of sub-populations and outliers within the study population (Neely 
et al. 2012). This could be especially relevant in very heterogeneous populations where 
a small sub-group of patients (e.g very low birth pre-term neonates) could have quite 
different clinical characteristics that could influence the drug´s disposition and/or effect 
(e.g rapidly changing renal function or an immature immune system). 
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In previous comparative performance studies of parametric and non-parametric 
population methods in analysing clinical data, non-parametric methods were better than 
parametric ones at analysing populations having unanticipated non-Gaussian or 
multimodal parameter distributions. In addition, using exact or accurate computations 
gave more precise parameter estimation, showed better stochastic convergence 
properties and proved more statistically consistent (the more subjects studied, the closer 
the estimated parameter values approached the true ones) as opposed to parametric 
algorithms that are not based on maximum likelihood but approximated functions, eg. 
FO, FOCE, FOCEI (first order conditional expectation)(Bustad et al. 2006).  
For analysis of in vitro and in vivo PK/PD models, where “individuals” are more 
homogeneous and behaviour is highly controlled, parameter estimates may be normally 
or log-normally distributed making the non-parametric analysis less necessary. There 
are no published comparisons of non-parametric (e.g Pmetrics) with parametric ML 
software programmes (e.g NONMEM, Monolix and ADAPT) for the analysis of 
experimental PK-PD infection model data. 
Limitations/weaknesses of the non-parametric modelling approach used in this 
project 
In order to complete a non-parametric analysis Pmetrics requires a fixed error 
model to weight the observations. In Pmetrics, each observation is weighted by the 
inverse of the variance (=1/error2). The error model is derived from the assay variance, 
which can be easily measured for PK studies but is more difficult to estimate for PD 
data (Övariance = SD= C0 + C1*[Observation]+C2*[Observation]2 + C3*[Observation]3 ). 
Additionally, the error model is multiplied by a scalar (g), which is estimated by 
Pmetrics and represents the environmental error or process noise not included in the 
assay variance (Error= SD* g)(Jelliffe et al. 2000). Inclusion of this scalar, therefore, 
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assumes that all the error in the data or model structure is proportional to the assay 
variance, which it may not be. This is in contrast to alternative parametric modelling 
software options where the error is estimated in the analysis. 
In addition, in Pmetrics there is no feature to separate the various sources of 
variability into their respective components. For example, the inter-individual 
variability (the diversity among the subjects in the ways they handle the drug) and the 
intra-individual variability (e.g rapid physiological changes in unstable patients and 
subsequent changing parameter values during the study period) from the environmental 
error (i.e the errors in preparing and giving the doses, recording the times at which 
serum concentrations were obtained, the assay error itself, the model misspecification, 
etc). On the contrary, parametric methods, such as NONMEM, are able to split the 
various sources of variability, whilst allowing two levels of random effects (noise): 
inter-individual and residual variability (Standing 2016). 
At the start of the project, a non-parametric or semi-parametric Monte Carlo 
Simulator was not available in Pmetrics. Thus, for Chapter (3) and (5), the population 
and individual simulations were performed using ADAPT 5, which assumes that the 
parameter estimates are normally or log-normally distributed. The impact of using 
parameter values estimated using a non-parametric method in a parametric simulator is 
unknown. Subsequently, a general-purpose Monte Carlo simulator within Pmetrics was 
used. This simulator samples new sets of parameter values from prior parametric or 
non-parametric distributions from the developed PK/PD model. From each sampled set 
of parameter values, the simulator calculates observations based on a template of 
different dosing inputs, output measurement times and relevant covariates. 
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8.3- CLINICAL PK STUDIES IN CHILDREN AND NEONATES 
Collecting concentration-time data of antimicrobials in children and neonates is 
essential for developing population PK models, which can be progressed into dosing 
regimens that are appropriate for the intended population and infection syndrome. 
For this thesis project, we conducted a clinical PK study of teicoplanin in 
prospectively recruited children and neonates (phase IV, open-label) from two different 
hospital settings (Alder Hey Children´s NHS Foundation Trust and the Liverpool 
Women´s Hospital).	 We had anecdotal evidence of clinical failures with teicoplanin 
therapy and had also observed “MIC creep” for CoNS often found at the breakpoint 
(4mg/L) (unpublished data). To further investigate the clinical pharmacology of 
teicoplanin in the paediatric population and to provide an insight into appropriate 
regimens for children, we performed the population PK study. 
Three clinical population PK modelling analysis are presented in this thesis: 
children (n=39), neonates (n=18), both together (n=57), receiving teicoplanin in the 
inpatient clinical setting. 
1) The population PK model in children > 1 month (n=39) revealed highly 
variable PK and was able to explain a 29% of variability in the population (Chapter 5). 
A standard 2-compartment PK model was developed, followed by structural models that 
incorporated weight. Weight was allowed to affect clearance (CL) using linear and 
allometric scaling terms. In this study, the linear model best accounted for the observed 
data and was subsequently chosen for Monte Carlo simulations. In addition, there was a 
much wider spread of drug exposure distribution (AUCs at steady state) when compared 
with adults. Thus, TDM should be performed routinely in children receiving 
teicoplanin. 
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Participants largely did not have renal impairment. The impact of reduced renal 
function on clearance and therefore dosing could not be assessed. We could not 
correlate drug exposure with effect/clinical outcomes in this study because there were 
only few documented infections. 
2) The population PK model in neonates (n=18). The PK allometric model best 
accounted for the observed data and was able to explain a 25 % of PK variability in the 
population (Chapter 6). The simulated median AUC 96-120 was 302.3 mg*h/L, median 
Cmin at 120 h was 12.9 mg/L. A 38.8% of patients attained a Cmin >15 mg/L by 120h. Of 
the multiple covariates that were studied, only weight accounted for any portion of the 
observed PK variability. Incorporation of weight into structural PK models resulted in 
better fits and statistically more likely solutions. Of note, we could have equally 
reasonably related weight to clearance using linear or power scaling terms, despite the 
convention for using a scaling exponent of 0.75 (Anderson & Holford 2008; Germovsek 
et al. 2016). We could not demonstrate any relationship between teicoplanin clearance 
and PMA, estimated glomerular filtration rate (eGFR) or serum creatinine. This was 
somewhat surprising because teicoplanin is almost completely renally (98%) cleared by 
glomerular filtration (A. P. Wilson 2000). The absence of any relationship probably 
reflected the small sample size, as well as the relatively poor estimates of eGFR in 
neonates using current nomograms (Haycock-Schwartz) (Schwartz et al. 1984). This 
finding does call into question whether teicoplanin dosing should be adjusted on the 
basis of eGFR and further studies are required to specifically address this question. 
This study was also too small to evaluate clinical exposure-response 
relationships. A Gram-positive pathogen was isolated in only 6/18 (33.3%) of patients. 
Hence, there was no opportunity to examine the relationship between the magnitude of 
any traditional pharmacodynamic indices (e.g. AUC:MIC) and outcome. Even in larger 
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datasets, the problem of culture negativity is frequently present. The use of CRP and a 
novel pharmacodynamic index (the AUC:EC50) was explored in this study. The 
rationale behind this ratio is that EC50 is an in vivo measure of drug potency and the 
AUC:EC50 is a measure of the exposure of drug relative to the potency of its effect. A 
major strength of this approach is that drug exposure targets are more individualised for 
a specific patient. The EC50 captures the impact of multiple variables on exposure- 
response relationships (e.g., resistance, high bacterial load, a persistent infective focus, 
biofilms and immune response). In contrast, when the measure of potency is the MIC 
alone, as for AUC:MIC, it is only the organism's characteristics that are considered. The 
model-Bayesian posterior estimates for EC50 ranged widely (0.6-18.7 mg/L) in the 
neonatal population, which again reflects highly variable pharmacodynamics. In this 
study, the AUC:EC50 predicted the terminal CRP levels after 5 days of therapy for a 
majority of patients.  
 
3) The population PK model across childhood (n=57) was able to explain only a 
28% of the variability in the population, confirming, on one hand, the high PK 
variability previously seen in neonates and children (Chapters 5 and 6), separately, and 
by other authors in similar paediatric populations (Lukas et al. 2004; Zhao et al. 2015a); 
and on the other hand, that a very high proportion of the inter-individual variability 
remains unexplained. Intra-individual day-to-day variability could represent a portion of 
the unexplained PK variability found, particularly in neonates and/or critically ill 
patients, nonetheless, measures were taken to decrease and control for this. Day-to-day 
changing serum creatinine and thus, eGFR values along the study were recorded to 
reflect the potential renal function´s changing pathophysiology. In addition, an inter-
occasion variability (IOV) factor was incorporated into the whole dataset to account for 
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other changing physiological variables, other than renal, between the two study visits 
(before and after 4 days of therapy)(Karlsson & Sheiner 1993). Nonetheless, the final 
model showed there was little IOV on a population level, suggesting that this factor 
could be adequate for description but less helpful for dose-control.  
In the covariate analysis, weight, as a surrogate of size, continues to be the most 
explanatory variable of teicoplanin´s behaviour in this model including neonates to 
older children, as in the previous population PK models of teicoplanin in paediatrics 
(Zhao et al. 2015b). It had an impact on both, clearance and volume of distribution (Ke) 
following an allometric scaling of factors (Anderson & Holford 2008). As for the renal 
function, we used the Schwartz-Haycock equation as the accepted standard to estimate 
GFR in children (Schwartz et al. 1984). In this study, eGFR was associated with 
teicoplanin clearance in both a linear and a power function manner, where GFR was the 
independent variable raised to a constant to be estimated (pw). Furthermore, the 
influence of growth and maturity in the renal function of children, was investigated with 
the patient´s age, indicating a similar power function association, as showed elsewhere 
(Heilbron, M. a Holliday, et al. 1991; Rhodin, Anderson, Peters, Coulthard, Wilkins, 
Cole, Chatelut, Grubb, Veal, Keir & Nick H. G. Holford 2009). On the other hand, a 
serum creatinine-based covariate accounting for the age (PNA/srCreat) was studied in 
the neonates and young infants < 3 months, where developmental changes occur in a 
more rapidly and pronounced way (Rhodin, Anderson, Peters, Coulthard, Wilkins, Cole, 
Chatelut, Grubb, Veal, Keir & Nick H. G. Holford 2009), and resulted in a better 
descriptor of teicoplanin elimination than the Schwartz equation in this sub-group of 
age. The usefulness of PNA/srCreat as a measure of renally eliminated drugs have been 
previously described in neonates receiving gentamicin and vancomycin (Neely & Floyd 
2015; Yamada et al. 2015). This renal function estimator now needs to be further 
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validated in this population and with other drugs that depend extensively on renal 
elimination. 
As discussed above, PK/PD models can combine available knowledge of PD, 
based on in vitro, animal or clinical data, with clinical PK. Because of the PK (and PD) 
variability in neonatal and paediatric patients, dosing simulations are required for 
different clinical covariates to propose dosing regimens suitable for individual patients. 
These dosing simulations can incorporate relevant patient characteristics known to 
affect PK, e.g. body size (weight) and organ function (eGFR). Attainment of PD targets 
can be predicted for different combinations of antimicrobial doses and pathogen 
susceptibilities, and optimised dosing regimens can be suggested for specific scenarios. 
Still, the predictions may be imperfect given the uncertainty in PK and PD present and 
should be validated in clinical studies. Furthermore, an individualised dosing and TDM 
approach can ensure optimal target attainment at the individual level and on real-time. 
 
Population PK/PD modelling of clinical data 	
In the case of modelling the clinical data, the aim was defining the PK (and if 
possible PD) variability and relevant explanatory clinical covariates in the target 
population. This understanding allowed subsequent simulations for target attainment 
analysis and to be used as Bayesian prior information in the individualised treatment of 
similar patients receiving the drugs of study.  
In the final study, a single teicoplanin population PK model for the three 
heterogeneous sub-populations across childhood (neonates, infants and older children 
up to 16 years old) was successfully developed with a non-parametric population 
modelling approach. This approach allowed increasing the sample size to 57 children, 
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which could further allow the investigation of the influence of covariates such as the 
eGFR and the age, whilst also exploring the major strength of Pmetrics for detecting 
unexpected sub-populations and outliers within the study population (Neely et al. 2012).  
A comparison of both parametric (NONMEM) and non-parametric (Pmetrics) 
methodologies would be needed to complement findings on estimates for teicoplanin´s 
Cl and Vc and the impact of size and maturation across childhood. For modelling 
clinical data, a more consistent and standardised approach between both methodologies 
to model development, fitting and reporting would be optimal. This would make 
comparisons and meta-analyses amongst different models possible. This way a more 
efficient development of clinical PK/PD knowledge amongst a highly vulnerable 
population would be reached to ultimately help improving patient´s clinical outcomes. 	
8.4- INDIVIDUALISED THERAPY 
In view of the high PK and PD variability in children and neonates, as well as 
the significant portion that results unexplained, a move towards individualised dosing is 
required. PK models coupled to a PD target can be used to design nomograms in which 
one or more patient characteristics that drive the PK variability are required to 
determine optimal dosing (Roberts et al. 2011). Dosing based on validated nomograms 
increase the probability of achieving PD targets as compared to conventional dosing 
(Cristallini et al. 2016). However, the significant amount of PK (and PD) variability that 
is not accounted for by covariates cannot be handled appropriately by nomograms. 
Bayesian calculations and forecasting of real patient´s clinical data are best suited to aid 
in the optimised use and truly individualised TDM of antimicrobials in general, and 
teicoplanin in particular (Roberts et al. 2014; Macdonald et al. 2008). 
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We used the model (prior past information) within a multiple-model Bayesian 
adaptive control algorithm. A multiple-model approach allows the use of multiple 
discrete individual models (one for each subject) as a discrete collection of points to 
find the most likely population parameter distribution. Each point (support point) 
contains a model parameter set of estimates and their associated individual probability. 
This algorithm was used to: 1) recompute the parameter distributions- based on the past 
experience in the general paediatric population- for an individual patient, and 2) to find 
the most likely balance of credibility between the population model and the new 
patient´s data, to predict future concentrations and calculate dosages to achieve target 
concentrations. This balance then can optimise teicoplanin therapy and inform 
individualised TDM in hospitalised neonates and children. In our study, early stage 
concentrations (first dosing interval plus a 48h trough), independently of steady-state 
conditions, allowed predicting the required dosage to achieve a desired recommended 
concentration target from day three of therapy. 
The impact of intra-patient variability needs to be carefully taken into account. 
A bedside feedback control tool allows the continuous update of teicoplanin 
concentration-time data and patient´s covariate information to be re-entered into the 
software. This can account for real intra-patient variability along therapy. Nonetheless, 
rapid assessment of patient samples (i.e teicoplanin quantification) before the next dose 
is required to reduce the impact of PK variability and maximise the use of BestDose. 
More recently, newer control algorithms, such as interacting multiple-model 
(IMM) analysis, could be best suited to account for the most unstable patients by letting 
parameter distributions change with each new data point (Macdonald et al. 2008). 
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8.5- FUTURE DIRECTIONS TO IMPROVE THE PK/PD TRANSLATIONAL 
PHARMACOLOGICAL APPROACH  
 From a clinical perspective, an improved development of the current PK/PD 
translational pharmacological approach is needed for: 1) the identification of optimal 
drug exposures in all sub-populations of paediatric patients and 2) the delivery of those 
optimal drug exposures to paediatric patients in a more individualised and controlled 
manner. 
  For the first requirement, pre-clinical PK/PD work needs to incorporate more 
correlation studies between drug exposures and the molecular characterisation of 
resistance development. Optimal drug exposures might be greater in the case of isolates 
exhibiting intrinsic survival advantages under prolonged drug pressure (i.e VISA 
isolates). Targeted in vitro HFIM studies would be best suited to undertake and 
characterize these exposure-effect complex relationships. 
Importantly, clinical PK/PD studies linking those drug exposures with 
suppression of emergence of resistance in the target population of patients would also 
be needed. Currently, there are no published studies as such. These are required to 
cross-validate and place into context the magnitude of drug exposures (and PD indexes) 
deemed relevant from the pre-clinical models of infections. These studies are potentially 
complex to conduct and would require: 1) well identified patients in terms of clinical 
and microbiological characteristics. This needs the investigation of the bacterial density 
size (i.e DNA bacterial load) at the time of therapy initiation and at the infection site; 2) 
the sensitive detection of emergence of resistance mechanisms from the causative 
pathogens infecting recruited patients; and 3) measurement of the concentration-time 
course of the drug and linked inflammatory biomarkers at the site of infection. 
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 For the second requirement, a PK/PD clinical population model from the target 
population would be developed, prospectively validated and used as prior information 
in the individualised PK-PD therapy software. This software ideally will use a dual-
output Bayesian adaptive control algorithm able to: a) let the parameter distributions 
predictions change according to the variable pathophysiological changes in the patient 
and (i.e interacting multiple model algorithm) b) adapt dosing not only to achieving a 
population-established drug exposure target but also to reduce the patient-specific host-
response biomarker ± bacterial load (i.e EC50) during the course of therapy. 
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8.6- FINAL CONCLUSIONS AND RECOMMENDATIONS 	
• The current strategy of using teicoplanin fixed population-based antibiotic 
regimens results in a wide range of drug exposures in neonates and children. A 
shift towards individualised dosing and TDM is required to: 1) maximise 
antimicrobial efficacy, 2) supress/minimize the emergence of resistance and 3) 
minimize potential drug-toxicity. 
• Evidence-based PK/PD dosing regimens for specific patient populations and 
infection syndromes are fundamental to improve clinical outcomes in patients 
with severe infection. 
• A population PK model of teicoplanin in children can be used as prior 
information to develop Bayesian adaptive control software to aid in the 
application of truly PK/PD based individualised therapy. The cost-effectiveness 
and feasibility of PK/PD-based individualised therapy in the real clinical context 
needs prospective evaluation. 
• A standardised approach for existing PK/PD modelling methodologies to model 
development, fitting and reporting would be optimal. This will allow to 
maximise the utility and sharing of information obtained from clinical PK/PD 
studies in children. 
• Clinical PK/PD studies need to be improved to provide maximally informative 
data from target populations. More PK-toxicodynamic studies to balance with 
the efficacy of higher PK/PD targets to combat the emergence of resistance are 
required. This is particular important in combination therapies and where there 
is limited toxicity clinical data from single dosing and from healthy adult 
volunteers. 
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• PK/PD information is currently difficult to obtain from patients, thus a 
pharmacological approach using pre-clinical, combined with clinical PK/PD 
information and mathematical and statistical modelling techniques will remain 
essential as a first step. Better experimental designs and tools are needed to 
determine the impact of factors such as, the human immune system and host-
response, the protein binding and the bacterial burden into the antimicrobial 
exposure-response relationships in patients. 	
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10.2- CASE REPORT FORM FOR THE PK (LIPSTIC STUDY) V.04 072013 	
				
1 
                                           LIPSTIC                                           
Liverpool Pharmacokinetic/Pharmacodynamics study 
of Teicoplanin in Children 
EudraCT No.: 2012-00538-12 
Case Report Form                                                                                      
Version 4 (July, 2013) 
Eligibility and Consent 
1st two letters of patient name: |__||__| 
1st three letters of patient surname:   |__||__||__| 
Centre number (LWFT: 01/ AHFT: 02): |__||__| 
Inclusion number in the study: |__||__| 
Date of inclusion: |__||__|/|__||__|/|__||__||__||__| (dd/mm/yyyy) 
Date of birth:         |__||__|/|__||__|/|__||__||__||__| 
Inclusion criteria 
 Yes No 
In-patients at AHFT or LWFT 
who are either: 
-Neonates (24-39 weeks 
gestational age, 0-28 days) 
-Infants/Toddlers aged 1 to 
24 months 
-Children aged 2 to 16 years 
                                                       
 
Who must be prescribed 
teicoplanin for suspected or 
confirmed Gram positive 
bacterial infection while in 
hospital, as part of their 
routine care.  
        
Provided parental informed 
consent 
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2 
 
Exclusion criteria 
 Yes No 
Unlikely to survive 72 hours 
after recruitment (as judged 
by the clinical team caring 
for the patient) 
  
 
Person(s) with parental responsibility has consented to: 
DNA sample                                                
 
Request a copy of the study results       
 
Consent form signed by the parents (or legal representative) 
Date |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
 
1 copy given to parents     yes    
original for research file    yes    
1 copy medical notes         yes    
 
 
Assent form signed by the patient (8-15 years old) 
1 copy given to parents/patient     yes    
original for research file                   yes    
1 copy medical notes                        yes    
 
 
Eligibility: 
Patient prescribed teicoplanin and is now eligible signed  ………………………………………  
Date ……………………….. 
Record eligibility determined by a qualified person 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3 
ONLY USE IN CASE OF WITHDRAWAL 
 
Consent Withdrawn by Parent  
Date of Withdrawn: |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
 
Name of Parent:      Date consent was withdrawn: 
Describe whether consent is withdrawn from the PK study, DNA or all. Confirm with parent if the data already 
collected may still be used.  
 
………………………………………………………………………………………………………………………………………………………………………….. 
 
Name of Person that discussed withdrawal of consent with the parent ……………………………………………………..  
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4 
Demographics 
For all ages 
Gender:        
   Male   Female                        
 
For neonates and infants ( and pre-term up to 3 years old): 
 Write a number 
Post menstrual age* 
at birth (= Gestational 
age) 
 
___ ___ weeks 
___ ___ days 
Post menstrual age 
when starting the 
study 
___ ___ weeks 
___ ___ days 
Corrected age if 
preterm (up to 3 yrs) 
 
                ___ ___ weeks/months 
___ ___ days 
Developmental and recruitment purposes!!! 
Weight (g) (at study 
inclusion) 
 
………………………………………. 
……………………………………… 
Height at study 
inclusion (cm) 
……………………………………….. 
………………………………………… 
ONLY FOR NEONATES (0-28 days) 
Apgar score at  5 
minutes                        
 
Apgar score at 10 
minutes 
 
 
Birth weight (g) 
 
 
Height at birth (cm) 
 
 
 Yes No 
Surfactant   
Fetal growth 
restriction** 
  
*Post-menstrual age= Gestational age (time elapsed between first day of last menstruation and birth) + Chronological age (time 
elapsed after birth)**According to the local curve, birth weight below the 9th centile 
For older children:  (at study inclusion) 
Weight (Kg):                                                                 Height (cm): 
DOB __/__/__             
(dd/mm/yyyy) 
Chronological 
age 
……………………………………….      
years/months/weeks/days 
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5 
 
Indication of teicoplanin treatment (at start of treatment, tick where appropriate) 
 
 Suspected infection (source not known)      □ 
 Proven (microbiologically documented) Gram positive infection       
(source not known)         □                                                                              
 Suspected Central Venous Catheter (CVC) infection/ 
central line-associated bloodstream infection (CLABSI)     □                  
 Proven Central Venous Catheter (CVC) infection/ CLABSI  □                
 Surgical-site infection (SSI)        □                                                                  
 Ventilator-associated pneumonia (VAP)          □                                        
 Other   (specify) ……………………………        □                                                   
 
 
Summary of teicoplanin administration 
 
Start of treatment   |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
End of treatment   |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
 
 
Has this patient been recruited into LIPSTIC before?   YES/NO 
Number of recruitment episode: |__|__| 
Remember, if teicoplanin treatment stopped for a few days and then, re-started again, this 
would count as a different episode. 
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6 
Study period 
Each day from the start to the end of treatment 
Dose 
number 
Not 
administered* 
 
 
 
dose 
mg 
Date  
 (dd/ mm/ yyyy) 
Start time of 
infusion/bolus 
 
Stop time of 
infusion/bolus 
 
Route of 
administration 
 (ie CVL/CVL single) 
1   ……/…../………    
2   ……/…../………    
3  ……/…../………    
4   ……/…../………    
5   ……/…../………    
6   ……/…../………    
7   ……/…../………    
8   ……/…../………    
9   ……/…../………    
10   ……/…../………    
11   ……/…../………    
12   ……/…../………    
13   ……/…../………    
14   ……/…../………    
15   ……/…../………    
16   ……/…../………    
17   ……/…../………    
18   ……/…../………    
19   ……/…../………    
20   ……/…../………    
21   ……/…../………    
*If teicoplanin was not administered code reason: a) no intravenous access; b) absent due to other procedure 
(e.g. theatre); c) other: describe. 
**If the stop time has not been completed then check the nursing notes for any record of a delay in the 
infusion. 
IMPORTANT!! If administered via a Broviac take into account the time needed for the drug to reach the blood. 
The time to record in the form is the time the drug reaches the blood. 
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7 
Co-administration 
Record all antimicrobials/antifungals, cyclosporine, cisplatin, inotropes, antiepileptics, steroids, albumin and 
caffeine given with 72 h prior to first dose of study drug and through the last dose of study drug therapy. 
Class Drug name Start date (day/ month/ 
year) 
Stop date (day/ month/ 
year) or check if continuing 
Antimicrobials    
    
    
    
Antifungals (ie Amphotericin B)    
Cisplatin    
Cyclosporine    
Inotropic drugs    
    
    
    
Steroids    
    
Antiepileptics    
    
Warfarin    
Albumin    
Furosemide    
Indomethacin    
Others:    
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8 
         Caffeine      Yes □                  No □ 
Dose Intravenous or oral Date (day/ month/ year) Start time of infusion 
or oral administration 
Stop time of infusion 
or oral administration 
     
     
The time to be recorded is the time the drug reaches the blood. 
 
PK Blood Sample Planner and Record of Collection Times 
 
1st Day (1st dose) of PK : |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
Last day of PK :                   |__|__|/|__|__|/|__|__|__|__| (dd/mm/yyyy) 
Day of teicoplanin treatment: a) day 1  (first dose) or b) day 1/ 2 (subsequent doses)  
                                                          If b, was a pre-dose sample obtained?    yes         no  
                                                       then   day 5 or day 6  or  day 7 
                                                       Was teicoplanin stopped early before day 5?   yes         no  
                                                       If yes, record reason:  .............................................. 
                                                       24h post-last dose treatment (Wash-out period)      
 
PK Blood Samples 
Stage 1         This stage is for sample strategy definition and data interim analysis for accuracy. It will comprise the first 
10 patients (including neonates). In this phase neonates will be only >1000 g. 
FOR NEONATES 
Group Weight Sampling times per dosing interval on day 1 and day 5-7 of 
teicoplanin treatment 
Maximum blood 
volume for all 
study 
samples*(ml per 
Kg body weight) 
A >1000g T1 T3 T24 1.2 ml 
< 1000g A1 T1  T24 0.8 ml 
A2 T1 T3  
A3  T3 T24 
B >1000g T1 T6 T24 1.2 ml 
<1000g B1 T1  T24 0.8 ml 
B2 T1 T3  
B3  T3 T24 
	 345	
	
			
9 
PK Blood Samples 
Stage 1         This stage is for sample strategy definition and data interim analysis for accuracy. It will comprise the first 
10 patients (including neonates > 1000 g). 
If neonates > 1000 g: record group A or B          Group:………. 
A: T1,T3,T24 
B: T1,T6,T24                                                            DAY 1 (first dose) 
(If not possible, record accurately all timing of doses since first dose and once consent is granted, include 
subsequent doses) 
Planned  Sample 
Schedule  
Planned 
Sample 
Time   
Actual 
Time 
sample 
collected 
Date and 
time 
sample 
frozen at  
-20°C 
(must be 
within 24 
hours of 
collection) 
Sample 
source 
capillary 
/central 
venous/ 
arterial 
Sample 
number 
T   1h      
 T 3h   
 
   
T   6h   
 
   
T   24h 
 
  
 
   
 
DAY 5-7 
Planned  
Sample 
Schedule  
Planned 
Sample 
Time   
Actual 
Time 
sample 
collected 
Date and 
time 
sample 
frozen at  
-20°C 
(must be 
within 24 
hours of 
collection) 
Sample source 
capillary 
/central 
venous/ 
arterial 
Sample number 
T 1h      
 T 3h   
 
   
T   6h   
 
   
T   24h 
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	10 
PRE-DOSE SAMPLING (Only if first dose of teicoplanin is missed on day 1) 
 
 
 
 
 
 
 
24 HOURS AFTER FINISHING TEICOPLAIN          In this first stage, if possible, a further sample at 24 hours of finishing 
the teicoplanin treatment will be taken for a “wash-out” period analysis.  
 
Planned  
Sample 
Schedule  
Planned 
Sample 
Time   
Actual Time 
sample 
collected 
Date and time 
sample frozen at  
-20°C  
(must be within 24 
hours of collection) 
Sample source 
capillary /central 
venous/ arterial 
Sample 
number 
 T W  
(+24 h) 
  
 
   
 
 
DNA SAMPLE (BLOOD SAMPLE) TO BE COLLECTED ONLY IN NON-TRANSFUSED PATIENTS 
 
Confirm the patient has not received a blood transfusion: (circle) YES/ NO 
 
Dates collected Date stored Sample number 
 
 
 
 
  
 
 
 
 
 
 
Planned  
Sample 
Schedule  
Actual Time 
sample 
collected 
Date and time 
sample frozen at  
-20°C  
(must be within 24 
hours of collection) 
Sample source 
capillary /central 
venous/ arterial 
Sample 
number 
 T    0h  
(pre-
dose 
sample) 
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11 
Microbiological data-Culture results 
Data reported 72 hours prior to start teicoplanin until day 10 after start of teicoplanin 
Include most recent Gram positive bacteria blood/ other sample (endotracheal tube secretion, surgical 
wound) culture. Teicoplanin MIC for positive Gram +ve samples needs to be required to Microbiology. 
 Samples for microbiological investigation should be stored only if Gram positive growth (Staphylococci, CoNs),  
please tick if this was ensured     □ 
Site of 
collection 
(code list) 
Date of 
collection 
Organism 
(state if no 
growth) 
Sensitivity/Resistanc
e to teicoplanin 
Date 
sample 
stored  
(if applicable) 
Sample 
number if 
stored 
MIC 
teicoplanin 
       
       
       
       
       
       
       
       
       
       
       
 
Code list: 1 Peripheral; 2 Central line; 3 Peritoneal fluid; 4 Endotracheal tube section; 5 Other (specify) 
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12 
Laboratory  results 
If more than one blood sample has been taken in the day record the first value available in the day  
(if assessed for clinical care) 
 72 hours 
prior to 
teicoplanin/ 
closest date 
Date: 
1st day of 
teicoplanin 
Date: 
Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
 
24h post-
treatment 
Date: 
 
Full Blood Count 
Haemoglobin          
WBC          
Platelets          
Haematocrit          
Biochemistry 
Creatinine          
Albumin          
Total 
Bilirubin 
         
Conjugated 
Bilirubin 
         
AST/ALT          
ALK 
Phosphate 
         
Amylase          
CRP          
Blood Gas 
pH          
PCO2          
PO2          
Glucose          
Ionized 
Calcium 
         
Lactate          
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13 
Summary of clinical history                                                             
Date of current admission to hospital Unit/ward……………………… 
End of hospitalization (if available)                      ……………………..  
Diagnosis at enrolment (including underlying conditions and surgery):        
1. 6. 
2. 7. 
3. 8. 
4. 9. 
5. 10. 
 
Diagnosis at end of therapy if different (including underlying conditions and surgery): 
1. 6. 
2. 7. 
3. 8. 
4. 9. 
5. 10. 
FOR ICU/HDU            
Ventilation    YES □    NO □ 
 1st day ventilation …………………………. 
Ventilation  Mode on Day 1 
PK samples 
Last Day PK 
samples  
HFO   
Pressure support /BIPAP   
CPAP   
Non-invasive CPAP   
Not ventilated   
ECMO   
Renal dyalisis:       Yes□         No□                           Peritoneal dyalisis      Yes□        No□                                          
Hemofiltration:    Yes□             No□                                                                                                                                                                
 
 
Cardiac Surgery        □ 
Oncology                   □ 
General surgical       □ 
General medical       □ 
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14 
Record transfusions during current admission 
Include Blood Product: Packed Red Cells      Fresh Frozen Plasma     Cryo    Human Albumin Solution      Platelets  
Date administered Blood Product  Volume (ml) 
   
   
   
   
   
   
   
 
FOR NEONATES, INFANTS AND PRE-TERM  
PDA      yes          Surgery                  yes        no             If yes date: 
              no           Indomethacin       yes        no             start date : ………………  end ……………………… 
                                    Ibuprofen                yes       no            start date:…………………….end…………………………  
                                  Prostin                   yes        no            start date:………………….end ………………………. 
Intervention 1st Day PK Samples Last Day PK Samples  
(day 5, 6, or 7) 
24 h post-last dose of 
treatment PK sample 
Nutrition:  
Parenteral  
Breast Milk 
Formula  
       
   
   
   
            
 
  
  
 
 
  
 
Gastroesophageal reflux                                                                                           
Phototherapy                                                                                            
Haemofiltration                                                                                            
ECMO                                                                                           
Cooling                                 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Outcome record from 1st dose until day 7 of treatment 
   
Outcome  Details Date 
Surgery –any surgical procedure  
 
 
Necrotising Enterocolitis  Surgical                    
Medical                     
 
Tolerability:–  
state if teicoplanin was stopped 
due to a clinical concern 
Reason stopped:  
Fitting    
Intra ventricular Haemorrhage 
 
 
Grade  I        
             II      
             III     
             IV     
Grade not recorded  
  
 
Comments  
Include any other information that may be relevant. 
Chronic clinical condition that may affect drug metabolism such as Downs, Cystic fibrosis, 
hydrops 
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16 
Pharmacovigilance  
 
During teicoplanin therapy, the study team will conduct a systematic daily review of patient records until 3 days after 
the last dose using electronic patient data system and consult carers and parents in order to identify adverse events. 
The expected adverse events are described in the summary of product characteristics (SmPC) in the protocol 
appendix A. The aim of the study is not to report on safety. The Sponsor does not wish to receive reports 
about well-recognised adverse events during teicoplanin administration.  
Serious Adverse Events Reactions or Suspected Serious Adverse Events or Reactions require expedited reporting  
except for the Expected Serious Adverse Events in the group populations studied *( critically ill/pre-term 
neonates/oncologic patients) at the discretion of Chief Investigator, treating physician.  
Serious adverse events are classed as: 
   
Result in death (excluded from expedited reporting in these patient groups)   
Life-threatening  
Requires hospitalisation or prolongation of existing hospitalization 
Results in persistent or significant disability or incapacity  
 
The Chief Investigator will be responsible for the reporting of the Suspected Unexpected Serious Adverse Reaction 
(SUSAR ) to the National Competent Authority and Ethics Committee as appropriate. 
 
Adverse event category: 
 
Adverse event details: 
 
Start date: 
 
Stop date: 
 
Action taken with study drug: 
 
Outcome: 
 
Intensity:  
 
Severity: 
 
General comments : 
 
                                                                                                                                                          
 
                                                                                                                                                       Adapted from TINN                                                                                                                 
 
Person completing the CRF (Date and signature):
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10.3- PARENTAL CONSENT FORM FOR THE PK STUDY (LIPSTIC) V.02 
			
LIPSTIC Study. Parental Consent Form.V.02. Date 01.02.2013 
EudraCT number 2012-005738-12                            Patient’s study number:                                           
Version 0.2 Date 01.02.2013                                                                                                                           
Page 1                                                                                       
 
                      Parental Consent Form                         
LIPSTIC: Liverpool Pharmacokinectic/Pharmacodynamics Study on 
Teicoplanin in Children 
 
A pharmacokinetic/pharmacodynamics study about teicoplanin, an antibiotic used to 
prevent and treat infections in neonates and children 
Researchers: Chief Investigator Dr Stéphane Paulus, Principal Investigator Dr Mark Turner, 
Research fellow Dr Virginia Ramos Martin. 
Name of baby/child: …………………………………………………………………………………………            
1. I confirm that I have read and understood the parent information leaflet and have had 
the opportunity to ask questions and these have been answered satisfactorily. 
2. I understand that my baby’s/child’s participation is voluntary and that we are free to 
withdraw at any time, without giving reason and without my baby’s/child’s medical care or   
legal rights being affected. 
3. I understand that sections of any of my baby’s/child’s medical notes may be looked at by 
the research team or the regulatory authorities for this research. I give permission for these 
individuals to have access to my baby’s/child’s records.  
4. I agree for my baby's/child´s samples of blood to be stored and used for current and 
future biological/genetic (DNA analysis) research projects relating to paediatric infections.    
I understand that these samples would be gifted and that no result on my baby’s/ child’s 
genes will be feedback to them or anyone else. 
 
5. I understand that my baby’s/child’s data may be analysed outside the trust (e.g. The 
University), protecting in any circumstance my baby’s/child’s confidentiality.  
6. I would like a summary of the results of the study when the research is completed. 
Name of parent:                                                    Relationship with the baby/child: 
Signature:                                                               Date: 
Researcher:                                           Signature:                                        Date: 
Photocopy and give 1 copy to the parent, 1 for research file, original in medical notes. 
 
Please, 
Initials in Box 
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10.4- PARENT INFORMATION LEAFLET V.02 
		
Parent Information Leaflet. LIPSTIC Study.V.02.22072013.  
 
 
Page 1 
Parent Information Leaflet. LIPSTIC study. Version 2. EudraCT number 2012-005738-12 
             Parent Information Leaflet      
LIPSTIC: Liverpool Pharmacokinectic/Pharmacodynamics Study on 
Teicoplanin in Children 
 
(A pharmacokinetic/pharmacodynamics study about teicoplanin, an 
antibiotic used to treat infections in neonates and children) 
Thank you for taking time to read this leaflet. We would like to invite you to allow your 
baby/child to join this research study. Before you decide, please read this leaflet which 
explains the study. A member of the research team will then be available to go through the 
leaflet with you and answer any questions you might have. Please, feel free to discuss the 
study with family members or friends if you wish. 
The purpose of this study is to evaluate how teicoplanin, an antibiotic, is handled by the 
body in children and neonates in order to update the drug dosage information for 
teicoplanin and provide an optimal dosage regimen. This drug has been used in children 
and neonates for a long time, when it was licensed (1989), extensive studies were not 
performed in the paediatric population and dosage regimen were mainly based in data from 
adults. This evaluation of an antimicrobial that is given as part of the routine clinical care, 
will help us to work out the most effective dose to treat infections, the time to wait 
between doses and the duration of the treatment. 
Why has my baby/child been chosen? 
You have been asked to consider taking part as your baby/child, during the time they are in 
hospital, they may require the antibiotic “teicoplanin” to prevent or treat infection. Your 
baby’s/child’s doctor (not the research team) may make a decision to start this antibiotic (it 
would be given through a drip as part of their clinical care).We would like to evaluate babies 
and children as soon as the treatment is started, therefore, we would like to ask for your 
consent at this stage. 
We would like to include 54 children (babies and older children) for this study. Some of the 
children (neonates) will be treated at Liverpool Women’s NHS foundation Trust and older 
children will be treated at Alder Hey Children’s NHS Foundation Trust as per routine 
practice. 
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Does my baby/child have to take part? 
No. It is up to you to decide whether your baby/child can take part. This decision will not 
affect the care your baby/child receives. If you do decide to take part and then change your 
mind, you are also free to withdraw at any time without giving a reason. You may request 
that any information already collected can also be withdrawn. 
 
What will happen to my baby/child if she/he takes part in this drug level study? 
 The research team will collect details from the baby’s/child’s medical notes To 
evaluate the level of the antibiotic in the baby’s/child’s blood we will collect 2-4 
blood samples the first day of treatment and 2-4 samples at day 3-7 of treatment       
(only 2 samples at day 1 and at day 3-7 for babies weighting less than 1000 grams). 
When babies/children require this antibiotic, they often require other blood samples 
for their clinical care, whenever possible, we will plan to take these at the same time 
as the study sample to minimise disturbing your baby or child. The amount of blood 
required per sample will be of 0.2ml (4-6 drops for each sample).).  
 In parallel, blood and other samples will be obtained routinely from patients for 
Microbiology investigation and when cultured positive for Gram positive bacteria, a 
determination of the microorganism susceptibility to teicoplanin (MIC) will be done 
and results collected for further analysis (pharmacodynamics). This information will 
be also used in the study. 
 ‘Genetics’ –Some babies/children may respond better to this antibiotic than others, 
this could be because different genes have a better response than others. We would 
like to asses this by analysing DNA obtained from blood already taken for your 
baby’s/child´s care. The genetic sample will only be used for the purpose of 
collecting information on your baby’s/child´s response to infection or this medicine. 
If you choose to consent to the “Genetics sample” you will be asked to sign the 
appropriate box on the consent form. 
 If your child is hospitalised in Alder Hey Children’s NHS Foundation Trust, this blood 
sampling (for dug levels) will be performed, when possible, in the clinical research 
facility (CRF) to ensure maximal precision and quality. This is a paediatric dedicated 
facility with trained nurse staff and a paediatrician. If your child is receiving intensive 
care or it is not feasible to move to this facility, sampling will be made as usual. 
Parents and caregivers are welcome to accompany their children in both 
circumstances during sampling. 
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What are the possible benefits of taking part? 
There are no direct benefits to your baby/child but the study may help the clinical team to 
know more about the best way to treat babies and children with this antibiotic in the future. 
Many studies of different treatments over the years have enabled us to develop the current 
care for babies and children. Studies involving children only provide expenses to families if 
they are required to travel, therefore, there will be no financial compensation. 
Are there any side effects? 
Teicoplanin would be given as part of the clinical care to treat a suspected or confirmed 
infection or to prevent an infection. Therefore, there are no additional side effects to this 
evaluation. Teicoplanin is a widely used drug that is already licensed for use in children and 
neonates. This study will check in more detail the effects of this drug by observing the 
effects of this treatment. 
What are the disadvantages or risks of this study when taking part? 
Taking blood samples may lead to some discomfort for the baby/child. Blood samples will be 
taken by staff experienced in taking blood in babies and children. The team will make an 
effort to minimise any distress with involvement of parents. 
 Some children will already have a line into a blood vessel to give fluid, other medicines or 
for monitoring, when possible, we will aim to take the sample from this line. In some cases, 
when this is not possible, then we may take a small amount of blood from a vein or a heel 
prick (the latter in babies). If we are unable to take the sample or if the baby/child is too 
distressed, then we will stop. 
What happens after the study? 
If you would like to receive a summary of the results of the study, this will be sent to you (if 
you agree, you will be asked to initial the appropriate box on the consent form). 
What if something concerns me? 
If you have any concern about the study you may speak to the researcher or the 
baby’s/child’s doctor or nurse who will discuss this with you and try to provide an answer. If 
you wish to complain, or have concerns about any aspect of the study, the National Health 
Service complaints mechanisms may be followed. 
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Will my taking part in this study be kept confidential? 
If you do consent to the research, your baby’s/child’s medical records will be accessed by 
the research team or inspected by regulatory authorities to check that the study is being 
carried out correctly. Your baby’s/child’s name or other personal details will not be given to 
anyone else outside the hospital. Data may be analysed outside the Trust (e,g. at The 
University), however, all information will be managed anonymised and stored confidentially. 
If you have agreed to a DNA sample this will be given a code so that it is confidential then 
stored in the Alder Hey Laboratory in Liverpool for a maximum of 10 years.  
 
What will happen to the results of the research study? 
The results will contribute to the information on the use of medicines for children and may 
be used to guide the dosage and administration of this drug for children and neonates. We 
will publish the results of the study in medical journals, present to other relevant staff and 
put a summary of the results onto the hospital website. The results will not be available 
until after the research has finished. If you would like us to send you a summary of the 
results please initial the appropriate section on the consent form. 
Who is organising and funding this research? 
The study is a MCRN (Medicines for Children Research Network)/LRN (Local Research 
Network) project and is supported by the National Institute of Health Research (NIHR) and 
the LRN. 
Who has reviewed the study other than the research team? 
The study has been reviewed by the UK National Research Ethics Service, The Medicines for 
Children LRN including doctors and nurses who are experts in the care of newborn babies 
and children. It has also been reviewed by the Research Governance Group at Liverpool 
Women’s NHS Foundation Trust and Alder Hey Children’s NHS Foundation Trust. 
 
 
 
 
 
 
	 358	
	
		
Parent Information Leaflet. LIPSTIC Study.V.02.22072013.  
 
 
Page 5 
Parent Information Leaflet. LIPSTIC study. Version 2. EudraCT number 2012-005738-12 
Contact for further information? 
-Dr Stéphane Paulus, Infectious Diseases Consultant. 
Alder Hey Children’s Hospital 
Telephone/email: stephane.paulus@alderhey.nhs.uk 
-Dr Mark Turner, Consultant Neonatologist. 
Liverpool Women’s Hospital Telephone/email: mark.turner@liverpool.ac.uk 
-Dr Virginia Ramos Martin. Clinical Research Fellow.  Paediatrician. 
Alder Hey Children’s Hospital and Liverpool Women’s Hospital. 
Telephone/email: Research mobile number 24h available (07891410007)) 
/vrmartin@liverpool.ac.uk 
 
The clinical team support this study, including the neonatal consultants or consultants at 
the Children’s Hospital.   
 
Thank you for reading this information sheet. 
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10.5- INFORMATION LEAFLET FOR CHILDREN < 8 YEARS OLD V.01, 8-12 
YEARS OLD V.02 AND 12-15 YEARS OLD V.03. 
	
Patient Information Leaflet under 8 LIPSTIC study  
Version 1.0  Dated 19 Dec 2012 
 
 
                                                                    
 
LIPSTIC: Liverpool Pharmacokinectic/Pharmacodynamics Study on 
Teicoplanin in Children 
 
INFORMATION FOR CHILDREN AGED UNDER 8 YEARS 
(to be read by parent or guardian) 
 
 
We have spoken to your mum and dad about taking some extra blood from 
you to look at one of the drugs you are currently receiving. This drug, 
called teicoplanin, is used to kill a bug that is causing an infection in your 
body. We are very interested in this drug and were wondering if you 
would mind helping us learn more about it.  
We are asking all of the children having this drug if they will let us take 
some bloods from their long-line, catheter or by fingerprick. 
 
These bloods will tell us how much of this drug is in the blood in your 
body. 
 
If you are happy for us to take these bloods but then change your mind, it 
is OK to tell us to stop. We won’t be upset or cross with you. 
 
If you have any questions we will be very happy to talk to you about the 
study again if you want. Ask your mum and dad and they will contact us.  
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INFORMATION FOR CHILDREN AGED 8-12 YEARS 
(to be read by parent or guardian) 
 
LIPSTIC: Liverpool Pharmacokinectic/Pharmacodynamics study on 
teicoplanin in children 
 
 
You are having a drug called teicoplanin as part of your treatment and we were 
wondering if you would be happy to take part in a research study. 
 
Please read this information sheet and talk about it with your mum and dad, 
your friends, and the doctors and nurses if you want. Ask us if there is anything 
that you are not sure about. Take plenty of time to decide whether or not you 
want to take part. 
 
1. Why are you doing this study? 
 
Teicoplanin has been used to treat infections for a long time. We know that 
when we give the same amount of drug to everybody, people will have very 
different levels of the drug in their blood, particularly children and adolescents. 
By taking your bloods we can measure the level of teicoplanin in your blood. 
 
2. Why have I been chosen? 
 
Everyone who is having teicoplanin in this hospital can take part in this study.  
 
3. Do I have to take part? 
 
No. It is up to you and your mum and dad to decide if you want to take part. If 
you take part but then change your mind that is okay and we will not be upset 
with you.  
 
4. What will happen if I take part? 
 
We will take 4 blood samples once you start your treatment with teicoplanin 
(day 1) and then another 4 samples at day 3 to 7 of your treatment. These blood 
samples will only be done during one course of your treatment.  The amount of 
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blood we take is small (ie: 4 teaspoons) and will not do you any harm. In addition, 
some babies/children may respond better to this antibiotic than others, this 
could be because different genes have a better response than others. We would 
like to asses this by analysing DNA obtained from blood already taken as part of 
your care. 
 
5.  Confidentiality 
 
All information collected about you for this study is confidential and will be 
stored securely in locked filing cabinets. 
 
6. What if something goes wrong? 
 
We are not expecting anything to go wrong but if there are any problems please 
tell us. If you are still unhappy in any way about the study your Mum and Dad 
can contact the hospital complaints department on your behalf.  
 
7. What will happen to the results of the study? 
 
The results of the study will be printed in medical magazines and may be used to 
change future treatment with teicoplanin. Your name will not be mentioned. 
 
8. Who is organising the study? 
 
The study is organised by a group of experts who work together to improve 
treatment for children with infections. 
  
9. Who can I ask if I want to know more? 
 
If you want to know anything else about this study please ask your doctor or the 
research nurses and they will be happy to talk to you again.  
 
     
Thank you for reading this information sheet.  
 
Contact: 
Dr. Virginia Ramos Martin/ Dr. Stephane Paulus (phone via switchboard) 
vrmartin@liv.ac.uk/ stephane.paulus@alderhey.nhs.uk 
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INFORMATION FOR CHILDREN AGED 12-15 YEARS 
(to be read by parent or guardian) 
 
LIPSTIC: Liverpool Pharmacokinectic/Pharmacodynamics study on 
teicoplanin in children 
 
 
We are asking you whether or not you would like to take part in a research study involving 
the drug teicoplanin, which will be given to treat a suspected or confirmed bacterial 
infection.   
 
Before you decide it is important for you to understand why the research is being done and 
what is involved. Please take time to read the following information carefully and discuss it 
with friends, relatives, doctors and nurses if you wish. Ask us if there is anything that is not 
clear or if you would like more information. Take the time to decide whether or not you 
wish to take part. 
 
1. What is the purpose of the study? 
 
Teicoplanin is an antibiotic that has been used in the treatment of a specific type of bacteria 
for many years. However, little is known about what happens to this drug after it enters the 
blood in children and neonates. We know from similar work with other drugs, that children 
differ in the way that they get rid of drugs from their blood. This study will measure how 
much drug is in the blood and see how and why this differs between children. This will help 
doctors to use this drug in the best way to treat infections in children. 
 
2. Why have I been chosen? 
 
Everyone who is going to receive teicoplanin while in hospital could take part in this study.  
 
3. Do I have to take part? 
 
No. Taking part in the study is entirely up to you. If you agree to take part and then later 
change your mind, you can stop at any time without giving a reason, this will not affect the 
treatment you receive.  
 
4. Consent/ Assent 
If you agree to take part in this study we will need your parents to sign a consent form and 
you could also sign the assent form. You will be given a copy of the assent form and this 
information sheet to keep.  
	 363	
		
			
Patient Information Leaflet 12-15. LIPSTIC Study.V.03.Date 05.08.2013.  
  
2 
Patient Information Leaflet 12-15. LIPSTIC study. Version 2. EudraCT number 2012-005738-12 
 
If you decide at any point not to continue taking part in this study, you can do so without 
giving us any explanation. 
 
5. What will happen if I take part? 
   
A blood sample will be taken from your long line or drip if possible, just after the first dose 
of teicoplanin is given. Three further blood samples will be taken over the first day of 
teicoplanin treatment. In addition, another 3-4 samples will be taken at day 3 oto 7 of 
treatment. The amount of blood required per sample will be minimal and should not cause 
you any problems.  The samples taken will allow us to measure levels of teicoplanin in the 
blood and look at variation between patients. 
In parallel, blood and other samples, if  necessary, such as samples from wound infections, 
will be obtained routinely from patients to see if the grow any bacteria in them causing the 
infection, and when finding growing bacteria, we will determine if that bacteria is 
susceptible to be killed at the amount of teicoplanin we are giving to treat the infection. In 
addition, some babies/children may respond better to this treatment than others, this could 
be because different genes have a better response than others. We would like to asses this 
by studying the DNA (the footprint that tells us how we are and makes everyone different) 
obtained from blood that has been already taken for your care. 
6. Are there any disadvantages or risks involved in my participation in the study? 
 
Taking blood samples may lead to some discomfort. Blood samples will be taken by staff 
experienced in taking blood in children. The team will make an effort to minimise any 
distress with involvement of parents. 
 Some children will already have a line into a blood vessel to give fluid, other medicines or 
for monitoring, when possible, we will aim to take the sample from this line. In some cases, 
when this is not possible, then we may take a small amount of blood from a vein. If we are 
unable to take the sample, then we will stop. 
 
7. What are the possible benefits of taking part? 
 
The information gained from the blood samples taken will not be of any help to you at the 
moment but may improve the way we use teicoplanin in the future in children. 
 
 
8. Confidentiality 
 
A study number will be given to you when you are first recruited onto the study. Only the 
first two letters of your first name and first three letters of your surname will be used. 
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Your blood samples and data will be all coded for analysis and they will be retained for the 
duration of the study. If you have agreed to a DNA sample this will be given a code as well 
so that it is confidential then stored in Alder Hey NHS Children´s Foundation Trust for a 
maximum of 10 years, which would allow us to do future research if it becomes appropriate. 
  
 
9. What if something goes wrong or I am unhappy about any aspect of the study? 
 
If you are unhappy about any aspect of the way you have been approached or treated 
during the course of this study, in the first instance please contact your consultant/ parent 
or guardian. If you are still unhappy, you can contact the hospital complaints department. 
 
10. What will happen to the results of the study? 
 
The study will run for approximately one year. Analysis will be carried out and the results 
published in medical journals, presented at international conferences and possibly used to 
modify future treatment. You will not be identified in any report or publication. 
 
11. Who is organising and funding the research?  
 
The study is a MCRN (Medicines for Children Research Network)/LRN (Local Research 
Network) project and is supported by the National Institute of Health Research (NIHR) and 
the LRN. 
12. Contact for further information 
 
If you require any further information please contact the consultant who is looking after 
you:  Dr Stephane Paulus, Infectious Diseases Consultant paediatrician. Telephone/email: 
stephane.paulus@alderhey.nhs.uk 
You also can contact: Dr Virginia Ramos Martin. Clinical Research Fellow.  Paediatrician. 
Telephone/email: Research mobile number 24h available (via the switchboard) 
/vrmartin@liverpool.ac.uk 
Thank you for reading this information sheet.  
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National Research Ethics Service 
 
NRES Committee North West - Liverpool East 
HRA NRES Centre Manchester 
Barlow House 
3rd Floor 
4 Minshull Street 
Manchester 
M1 3DZ 
 
Telephone: 0161 625 7832  
Facsimile: 0161 625 7299 
27 March 2013 
 
Dr Stephane Paulus 
Alder Hey Children's NHS Foundation Trust 
Eaton Road 
Liverpool 
L12 2AP 
 
 
Dear Dr Paulus 
 
Study title: Liverpool Pharmacokinetic/pharmacodynamics study of 
teicoplanin in children (LIPSTIC). 
REC reference: 13/NW/0023 
Protocol number: LIPSTIC.V.01 
EudraCT number: 2012-005738-12 
IRAS project ID: 120870 
 
Thank you for your letter of 14 February 2013, responding to the Committee’s request for further 
information on the above research and submitting revised documentation. 
 
The further information has been considered on behalf of the Committee by the Chair.  
 
We plan to publish your research summary wording for the above study on the NRES website, 
together with your contact details, unless you expressly withhold permission to do so.  
Publication will be no earlier than three months from the date of this favourable opinion letter.  
Should you wish to provide a substitute contact point, require further information, or wish to 
withhold permission to publish, please contact the Co-ordinator Miss Helen Penistone, 
nrescommittee.northwest-liverpooleast@nhs.net. 
 
Confirmation of ethical opinion 
 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the above 
research on the basis described in the application form, protocol and supporting documentation 
as revised, subject to the conditions specified below. 
 
Ethical review of research sites 
 
NHS sites 
 
The favourable opinion applies to all NHS sites listed in the application, subject to management 
permission being obtained from the NHS/HSC R&D office prior to the start of the study (see 
"Conditions of the favourable opinion" below). 
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Non-NHS sites 
 
The Committee has not yet been notified of the outcome of any site-specific assessment (SSA) 
for the non-NHS research site(s) taking part in this study.  The favourable opinion does not 
therefore apply to any non-NHS site at present.  We will write to you again as soon as one 
Research Ethics Committee has notified the outcome of a SSA.  In the meantime no study 
procedures should be initiated at non-NHS sites. 
 
Conditions of the favourable opinion 
 
The favourable opinion is subject to the following conditions being met prior to the start of the 
study. 
 
Management permission or approval must be obtained from each host organisation prior to the 
start of the study at the site concerned. 
 
Management permission ("R&D approval") should be sought from all NHS organisations 
involved in the study in accordance with NHS research governance arrangements. 
 
Guidance on applying for NHS permission for research is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk.   
 
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites ("participant identification centre"), guidance should be sought from 
the R&D office on the information it requires to give permission for this activity. 
 
For non-NHS sites, site management permission should be obtained in accordance with the 
procedures of the relevant host organisation.  
 
Sponsors are not required to notify the Committee of approvals from host organisations 
 
Clinical trial authorisation must be obtained from the Medicines and Healthcare products 
Regulatory Agency (MHRA). 
 
The sponsor is asked to provide the Committee with a copy of the notice from the MHRA, either 
confirming clinical trial authorisation or giving grounds for non-acceptance, as soon as this is 
available. 
 
The Committee specified the following additional condition: 
 
x Blood samples stored, for future DNA analysis, within the Trust should be stored under 
the terms of the Human Tissue Authority Licence.    
 
It is the responsibility of the sponsor to ensure that all the conditions are complied with 
before the start of the study or its initiation at a particular site (as applicable). 
 
You should notify the REC in writing once all conditions have been met (except for site 
approvals from host organisations) and provide copies of any revised documentation 
with updated version numbers. The REC will acknowledge receipt and provide a final list 
of the approved documentation for the study, which can be made available to host 
organisations to facilitate their permission for the study. Failure to provide the final 
versions to the REC may cause delay in obtaining permissions.   
 
Approved documents 
 
The final list of documents reviewed and approved by the Committee is as follows: 
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Document    Version    Date    
REC application: 120870/396576/1/628    19 December 
2012  
Protocol  1.0  19 December 
2012  
Investigator CV: Stephane Christian Paulus   20 December 
2012  
Participant Information Sheet: Parent Information Leaflet  1  19 December 
2012  
Participant Consent Form  1.0  19 December 
2012  
Participant Information Sheet: for children aged 8-12 years  1.0  19 December 
2012  
Participant Information Sheet: for children aged under 8 years  1.0  19 December 
2012  
Response to Request for Further Information from Dr Paulus 
and Dr Ramos 
 14 February 2013  
Participant Information Sheet: for children aged 12-15 years  02  04 February 2013  
Participant Consent Form: Parental Consent Form   02  01 February 2013  
Participant Consent Form: Assent Form for patients aged 8-
15 years  
1.0  18 January 2013  
 
Statement of compliance 
 
This Committee is recognised by the United Kingdom Ethics Committee Authority under the 
Medicines for Human Use (Clinical Trials) Regulations 2004, and is authorised to carry out the 
ethical review of clinical trials of investigational medicinal products. 
 
The Committee is fully compliant with the Regulations as they relate to ethics committees and 
the conditions and principles of good clinical practice. 
 
The Committee is constituted in accordance with the Governance Arrangements for Research 
Ethics Committees and complies fully with the Standard Operating Procedures for Research 
Ethics Committees in the UK. 
 
After ethical review 
 
Reporting requirements 
 
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
 
x Notifying substantial amendments 
x Adding new sites and investigators 
x Notification of serious breaches of the protocol 
x Progress and safety reports 
x Notifying the end of the study 
 
The NRES website also provides guidance on these topics, which is updated in the light of 
changes in reporting requirements or procedures. 
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Feedback 
 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the website. 
 
Further information is available at National Research Ethics Service website > After Review 
 
13/NW/0023                          Please quote this number on all correspondence 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/  
 
With the Committee’s best wishes for the success of this project. 
 
Yours sincerely 
 
 
 
On behalf of 
Mrs Glenys J Hunt 
Chair 
 
Email:   nrescommittee.northwest-liverpooleast@nhs.net 
 
Enclosures:  “After ethical review – guidance for researchers” 
    
 
Copy to:  Dr Matthew Peak 
Research and Development Office 
Alder Hey Children's NHS Foundation Trust 
Eaton Road 
Liverpool 
L12 2AP 
 
Ms Dot Lambert,  
Alder Hey Children's NHS Foundation Trust 
Eaton Road 
Liverpool 
L12 2AP 
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